,compound_id,standard_inchi_key,compound_name,synonym,target_id,target_pref_name,gene_names,wildtype_or_mutant,mutation_info,pubmed_id,standard_type,standard_relation,standard_value,standard_units,activity_comment,ep_action_mode,assay_format,assaytype,assay_subtype,inhibitor_type,detection_tech,assay_cell_line,compound_concentration_value,compound_concentration_value_unit,substrate_type,substrate_relation,substrate_value,substrate_units,assay_description,title,journal,doc_type,annotation_comments,pDTC_Value,SMILES
0,CHEMBL12,AAOVKJBEBIDNHE-UHFFFAOYSA-N,DIAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
1,CHEMBL12,AAOVKJBEBIDNHE-UHFFFAOYSA-N,DIAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
2,CHEMBL1090526,ABDWUBPDHWDFCV-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,0.7,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.154901959985743,C[C@H](C1=C(CC2=C1C=CC(=C2)F)CCN(C)C)C3=NC=CN=C3OC
3,CHEMBL1090526,ABDWUBPDHWDFCV-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20800486.0,Ki,=,0.7,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.154901959985743,C[C@H](C1=C(CC2=C1C=CC(=C2)F)CCN(C)C)C3=NC=CN=C3OC
4,CHEMBL60435,ABEZUHIZVKNNOT-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,95499.26,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.019999993643078,C1C[C@@H](NC1)CC(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
5,CHEMBL990,ABJKWBDEJIDSJZ-UHFFFAOYSA-N,BUTENAFINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32
6,CHEMBL990,ABJKWBDEJIDSJZ-UHFFFAOYSA-N,BUTENAFINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32
10,CHEMBL270853,ABOWDNIHZHLENL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCCN4CCC5=CC6=C(C=C5CC4)C(=O)N(C6)C
11,CHEMBL256659,ABWRXTVIPWIMTE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)N=C(O5)C(F)(F)F
12,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,11000.0,NM,,,,binding,,,,,,,,,,,,,,,,4.958607314841775,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
13,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,17000.0,NM,,,,binding,,,,,,,,,,,,,,,,4.769551078621726,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
14,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,23000.0,NM,,,,binding,,,,,,,,,,,,,,,,4.638272163982407,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
15,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,Ki,=,20.6,NM,,,cell_based,binding,,,,,,,,,,,,,,,,7.686132779630847,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
16,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,Ki,=,58.8,NM,,,cell_based,binding,,,,,,,,,,,,,,,,7.230622673923862,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
17,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,Ki,=,140.0,NM,,,,binding,,,,,,,,,,,,,,,,6.853871964321762,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
18,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27639363.0,Ki,=,16.6,NM,,,,,,,,,,,,,,,,,,,,7.779891911959945,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
19,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27639363.0,Ki,=,115.0,NM,,,,,,,,,,,,,,,,,,,,6.939302159646388,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
20,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27639363.0,Ki,=,186.0,NM,,,,,,,,,,,,,,,,,,,,6.730487055782084,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
21,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27639363.0,Ki,=,1998.0,NM,,,,,,,,,,,,,,,,,,,,5.699404516110037,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
22,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,24.0,NM,,,,,,,,,,,,,,,,,,,,7.619788758288394,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
23,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,247.0,NM,,,,,,,,,,,,,,,,,,,,6.607303046740334,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
24,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,268.0,NM,,,,,,,,,,,,,,,,,,,,6.5718652059712115,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
25,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,290.0,NM,,,,,,,,,,,,,,,,,,,,6.537602002101044,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
26,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,293.0,NM,,,,,,,,,,,,,,,,,,,,6.533132379645891,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
27,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,327.0,NM,,,,,,,,,,,,,,,,,,,,6.485452247339714,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
28,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,553.0,NM,,,,,,,,,,,,,,,,,,,,6.257274868695301,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
29,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,560.0,NM,,,,,,,,,,,,,,,,,,,,6.251811972993799,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
30,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,822.0,NM,,,,,,,,,,,,,,,,,,,,6.0851281824599495,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
31,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,998.0,NM,,,,,,,,,,,,,,,,,,,,6.000869458712629,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
32,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,1087.0,NM,,,,,,,,,,,,,,,,,,,,5.963770455913705,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
33,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,1437.0,NM,,,,,,,,,,,,,,,,,,,,5.842543231865775,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
34,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,3224.0,NM,,,,,,,,,,,,,,,,,,,,5.491604966866947,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
35,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,3867.0,NM,,,,,,,,,,,,,,,,,,,,5.412625827926934,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
36,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27839919.0,Ki,>,10000.0,NM,,,cell_based,binding,,,,,,,,,,,,,,,,5.0,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
37,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,5.8,NM,,,,,,,,,,,,,,,,,,,,8.236572006437063,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
38,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,5.01,NM,,,,,,,,,,,,,,,,,,,,8.300162274132754,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
39,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,,,,,,7.199970640755866,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
40,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,6.31,NM,,,,,,,,,,,,,,,,,,,,8.199970640755867,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
41,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,8.91,NM,,,,,,,,,,,,,,,,,,,,8.050122295963126,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
42,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N
43,CHEMBL765,ACGDKVXYNVEAGU-UHFFFAOYSA-N,GUANETHIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCCN(CCC1)CCN=C(N)N
44,CHEMBL765,ACGDKVXYNVEAGU-UHFFFAOYSA-N,GUANETHIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCCN(CCC1)CCN=C(N)N
45,CHEMBL496,ACGUYXCXAPNIKK-UHFFFAOYSA-N,HEXACHLOROPHENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl
46,CHEMBL496,ACGUYXCXAPNIKK-UHFFFAOYSA-N,HEXACHLOROPHENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl
47,CHEMBL14638,ACQBHJXEAYTHCY-UHFFFAOYSA-N,CIPROXIFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12606603.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3
48,CHEMBL14638,ACQBHJXEAYTHCY-UHFFFAOYSA-N,CIPROXIFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15033391.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3
49,CHEMBL14638,ACQBHJXEAYTHCY-UHFFFAOYSA-N,CIPROXIFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15608078.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3
50,CHEMBL14638,ACQBHJXEAYTHCY-UHFFFAOYSA-N,CIPROXIFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18683917.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor,The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3
51,CHEMBL14638,ACQBHJXEAYTHCY-UHFFFAOYSA-N,CIPROXIFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,>,2511.89,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3
52,CHEMBL272694,ACRMNEFOWLXFLY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C
53,CHEMBL96732,ACTVOFFLDWZANE-KHMGXFTDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,27.0,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.568636235841013,CN(C)CC1C[C@@H]2[C@H](O1)C3=CC=CC=C3CC4=CC=CC=C24
54,CHEMBL329566,ACTVOFFLDWZANE-NSISKUIASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,0.54,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.267606240177031,CN(C)C[C@H]1C[C@H]2[C@H](O1)C3=CC=CC=C3CC4=CC=CC=C24
55,CHEMBL329566,ACTVOFFLDWZANE-NSISKUIASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,0.43,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,9.366531544420413,CN(C)C[C@H]1C[C@H]2[C@H](O1)C3=CC=CC=C3CC4=CC=CC=C24
56,CHEMBL92667,ACTVOFFLDWZANE-ODFWGIBRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,0.7,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.154901959985743,CN(C)CC1C[C@H]2[C@H](O1)C3=CC=CC=C3CC4=CC=CC=C24
57,CHEMBL329268,ACTVOFFLDWZANE-PWIZWCRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,0.63,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.200659450546418,CN(C)C[C@@H]1C[C@H]2[C@H](O1)C3=CC=CC=C3CC4=CC=CC=C24
58,CHEMBL327651,ACTVOFFLDWZANE-VDGAXYAQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,3.74,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.42712839779952,CN(C)C[C@@H]1C[C@@H]2[C@@H](O1)C3=CC=CC=C3CC4=CC=CC=C24
59,CHEMBL1069,ACWBQPMHZXGDFX-QFIPXVFZSA-N,VALSARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O
60,CHEMBL1069,ACWBQPMHZXGDFX-QFIPXVFZSA-N,VALSARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O
63,CHEMBL1669412,ADLLYWYUHVDQBH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,4.3,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.366531544420413,C1CN(C1)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4
64,CHEMBL115769,ADQZGIYHFQQPRB-UHFFFAOYSA-N,RWJ-68354,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=NC2=C1C(=C(N2)C3=CC=C(C=C3)F)C4=CC=NC=C4)N
65,CHEMBL115769,ADQZGIYHFQQPRB-UHFFFAOYSA-N,RWJ-68354,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=NC2=C1C(=C(N2)C3=CC=C(C=C3)F)C4=CC=NC=C4)N
67,CHEMBL1702607,ADVPTQAUNPRNPO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(C(C(=O)O)N)S(=O)O
68,CHEMBL322194,ADZSGFZICHOKOJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.42,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.192464971931146,CCOCCN1C2=CC=CC=C2N=C1C(=O)C3CCN(CC3)CCC4(CCN(C4)C(=O)C5=CC(=C(C(=C5)OC)OC)OC)C6=CC=CC=C6
69,CHEMBL322194,ADZSGFZICHOKOJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,381.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.419075024324381,CCOCCN1C2=CC=CC=C2N=C1C(=O)C3CCN(CC3)CCC4(CCN(C4)C(=O)C5=CC(=C(C(=C5)OC)OC)OC)C6=CC=CC=C6
72,CHEMBL470564,AECNWVFAWBLCAX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,3500.0,NM,,,,,,,,,,,,,,,,,,,,5.455931955649724,CC(C1=CC=CC=C1)C(=O)NC(=NCCCC2=CN=CN2)N
74,CHEMBL252557,AEMRFAOFKBGASW-UHFFFAOYSA-N,GLYCOLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)O
75,CHEMBL252557,AEMRFAOFKBGASW-UHFFFAOYSA-N,GLYCOLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)O
79,CHEMBL44884,AEUTYOVWOVBAKS-UWVGGRQHSA-N,ETHAMBUTOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NCCN[C@@H](CC)CO
80,CHEMBL44884,AEUTYOVWOVBAKS-UWVGGRQHSA-N,ETHAMBUTOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NCCN[C@@H](CC)CO
81,CHEMBL513893,AEWLECDUIOHVBW-QBNMFFNISA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18768318.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Synthesis and evaluation of a spiro-isobenzofuranone class of histamine H3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(CCN1CCCCC1)C(=O)C2CCC3(CC2)C4=C(C=C(C=C4)OC)C(=O)O3
82,CHEMBL2171022,AEWQIKDEAWAPPV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,100.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC(=CC=C4)OCC(=O)O
83,CHEMBL398996,AFNIUHMJOXEVTF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,CS(=O)(=O)C1=CC=C(C=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5.C(=O)O
84,CHEMBL1221,AFNXATANNDIXLG-UHFFFAOYSA-N,SULCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CSC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl
85,CHEMBL1221,AFNXATANNDIXLG-UHFFFAOYSA-N,SULCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CSC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl
86,CHEMBL486964,AFTLSANLJDCKNX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,2300.0,NM,,,,,,,,,,,,,,,,,,,,5.638272163982407,CC(C1CCCCC1)C(=O)NC(=NCCCC2=CN=CN2)N
87,CHEMBL486964,AFTLSANLJDCKNX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,6000.0,NM,,,,,,,,,,,,,,,,,,,,5.221848749616356,CC(C1CCCCC1)C(=O)NC(=NCCCC2=CN=CN2)N
89,CHEMBL508112,AFZSMODLJJCVPP-UHFFFAOYSA-N,BENZOTHIAZYL DISULFIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)N=C(S2)SSC3=NC4=CC=CC=C4S3
90,CHEMBL508112,AFZSMODLJJCVPP-UHFFFAOYSA-N,BENZOTHIAZYL DISULFIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)N=C(S2)SSC3=NC4=CC=CC=C4S3
91,CHEMBL134342,AGBQKNBQESQNJD-SSDOTTSWSA-N,LIPOIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CSS[C@@H]1CCCCC(=O)O
92,CHEMBL134342,AGBQKNBQESQNJD-SSDOTTSWSA-N,LIPOIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CSS[C@@H]1CCCCC(=O)O
93,CHEMBL267744,AGHANLSBXUWXTB-UHFFFAOYSA-N,TICRYNAFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl
94,CHEMBL267744,AGHANLSBXUWXTB-UHFFFAOYSA-N,TICRYNAFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl
95,CHEMBL270376,AGHXSXMZVMLSGU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=C(SC(=N1)C)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(F)(F)F
97,CHEMBL1741,AGOYDEPGAOXOCK-KCBOHYOISA-N,CLARITHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O
98,CHEMBL1741,AGOYDEPGAOXOCK-KCBOHYOISA-N,CLARITHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O
99,CHEMBL330172,AHIOIWMCDDMDRL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.38,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.195179321278838,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CN=CC=C6)C7=CC=CC=C7
100,CHEMBL330172,AHIOIWMCDDMDRL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,416.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.380906669373257,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CN=CC=C6)C7=CC=CC=C7
101,CHEMBL490,AHOUBRCZNHFOSL-YOEHRIQHSA-N,PAROXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
102,CHEMBL490,AHOUBRCZNHFOSL-YOEHRIQHSA-N,PAROXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
103,CHEMBL490,AHOUBRCZNHFOSL-YOEHRIQHSA-N,PAROXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
104,CHEMBL402422,AHTVKTAOAOXKMG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C
105,CHEMBL1090186,AIGMIQVSRPRWAQ-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.3,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693163,C[C@H](C1=C(CC2=C1C=CC(=C2)OC)CCN(C)C)C3=NC=CN=C3OC
106,CHEMBL583,AIJTTZAVMXIJGM-UHFFFAOYSA-N,GREPAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F
107,CHEMBL583,AIJTTZAVMXIJGM-UHFFFAOYSA-N,GREPAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F
108,CHEMBL567993,AIMNRLCNWYRUPJ-HDICACEKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344075,CC1=CC(=CC=C1)C(=O)NC2CCC(CC2)NC3=NC=C(C(=N3)N(C)C)C
109,CHEMBL1767144,AIQKTJZHRRQKTE-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,>,1584.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,5.800000874803203,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)C(=O)O
110,CHEMBL180233,AITHPZKEMCVCDZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,9.55,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human Histamine H1 receptor in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.019996628416253,CC(C)OC(=O)N(CCC#CC1=CC=C(C=C1)OCCCCN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)O
111,CHEMBL14,AIXAANGOTKPUOY-UHFFFAOYSA-N,CARBACHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOC(=O)N.[Cl-]
112,CHEMBL14,AIXAANGOTKPUOY-UHFFFAOYSA-N,CARBACHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOC(=O)N.[Cl-]
115,CHEMBL54440,AJLFOPYRIVGYMJ-INTXDZFKSA-N,MEVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1CCC=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O
116,CHEMBL54440,AJLFOPYRIVGYMJ-INTXDZFKSA-N,MEVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1CCC=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O
117,CHEMBL1618305,AJPSBXJNFJCCBI-YOHUGVJRSA-N,NALOXONAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCN1[C@H]2[C@]3([C@]4(C5=C(C2)C=CC(=C5O[C@H]4/C(=N/N=C\6/[C@@H]7OC8=C(C=CC9=C8[C@]72[C@]([C@@H](C9)N(CC2)CC=C)(CC6)O)O)/CC3)O)CC1)O
118,CHEMBL1618305,AJPSBXJNFJCCBI-YOHUGVJRSA-N,NALOXONAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCN1[C@H]2[C@]3([C@]4(C5=C(C2)C=CC(=C5O[C@H]4/C(=N/N=C\6/[C@@H]7OC8=C(C=CC9=C8[C@]72[C@]([C@@H](C9)N(CC2)CC=C)(CC6)O)O)/CC3)O)CC1)O
121,CHEMBL2208426,AJUWTQZJBKWQNV-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,100.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CS(=O)(=O)C1=CC=C(S1)C(=O)NC[C@H](CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)O
123,CHEMBL593494,AKEGHAUFMKCWGX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,64.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,7.1938200260161125,CNCCC(C1=CC=CC=C1)C2=CC=CC=C2
124,CHEMBL364713,AKNNEGZIBPJZJG-MSOLQXFVSA-N,NOSCAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC2=CC3=C(C(=C2[C@@H]1[C@@H]4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3
125,CHEMBL364713,AKNNEGZIBPJZJG-MSOLQXFVSA-N,NOSCAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC2=CC3=C(C(=C2[C@@H]1[C@@H]4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3
127,CHEMBL158352,AKTMNFPHGGUJFY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,251.19,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.599997654072044,C1=C(NC=N1)CCCCCCCCCCCN
128,CHEMBL158352,AKTMNFPHGGUJFY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,398107170553497.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.6,C1=C(NC=N1)CCCCCCCCCCCN
130,CHEMBL1255834,ALFGDCNSEBJYSP-UHFFFAOYSA-N,BW-723C86,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8730737.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N
131,CHEMBL1255834,ALFGDCNSEBJYSP-UHFFFAOYSA-N,BW-723C86,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N
132,CHEMBL1255834,ALFGDCNSEBJYSP-UHFFFAOYSA-N,BW-723C86,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N
133,CHEMBL1783963,ALOWJQCLRWGVOV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,110.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.958607314841775,CC1=NC=C(C=C1)CCN2C3=C(CN(CC3)C)C4=C2C=CC(=C4)F
134,CHEMBL1783963,ALOWJQCLRWGVOV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,730.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.136677139879544,CC1=NC=C(C=C1)CCN2C3=C(CN(CC3)C)C4=C2C=CC(=C4)F
135,CHEMBL60143,ALQYYBXQKWSMNS-HHHXNRCGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,5495.41,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.259999900311453,CC(C)(C)OC(=O)N[C@H](CC1=CC=CC=C1)C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
136,CHEMBL240567,ALWGROOEKGXBRR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CCC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC(=CC(=C5)F)F.C(=O)O
137,CHEMBL3357035,AMBATUWSQRROKC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,1274.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,5.894830572000668,CC(C)COC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
138,CHEMBL2207284,AMEQLQYPRVOFMB-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934842,CNS(=O)(=O)C1=CC2=C(C=C1)C(=CNC2=O)C(=O)NC[C@H](CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl)O
139,CHEMBL1909080,AMGRXJSJSONEEG-UHFFFAOYSA-L,STRONTIUM CHLORIDE HEXAHYDRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,O.O.O.O.O.O.[Cl-].[Cl-].[Sr+2]
140,CHEMBL1909080,AMGRXJSJSONEEG-UHFFFAOYSA-L,STRONTIUM CHLORIDE HEXAHYDRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,O.O.O.O.O.O.[Cl-].[Cl-].[Sr+2]
142,CHEMBL2208420,AMQPWRCXJRAWTN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892137,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)CCCOC3=CC=CC(=C3)C#N
143,CHEMBL1946256,ANQFIBHZMVNJLK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,,,,Not Active,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CC3=NC4=CC=CC=C4S3
144,CHEMBL1242950,ANTKBACNWQHQJE-UHFFFAOYSA-N,AC-42,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20684563.0,Ki,=,610.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor by radioligand displacement assay,"Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.",J. Med. Chem.,PUBLICATION,,6.214670164989233,CCCCC1CCN(CC1)CCCC(=O)C2=CC=CC=C2C
145,CHEMBL451,ANTSCNMPPGJYLG-UHFFFAOYSA-N,CHLORDIAZEPOXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,1795.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.745935547085662,CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O
146,CHEMBL451,ANTSCNMPPGJYLG-UHFFFAOYSA-N,CHLORDIAZEPOXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,208.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.681936665037238,CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O
148,CHEMBL521589,ANZXOIAKUNOVQU-UHFFFAOYSA-N,BAMBUTEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O
149,CHEMBL521589,ANZXOIAKUNOVQU-UHFFFAOYSA-N,BAMBUTEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O
150,CHEMBL460499,AOCCBINRVIKJHY-UHFFFAOYSA-N,CARMOFUR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F
151,CHEMBL460499,AOCCBINRVIKJHY-UHFFFAOYSA-N,CARMOFUR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F
152,CHEMBL194206,AOENLUNXEDMDRT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=C(C=C4)F)OC
153,CHEMBL53463,AOJJSUZBOXZQNB-TZSSRYMLSA-N,DOXORUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
154,CHEMBL53463,AOJJSUZBOXZQNB-TZSSRYMLSA-N,DOXORUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
155,CHEMBL417,AOJJSUZBOXZQNB-VTZDEGQISA-N,EPIRUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
156,CHEMBL417,AOJJSUZBOXZQNB-VTZDEGQISA-N,EPIRUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
157,CHEMBL96442,AOMZRTTZRBZOAC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.44,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.191114132640188,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CC=N6)C7=CC=CC=C7
158,CHEMBL96442,AOMZRTTZRBZOAC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,366.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.436518914605589,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CC=N6)C7=CC=CC=C7
159,CHEMBL1277492,AOSLQNBDHSOLAE-HAQQTFLXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,199.53,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.699991797446187,C1C[C@H](CN(C1)C2CCC3(C2)C4=CC=CC=C4OC5=C(C3=O)C=C(C=C5)Cl)C(=O)O
160,CHEMBL1200623,AOXRBFRFYPMWLR-XGXHKTLJSA-N,ETHYLESTRENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CCCC[C@H]34)C)O
161,CHEMBL1200623,AOXRBFRFYPMWLR-XGXHKTLJSA-N,ETHYLESTRENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CCCC[C@H]34)C)O
164,CHEMBL267345,APKFDSVGJQXUKY-INPOYWNPSA-N,AMPHOTERICIN B,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O
165,CHEMBL267345,APKFDSVGJQXUKY-INPOYWNPSA-N,AMPHOTERICIN B,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O
168,CHEMBL878,AQCHWTWZEMGIFD-UHFFFAOYSA-N,METOLAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl
169,CHEMBL878,AQCHWTWZEMGIFD-UHFFFAOYSA-N,METOLAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl
170,CHEMBL452861,AQHHHDLHHXJYJD-AWEZNQCLSA-N,(-)-PROPANOLOL ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@@H](COC1=CC=CC2=CC=CC=C21)O
171,CHEMBL452861,AQHHHDLHHXJYJD-AWEZNQCLSA-N,(-)-PROPANOLOL ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@@H](COC1=CC=CC2=CC=CC=C21)O
172,CHEMBL275742,AQHHHDLHHXJYJD-CQSZACIVSA-N,DEXPROPRANOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O
173,CHEMBL275742,AQHHHDLHHXJYJD-CQSZACIVSA-N,DEXPROPRANOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O
174,CHEMBL27,AQHHHDLHHXJYJD-UHFFFAOYSA-N,PROPRANOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
175,CHEMBL27,AQHHHDLHHXJYJD-UHFFFAOYSA-N,PROPRANOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
176,CHEMBL27,AQHHHDLHHXJYJD-UHFFFAOYSA-N,PROPRANOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O
177,CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC1=C(N=CN1)CSCCNC(=NC)NC#N
178,CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CSCCNC(=NC)NC#N
179,CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CSCCNC(=NC)NC#N
181,CHEMBL2171045,AQIZHUDMGJRAMJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415902,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC=CC(=C4)C(F)(F)F
182,CHEMBL768,AQNDDEOPVVGCPG-UHFFFAOYSA-N,ESMOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O
183,CHEMBL768,AQNDDEOPVVGCPG-UHFFFAOYSA-N,ESMOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O
184,CHEMBL517244,AQQFXOLTZFTABW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,40.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,CN(CCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24)CC5=CC=C(C=C5)OCCCN6CCCCC6
185,CHEMBL3094114,AQRDKFVOYVDLCT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,=,1000.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CC1CN2CCC3=C(CC2)C=C(C=C3)OCC4=CC=CC=C4
186,CHEMBL2158791,AQVKRBFXFFKXJV-NDEPHWFRSA-N,AZ-12436092,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,158.49,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593398,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@](C)(CC4=CC=C(C=C4)F)C(=O)O
187,CHEMBL571819,ARFONFXLNJVMPP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,,,,Not Active,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC=C(C=C1)CCCC(=O)N2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
188,CHEMBL1614641,ARPYQKTVRGFPIS-VIFPVBQESA-N,FLUNOXAPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)F)C(=O)O
189,CHEMBL1614641,ARPYQKTVRGFPIS-VIFPVBQESA-N,FLUNOXAPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)F)C(=O)O
190,CHEMBL1276860,ASARBMLXIRIMCK-SABQLHICSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.400007822415902,C1CC2(CC1N3C[C@@H]4[C@H](C3)C4C(=O)O)CC5=CC=CC=C5CC6=CC=CC=C26
193,CHEMBL659,ASUTZQLVASHGKV-JDFRZJQESA-N,GALANTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O
194,CHEMBL659,ASUTZQLVASHGKV-JDFRZJQESA-N,GALANTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O
195,CHEMBL446,ASWVTGNCAZCNNR-UHFFFAOYSA-N,SULFAMETHAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C
196,CHEMBL446,ASWVTGNCAZCNNR-UHFFFAOYSA-N,SULFAMETHAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C
197,CHEMBL444633,ATEBXHFBFRCZMA-VXTBVIBXSA-N,RIFABUTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=NC6(CCN(CC6)CC(C)C)N=C25)O)/C
198,CHEMBL444633,ATEBXHFBFRCZMA-VXTBVIBXSA-N,RIFABUTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=NC6(CCN(CC6)CC(C)C)N=C25)O)/C
199,CHEMBL2171021,ATPAZLJUTRYFNR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934842,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C3CCN(CC3)C(=O)C4=CC(=CC=C4)S(=O)(=O)C)Cl
201,CHEMBL158780,AUTKMGMMFJXIDV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,175.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,6.756961951313706,C1C2=CC=CC=C2C(C3=CC=CC=C31)CCCN
202,CHEMBL50588,AUVVAXYIELKVAI-CKBKHPSWSA-N,EMETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC
203,CHEMBL50588,AUVVAXYIELKVAI-CKBKHPSWSA-N,EMETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC
204,CHEMBL1544,AUYYCJSJGJYCDS-LBPRGKRZSA-N,LIOTHYRONINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O
205,CHEMBL1544,AUYYCJSJGJYCDS-LBPRGKRZSA-N,LIOTHYRONINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O
206,CHEMBL964,AUZONCFQVSMFAP-UHFFFAOYSA-N,DISULFIRAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)C(=S)SSC(=S)N(CC)CC
207,CHEMBL964,AUZONCFQVSMFAP-UHFFFAOYSA-N,DISULFIRAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)C(=S)SSC(=S)N(CC)CC
208,CHEMBL66388,AVBATPOOKQCBKS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12798320.0,Ki,=,4085.0,NM,,,,,,,,,,,,,,,Compound was tested for its binding affinity towards human H1 receptor,"A new class of histamine H(3)-receptor antagonists: synthesis and structure-activity relationships of 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.388807939131565,C1CCC2=C(C3=CC=CC=C3N=C2CC1)NCCCN4CCCC4
209,CHEMBL563451,AVFYUSOOXDDQAW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,1.5,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.823908740944319,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2N4CCC(CC4)N(C)C
210,CHEMBL174,AVKUERGKIZMTKX-NJBDSQKTSA-N,AMPICILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C
211,CHEMBL174,AVKUERGKIZMTKX-NJBDSQKTSA-N,AMPICILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C
214,CHEMBL456,AVOLMBLBETYQHX-UHFFFAOYSA-N,ETHACRYNIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl
215,CHEMBL456,AVOLMBLBETYQHX-UHFFFAOYSA-N,ETHACRYNIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl
216,CHEMBL3094128,AVVIXBQVVAAVHK-QHCPKHFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,>,2511.89,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,C1CCN(CC1)CCCOC2=CC=C(C=C2)CN3CC[C@@H](C3)NC(=O)C4=CC5=C(C=C4)OCO5
217,CHEMBL603049,AVZFSLTZULXZCC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,31.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.508638306165727,CC1=CC=C(C=C1)CCN2C3=C(CN(CC3)C)C4=C2C=CC(=C4)F
218,CHEMBL1946122,AWIYLVWAILOVMX-RLAPIPATSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,4149.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,5.382056565171027,C1C[C@H]2CC(C[C@@H]1N2CCCOC3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O
219,CHEMBL3321789,AWIYLVWAILOVMX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,4149.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.382056565171027,C1CC2CC(CC1N2CCCOC3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O
222,CHEMBL1767165,AWKFJGDSZGEFRY-UUWRZZSWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,7.94,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.100179497572904,COC1=CC=C(C=C1)CC2=NN(C(=O)C3=CC=CC=C32)C[C@H]4CCCN4CCCCC5=CC=C(C=C5)OCCCN6CCCCCC6
223,CHEMBL64479,AWRHPMGJQNISSW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,870.96,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.060001790087838,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)CCC
224,CHEMBL540982,AWYSEPZPTVMKBT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,11.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,7.958607314841775,CN(C)CCC1=C(C2=CC=CC=C2S1)CC3=CC=C(C=C3)F
225,CHEMBL60559,AXEYQIQVIRZLKE-JOCHJYFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,9772.37,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.010000098195094,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CSC=C4)N
226,CHEMBL1095819,AXIFLPLKZRNVDP-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,0.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.045757490560675,CN1CCC[C@H](C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
227,CHEMBL1087089,AXIFLPLKZRNVDP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,0.5,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.301029995663981,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
228,CHEMBL440294,AXKPFOAXAHJUAG-UHFFFAOYSA-N,PIPAMPERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,2400.0,NM,,,,,,,,,,,,,,,,,,,,5.619788758288394,C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N
229,CHEMBL18972,AXNGJCOYCMDPQG-UHFFFAOYSA-N,GLEMANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15999145.0,Ki,=,1604.0,NM,,,,,,,,,,,,,,,,,,,,5.794795636051855,C1CN(CCC1C(C2=CC=CC=C2)O)CCC3=CC=CC=C3
232,CHEMBL556506,AYEYSXMZCARQKR-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,1.3,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,8.886056647693163,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)C
233,CHEMBL556506,AYEYSXMZCARQKR-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.3,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693163,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)C
234,CHEMBL556506,AYEYSXMZCARQKR-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20800486.0,Ki,=,1.5,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.823908740944319,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)C
235,CHEMBL556506,AYEYSXMZCARQKR-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,1.3,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693163,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)C
237,CHEMBL2158790,AYPGYVOWMUSFPT-NDEPHWFRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,31.62,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.50003813440381,CC1=C(C=CC(=C1Cl)Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@](C)(CC4=CC=C(C=C4)F)C(=O)O
238,CHEMBL1278113,AYWYOYAKLYFQAR-JVPYDEADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,100.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.0,C1C[C@@]2(CC1N3CCNC(C3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25
241,CHEMBL3238444,BAAHTFHSCKWFDS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,=,29512.09,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,4.530000033355806,CC1=NN=C(N1C2=CC=C(C=C2)OCCCN3CCCCC3)C
242,CHEMBL559664,BACLISNXCXJOMR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,40.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CC(=O)O
243,CHEMBL559664,BACLISNXCXJOMR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,40.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.3979400086720375,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CC(=O)O
244,CHEMBL2158778,BATQCPTUBUKUDO-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,398.11,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.399996913372259,C1CN(CCC1CN2CCC(CC2)OC3=CC=C(C=C3)Cl)[C@@H](CC4=CC=C(C=C4)F)C(=O)O
245,CHEMBL565551,BAZQBEOFVYAFHT-CALCHBBNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,810.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0915149811213505,CC1=CN=C(N=C1N(C)C)NC2CCC(CC2)NC(=O)C3=CC=C(C=C3)F
246,CHEMBL1669420,BBPIYFSEHZGVJE-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,48.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.318758762624412,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CS4
247,CHEMBL1222695,BBQVIKFUQPNVLK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450609,CC(C)(CN1CCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC(=C4)Cl)C(=O)O
249,CHEMBL11,BCGWQEUPMDMJNV-UHFFFAOYSA-N,IMIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,16.0,NM,,,,,,,,,,,,,,,,,,,,7.795880017344075,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31
250,CHEMBL11,BCGWQEUPMDMJNV-UHFFFAOYSA-N,IMIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,37.0,NM,,,,,,,,,,,,,,,,,,,,7.431798275933005,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31
251,CHEMBL11,BCGWQEUPMDMJNV-UHFFFAOYSA-N,IMIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23919353.0,IC50,=,27.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by radioligand binding assay,Polypharmacology - foe or friend?,J. Med. Chem.,PUBLICATION,,7.568636235841013,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31
259,CHEMBL1783974,BDDPDGBPFDDYBY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,2790.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.554395796726403,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C4CCN(CC4)C)CCC5=CN=CC=C5
260,CHEMBL1783974,BDDPDGBPFDDYBY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C4CCN(CC4)C)CCC5=CN=CC=C5
262,CHEMBL157273,BDMUROBIUYESLK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,398.11,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.399996913372259,C1=CN=CC=C1CCCCCCCCCCCCN
263,CHEMBL157273,BDMUROBIUYESLK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,251188643150958.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.4,C1=CN=CC=C1CCCCCCCCCCCCN
264,CHEMBL1774498,BDOFZYNAHBHVET-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,54.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.267606240177032,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4CCC5=C3C=C(C=C5)CC(=O)O
265,CHEMBL271073,BDRCTGAXOWRNQU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=C(OC=N1)C2=NN=C(N2C)SCCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)C
266,CHEMBL608689,BDSUMBDGCUOHGR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,70.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,7.154901959985743,CN(C)CCCC(C1=CC=CC=C1)C2=CC=CC=C2
267,CHEMBL1276859,BEAHZBHBRZMAIL-OSHJFMDRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.50003813440381,C1C[C@@]2(CC1N3CCC(C3)CC(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25
270,CHEMBL150161,BETHXCLHMRGYBW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16621538.0,Ki,=,259.6,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor by radioligand binding assay,"Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.585695311871668,C1CN(CC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
271,CHEMBL150161,BETHXCLHMRGYBW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16621538.0,Ki,=,1467.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor by radioligand binding assay,"Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.833569886156718,C1CN(CC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
272,CHEMBL150161,BETHXCLHMRGYBW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,259.6,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.585695311871668,C1CN(CC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
273,CHEMBL150161,BETHXCLHMRGYBW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,1467.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,5.833569886156718,C1CN(CC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
274,CHEMBL94834,BEYBSSSCFNIKNG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.33,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.198596289982644,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC=C(C=C7)C(F)(F)F
275,CHEMBL94834,BEYBSSSCFNIKNG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,473.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.325138859262188,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC=C(C=C7)C(F)(F)F
276,CHEMBL42442,BEZZFPOZAYTVHN-UHFFFAOYSA-N,OXFENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3
277,CHEMBL42442,BEZZFPOZAYTVHN-UHFFFAOYSA-N,OXFENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3
278,CHEMBL588119,BFCDFTHTSVTWOG-YLJYHZDGSA-N,SULOCTIDIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,5176.8,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.285938613185849,CCCCCCCCN[C@H](C)[C@H](C1=CC=C(C=C1)SC(C)C)O
279,CHEMBL588119,BFCDFTHTSVTWOG-YLJYHZDGSA-N,SULOCTIDIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,2475.9,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.606266900170992,CCCCCCCCN[C@H](C)[C@H](C1=CC=C(C=C1)SC(C)C)O
280,CHEMBL256481,BFIAPIAYPVHYPQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCCN4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C
282,CHEMBL691,BFPYWIDHMRZLRN-SLHNCBLASA-N,ETHINYL ESTRADIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O
283,CHEMBL691,BFPYWIDHMRZLRN-SLHNCBLASA-N,ETHINYL ESTRADIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O
284,CHEMBL283036,BFQIOOYNLCWKIJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)C(F)(F)F
286,CHEMBL1200604,BGDKAVGWHJFAGW-UHFFFAOYSA-N,TROPICAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2
287,CHEMBL1200604,BGDKAVGWHJFAGW-UHFFFAOYSA-N,TROPICAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2
289,CHEMBL267044,BGRJTUBHPOOWDU-NSHDSACASA-N,LEVOSULPIRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
290,CHEMBL267044,BGRJTUBHPOOWDU-NSHDSACASA-N,LEVOSULPIRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
291,CHEMBL26,BGRJTUBHPOOWDU-UHFFFAOYSA-N,SULPIRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
292,CHEMBL26,BGRJTUBHPOOWDU-UHFFFAOYSA-N,SULPIRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
293,CHEMBL1092812,BHMPPLVSPUZBNL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,120.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,CC(C1=CN=C(C=C1)OC)C2=C(SC3=CC=CC=C32)CCN(C)C
294,CHEMBL205596,BHQCQFFYRZLCQQ-OELDTZBJSA-N,CHOLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C
295,CHEMBL205596,BHQCQFFYRZLCQQ-OELDTZBJSA-N,CHOLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C
296,CHEMBL64667,BHZVLTKKVOPLTE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1047.13,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.979999397807417,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)N3CCCC3
298,CHEMBL3084803,BIDUPMYXGFNAEJ-APGVDKLISA-N,ASTROMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H]([C@@H]([C@@H]([C@H]([C@H]2O)N(C)C(=O)CN)OC)O)N)N)N
299,CHEMBL3084803,BIDUPMYXGFNAEJ-APGVDKLISA-N,ASTROMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H]([C@@H]([C@@H]([C@H]([C@H]2O)N(C)C(=O)CN)OC)O)N)N)N
300,CHEMBL1629810,BIIFEDMBGOQTDO-USCPGHQQSA-N,2-HYDROXYPROPYL-BETA-CYCLODEXTRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(COC[C@H]1[C@H]2[C@H]([C@@H](CO1)O[C@H]3[C@@H](O[C@H]([C@H]([C@@H]3O)O)O[C@H]4[C@@H](O[C@H]([C@H]([C@@H]4O)O)O[C@H]5[C@@H](O[C@H]([C@H]([C@@H]5O)O)O[C@H]6[C@@H](O[C@H]([C@H]([C@@H]6O)O)O[C@H]7[C@@H](O[C@H]([C@H]([C@@H]7O)O)O[C@H]8[C@@H](O[C@H]([C@H]([C@@H]8O)O)O[C@H]9[C@@H](O[C@@H](O2)[C@H]([C@@H]9O)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)O)O
301,CHEMBL1629810,BIIFEDMBGOQTDO-USCPGHQQSA-N,2-HYDROXYPROPYL-BETA-CYCLODEXTRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(COC[C@H]1[C@H]2[C@H]([C@@H](CO1)O[C@H]3[C@@H](O[C@H]([C@H]([C@@H]3O)O)O[C@H]4[C@@H](O[C@H]([C@H]([C@@H]4O)O)O[C@H]5[C@@H](O[C@H]([C@H]([C@@H]5O)O)O[C@H]6[C@@H](O[C@H]([C@H]([C@@H]6O)O)O[C@H]7[C@@H](O[C@H]([C@H]([C@@H]7O)O)O[C@H]8[C@@H](O[C@H]([C@H]([C@@H]8O)O)O[C@H]9[C@@H](O[C@@H](O2)[C@H]([C@@H]9O)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)O)O
302,CHEMBL1935426,BITWXVYTBYRISR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153342.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC(C1)N2CCC3(CCC4=C(O3)C=CC(=C4)OCC5CCS(=O)(=O)CC5)CC2
305,CHEMBL445206,BJIOGJUNALELMI-ARJAWSKDSA-N,ISOEUGENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C/C=C\C1=CC(=C(C=C1)O)OC
306,CHEMBL445206,BJIOGJUNALELMI-ARJAWSKDSA-N,ISOEUGENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C/C=C\C1=CC(=C(C=C1)O)OC
307,CHEMBL402794,BJQHLKABXJIVAM-BGYRXZFFSA-N,BIS(2-ETHYLHEXYL)PHTHALATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC[C@@H](CC)COC(=O)C1=CC=CC=C1C(=O)OC[C@@H](CC)CCCC
308,CHEMBL402794,BJQHLKABXJIVAM-BGYRXZFFSA-N,BIS(2-ETHYLHEXYL)PHTHALATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC[C@@H](CC)COC(=O)C1=CC=CC=C1C(=O)OC[C@@H](CC)CCCC
309,CHEMBL430368,BKLPUYQJSHHECO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC(=CC(=C4)F)F.C(=O)O
310,CHEMBL157138,BKRGVLQUQGGVSM-KBXCAEBGSA-N,LISURIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,160.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.795880017344075,CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
311,CHEMBL157138,BKRGVLQUQGGVSM-KBXCAEBGSA-N,LISURIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,19.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.721246399047171,CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
313,CHEMBL278172,BLFLLBZGZJTVJG-UHFFFAOYSA-N,BENZOCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=CC=C(C=C1)N
314,CHEMBL278172,BLFLLBZGZJTVJG-UHFFFAOYSA-N,BENZOCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=CC=C(C=C1)N
315,CHEMBL15245,BLGXFZZNTVWLAY-SCYLSFHTSA-N,YOHIMBINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O
316,CHEMBL15245,BLGXFZZNTVWLAY-SCYLSFHTSA-N,YOHIMBINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O
317,CHEMBL499,BLJRIMJGRPQVNF-JTQLQIEISA-N,TIMOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O
318,CHEMBL499,BLJRIMJGRPQVNF-JTQLQIEISA-N,TIMOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O
319,CHEMBL1306,BLSQLHNBWJLIBQ-OZXSUGGESA-N,TERCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl
320,CHEMBL1306,BLSQLHNBWJLIBQ-OZXSUGGESA-N,TERCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl
321,CHEMBL567597,BLUAFEHZUWYNDE-DKGJTOOQSA-N,ARTEMISININ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@@](O3)(OO4)C)C
322,CHEMBL567597,BLUAFEHZUWYNDE-DKGJTOOQSA-N,ARTEMISININ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@@](O3)(OO4)C)C
323,CHEMBL1070,BLXXJMDCKKHMKV-UHFFFAOYSA-N,NABUMETONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC
324,CHEMBL1070,BLXXJMDCKKHMKV-UHFFFAOYSA-N,NABUMETONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC
326,CHEMBL1381010,BMBIEKJDTGAZCY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-mepyramine from human histamine H1 receptor expressed in HEK293T cells after 1 to 1.5 hrs by liquid scintillation counting analysis,Structure-based virtual screening for fragment-like ligands of the G protein-coupled histamine H4receptor,MedChemComm,PUBLICATION,,5.0,CC1=CC(=NC(=N1)N2CCOCC2)N3CCN(CC3)C
330,CHEMBL302005,BMMSDSQQAGDCHS-RQZCQDPDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,Ki,=,11.0,NM,,,,,,,,,,,,,,,Inhibition constant against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,7.958607314841775,CN(C)C/C=C/1\C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O
331,CHEMBL302005,BMMSDSQQAGDCHS-RQZCQDPDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22931505.0,Ki,=,11.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Chemokine receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.958607314841775,CN(C)C/C=C/1\C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O
333,CHEMBL192,BNRNXUUZRGQAQC-UHFFFAOYSA-N,SILDENAFIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
334,CHEMBL192,BNRNXUUZRGQAQC-UHFFFAOYSA-N,SILDENAFIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
336,CHEMBL197796,BNXUKTBRYQQOIZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=C(C=C4)SC)OC
337,CHEMBL1200545,BOBLHFUVNSFZPJ-JOYXJVLSSA-N,DIFLORASONE DIACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)OC(=O)C)C)O)F)C)F
338,CHEMBL1200545,BOBLHFUVNSFZPJ-JOYXJVLSSA-N,DIFLORASONE DIACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)OC(=O)C)C)O)F)C)F
339,CHEMBL214311,BOQXUEKBVIXPKQ-JSGCOSHPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,EC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in 293-EBNA cells by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,5.0,C1[C@@H]([C@H]1C2=CN=CN2)CCNCC3=CC=C(C=C3)Cl
340,CHEMBL214311,BOQXUEKBVIXPKQ-JSGCOSHPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,IC50,=,8500.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human H1 receptor expressed in 293-EBNA cells assessed as inhibition of histamine agonist activity by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,5.070581074285707,C1[C@@H]([C@H]1C2=CN=CN2)CCNCC3=CC=C(C=C3)Cl
341,CHEMBL213886,BOQXUEKBVIXPKQ-TZMCWYRMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,EC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in 293-EBNA cells by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,5.0,C1[C@H]([C@@H]1C2=CN=CN2)CCNCC3=CC=C(C=C3)Cl
342,CHEMBL213886,BOQXUEKBVIXPKQ-TZMCWYRMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,IC50,=,6800.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human H1 receptor expressed in 293-EBNA cells assessed as inhibition of histamine agonist activity by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,5.167491087293763,C1[C@H]([C@@H]1C2=CN=CN2)CCNCC3=CC=C(C=C3)Cl
343,CHEMBL427216,BOVGTQGAOIONJV-UHFFFAOYSA-N,GLICLAZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
344,CHEMBL427216,BOVGTQGAOIONJV-UHFFFAOYSA-N,GLICLAZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
345,CHEMBL539843,BOYLPLUVCXUHDJ-UHFFFAOYSA-N,VAPITADINE DIHYDROCHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771458.0,Ki,=,19.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for H1 histamine receptor expressed in CHO cells,"Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines.",J. Med. Chem.,PUBLICATION,,7.721246399047171,C1CN2C(=CN=C2C3(CCNCC3)C4=CC=CC=C41)C(=O)N.Cl.Cl
346,CHEMBL1940420,BPDDCCYSOYRMEC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,262.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,6.581698708680254,C1CN(CCN1CCCOC2=CC=C(C=C2)F)C3=CC=CC=N3
347,CHEMBL1774504,BPDWWCSMAZGENY-AQHIEDMUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,63.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.200659450546418,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CC/C=C\3/C4=CC=CC=C4COC5=C3C=C(C=C5)C(=O)O
348,CHEMBL240178,BPDXEOHDRPKAKE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,CS(=O)(=O)C1=CC=C(C=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OC4CCN(CC4)C5CCCC5.C(=O)O
349,CHEMBL400224,BPXYTXXFLQUXFX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)C(=O)N6CCC6.C(=O)O
351,CHEMBL275507,BPZGZNLONLANFE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,794.33,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.0999990348465305,C1=CC=C(C=C1)C(CCC2=NC=C(N2)CCN)C3=CC=CC=C3
352,CHEMBL275507,BPZGZNLONLANFE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,501187233627271.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.699999999999999,C1=CC=C(C=C1)C(CCC2=NC=C(N2)CCN)C3=CC=CC=C3
353,CHEMBL398615,BQDBKDMTIJBJLA-UHFFFAOYSA-N,METOPIMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,Ki,=,8.4,NM,,,,binding,,,,,,,,,,,,,,,,8.075720713938118,CS(=O)(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)C(=O)N
360,CHEMBL1783964,BRMMBDRDSQRBHU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,120.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,CN1CCC2=C(C1)C3=CC=CC=C3N2CCC4=CC=NC=C4
361,CHEMBL1783964,BRMMBDRDSQRBHU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,500.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,CN1CCC2=C(C1)C3=CC=CC=C3N2CCC4=CC=NC=C4
365,CHEMBL193639,BSOLCASXROXPRZ-MQSINFNDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,0.52,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,9.2839966563652,CN(C)C[C@H]1CC2[C@H](O1)C3=C(C=CC(=C3)F)SC4=CC=CC=C24
366,CHEMBL193639,BSOLCASXROXPRZ-MQSINFNDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,0.6,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,9.221848749616356,CN(C)C[C@H]1CC2[C@H](O1)C3=C(C=CC(=C3)F)SC4=CC=CC=C24
367,CHEMBL366164,BSOLCASXROXPRZ-MUKKUYKPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,1.4,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.853871964321762,CN(C)C[C@H]1C[C@H]2[C@H](O1)C3=C(C=CC(=C3)F)SC4=CC=CC=C24
368,CHEMBL363581,BSOLCASXROXPRZ-SHZHJNINSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,1.2,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.920818753952375,CN(C)C[C@@H]1CC2[C@H](O1)C3=C(C=CC(=C3)F)SC4=CC=CC=C24
370,CHEMBL320003,BSVGNAQMDXJFNE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.39,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.1944991418416,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4)C6=CC(=C(C=C6)Cl)Cl
371,CHEMBL25,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,ASPIRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC1=CC=CC=C1C(=O)O
372,CHEMBL25,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,ASPIRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC1=CC=CC=C1C(=O)O
373,CHEMBL104344,BTCOIJOGNYPDOY-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,2500.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,C1CN(C[C@H]1NS(=O)(=O)C2=CC=C(C=C2)Cl)CCCOC3=CC=C(C=C3)C(=O)C4CC4
374,CHEMBL239964,BTGWCFVBMYAJIJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CCC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)C#N.C(=O)O
376,CHEMBL106596,BTQCFHMSBTVCNT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,7762.47,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.110000065251387,C1CC(CN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N)O
377,CHEMBL328573,BTSCZNWXJQSJIE-QFBILLFUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,0.64,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.193820026016112,CN(C)C[C@@H]1C[C@@H]2C3=CC=CC=C3CC4=CC=CC=C4N2O1
378,CHEMBL83658,BTSCZNWXJQSJIE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,6.76,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.170053304058364,CN(C)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1
379,CHEMBL83658,BTSCZNWXJQSJIE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1
380,CHEMBL83658,BTSCZNWXJQSJIE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,6.76,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.170053304058364,CN(C)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1
381,CHEMBL83658,BTSCZNWXJQSJIE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12443779.0,IC50,=,6.76,NM,,,,,,,,,,,,,,,Binding affinity against Histamine H1 receptor,2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT(2C) antagonist with potential anxiolytic properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.170053304058364,CN(C)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1
382,CHEMBL105071,BTXYSVCTMDAUJN-QHCPKHFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,2300.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.638272163982407,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
383,CHEMBL1762,BUJAGSGYPOAWEI-UHFFFAOYSA-N,TOCAINIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)NC(=O)C(C)N
384,CHEMBL1762,BUJAGSGYPOAWEI-UHFFFAOYSA-N,TOCAINIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)NC(=O)C(C)N
392,CHEMBL257901,BVMLPMCCWDUGDH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCN4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C
393,CHEMBL1092496,BVRYNXDISKCAFZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,69.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.161150909262744,CC1=NC=C(C=C1)C(C)C2=C(SC3=CC=CC=C32)CCN(C)C
394,CHEMBL1910379,BWBDWEIXBARWJD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,776.25,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.109998386815364,COC1=CC=C(C=C1)CN(CCN2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)Cl)C5=CC=CC=N5
397,CHEMBL63003,BWVYMOZIPOAYMY-MUUNZHRXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CC=CC5=CC=CC=C54)N
398,CHEMBL294502,BXDDBQXEMSRCFW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1905.46,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.720000163638921,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)CC
399,CHEMBL1765111,BXUKKRHEMKVWOY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.79997073344623,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCN3CCCC(CC3)N4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl
400,CHEMBL1460,BXZVVICBKDXVGW-NKWVEPMBSA-N,DIDANOSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O
401,CHEMBL1460,BXZVVICBKDXVGW-NKWVEPMBSA-N,DIDANOSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O
402,CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl
403,CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl
404,CHEMBL292275,BYKHDCPMWIUHPJ-VGOFMYFVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,616.6,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.209996479609511,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)/C=C/C3=CC=C(C=C3)OC
405,CHEMBL256650,BYMRLNXYRMIIKD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C
406,CHEMBL628,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,PENTOXIFYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C
407,CHEMBL628,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,PENTOXIFYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C
409,CHEMBL20,BZKPWHYZMXOIDC-UHFFFAOYSA-N,ACETAZOLAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=NN=C(S1)S(=O)(=O)N
410,CHEMBL20,BZKPWHYZMXOIDC-UHFFFAOYSA-N,ACETAZOLAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=NN=C(S1)S(=O)(=O)N
412,CHEMBL1630579,BZRYYBWNOUALTQ-UHFFFAOYSA-N,MYRTECAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOCCC1=CCC2CC1C2(C)C
413,CHEMBL1630579,BZRYYBWNOUALTQ-UHFFFAOYSA-N,MYRTECAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOCCC1=CCC2CC1C2(C)C
416,CHEMBL147077,CAAOWRJNPRFDJE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,9857099.0,Ki,=,491.0,NM,,,,,,,,,,,,,,,Binding affinity for recombinant human Histamine H1 receptor using [3H]pyrilamine as radioligand.,Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia.,J. Med. Chem.,PUBLICATION,,6.308918507877031,CC1=C(C(C(=C(N1)C)C(=O)NCCCN2CCC(CC2)(C3=CC=CC=C3)C(=O)OC)C4=CC=C(C=C4)[N+](=O)[O-])C(=O)NC
418,CHEMBL855,CBEQULMOCCWAQT-WOJGMQOQSA-N,TRIPROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,,,,,,9.0,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3
420,CHEMBL855,CBEQULMOCCWAQT-WOJGMQOQSA-N,TRIPROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8496700.0,Ki,=,1.6,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from histamine H1 receptor,The role of receptor binding in drug discovery.,J. Nat. Prod.,PUBLICATION,,8.795880017344075,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3
421,CHEMBL855,CBEQULMOCCWAQT-WOJGMQOQSA-N,TRIPROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,,,,,,9.0,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3
422,CHEMBL855,CBEQULMOCCWAQT-WOJGMQOQSA-N,TRIPROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.11,NM,,,,,,,,,,,,,,,,,,,,8.954677021213342,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3
423,CHEMBL855,CBEQULMOCCWAQT-WOJGMQOQSA-N,TRIPROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.53,NM,,,,,,,,,,,,,,,,,,,,8.8153085691824,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3
424,CHEMBL855,CBEQULMOCCWAQT-WOJGMQOQSA-N,TRIPROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,3.01,NM,,,,,,,,,,,,,,,,,,,,8.521433504406156,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3
425,CHEMBL1159650,CBGUOGMQLZIXBE-XGQKBEPLSA-N,CLOBETASOL PROPIONATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCl
426,CHEMBL1159650,CBGUOGMQLZIXBE-XGQKBEPLSA-N,CLOBETASOL PROPIONATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCl
427,CHEMBL395110,CBHCDHNUZWWAPP-UHFFFAOYSA-N,MEPAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,27.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.568636235841013,CN1CCCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42
428,CHEMBL395110,CBHCDHNUZWWAPP-UHFFFAOYSA-N,MEPAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,3.13,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.504455662453552,CN1CCCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42
429,CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5
430,CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5
432,CHEMBL2171020,CCJZAFYMSHLKFH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934842,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CNC(=O)C5=CC=CC=C54
435,CHEMBL2158825,CCXXDPNVVABEGJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,15.85,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.79997073344623,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=CC=C4CC(=O)O
436,CHEMBL10,CDMGBJANTYXAIV-UHFFFAOYSA-N,SB-203580,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F
437,CHEMBL10,CDMGBJANTYXAIV-UHFFFAOYSA-N,SB-203580,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F
438,CHEMBL2107687,CEJGGHKJHDHLAZ-UHFFFAOYSA-M,VALETHAMATE BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)C(C1=CC=CC=C1)C(=O)OCC[N+](C)(CC)CC.[Br-]
439,CHEMBL2107687,CEJGGHKJHDHLAZ-UHFFFAOYSA-M,VALETHAMATE BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)C(C1=CC=CC=C1)C(=O)OCC[N+](C)(CC)CC.[Br-]
440,CHEMBL494093,CEUMRIVIGREJGB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,9120.11,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.039999923502186,CN1CCN(CC1)C2=NC(=NC3=C2CCC4=CC=CC=C43)N
441,CHEMBL1112,CEUORZQYGODEFX-UHFFFAOYSA-N,ARIPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,29.7,NM,,,,,,,,,,,,,,,,,,,,7.527243550682788,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
442,CHEMBL1112,CEUORZQYGODEFX-UHFFFAOYSA-N,ARIPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12784105.0,Ki,=,25.1,NM,,,,,,,,,,,,,,,,,,,,7.600326278518962,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
443,CHEMBL1112,CEUORZQYGODEFX-UHFFFAOYSA-N,ARIPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27173799.0,IC50,=,420.0,NM,,,,,,,,,,,,,,,Antagonistic activity at histamine1 receptor (unknown origin) after 10 mins by FLIPR assay,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.376750709602099,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
444,CHEMBL1112,CEUORZQYGODEFX-UHFFFAOYSA-N,ARIPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,25.1,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,7.600326278518962,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
445,CHEMBL1112,CEUORZQYGODEFX-UHFFFAOYSA-N,ARIPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay,,MedChemComm,PUBLICATION,,7.0,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
446,CHEMBL93321,CEXVQARQHVKRBU-RMNMTYGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,9.6,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.017728766960431,CN(C)CC1C[C@H]2[C@H](O1)C3=CC=CC=C3COC4=CC=CC=C24
447,CHEMBL61070,CFANDXVYVGVAJZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,602.56,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.219999701663429,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CCCCC3
448,CHEMBL508102,CFOYWRHIYXMDOT-UHFFFAOYSA-N,CARBIMAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N1C=CN(C1=S)C
449,CHEMBL508102,CFOYWRHIYXMDOT-UHFFFAOYSA-N,CARBIMAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N1C=CN(C1=S)C
450,CHEMBL27979,CFUHKRLMDNFZED-SFTDATJTSA-N,"A-349,821",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12657274.0,Ki,=,2344.23,NM,,,,,,,,,,,,,,,Binding affinity towards human histaminergic (H1) receptor,Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6299997805248845,C[C@H]1CC[C@@H](N1CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N4CCOCC4)C
451,CHEMBL62421,CGDJUGZQGOTFLF-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,35481.34,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.449999986821809,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](C)N
452,CHEMBL6,CGIGDMFJXJATDK-UHFFFAOYSA-N,INDOMETHACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O
453,CHEMBL6,CGIGDMFJXJATDK-UHFFFAOYSA-N,INDOMETHACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O
454,CHEMBL95076,CGNVNXXLENQGRB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.35,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.197226274708024,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCOCC6=CC=CO6)C7=CC=CC=C7
455,CHEMBL2158773,CGPUMTTUBWGRHT-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,15.85,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.79997073344623,CC1=CC(=CC=C1)C[C@@H](C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
457,CHEMBL560386,CHCVZZOPCAVWNV-HTAPYJJXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19520574.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human histamine H1 receptor,"Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1[C@@H](OC2=C(C=CC=C2S1(=O)=O)OC)C3=CC=C(C=C3)OCCCN4CCCC4
458,CHEMBL64021,CHEGJFNZXABNBU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,380.19,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.41999931041096,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3=CC=CC(=C3)C
460,CHEMBL2037531,CHGXPKZHRZIZSQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22520153.0,Ki,=,52.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 histamine receptor by liquid scintillation assay,Benzothiazoles as probes for the 5HT(1A) receptor and the serotonin transporter (SERT): A search for new dual-acting agents as potential antidepressants.,Eur. J. Med. Chem.,PUBLICATION,,7.2839966563652006,C1CN(CCC1C2=CC=CC=C2)CCCCC(=O)C3=NC4=CC=CC=C4S3
462,CHEMBL56337,CHNUOJQWGUIOLD-NFZZJPOKSA-N,EPALRESTAT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C/C(=C\C1=CC=CC=C1)/C=C\2/C(=O)N(C(=S)S2)CC(=O)O
463,CHEMBL56337,CHNUOJQWGUIOLD-NFZZJPOKSA-N,EPALRESTAT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C/C(=C\C1=CC=CC=C1)/C=C\2/C(=O)N(C(=S)S2)CC(=O)O
464,CHEMBL241694,CHNXZKVNWQUJIB-CEGNMAFCSA-N,ETHISTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C
465,CHEMBL241694,CHNXZKVNWQUJIB-CEGNMAFCSA-N,ETHISTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C
468,CHEMBL2432039,CHZUEGVOEFMIJH-ZKRSMWHSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,=,4736.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.324588306285136,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC67C8C9C6C1C9C8C71
470,CHEMBL2146813,CIAWHNGOFJZBCL-MGBGTMOVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,17.38,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,7.7599502278873524,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@@H]3CN4C(=O)C5=C(C=NC=C5)C(=N4)CC6=CC=C(C=C6)Cl
471,CHEMBL1572,CIDUJQMULVCIBT-MQDUPKMGSA-N,NETILMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N
472,CHEMBL1572,CIDUJQMULVCIBT-MQDUPKMGSA-N,NETILMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N
473,CHEMBL79496,CIIWLVZNBDXUIV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)C(=O)C1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1
474,CHEMBL464811,CILDROBPHGWMGB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,190.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.721246399047171,C1CCN(CC1)CCCOC2=CC=C(C=C2)CN3CCN(CC3)C4=NC5=C(C=CC(=C5)Cl)NC6=CC=CC=C64
476,CHEMBL156131,CISTXXCPQIZSIS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,31622776601683.8,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.5,C1=CC=C(C=C1)C2=NC(=CS2)CCN
478,CHEMBL196,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,ASCORBATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O
479,CHEMBL196,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,ASCORBATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O
480,CHEMBL459,CJCSPKMFHVPWAR-JTQLQIEISA-N,METHYLDOPA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N
481,CHEMBL459,CJCSPKMFHVPWAR-JTQLQIEISA-N,METHYLDOPA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N
482,CHEMBL2105617,CJDRUOGAGYHKKD-FUIWMBJSSA-N,AJMALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1C2CC3C4C5(CC(C2[C@H]5O)N3C1O)C6=CC=CC=C6N4C
483,CHEMBL2105617,CJDRUOGAGYHKKD-FUIWMBJSSA-N,AJMALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1C2CC3C4C5(CC(C2[C@H]5O)N3C1O)C6=CC=CC=C6N4C
484,CHEMBL481153,CJGNMVAAMQAWEF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23707254.0,Ki,=,29.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor (unknown origin) by PDSP assay,Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.5376020021010435,C1CCN(C1)CCOC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42
485,CHEMBL73706,CJHFYNOETGOKCU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,550.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.259637310505756,C1CN(CCN1CC2=CC=C(O2)C#CCCN(C(=O)N)O)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
486,CHEMBL1767145,CJMVJEMHSLDPMO-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.501,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.300162274132754,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC(=CC=C4)F
488,CHEMBL64884,CJXQVUBYAQWRHD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,56.23,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.250031916490597,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=CN3C
491,CHEMBL157843,CKIRNALZCRYDMF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,1000000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-6.0,C1=CC=NC(=C1)CCCCCCCCCCCCN
493,CHEMBL1082723,CKLPLPZSUQEDRT-WPCRTTGESA-N,NITD609,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20813948.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human recombinant histamine H1 receptor,"Spiroindolones, a potent compound class for the treatment of malaria.",Science,PUBLICATION,,5.0,C[C@H]1CC2=C([C@]3(N1)C4=C(C=CC(=C4)Cl)NC3=O)NC5=CC(=C(C=C25)F)Cl
496,CHEMBL274767,CKMBGNSZMPWQNH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,794328234724282.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.9,C1=CC=C(C=C1)C(CCCCC2=NC=C(N2)CCN)C3=CC=CC=C3
498,CHEMBL1923528,CLEGTFPJUAEKOX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,2290.87,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.639999555020352,CNCC(CN1C2CCCCC2C3=CC=CC=C31)O
499,CHEMBL1200558,CLKOFPXJLQSYAH-ABRJDSQDSA-N,BACITRACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4
500,CHEMBL1200558,CLKOFPXJLQSYAH-ABRJDSQDSA-N,BACITRACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4
501,CHEMBL270602,CLKWUUNGQCSMKW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803203,CC1=CN=C(C=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(F)(F)F
505,CHEMBL2208432,CLQMFOOMFPNKNA-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)N3C4=CC=CC=C4NC3=O)O
506,CHEMBL3357042,CLTMMUQENFHOIL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,289.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,6.539102157243452,CC(C)CC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
507,CHEMBL1515611,CMCCHHWTTBEZNM-UHFFFAOYSA-N,BROMISOVALUM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(C(=O)NC(=O)N)Br
508,CHEMBL1515611,CMCCHHWTTBEZNM-UHFFFAOYSA-N,BROMISOVALUM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(C(=O)NC(=O)N)Br
509,CHEMBL88,CMSMOCZEIVJLDB-UHFFFAOYSA-N,CYCLOPHOSPHAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CNP(=O)(OC1)N(CCCl)CCCl
510,CHEMBL88,CMSMOCZEIVJLDB-UHFFFAOYSA-N,CYCLOPHOSPHAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CNP(=O)(OC1)N(CCCl)CCCl
511,CHEMBL154,CMWTZPSULFXXJA-VIFPVBQESA-N,NAPROXEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O
512,CHEMBL154,CMWTZPSULFXXJA-VIFPVBQESA-N,NAPROXEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O
515,CHEMBL2432047,CNPQMMDLXZBMLB-KPCGFGSOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC6=CN=CC=C6
517,CHEMBL270239,COKSKIXACCXTRS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCC(C)N4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C
518,CHEMBL820,COVZYZSDYWQREU-UHFFFAOYSA-N,BUSULFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)OCCCCOS(=O)(=O)C
519,CHEMBL820,COVZYZSDYWQREU-UHFFFAOYSA-N,BUSULFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)OCCCCOS(=O)(=O)C
520,CHEMBL478617,CPDKHEPGGZULPR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,635.4,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.196952789508871,C1CC2CC(CC1N2CCCC(=O)C3=CC=C(C=C3)F)(C4=CC=CC=C4)O
521,CHEMBL1454946,CPEUVMUXAHMANV-UHFFFAOYSA-N,FLUBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(C=C3)F
522,CHEMBL1454946,CPEUVMUXAHMANV-UHFFFAOYSA-N,FLUBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(C=C3)F
523,CHEMBL16073,CPJSUEIXXCENMM-UHFFFAOYSA-N,PHENACETIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=CC=C(C=C1)NC(=O)C
524,CHEMBL16073,CPJSUEIXXCENMM-UHFFFAOYSA-N,PHENACETIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=CC=C(C=C1)NC(=O)C
526,CHEMBL2432051,CPLYGLAQLNAQOI-SEDVZXITSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,=,5569.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.254222782110241,COC1=CC(=CC(=C1OC)OC)CN[C@H]2C3C4CC5C2C6C3CC4C56
527,CHEMBL404956,CPNTXNSOEZESIH-QZTJIDSGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18387300.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC1=C(C=CC(=C1)F)O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3
531,CHEMBL1321,CPTBDICYNRMXFX-UHFFFAOYSA-N,PROCARBAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC(=O)C1=CC=C(C=C1)CNNC
532,CHEMBL1321,CPTBDICYNRMXFX-UHFFFAOYSA-N,PROCARBAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC(=O)C1=CC=C(C=C1)CNNC
533,CHEMBL82714,CQGTWGRGLDAJSE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,1.66,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.779891911959945,CC1(CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1)CN(C)C
534,CHEMBL82714,CQGTWGRGLDAJSE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,61.66,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.209996479609511,CC1(CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1)CN(C)C
535,CHEMBL510139,CQIUKKVOEOPUDV-IYSWYEEDSA-N,CITRININ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H](OC=C2C1=C(C(=C(C2=O)C(=O)O)O)C)C
536,CHEMBL510139,CQIUKKVOEOPUDV-IYSWYEEDSA-N,CITRININ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H](OC=C2C1=C(C(=C(C2=O)C(=O)O)O)C)C
538,CHEMBL310018,CQJJYGDKIDMYJM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,676.08,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.170001911302621,CN(C)CCCC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1
539,CHEMBL1210154,CQUWKHKELQQYRI-KGENOOAVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20591666.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in HEK293 cells,A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C/C(=N\OC(=O)NC1=CC=CC=C1)/C2=CC=CC(=C2)C3=CC=CS3
540,CHEMBL102416,CRGOWMIZBWIMTB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,575.44,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2399999527072705,C1CN(CCC1O)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
542,CHEMBL486963,CSAKAHRWRJLYBQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,2900.0,NM,,,,,,,,,,,,,,,,,,,,5.5376020021010435,C1=CC=C(C=C1)CCCCC(=O)NC(=NCCCC2=CN=CN2)N
544,CHEMBL2171024,CSSKAGWIWQOQME-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,125.89,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455316,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC(=CC=C4)C(=O)O
545,CHEMBL1289,CTETYYAZBPJBHE-UHFFFAOYSA-N,HALOPROGIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=CC(=C1Cl)Cl)Cl)OCC#CI
546,CHEMBL1289,CTETYYAZBPJBHE-UHFFFAOYSA-N,HALOPROGIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=CC(=C1Cl)Cl)Cl)OCC#CI
547,CHEMBL94726,CTPOZVITFCJCLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.59,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.18111458540599,COC1=C(C(=C(C=C1)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC8=C(C=C7)OCO8)OC)OC
549,CHEMBL1068,CTRLABGOLIVAIY-UHFFFAOYSA-N,OXCARBAZEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N
550,CHEMBL1068,CTRLABGOLIVAIY-UHFFFAOYSA-N,OXCARBAZEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N
551,CHEMBL2158824,CUIDNQSCWXAPRS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755866,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=C(C=C4)C(=O)O
552,CHEMBL2205822,CUIQKJJPRAKRJM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCCC7=CC(=CC=C7)F)O
553,CHEMBL318369,CUKBOHPSSFJJFQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.02,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.220403508742175,CCOC(=O)CCCN1C2=CC=CC=C2N=C1C(=O)C3CCN(CC3)CCC4(CCN(C4)C(=O)C5=CC(=C(C(=C5)OC)OC)OC)C6=CC(=C(C=C6)Cl)Cl
556,CHEMBL1123,CURUTKGFNZGFSE-UHFFFAOYSA-N,DICYCLOMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2
557,CHEMBL1123,CURUTKGFNZGFSE-UHFFFAOYSA-N,DICYCLOMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2
558,CHEMBL444353,CVHQTOGEHBNYHC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771458.0,Ki,=,12.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for H1 histamine receptor expressed in CHO cells,"Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines.",J. Med. Chem.,PUBLICATION,,7.920818753952375,CN1C=CC2=C1C(=O)CN3C=CN=C3C2=C4CCNCC4
559,CHEMBL278462,CVKJAXCQPFOAIN-VXGBXAGGSA-N,CIPRALISANT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15608078.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(C)(C)CCC#C[C@@H]1C[C@H]1C2=CN=CN2
561,CHEMBL256653,CVPRWHZDWBRVGS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3981.07,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,CC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CN=CC=C5
562,CHEMBL550818,CVUXESFCUHCXHB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,3.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.4089353929735,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
563,CHEMBL550818,CVUXESFCUHCXHB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20347297.0,Ki,=,3.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.4089353929735,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
564,CHEMBL550818,CVUXESFCUHCXHB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,3.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.4089353929735,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
566,CHEMBL2030631,CWEGCQIIDCZZED-UHFFFAOYSA-N,N-BENZYLPYRROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CC2=CC=CC=C2
567,CHEMBL64334,CWMROIPYLYIONF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,660.69,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.180002266489224,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)CCCC
568,CHEMBL2158781,CWXOTCCLEKNUJY-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,158.49,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593398,CC1=C(C=CC(=C1)F)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=C(C=C4)F)C(=O)O
569,CHEMBL1231530,CWXYHOHYCJXYFQ-UHFFFAOYSA-N,BETAMIPRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)NCCC(=O)O
570,CHEMBL1231530,CWXYHOHYCJXYFQ-UHFFFAOYSA-N,BETAMIPRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)NCCC(=O)O
572,CHEMBL1276948,CXDSZAINFKAKPN-AKRCKQFNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,6.31,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,8.199970640755867,C1C[C@@]2(CC1N3CC(C3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25
573,CHEMBL239510,CXJWCTREHRSRNG-BDQAORGHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C[C@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.C(=O)O
574,CHEMBL239080,CXJWCTREHRSRNG-VEIFNGETSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.C(=O)O
575,CHEMBL16,CXOFVDLJLONNDW-UHFFFAOYSA-N,PHENYTOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3
576,CHEMBL16,CXOFVDLJLONNDW-UHFFFAOYSA-N,PHENYTOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3
577,CHEMBL210578,CXQUOFVDYCOSEZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16621538.0,Ki,=,8780.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor by radioligand binding assay,"Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.056505484093897,C1CC2CC(CC1N2CCCC(=O)C3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O
578,CHEMBL210578,CXQUOFVDYCOSEZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,8780.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,5.056505484093897,C1CC2CC(CC1N2CCCC(=O)C3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O
579,CHEMBL210578,CXQUOFVDYCOSEZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,8780.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.056505484093897,C1CC2CC(CC1N2CCCC(=O)C3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O
580,CHEMBL271702,CXSFVUWINAYILW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=CN=C(C=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)C(=NO5)C
581,CHEMBL1201024,CXYRUNPLKGGUJF-XKTSLVMZSA-M,METHSCOPOLAMINE BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1([C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-]
582,CHEMBL1201024,CXYRUNPLKGGUJF-XKTSLVMZSA-M,METHSCOPOLAMINE BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1([C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-]
583,CHEMBL2171014,CYAXTHULEFHIMG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C3CCN(CC3)C(=O)NS(=O)(=O)C4=CC=C(C=C4)N(C)C)Cl
584,CHEMBL404520,CYDMQBQPVICBEU-XRNKAMNCSA-N,CHLORTETRACYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)N)N(C)C)O
585,CHEMBL404520,CYDMQBQPVICBEU-XRNKAMNCSA-N,CHLORTETRACYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)N)N(C)C)O
587,CHEMBL75880,CYXKNKQEMFBLER-UHFFFAOYSA-N,PERHEXILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3
588,CHEMBL75880,CYXKNKQEMFBLER-UHFFFAOYSA-N,PERHEXILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3
590,CHEMBL1783961,CZCOISNXSIJAAK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,650.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.187086643357144,CN1CCC2=C(C1)C3=C(N2CCC4=CN=CC=C4)C=CC(=C3)F
591,CHEMBL1783961,CZCOISNXSIJAAK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,930.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.031517051446065,CN1CCC2=C(C1)C3=C(N2CCC4=CN=CC=C4)C=CC(=C3)F
592,CHEMBL311469,CZIHNRWJTSTCEX-UHFFFAOYSA-N,2-ACETYLAMINOFLUORENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2
593,CHEMBL311469,CZIHNRWJTSTCEX-UHFFFAOYSA-N,2-ACETYLAMINOFLUORENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2
594,CHEMBL98350,CZQHHVNHHHRRDU-UHFFFAOYSA-N,LY-294002,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
595,CHEMBL98350,CZQHHVNHHHRRDU-UHFFFAOYSA-N,LY-294002,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4
596,CHEMBL1092600,CZXWYWSRENNIBD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,11.9,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.924453038607469,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)CC3=NC=CN=C3
597,CHEMBL1277125,DADRXTGBZRBZMD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,100.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.0,C1CN(CC(=C1)C(=O)O)C2CCC3(C2)CC4=CC=CC=C4OC5=CC=CC=C35
598,CHEMBL241329,DARWEDNPGILOPQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18020391.0,Ki,=,270.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling.,J. Med. Chem.,PUBLICATION,,6.568636235841013,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC(=O)C3=CN=CC(=C3)C)Cl
601,CHEMBL897,DBABZHXKTCFAPX-UHFFFAOYSA-N,PROBENECID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O
602,CHEMBL897,DBABZHXKTCFAPX-UHFFFAOYSA-N,PROBENECID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O
603,CHEMBL710,DBEPLOCGEIEOCV-WSBQPABSSA-N,FINASTERIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C
604,CHEMBL710,DBEPLOCGEIEOCV-WSBQPABSSA-N,FINASTERIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C
605,CHEMBL1277217,DBFNYFZBHMQFLI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,158.49,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.799998134593398,C1CC2(CC1N3CCC(CC3)(C(=O)O)F)CC4=CC=CC=C4OC5=CC=CC=C25
606,CHEMBL248702,DBGIVFWFUFKIQN-VIFPVBQESA-N,DEXFENFLURAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
607,CHEMBL248702,DBGIVFWFUFKIQN-VIFPVBQESA-N,DEXFENFLURAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F
608,CHEMBL1062,DBPWSSGDRRHUNT-CEGNMAFCSA-N,HYDROXYPROGESTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O
609,CHEMBL1062,DBPWSSGDRRHUNT-CEGNMAFCSA-N,HYDROXYPROGESTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O
610,CHEMBL871,DBVJJBKOTRCVKF-UHFFFAOYSA-N,ETIDRONIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(O)(P(=O)(O)O)P(=O)(O)O
611,CHEMBL871,DBVJJBKOTRCVKF-UHFFFAOYSA-N,ETIDRONIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(O)(P(=O)(O)O)P(=O)(O)O
615,CHEMBL1767140,DCGYGKIBQOAKTB-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.316,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.500312917381596,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)F
616,CHEMBL139,DCOPUUMXTXDBNB-UHFFFAOYSA-N,DICLOFENAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl
617,CHEMBL139,DCOPUUMXTXDBNB-UHFFFAOYSA-N,DICLOFENAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl
618,CHEMBL2158817,DCPIUFZZSDRFTC-AJZOCDQUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,19.95,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@H]3CN(CCO3)C(C4=CC=CC=C4)C(=O)O
619,CHEMBL2158818,DCPIUFZZSDRFTC-PPUHSXQSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H]3CN(CCO3)C(C4=CC=CC=C4)C(=O)O
620,CHEMBL105669,DCSHODGQAYSURK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,27.54,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.560036064079095,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=C(C=C(C=C3)C#N)C
621,CHEMBL1729,DCSUBABJRXZOMT-UHFFFAOYSA-N,CISAPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F
622,CHEMBL1729,DCSUBABJRXZOMT-UHFFFAOYSA-N,CISAPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F
623,CHEMBL40,DDBREPKUVSBGFI-UHFFFAOYSA-N,PHENOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
624,CHEMBL40,DDBREPKUVSBGFI-UHFFFAOYSA-N,PHENOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
625,CHEMBL476323,DDDZBLNULGDPGA-UHFFFAOYSA-N,MK-0249,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18598020.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human histamine H1 receptor,"Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.",J. Med. Chem.,PUBLICATION,,5.0,CC1=NC2=CC=CC(=C2C(=O)N1C3=CC=C(C=C3)OCCCN4CCCC4)C(F)(F)F
626,CHEMBL558467,DDHSIUUOIYFUOU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,1.8,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.744727494896694,CN(C)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
627,CHEMBL2367892,DDTDNCYHLGRFBM-YZEKDTGTSA-N,TEICOPLANIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N[C@H]1[C@H]([C@@H]([C@@H](O[C@H]1O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O[C@@H]5[C@H]([C@@H]([C@@H]([C@H](O5)CO)O)O)O)C6=C(C=CC(=C6)[C@H](C(=O)N3)NC(=O)[C@H]7C8=CC(=C(C(=C8)OC9=C(C=C2C=C9)Cl)O[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)CO)O)O)NC(=O)C)OC1=C(C=C(C[C@@H]2C(=O)N[C@@H](C3=CC(=CC(=C3)OC3=C(C=CC(=C3)[C@H](C(=O)N2)N)O)O)C(=O)N7)C=C1)Cl)O)C(=O)O)CO)O)O
628,CHEMBL2367892,DDTDNCYHLGRFBM-YZEKDTGTSA-N,TEICOPLANIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N[C@H]1[C@H]([C@@H]([C@@H](O[C@H]1O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O[C@@H]5[C@H]([C@@H]([C@@H]([C@H](O5)CO)O)O)O)C6=C(C=CC(=C6)[C@H](C(=O)N3)NC(=O)[C@H]7C8=CC(=C(C(=C8)OC9=C(C=C2C=C9)Cl)O[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)CO)O)O)NC(=O)C)OC1=C(C=C(C[C@@H]2C(=O)N[C@@H](C3=CC(=CC(=C3)OC3=C(C=CC(=C3)[C@H](C(=O)N2)N)O)O)C(=O)N7)C=C1)Cl)O)C(=O)O)CO)O)O
629,CHEMBL562,DDUHZTYCFQRHIY-RBHXEPJQSA-N,GRISEOFULVIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC
630,CHEMBL562,DDUHZTYCFQRHIY-RBHXEPJQSA-N,GRISEOFULVIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC
634,CHEMBL3350037,DEQANNDTNATYII-JDBXKHNRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@@H](CO)[C@@H](C)O)O
635,CHEMBL3350037,DEQANNDTNATYII-JDBXKHNRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@@H](CO)[C@@H](C)O)O
636,CHEMBL43064,DERZBLKQOCDDDZ-JLHYYAGUSA-N,CINNARIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,74.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.130768280269024,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4
637,CHEMBL43064,DERZBLKQOCDDDZ-JLHYYAGUSA-N,CINNARIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,8.62,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.064492734175287,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4
638,CHEMBL1923522,DFBFDRZHAVAEKE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,61.66,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,7.209996479609511,CN1CCN(CC1)C2=NC3=C(C=NN3C)C(=N2)N4CCCC4
639,CHEMBL1923522,DFBFDRZHAVAEKE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,62.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,7.2076083105017466,CN1CCN(CC1)C2=NC3=C(C=NN3C)C(=N2)N4CCCC4
640,CHEMBL1873703,DFBKLUNHFCTMDC-PICURKEMSA-N,DIELDRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl
641,CHEMBL1873703,DFBKLUNHFCTMDC-PICURKEMSA-N,DIELDRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl
642,CHEMBL460402,DFBYKWKCUIKCPG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,686.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.163675884293248,CN(CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31)C(=O)C4=CC=C(C=C4)OCCCN5CCCCC5
643,CHEMBL1935436,DFNGZIPWXHTTPA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,C1CC(CN(C1)CCO)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
644,CHEMBL2178582,DFOFEBXXZMVAGG-MZJWZYIUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22931505.0,Ki,=,20.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Chemokine receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.698970004336019,C1CC(CN(C1)C/C=C/2\C3=CC=CC=C3COC4=C2C=C(C=C4)CC(=O)O)CC5=CC=CC=C5
645,CHEMBL1140,DFPAKSUCGFBDDF-UHFFFAOYSA-N,NIACINAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)C(=O)N
646,CHEMBL1140,DFPAKSUCGFBDDF-UHFFFAOYSA-N,NIACINAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)C(=O)N
647,CHEMBL451821,DFTFGLPAHCOAEP-TVSVWYSMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18683917.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor,The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.0,C[C@H]1[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)N(C)C(=O)[C@@H](C(C)C)NC)C)CN1C
648,CHEMBL540634,DFUGESMXMUMLJG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)Cl.Cl
649,CHEMBL452,DGBIGWXXNGSACT-UHFFFAOYSA-N,CLONAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl
650,CHEMBL452,DGBIGWXXNGSACT-UHFFFAOYSA-N,CLONAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl
652,CHEMBL425358,DGLAILDSPYOZLT-GDLZYMKVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,305.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.515700160653214,C1CN(CCN1CCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl
653,CHEMBL316561,DGMKFQYCZXERLX-UHFFFAOYSA-N,PROGLUMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1
654,CHEMBL316561,DGMKFQYCZXERLX-UHFFFAOYSA-N,PROGLUMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1
655,CHEMBL1783890,DGWKVXVCPCPOAK-UHFFFAOYSA-N,GSK207040,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24269482.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803203,CNC(=O)C1=CN=C(C=N1)OC2=CC3=C(CCN(CC3)C4CCC4)C=C2
657,CHEMBL2146812,DGZLHXBKGBELTQ-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,1.29,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,8.88941028970075,CN1CCC[C@@H]1CN2C(=O)C3=NC=CN=C3C(=N2)CC4=CC=C(C=C4)Cl
658,CHEMBL287052,DHGUFKPZDMQBED-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,1780.0,NM,,,,,,,,,,,,,,,,,,,,5.749579997691106,C1=CC(=CC(=C1)Cl)C2=NC=C(N2)CCN
660,CHEMBL287052,DHGUFKPZDMQBED-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1995.26,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1=CC(=CC(=C1)Cl)C2=NC=C(N2)CCN
661,CHEMBL287052,DHGUFKPZDMQBED-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,158489319246111.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.199999999999999,C1=CC(=CC(=C1)Cl)C2=NC=C(N2)CCN
662,CHEMBL1078642,DHHDEHNHEBYRPQ-UHFFFAOYSA-N,UR-PI376,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19791743.0,Ki,=,25703.96,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells,Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.,J. Med. Chem.,PUBLICATION,,4.589999963296594,C1=CC=C(C=C1)SCCNC(=NCCCCC2=CN=CN2)NC#N
667,CHEMBL773,DHMQDGOQFOQNFH-UHFFFAOYSA-N,GLYCINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)N
668,CHEMBL773,DHMQDGOQFOQNFH-UHFFFAOYSA-N,GLYCINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)N
669,CHEMBL2205821,DHQYUPWRESNGBC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCCC7=CC=CC=C7)O
670,CHEMBL48449,DHZBEENLJMYSHQ-XCVPVQRUSA-N,CANTHARIDIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)OC2=O)C)O3
671,CHEMBL48449,DHZBEENLJMYSHQ-XCVPVQRUSA-N,CANTHARIDIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)OC2=O)C)O3
673,CHEMBL571390,DIADJINIBFEMEL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,16.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.795880017344075,CC1=CC=C(C=C1)CN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
674,CHEMBL1783959,DICDOOGFHQRKKL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,100.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CN1CCC2=C(C1)C3=CC=CC=C3N2CCC4=CN=CC=C4
675,CHEMBL1783959,DICDOOGFHQRKKL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,410.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3872161432802645,CN1CCC2=C(C1)C3=CC=CC=C3N2CCC4=CN=CC=C4
676,CHEMBL102840,DIEXZKWJXAPYGJ-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,14000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NS(=O)(=O)C3=CC=C(C=C3)C#N
677,CHEMBL95051,DIPBPGRFGZKMEF-UHFFFAOYSA-N,MDL-28163,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,IC50,=,59.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,7.229147988357856,COC1=CC=C(C=C1)CCN2CCC(CC2)C(=O)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
678,CHEMBL95051,DIPBPGRFGZKMEF-UHFFFAOYSA-N,MDL-28163,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,7.23,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.14086170270547,COC1=CC=C(C=C1)CCN2CCC(CC2)C(=O)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
679,CHEMBL95051,DIPBPGRFGZKMEF-UHFFFAOYSA-N,MDL-28163,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,59.0,NM,,,,,,,,,,,,,,,Compound was evaluated for the antagonistic activity against H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.229147988357856,COC1=CC=C(C=C1)CCN2CCC(CC2)C(=O)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
680,CHEMBL240393,DIQMIXLXBUWZKA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,3162.28,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.499999678657065,CS(=O)(=O)C1=CC=CC(=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OCCCN4CCCCC4.C(=O)O
681,CHEMBL580,DIWRORZWFLOCLC-UHFFFAOYSA-N,LORAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl
682,CHEMBL580,DIWRORZWFLOCLC-UHFFFAOYSA-N,LORAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl
684,CHEMBL2208430,DIXSEWSBXAEKKY-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.50003813440381,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC4=CC=CC=C43)O
685,CHEMBL487894,DJGAAPFSPWAYTJ-UHFFFAOYSA-M,DIPYRONE SODIUM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].[Na+]
686,CHEMBL487894,DJGAAPFSPWAYTJ-UHFFFAOYSA-M,DIPYRONE SODIUM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].[Na+]
687,CHEMBL2171016,DJGWTFPDOGEBKS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934842,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C3CCN(CC3)S(=O)(=O)NC(=O)C4=CC=CC=C4)Cl
688,CHEMBL273165,DJHAFQLSNXBKIX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCC(C)N4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C
689,CHEMBL1093058,DJILKXZJMQURGL-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,4.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.356547323513812,C[C@H](C1=C(SC2=CC=CC=C21)CCN(C)C)N3C=CC=N3
692,CHEMBL519240,DJKJVWJQAVGLHJ-YPMHNXCESA-N,A-987306,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18983139.0,Ki,=,3548.13,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.",J. Med. Chem.,PUBLICATION,,5.450000476425332,C1CC[C@H]2[C@@H](C1)C3=C(O2)CCC4=C3N=C(N=C4N5CCNCC5)N
693,CHEMBL331603,DJUHRAPXNFPKDW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,171.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,6.767003889607846,CCCC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
694,CHEMBL267930,DKGZKTPJOSAWFA-UHFFFAOYSA-N,SPIPERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,476.19,NM,,,,,,,,,,,,,,,,,,,,6.322219729028618,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F
695,CHEMBL267930,DKGZKTPJOSAWFA-UHFFFAOYSA-N,SPIPERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,480.0,NM,,,,,,,,,,,,,,,,,,,,6.318758762624412,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F
696,CHEMBL1531134,DKMFBWQBDIGMHM-UHFFFAOYSA-N,MELPERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,580.0,NM,,,,,,,,,,,,,,,,,,,,6.236572006437063,CC1CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F
697,CHEMBL660,DKNWSYNQZKUICI-UHFFFAOYSA-N,AMANTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C2CC3CC1CC(C2)(C3)N
698,CHEMBL660,DKNWSYNQZKUICI-UHFFFAOYSA-N,AMANTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C2CC3CC1CC(C2)(C3)N
699,CHEMBL321320,DKTSZKSSVLOHMC-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,3600.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,C1CN(C[C@H]1NS(=O)(=O)C2=CC(=CC=C2)Cl)CCCOC3=CC=C(C=C3)C(=O)C4CC4
700,CHEMBL2158830,DKVGJRLHFIQFEM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,39.81,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415902,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=C(C=C4)OCC(=O)O
701,CHEMBL75435,DKYWVDODHFEZIM-NSHDSACASA-N,DEXKETOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
702,CHEMBL75435,DKYWVDODHFEZIM-NSHDSACASA-N,DEXKETOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
703,CHEMBL571,DKYWVDODHFEZIM-UHFFFAOYSA-N,KETOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
704,CHEMBL571,DKYWVDODHFEZIM-UHFFFAOYSA-N,KETOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O
705,CHEMBL1909050,DLDAZIVPAOLETE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3
706,CHEMBL1909050,DLDAZIVPAOLETE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3
707,CHEMBL513,DLGOEMSEDOSKAD-UHFFFAOYSA-N,CARMUSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCl)NC(=O)N(CCCl)N=O
708,CHEMBL513,DLGOEMSEDOSKAD-UHFFFAOYSA-N,CARMUSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCl)NC(=O)N(CCCl)N=O
709,CHEMBL1915535,DLKAQKCVCFAVIS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21955944.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C)(C)CCNC1=CC(=NC=N1)N2CCN(CC2)C
710,CHEMBL288772,DLMPCEBSXNLTAT-XMMPIXPASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,398.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.400116927926312,CC1=C([C@H](CC(=O)N1C)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)C4=C(C=C(C=C4)F)C#N
711,CHEMBL2207664,DLONTNINHYMHFB-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,10.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C=C3C(F)(F)F)O)Cl
712,CHEMBL3233432,DLXKEWOEEPMPHX-PMACEKPBSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24559051.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,J. Med. Chem.,PUBLICATION,,,C1CN(C[C@@H]2[C@H]1N3CCOC4=CC=CC2=C43)CCCC(=O)C5=CC=C(C=C5)F
716,CHEMBL127,DMJNNHOOLUXYBV-PQTSNVLCSA-N,MEROPENEM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O
717,CHEMBL127,DMJNNHOOLUXYBV-PQTSNVLCSA-N,MEROPENEM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O
719,CHEMBL1774494,DMMAFYCLHWGPBF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,128.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.892790030352131,CC(C1=CC2=C(C=C1)OCC3=CC=CC=C3N2CCCN4CCCN(CC4)C5=CC(=O)N(C(=O)N5C)C)C(=O)O
720,CHEMBL434684,DMQAXIJUTYJHIV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,28.84,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.540004743952609,CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CN(C)C
721,CHEMBL2158831,DMQWGZFKPDYZCH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755866,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)CC4=CC=CC=C4C(=O)O
724,CHEMBL286398,DNIAPMSPPWPWGF-UHFFFAOYSA-N,PROPYLENE GLYCOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CO)O
725,CHEMBL286398,DNIAPMSPPWPWGF-UHFFFAOYSA-N,PROPYLENE GLYCOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CO)O
726,CHEMBL570695,DNIULMBWQYTFJT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,155.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.809668301829708,CC1=CC=C(C=C1)CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
728,CHEMBL1200709,DNTGGZPQPQTDQF-XBXARRHUSA-N,CROTAMITON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(C1=CC=CC=C1C)C(=O)/C=C/C
729,CHEMBL1200709,DNTGGZPQPQTDQF-XBXARRHUSA-N,CROTAMITON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(C1=CC=CC=C1C)C(=O)/C=C/C
730,CHEMBL1405,DNXHEGUUPJUMQT-CBZIJGRNSA-N,ESTRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O
731,CHEMBL1405,DNXHEGUUPJUMQT-CBZIJGRNSA-N,ESTRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O
732,CHEMBL1466,DOBMPNYZJYQDGZ-UHFFFAOYSA-N,DICUMAROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O
733,CHEMBL1466,DOBMPNYZJYQDGZ-UHFFFAOYSA-N,DICUMAROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O
734,CHEMBL822,DOMXUEMWDBAQBQ-WEVVVXLNSA-N,TERBINAFINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21
735,CHEMBL822,DOMXUEMWDBAQBQ-WEVVVXLNSA-N,TERBINAFINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21
737,CHEMBL271083,DOTHXJXYLNKQOQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)C(C(F)(F)F)(F)F
739,CHEMBL1282,DOUYETYNHWVLEO-UHFFFAOYSA-N,IMIQUIMOD,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
740,CHEMBL1282,DOUYETYNHWVLEO-UHFFFAOYSA-N,IMIQUIMOD,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
743,CHEMBL74779,DOXXMQHNZRHZPH-RPBOFIJWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,660.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.180456064458132,C1C[C@H](O[C@@H]1CN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C#CCCN(C(=O)N)O
745,CHEMBL2208436,DPJWTHMHDTUYEX-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,501.19,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,C1CN(CCC1NC[C@@H](COC2=CC=CC(=C2)C#N)O)CC3=CC(=C(C=C3)Cl)Cl
747,CHEMBL83220,DQAMCNMFLLPWQR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1)C(=O)C(F)(F)F
748,CHEMBL19019,DQCKKXVULJGBQN-XFWGSAIBSA-N,NALTREXONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O
749,CHEMBL19019,DQCKKXVULJGBQN-XFWGSAIBSA-N,NALTREXONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O
750,CHEMBL1198,DQKXQSGTHWVTAD-UHFFFAOYSA-N,PRAMOXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC1=CC=C(C=C1)OCCCN2CCOCC2
751,CHEMBL1198,DQKXQSGTHWVTAD-UHFFFAOYSA-N,PRAMOXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC1=CC=C(C=C1)OCCCN2CCOCC2
752,CHEMBL856,DQMZLTXERSFNPB-UHFFFAOYSA-N,PRIMIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2
753,CHEMBL856,DQMZLTXERSFNPB-UHFFFAOYSA-N,PRIMIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2
755,CHEMBL63002,DRCFWAFIBAFOCV-RUZDIDTESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,4365.16,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.359999833093897,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CC5=CC=CC=C5S4)N
756,CHEMBL2207278,DREBLEJJYUKNLT-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,7.94,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC(=C4)F)O
759,CHEMBL45,DRLFMBDRBRZALE-UHFFFAOYSA-N,MELATONIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC
760,CHEMBL45,DRLFMBDRBRZALE-UHFFFAOYSA-N,MELATONIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC
761,CHEMBL1557680,DRQJSDYVORTCEY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15798001.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCC(=O)N1C(CC(C2=CC=CC=C21)N(C3=CC=CC=C3)C(=O)C)C
764,CHEMBL434001,DSKGOKHOBPYUEE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,5370.32,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.269999835325842,C1CN(CCN1CCO)C2=NC=NC3=C2OC4=CC=CC=C43
766,CHEMBL517407,DSRXHDAICZGTCK-ORBVJSQLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,295.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.530177984021837,CN(CC/C=C/1\C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)CC4=CC=C(C=C4)OCCCN5CCCCC5
767,CHEMBL2252949,DSSYKIVIOFKYAU-OIBJUYFYSA-N,(-)-CAMPHOR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C1(C)C)CC2=O
768,CHEMBL2252949,DSSYKIVIOFKYAU-OIBJUYFYSA-N,(-)-CAMPHOR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C1(C)C)CC2=O
769,CHEMBL504760,DSSYKIVIOFKYAU-XCBNKYQSSA-N,CAMPHOR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12CC[C@@H](C1(C)C)CC2=O
770,CHEMBL504760,DSSYKIVIOFKYAU-XCBNKYQSSA-N,CAMPHOR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12CC[C@@H](C1(C)C)CC2=O
771,CHEMBL1083162,DTGZGHPOXFQXNP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20452213.0,EC50,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in human SK-N-MC cells,Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=CC(=C1)OCCCNCCC2=CN=CN2)C3=NC4=C(N3)C=CC(=C4C)F
772,CHEMBL1092598,DTQWVENQVGQFAP-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,0.8,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.096910013008056,C[C@H](C1=C(CC2=CC=CC=C21)CCN(C)C)C3=NC=CS3
773,CHEMBL238870,DTTUPIQCRQKVGO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CCCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O
774,CHEMBL96467,DTYAFBJXWWLRMA-QMHKHESXSA-N,SNAP-7915,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10956183.0,Ki,=,54.0,NM,,,,,,,,,,,,,,,"Binding affinity towards Histamine H1 receptor in human brain tissue preparation, using [3H]rauwolscine as radioligand.",De novo design of a novel oxazolidinone analogue as a potent and selective alpha1A adrenergic receptor antagonist with high oral bioavailability.,J. Med. Chem.,PUBLICATION,,7.267606240177032,C[C@H]1[C@@H](N(C(=O)O1)C(=O)NCCCN2CCC(CC2)C3=CC=C(C=C3)F)C4=CC(=C(C=C4)F)F
775,CHEMBL2207285,DTYDZUZTWZDAGL-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,5.01,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,C1CC1NS(=O)(=O)C2=CC3=C(C=C2)C(=CNC3=O)C(=O)NC[C@H](CN4CCC(CC4)OC5=CC(=C(C=C5)Cl)Cl)O
776,CHEMBL3357049,DUCSQMQJPSZEAW-JOCHJYFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,4647.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,5.332827327521132,CC(C)C[C@H](C(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1)N
777,CHEMBL137781,DUKNIHFTDAXJON-MUIJYRPGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12213075.0,Ki,=,500.0,NM,,,,,,,,,,,,,,,Binding affinity against Histamine H1 receptor,"Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).",J. Med. Chem.,PUBLICATION,,6.301029995663981,C[C@@H]1C[C@@H](N1C(=O)[C@H]2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C)C
778,CHEMBL343755,DUKNIHFTDAXJON-ORPLUIKVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12213075.0,Ki,=,2500.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor,"Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).",J. Med. Chem.,PUBLICATION,,5.6020599913279625,C[C@H]1C[C@@H](N1C(=O)[C@H]2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C)C
779,CHEMBL138989,DUKNIHFTDAXJON-RCZCSUKSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12213075.0,Ki,=,1400.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor,"Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).",J. Med. Chem.,PUBLICATION,,5.853871964321762,C[C@@H]1C[C@H](N1C(=O)[C@H]2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C)C
780,CHEMBL328187,DUTDDZFCPPOWFH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,1500.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,5.823908740944319,CN1C=C(N=N1)C2=CC3=C(C=C2)N(C=C3C4CCN(CC4)CCN5CCNC5=O)C6=CC=C(C=C6)F
781,CHEMBL1783970,DUUHEGAGOHEODE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,320.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.494850021680094,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=NC=CN=C4
782,CHEMBL1783970,DUUHEGAGOHEODE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,7940.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.100179497572904,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=NC=CN=C4
784,CHEMBL608560,DUZFRLZTNIIHKJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC(=CC=C7)F)O
785,CHEMBL608560,DUZFRLZTNIIHKJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC(=CC=C7)F)O
787,CHEMBL334255,DVBJBNKEBPCGSY-UHFFFAOYSA-M,CETYLPYRIDINIUM BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1.[Br-]
788,CHEMBL334255,DVBJBNKEBPCGSY-UHFFFAOYSA-M,CETYLPYRIDINIUM BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1.[Br-]
790,CHEMBL3104091,DVSMVUMYJDOPJQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,=,50.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,CN1CCC2=C(C1)C3=CC=CC4=C3N2C5=CC=CC=C5CC4
791,CHEMBL3104091,DVSMVUMYJDOPJQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,CN1CCC2=C(C1)C3=CC=CC4=C3N2C5=CC=CC=C5CC4
794,CHEMBL1774499,DVZWFDDQIOLGDS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,75.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.1249387366083,CC(C)(C1=CC2=C(CCC3=CC=CC=C3N2CCCN4CCCN(CC4)C5=CC(=O)N(C(=O)N5C)C)C=C1)C(=O)O
795,CHEMBL273170,DWIXBLOYUJIYNT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17998160.0,Ki,=,8.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.096910013008056,CC1C2=C(C=CC(=C2Cl)Cl)NC(=N1)N
796,CHEMBL2158815,DWNROPYUHGRJJG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755866,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(C4=CC=CC=C4)C(=O)O
797,CHEMBL1319362,DWSGTFTVBLXELC-RDYJJYPNSA-N,HOMATROPINE HYDROBROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O.Br
798,CHEMBL1319362,DWSGTFTVBLXELC-RDYJJYPNSA-N,HOMATROPINE HYDROBROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O.Br
799,CHEMBL120055,DWSOZYFSYVOVOC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Compound was tested for its affinity towards histaminergic (H 1) receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1N2CCN(CC2)C(=O)COC3=CC4=C(C=C3)NC=C4CCN
800,CHEMBL1651208,DWTYHCYVKJONSP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23009245.0,IC50,=,8150.0,NM,,,,,,,,,,,,,,,Inhibition of radioligand binding to human histamine H1 receptor,Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence.,J. Med. Chem.,PUBLICATION,,5.088842391260023,C1CCC(C1)N2CC3=C(C2=O)C=CC(=C3)OCC4=CC(=CC=C4)C5=CC(=C(C=C5)Cl)C(=O)O
803,CHEMBL272300,DXIJUOOAQKSDNE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCC(C)N4CCC5=CC6=C(C=C5CC4)C(=O)N(C6)C
804,CHEMBL340199,DXJUCAUQIHNOAF-AEFFLSMTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,122.0,NM,,,,,,,,,,,,,,,,,,,,6.913640169325252,CN(C)[C@H]1C[C@H](C2=CC=CC=C2C1)C3=CC=CC=C3
805,CHEMBL340199,DXJUCAUQIHNOAF-AEFFLSMTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,129.0,NM,,,,,,,,,,,,,,,,,,,,6.889410289700751,CN(C)[C@H]1C[C@H](C2=CC=CC=C2C1)C3=CC=CC=C3
806,CHEMBL127307,DXJUCAUQIHNOAF-SJLPKXTDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.65,NM,,,,,,,,,,,,,,,,,,,,8.782516055786093,CN(C)[C@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC=CC=C3
807,CHEMBL127307,DXJUCAUQIHNOAF-SJLPKXTDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,2.5,NM,,,,,,,,,,,,,,,,,,,,8.602059991327963,CN(C)[C@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC=CC=C3
808,CHEMBL104945,DXJUCAUQIHNOAF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,2.49,NM,,,,,,,,,,,,,,,,,,,,8.603800652904264,CN(C)C1CC(C2=CC=CC=C2C1)C3=CC=CC=C3
809,CHEMBL104945,DXJUCAUQIHNOAF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,4.26,NM,,,,,,,,,,,,,,,,,,,,8.370590400897282,CN(C)C1CC(C2=CC=CC=C2C1)C3=CC=CC=C3
810,CHEMBL104945,DXJUCAUQIHNOAF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,13.6,NM,,,,,,,,,,,,,,,,,,,,7.866461091629782,CN(C)C1CC(C2=CC=CC=C2C1)C3=CC=CC=C3
811,CHEMBL104945,DXJUCAUQIHNOAF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,14.7,NM,,,,,,,,,,,,,,,,,,,,7.8326826652518236,CN(C)C1CC(C2=CC=CC=C2C1)C3=CC=CC=C3
812,CHEMBL3402679,DXJUCAUQIHNOAF-WMZOPIPTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,29.9,NM,,,,,,,,,,,,,,,,,,,,7.52432881167557,CN(C)[C@@H]1C[C@H](C2=CC=CC=C2C1)C3=CC=CC=C3
813,CHEMBL3402679,DXJUCAUQIHNOAF-WMZOPIPTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,42.4,NM,,,,,,,,,,,,,,,,,,,,7.372634143407267,CN(C)[C@@H]1C[C@H](C2=CC=CC=C2C1)C3=CC=CC=C3
815,CHEMBL31714,DXTYGLAQRALLEG-LFYBBSHMSA-N,CP-96021,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=NC2=C(N1C3=CC=C(C=C3)OCC4=CC(=CC=C4)/C=C/C5=NC6=C(S5)C=CC(=C6)F)C=CN=C2
816,CHEMBL1767142,DXZJJDOMGLPHDI-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,398.11,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,6.399996913372259,CC(C)(C)C1=CC=C(C=C1)CC2=NN(C(=O)C3=CC=CC=C32)C[C@H]4CCCN4C
817,CHEMBL269994,DYDLMZLLICKPBG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)CCCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)C
818,CHEMBL240352,DYKCULOUGOBIOM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(C1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F
819,CHEMBL316068,DYRUSALPYKCZDY-RYLMWKJUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,1.2,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.920818753952375,CN1CCN(CC1)CC2C[C@H]3[C@H](O2)C4=CC=CC=C4SC5=CC=CC=C35
820,CHEMBL196598,DZKYLEMMURXALW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=C(C=C4)C(F)(F)F)OC
821,CHEMBL101634,DZXOBJYKYJVJJV-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,11000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.958607314841775,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)C3=CSC(=N3)C4=CN=CC=C4
822,CHEMBL850,DZZWHBIBMUVIIW-DTORHVGOSA-N,SPARFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F
823,CHEMBL850,DZZWHBIBMUVIIW-DTORHVGOSA-N,SPARFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F
824,CHEMBL182150,FAIMGWSOSCFGRU-IYBDPMFKSA-N,ATC-0175,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,CN(C)C1=NC(=NC2=CC=CC=C21)NC3CCC(CC3)NC(=O)C4=CC(=C(C=C4)F)F
825,CHEMBL1560,FAKRSMQSSFJEIM-RQJHMYQMSA-N,CAPTOPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
826,CHEMBL1560,FAKRSMQSSFJEIM-RQJHMYQMSA-N,CAPTOPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
827,CHEMBL1200600,FAOZLTXFLGPHNG-KNAQIMQKSA-N,FLUOROMETHOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O
828,CHEMBL1200600,FAOZLTXFLGPHNG-KNAQIMQKSA-N,FLUOROMETHOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O
829,CHEMBL2208416,FAPBWZUNGKHHJO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,IC50,=,5011.87,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.300000202445418,C1CC(C1)C(=O)NC2=CC=CC=C2OCC(CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl)O
830,CHEMBL1278020,FAXDKDSDNWXAIS-NASUQTAISA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.79997073344623,COC(=O)C1=CCCN(C1)C2CC[C@@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35
831,CHEMBL418658,FAZLRTUIRXGMGN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,724.44,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.139997578098902,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CN=CC=C3
832,CHEMBL196370,FBDANPRMCCLYRK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=CC=C4OC)OC
833,CHEMBL457957,FBGLPECKCFZJFU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,559.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.252588192113577,CN(CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31)C(=O)CC4=CC=C(C=C4)OCCCN5CCCCC5
834,CHEMBL34259,FBOZXECLQNJBKD-ZDUSSCGKSA-N,METHOTREXATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
835,CHEMBL34259,FBOZXECLQNJBKD-ZDUSSCGKSA-N,METHOTREXATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
836,CHEMBL689,FBPFZTCFMRRESA-KVTDHHQDSA-N,MANNITOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O
837,CHEMBL689,FBPFZTCFMRRESA-KVTDHHQDSA-N,MANNITOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O
838,CHEMBL606036,FCDNLGMRDAOTCR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,98.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.008773924307505,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=C(C=C4)C(F)(F)F
839,CHEMBL160933,FCRIMCQUUZFBDN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,25.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,7.6020599913279625,CN(C)CC1C2=CC=CC=C2CC3=CC=CC=C13
840,CHEMBL563271,FDBNTQCFINBNNL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,88.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.055517327849832,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)OCC(=O)O
841,CHEMBL21,FDDDEECHVMSUSB-UHFFFAOYSA-N,SULFANILAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1N)S(=O)(=O)N
842,CHEMBL21,FDDDEECHVMSUSB-UHFFFAOYSA-N,SULFANILAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1N)S(=O)(=O)N
843,CHEMBL476,FDKXTQMXEQVLRF-ZHACJKMWSA-N,DACARBAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)/N=N/C1=C(NC=N1)C(=O)N
844,CHEMBL476,FDKXTQMXEQVLRF-ZHACJKMWSA-N,DACARBAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)/N=N/C1=C(NC=N1)C(=O)N
845,CHEMBL1078745,FDVIZOQPGHRQNB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,3600.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,CCOC1=CC(=CC(=C1)CN2CCC(CC2)NC3=NC4=CC=CC=C4O3)OC5CCOCC5
846,CHEMBL62596,FDVYBGCVXDDGND-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)[C@@H]4CC(=O)N4
847,CHEMBL423666,FDVYBGCVXDDGND-SFHVURJKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,21877.62,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.659999925349902,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)[C@H]4CC(=O)N4
848,CHEMBL989,FEBLZLNTKCEFIT-VSXGLTOVSA-N,FLUOCINOLONE ACETONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O
849,CHEMBL989,FEBLZLNTKCEFIT-VSXGLTOVSA-N,FLUOCINOLONE ACETONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O
851,CHEMBL1774490,FEHNLVPCVHLEHQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,140.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.853871964321762,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCN3C4=CC=CC=C4COC5=C3C=C(C=C5)C(=O)O
852,CHEMBL2207276,FEIOPVQTLJUJBR-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450609,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC(=C4)S(=O)(=O)C)O
854,CHEMBL46,FELGMEQIXOGIFQ-UHFFFAOYSA-N,ONDANSETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C
855,CHEMBL46,FELGMEQIXOGIFQ-UHFFFAOYSA-N,ONDANSETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C
857,,FERVXSHGEVPGHF-UHFFFAOYSA-N,41149-66-0,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8335064.0,Ki,=,6.0,NM,,,,,,,,,,,,,,,,,,,,8.221848749616356,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCC[N+](C)(C)C
858,CHEMBL274119,FFEARJCKVFRZRR-UHFFFAOYSA-N,RACEMETHIONINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CSCCC(C(=O)O)N
859,CHEMBL310604,FFFHZYDWPBMWHY-UHFFFAOYSA-N,HOMOCYSTEINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(CS)C(C(=O)O)N
860,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
861,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
862,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N
863,CHEMBL291882,FFIKBIOXICZKHW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450609,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=C(C=CS3)Cl
864,CHEMBL1222728,FFNIMQCKAVUSKV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20667729.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Antagonist activity at human histamine H1 receptor,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,CN1CCN(CC1)C(C2=CC=CC=C2)C3=NN=NN3CC4=CC=CC=C4
865,CHEMBL1259188,FGHKCRNDQSRICR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,,CN1N=C(N=N1)CC2=CC3=C(C=C2)N(C=C3C4CCN(CC4)CCN5CCNC5=O)C6=CC=C(C=C6)F
866,CHEMBL1940403,FGTGRXMIFIZGBG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,115.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.939302159646388,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCSC3=CC=C(C=C3)F
867,CHEMBL2171034,FGWSLMPEBIIYTF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC=C(C=C4)F
868,CHEMBL219916,FGXWKSZFVQUSTL-UHFFFAOYSA-N,DOMPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,1344.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.871600731282194,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O
869,CHEMBL219916,FGXWKSZFVQUSTL-UHFFFAOYSA-N,DOMPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,156.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.806875401645539,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O
870,CHEMBL267648,FHFYDNQZQSQIAI-UHFFFAOYSA-N,PEFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O
871,CHEMBL267648,FHFYDNQZQSQIAI-UHFFFAOYSA-N,PEFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O
872,CHEMBL1125,FHPIXVHJEIZKJW-UHFFFAOYSA-N,DESMETHYLOLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,22.0,NM,,,,,,,,,,,,,,,In vitro binding affinity of compound against histamine H1 neuronal receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.657577319177793,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCNCC4
874,CHEMBL1092766,FHUODQKGUFFZJE-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,2.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.537602002101044,C[C@H](C1=C(N=CC=C1)Cl)C2=C(SC3=CC=CC=C32)CCN(C)C
875,CHEMBL62660,FHVOGKHFMPAIBO-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,46773.51,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.330000038335378,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](CO)N
876,CHEMBL458019,FIKAKWIAUPDISJ-UHFFFAOYSA-L,PARAQUAT DICHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C.[Cl-].[Cl-]
877,CHEMBL458019,FIKAKWIAUPDISJ-UHFFFAOYSA-L,PARAQUAT DICHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C.[Cl-].[Cl-]
878,CHEMBL1278201,FIMFEAXKPOZWDG-VUNKPPBISA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.79997073344623,C1C[C@@]2(CC1N3CCC(C3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25
879,CHEMBL3233411,FINYFOYZAZLCFE-FPOVZHCZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24559051.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,J. Med. Chem.,PUBLICATION,,,CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC5=NOC6=CC=CC=C65
881,CHEMBL154695,FJCPGOQOVQYZGS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,15848931924611.1,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.199999999999999,C1=CC=C(C=C1)CC2=NC(=CS2)CCN
883,CHEMBL3417585,FJHKZEVPGYADEG-XOKHGSTOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25827402.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human H1R,"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,5.0,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)[C@H]4[C@@H]3C4
884,CHEMBL3417586,FJHKZEVPGYADEG-XYPHTWIQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25827402.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human H1R,"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,5.0,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)[C@@H]4[C@H]3C4
885,CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2
886,CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2
887,CHEMBL2220442,FJLGEFLZQAZZCD-VAWYXSNFSA-N,FLUVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)N1C2=CC=CC=C2C(=C1/C=C/C(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F
888,CHEMBL2220442,FJLGEFLZQAZZCD-VAWYXSNFSA-N,FLUVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)N1C2=CC=CC=C2C(=C1/C=C/C(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F
889,CHEMBL507360,FJPDUNSHNPHJFS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18952421.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human histamine H1 receptor,Development of novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1C(=NC2=C(C1=O)C=CN=C2OC)C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5
891,CHEMBL312082,FJXRDARXFNFHEP-NBXNUCLWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,190.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.721246399047171,CC(C#CC1=CC=C(O1)CN2CCN(CC2)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl)N(C(=O)N)O
893,CHEMBL403,FKENQMMABCRJMK-RITPCOANSA-N,SULBACTAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)C
894,CHEMBL403,FKENQMMABCRJMK-RITPCOANSA-N,SULBACTAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)C
895,CHEMBL282829,FKHBXKAEVUTBRK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCC1=CC=C(C=C1)N2CCN(CC2)CC3=CNC4=C3C=CC=N4
896,CHEMBL43860,FKKPXTRMLVLGJG-JOCHJYFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,19.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.721246399047171,CC1=C([C@H](CC(=O)N1)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)C4=CC=C(C=C4)F
898,CHEMBL2158816,FLDDBSYUKQDTDX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755866,C1CC(CN(C1)C(C2=CC=CC=C2)C(=O)O)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
899,CHEMBL1242923,FLGSUSWMWSZVMP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20684563.0,Ki,=,780.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor by radioligand displacement assay,"Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.",J. Med. Chem.,PUBLICATION,,6.107905397309519,C1CN(CCC1NC(=O)CC2=CC=CC=C2)CCCN3C(=O)COC4=CC=CC=C43
900,CHEMBL94906,FLHDOLQPNXOYNQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.6,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.18045606445813,CCOCCN1C2=CC=CC=C2N=C1C(=O)C3CCN(CC3)CCC4(CCN(C4=O)CC5=CC(=C(C(=C5)OC)OC)OC)C6=CC=C(C=C6)F
901,CHEMBL401576,FLIIXHVRMXEDPQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,630.96,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.199998172182031,CC1=NOC2=C1C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CC=C(C=C5)C(F)(F)F
902,CHEMBL16192,FLNYLINBEZROPL-NSOVKSMOSA-N,CP-96345,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,~,10000.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC=CC=C1CN[C@@H]2[C@@H](N3CCC2CC3)C(C4=CC=CC=C4)C5=CC=CC=C5
904,CHEMBL2207665,FLTAIVXWWOKLBO-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,5.01,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,CN1C=C(C(=CC1=O)C(F)(F)F)C(=O)NC[C@H](CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)O
905,CHEMBL10971,FLTBEMVEAFMWDD-UHFFFAOYSA-N,SCH-37370,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,7.0,CC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
906,CHEMBL550337,FLZIWHXEHDCVMN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.2,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.657577319177793,CN(CCOC)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
907,CHEMBL1475,FMHHVULEAZTJMA-UHFFFAOYSA-N,TRIOXSALEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)OC2=C1C=C3C=C(OC3=C2C)C
908,CHEMBL1475,FMHHVULEAZTJMA-UHFFFAOYSA-N,TRIOXSALEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)OC2=C1C=C3C=C(OC3=C2C)C
910,CHEMBL31184,FMMWHPNWAFZXNH-UHFFFAOYSA-N,BENZO[DEF]CHRYSENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3
911,CHEMBL31184,FMMWHPNWAFZXNH-UHFFFAOYSA-N,BENZO[DEF]CHRYSENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3
912,CHEMBL2146810,FNEORDYLRZOEEP-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.631,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.199970640755865,CCCCN1CCC[C@@H]1CN2C(=O)C3=C(C(=N2)CC4=CC=C(C=C4)Cl)N=CC=C3
914,CHEMBL359122,FNLZNEYPJNEYFH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,2511.89,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1=CN=CC=C1CCCCCCCCCCN
915,CHEMBL359122,FNLZNEYPJNEYFH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,199526231496888.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.3,C1=CN=CC=C1CCCCCCCCCCN
918,CHEMBL585,FNYLWPVRPXGIIP-UHFFFAOYSA-N,TRIAMTERENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N
919,CHEMBL585,FNYLWPVRPXGIIP-UHFFFAOYSA-N,TRIAMTERENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N
920,CHEMBL238872,FOCPBTUUAJZSNL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CCCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O
922,CHEMBL2158827,FOQNONLDPFMOKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,19.95,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=C(C=C4)CC(=O)O
924,CHEMBL1077908,FPAJMJGGDZGJPZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,199.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.701146923590294,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=C(O3)C=CC(=C4)NS(=O)(=O)C5=CC=CC=C5)OC
925,CHEMBL51,FPCCSQOGAWCVBH-UHFFFAOYSA-N,KETANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22694093.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.,J. Med. Chem.,PUBLICATION,,8.698970004336019,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O
926,CHEMBL100454,FPDIERBPQFAFSI-UHFFFAOYSA-N,2-HYDROXY-METHYLOLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,6.0,NM,,,,,,,,,,,,,,,In vitro binding affinity of compound against histamine H1 neuronal receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.221848749616356,CN1CCN(CC1)C2=NC3=CC=CC=C3NC4=C2C=C(S4)CO
927,CHEMBL2205835,FPHVMMXTLGSYHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC=CC=C7)O
928,CHEMBL2205835,FPHVMMXTLGSYHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC=CC=C7)O
929,CHEMBL519609,FPUKGJMTLUQGFZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23707254.0,Ki,=,430.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor (unknown origin) by PDSP assay,Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.366531544420414,CCN(CC)CCCOC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31
931,CHEMBL255619,FQKBVZIGJYRJIJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)CC6CC6
932,CHEMBL1370561,FQPFAHBPWDRTLU-UHFFFAOYSA-N,AMINOPHYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N
933,CHEMBL1370561,FQPFAHBPWDRTLU-UHFFFAOYSA-N,AMINOPHYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N
935,CHEMBL3311308,FQUAFMNPXPXOJE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24881566.0,IC50,>,39810.72,NM,,,,,,,,,,,,,,,Antagonist activity at human histamine H1 receptor by luminescence assay,Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.399999967876858,CC1=CC(=C(C(=C1)C)NS(=O)(=O)C2=CC=C(C=C2)OC)C
936,CHEMBL1082036,FRDOPYUUNJUZKI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,38400.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.4156687756324695,CCOC1=CC(=CC(=C1)CN2CCC(CC2)NC3=NC4=C(O3)C=CC(=C4)S(=O)(=O)CC)OC5CCOCC5
937,CHEMBL427836,FRHJULSNWZOUMW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CCC1=NC2=C(O1)C=CC3=C2CCN(CC3)CCCSC4=NN=C(N4C)C5=C(N=CO5)C
938,CHEMBL1767156,FRUMSZUUBXPHHF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,1.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.0,CN1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
939,CHEMBL560741,FRXWLMMHSBOBJK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,0.6,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,9.221848749616356,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=CC=C(C=C3)F
940,CHEMBL1909049,FSIWGHXVLYRBFQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3
941,CHEMBL1909049,FSIWGHXVLYRBFQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3
942,CHEMBL1076211,FSKFPVLPFLJRQB-UHFFFAOYSA-N,TOLPERISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2
943,CHEMBL1076211,FSKFPVLPFLJRQB-UHFFFAOYSA-N,TOLPERISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2
944,CHEMBL1222625,FSQHSKMGRAIYLO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.50003813440381,C=C(CN1CCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC=C4)C(=O)O
945,CHEMBL189171,FSQKKOOTNAMONP-UHFFFAOYSA-N,ACEMETACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O
946,CHEMBL189171,FSQKKOOTNAMONP-UHFFFAOYSA-N,ACEMETACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O
948,CHEMBL213912,FSRSEANZUZHDHK-UHFFFAOYSA-N,VUF-6884,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16854056.0,EC50,=,6.76,NM,,,cell_based,,,,,,,,,,,,Activity at human histamine H1 receptor transfected in COS7 cells by NF-kappaB luciferase reporter assay,Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives.,J. Med. Chem.,PUBLICATION,,8.170053304058364,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)OC4=CC=CC=C42
949,CHEMBL213912,FSRSEANZUZHDHK-UHFFFAOYSA-N,VUF-6884,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16854056.0,Ki,=,7.76,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor,Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives.,J. Med. Chem.,PUBLICATION,,8.110138278741811,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)OC4=CC=CC=C42
951,CHEMBL213912,FSRSEANZUZHDHK-UHFFFAOYSA-N,VUF-6884,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19053770.0,Ki,=,7.76,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach.,J. Med. Chem.,PUBLICATION,,8.110138278741811,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)OC4=CC=CC=C42
952,CHEMBL213912,FSRSEANZUZHDHK-UHFFFAOYSA-N,VUF-6884,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,8.318,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.079981083971084,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)OC4=CC=CC=C42
953,CHEMBL976,FSVJFNAIGNNGKK-UHFFFAOYSA-N,PRAZIQUANTEL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2
954,CHEMBL976,FSVJFNAIGNNGKK-UHFFFAOYSA-N,PRAZIQUANTEL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2
955,CHEMBL744,FTALBRSUTCGOEG-UHFFFAOYSA-N,RILUZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
956,CHEMBL744,FTALBRSUTCGOEG-UHFFFAOYSA-N,RILUZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
957,,FTCWKSGDHXCEMZ-UHFFFAOYSA-N,K117,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15798001.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC1CC(C2=CC=CC=C2N1C(=O)C3=CC=CC=C3)N(C4=CC=CC=C4)C(=O)C(C)C
961,CHEMBL83668,FUSNMLFNXJSCDI-UHFFFAOYSA-N,TOLNAFTATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC=C1)N(C)C(=S)OC2=CC3=CC=CC=C3C=C2
962,CHEMBL83668,FUSNMLFNXJSCDI-UHFFFAOYSA-N,TOLNAFTATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC=C1)N(C)C(=S)OC2=CC3=CC=CC=C3C=C2
964,CHEMBL105567,FUYGZJGUDRONJU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,758.58,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.119998611678231,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CSC=C3
966,CHEMBL12948,FVLVBPDQNARYJU-UHFFFAOYSA-N,SEMUSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CCC(CC1)NC(=O)N(CCCl)N=O
967,CHEMBL12948,FVLVBPDQNARYJU-UHFFFAOYSA-N,SEMUSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CCC(CC1)NC(=O)N(CCCl)N=O
968,CHEMBL1946253,FVMDOYQNOWAVCQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,1247.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,5.904133546521457,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCCC3=CC=C(C=C3)F
969,CHEMBL3094215,FVUHMXKJJTVQKK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,=,1995.26,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC3=C(CCN(CC3)CC4CC4)C=C2
971,CHEMBL594721,FWRAMRVPMYVJMR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773175.0,Ki,>,1000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in Sf9 cells co-expressing RGS4,"2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CN1CCN(CC1)C2=NC(=NC(=C2)NCC3=CC=CC=C3Cl)N
972,CHEMBL64773,FWXQEINBRJTOSP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1202.26,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920001601921648,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)NC(C)C
973,CHEMBL256477,FXBRDXOXJHZPDA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,630.96,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.199998172182031,CCC1=NN(C2=C1C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)C
974,CHEMBL193435,FXHLGRYCQSRFHY-MQSINFNDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,42.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,7.376750709602099,CN(C)C[C@H]1CC2[C@H](O1)C3=C(C=CC(=C3)Br)OC4=CC=CC=C24
975,CHEMBL195856,FXHLGRYCQSRFHY-SHZHJNINSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor; Not tested,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,,CN(C)C[C@@H]1CC2[C@H](O1)C3=C(C=CC(=C3)Br)OC4=CC=CC=C24
976,CHEMBL319000,FXIPXWLVYIHFEP-OAQYLSRUSA-N,A-331440,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,1905.46,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.720000163638921,CN(C)[C@@H]1CCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
977,CHEMBL160581,FYCXANKHKYEXTR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Compound was tested for its affinity towards histaminergic (H 1) receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CN(CCN1C2=CC=CC3=CC=CC=C32)C(=O)COC4=CC5=C(C=C4)NC=C5CCN
979,CHEMBL602850,FYGREZKTJIXWIH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC(=CC=C7)F)O
980,CHEMBL602850,FYGREZKTJIXWIH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC(=CC=C7)F)O
981,CHEMBL608,FYPMFJGVHOHGLL-UHFFFAOYSA-N,PROBUCOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C
982,CHEMBL608,FYPMFJGVHOHGLL-UHFFFAOYSA-N,PROBUCOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C
984,CHEMBL1923521,FZBQOBOSIQUVSG-UHFFFAOYSA-N,4-(2-BENZYLPHENOXY)PIPERIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,6.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,8.221848749616356,C1CNCCC1OC2=CC=CC=C2CC3=CC=CC=C3
985,CHEMBL1923521,FZBQOBOSIQUVSG-UHFFFAOYSA-N,4-(2-BENZYLPHENOXY)PIPERIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,6.31,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,8.199970640755867,C1CNCCC1OC2=CC=CC=C2CC3=CC=CC=C3
986,CHEMBL1643900,FZIIBLBHXXRTMG-RAOGCBAWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21146989.0,Ki,=,2376.0,NM,,,,,,,,,,,,,,,Inhibition of H1 receptor,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.624153563690844,C1C2C3CC4C2[C@@H](C5C1C3C45)NCCC6=CC(=CC=C6)F
987,CHEMBL1643900,FZIIBLBHXXRTMG-RAOGCBAWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,=,2376.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.624153563690844,C1C2C3CC4C2[C@@H](C5C1C3C45)NCCC6=CC(=CC=C6)F
989,CHEMBL1643901,GACBJAOXQGFNDL-RAOGCBAWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21146989.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor at 10 uM,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(CC1=CC(=CC=C1)F)[C@H]2C3C4CC5C2C6C3CC4C56
990,CHEMBL1643901,GACBJAOXQGFNDL-RAOGCBAWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.0,CN(CC1=CC(=CC=C1)F)[C@H]2C3C4CC5C2C6C3CC4C56
992,CHEMBL116463,GALCSZPFCCZIBC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,454.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,6.342944147142896,C1CN(CCC1NC(=O)OCCC2=CC=C(C=C2)C#N)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
993,CHEMBL553025,GBABOYUKABKIAF-IELIFDKJSA-N,VINORELBINE BASE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC
994,CHEMBL553025,GBABOYUKABKIAF-IELIFDKJSA-N,VINORELBINE BASE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC
995,CHEMBL578,GBXSMTUPTTWBMN-XIRDDKMYSA-N,ENALAPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O
996,CHEMBL578,GBXSMTUPTTWBMN-XIRDDKMYSA-N,ENALAPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O
998,CHEMBL471724,GCEYKTZXUXSFFO-UHFFFAOYSA-N,UR-PI287,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19317445.0,EC50,=,2570.4,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in insect Sf9 cells co-expressing RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting,N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.,J. Med. Chem.,PUBLICATION,,5.589999287456538,CC(C)C(=O)NC(=NCCCC1=CN=CN1)N
999,CHEMBL1395,GCKMFJBGXUYNAG-HLXURNFRSA-N,METHYLTESTOSTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C
1000,CHEMBL1395,GCKMFJBGXUYNAG-HLXURNFRSA-N,METHYLTESTOSTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C
1001,CHEMBL1783962,GDGRKDCFXHOMEX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,>,10000.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC2=C(C1)C3=C(N2CCC4=CN=CC=C4)C=CC(=C3)C(F)(F)F
1002,CHEMBL1783962,GDGRKDCFXHOMEX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CN=CC=C4)C=CC(=C3)C(F)(F)F
1003,CHEMBL181,GDLBFKVLRPITMI-UHFFFAOYSA-N,DIAZOXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl
1004,CHEMBL181,GDLBFKVLRPITMI-UHFFFAOYSA-N,DIAZOXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl
1005,CHEMBL415,GDLIGKIOYRNHDA-UHFFFAOYSA-N,CLOMIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,85.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.070581074285707,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl
1006,CHEMBL415,GDLIGKIOYRNHDA-UHFFFAOYSA-N,CLOMIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,9.83,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.007446482167865,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl
1007,CHEMBL2171037,GDRRHBZSXZXDLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,CN(C)C1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
1008,CHEMBL1091774,GDVOQNXWYQVYJH-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,IC50,=,6100.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.214670164989233,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN4CCCC4
1010,CHEMBL314107,GEDGEGJCGBTAON-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,16.98,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.770062314092066,CN(C)CC1CC2C3=C(CC4=C(N2O1)C=C(C=C4)F)C=CC(=C3)F
1011,CHEMBL47482,GEICAQNIOJFRQN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,197.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,6.705533773838407,C1C2=CC=CC=C2C(C3=CC=CC=C31)CN
1012,CHEMBL2158785,GEMBQNHUTJFAFL-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CC1=C(C=CC(=C1Cl)C#N)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=C(C=C4)F)C(=O)O
1013,CHEMBL1092377,GETROLYXSDDSDH-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,2.7,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.568636235841012,C[C@H](C1=C(SC2=CC=CC=C21)CCN(C)C)C3=C(C=CC=N3)F
1014,CHEMBL2355126,GFBKORZTTCHDGY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,4.0,NM,,,,,,,,,,,,,,,,,,,,8.397940008672037,CN1CCN(CC1)CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C
1015,CHEMBL1201,GFBKORZTTCHDGY-UWVJOHFNSA-N,THIOTHIXENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,5.88,NM,,,,,,,,,,,,,,,,,,,,8.230622673923861,CN1CCN(CC1)CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C
1016,CHEMBL1201,GFBKORZTTCHDGY-UWVJOHFNSA-N,THIOTHIXENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,4.4,NM,,,,,,,,,,,,,,,,,,,,8.356547323513812,CN1CCN(CC1)CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C
1017,CHEMBL1201,GFBKORZTTCHDGY-UWVJOHFNSA-N,THIOTHIXENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,6.0,NM,,,,,,,,,,,,,,,,,,,,8.221848749616356,CN1CCN(CC1)CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C
1018,CHEMBL556782,GFGGZTNVJUNZEE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,CC1=CC=C(C=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5.Cl
1020,CHEMBL1451,GFNANZIMVAIWHM-OBYCQNJPSA-N,TRIAMCINOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O
1021,CHEMBL1451,GFNANZIMVAIWHM-OBYCQNJPSA-N,TRIAMCINOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O
1022,CHEMBL1767149,GFOPLENUCATIPC-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.251,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.600326278518962,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC(=C(C=C4)F)F
1024,CHEMBL404363,GGTFAVLCBBVKHN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,3981.07,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)N=C(O6)C(F)(F)F
1025,CHEMBL561981,GGTPJIUWVNXICI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,>,500.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=CC=CC(=C53)C(=O)O
1026,CHEMBL880,GGXKWVWZWMLJEH-UHFFFAOYSA-N,FAMCICLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C
1027,CHEMBL880,GGXKWVWZWMLJEH-UHFFFAOYSA-N,FAMCICLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C
1028,CHEMBL185,GHASVSINZRGABV-UHFFFAOYSA-N,FLUOROURACIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=O)NC(=O)N1)F
1029,CHEMBL185,GHASVSINZRGABV-UHFFFAOYSA-N,FLUOROURACIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=O)NC(=O)N1)F
1030,CHEMBL319535,GHVPKFCDNOFWEW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.6,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.18045606445813,CC(C)OC1=CC=CC(=C1)CC(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC8=C(C=C7)OCO8
1031,CHEMBL559060,GHZHZIJXYOTTAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,4.5,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.346787486224656,C1CN(CCC1NCC2CCOCC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
1032,CHEMBL558468,GIEBQTVDYXTBCS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.619788758288394,CN(C)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)OC
1034,CHEMBL152221,GIGMUWUHKTVYOI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,3981.07,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.40000018605658,C1CCN(C1)CCCCCCCCCCCCC2=CN=CN2
1035,CHEMBL152221,GIGMUWUHKTVYOI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,501187233627271.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.699999999999999,C1CCN(C1)CCCCCCCCCCCCC2=CN=CN2
1036,CHEMBL1201203,GIJXKZJWITVLHI-PMOLBWCYSA-N,BENZTROPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,3.18,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.497572880015568,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
1037,CHEMBL1201203,GIJXKZJWITVLHI-PMOLBWCYSA-N,BENZTROPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.37,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.431798275933005,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
1038,CHEMBL116590,GIJXKZJWITVLHI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,1.1,NM,,,,,,,,,,,,,,,,,,,,8.958607314841775,CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4
1039,CHEMBL1277035,GIZCWMURBFLMON-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,199.53,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.699991797446187,C1CC2(CC1N3CC(=CC(=O)O)C3)CC4=CC=CC=C4CC5=CC=CC=C25
1040,CHEMBL2207277,GJJRSPSNZFRQIQ-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,63.1,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755866,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=C(C=C4)S(=O)(=O)C)O
1041,CHEMBL1277584,GJQONOYIKURBSD-IYRGYZHQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.700057099977233,C1C[C@H](CN(C1)C2CC[C@@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35)C(=O)O
1042,CHEMBL328250,GJSLOMWRLALDCT-UHFFFAOYSA-N,ADINAZOLAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
1043,CHEMBL134,GJSURZIOUXUGAL-UHFFFAOYSA-N,CLONIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
1044,CHEMBL134,GJSURZIOUXUGAL-UHFFFAOYSA-N,CLONIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl
1045,CHEMBL698,GKCBAIGFKIBETG-UHFFFAOYSA-N,TETRACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
1046,CHEMBL698,GKCBAIGFKIBETG-UHFFFAOYSA-N,TETRACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C
1047,CHEMBL194837,GKDBTHSYQZTDAJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16134937.0,IC50,=,3.5,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,"6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode.",J. Med. Chem.,PUBLICATION,,8.455931955649724,CC1=CC(=NC2=C1C=C(C=C2)NC(=O)COC3=C(C=C(C=C3)Cl)Cl)OCCN(C)C
1048,CHEMBL256016,GKDLNLYIGUXYSK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)C(C)C
1050,CHEMBL954,GKIRPKYJQBWNGO-OCEACIFDSA-N,ENCLOMIPHENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3
1051,CHEMBL954,GKIRPKYJQBWNGO-OCEACIFDSA-N,ENCLOMIPHENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3
1052,CHEMBL2158772,GKKOWDZJMOVEBY-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,31.62,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.50003813440381,CC1=CC=CC=C1C[C@@H](C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
1053,CHEMBL2171050,GKKYKABOCZBQRA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,1000.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)F)F
1056,CHEMBL460291,GKQPCPXONLDCMU-CCEZHUSRSA-N,LACIDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C
1057,CHEMBL460291,GKQPCPXONLDCMU-CCEZHUSRSA-N,LACIDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C
1058,CHEMBL199824,GKTQBPYMIGXPKG-JVVVGQRLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16392798.0,Ki,=,150.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,"Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.",J. Med. Chem.,PUBLICATION,,6.823908740944319,CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=CC=CC4=C3C=C(C=C4)O[11CH3]
1059,CHEMBL1771,GKTWGGQPFAXNFI-HNNXBMFYSA-N,CLOPIDOGREL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
1060,CHEMBL1771,GKTWGGQPFAXNFI-HNNXBMFYSA-N,CLOPIDOGREL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
1062,CHEMBL1783975,GLNBRPIPBOSSGY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,7570.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.120904120499927,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C4CCN(CC4)C)CCC5=CC=NC=C5
1063,CHEMBL1783975,GLNBRPIPBOSSGY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C4CCN(CC4)C)CCC5=CC=NC=C5
1064,CHEMBL1425,GLVAUDGFNGKCSF-UHFFFAOYSA-N,MERCAPTOPURINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1)C(=S)N=CN2
1065,CHEMBL1425,GLVAUDGFNGKCSF-UHFFFAOYSA-N,MERCAPTOPURINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1)C(=S)N=CN2
1066,CHEMBL73135,GLXQEUGDWMYWCC-AREMUKBSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,150.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,C1CN(CCN1CC2=CC=C(O2)C#CCCN(C(=O)N)O)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl
1067,CHEMBL73135,GLXQEUGDWMYWCC-AREMUKBSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,Ki,=,150.0,NM,,,,,,,,,,,,,,,Inhibition constant against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,6.823908740944319,C1CN(CCN1CC2=CC=C(O2)C#CCCN(C(=O)N)O)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl
1068,CHEMBL25719,GLZPCOQZEFWAFX-JXMROGBWSA-N,GERANIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=CCC/C(=C/CO)/C)C
1069,CHEMBL25719,GLZPCOQZEFWAFX-JXMROGBWSA-N,GERANIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=CCC/C(=C/CO)/C)C
1070,CHEMBL330462,GMDILGHWZUFMEQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.8,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.167491087293763,CCOC1=CC(=CC(=C1OCC)OCC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC(=C(C=C7)OC)OC
1071,CHEMBL323562,GMFZCHLJVCOHAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,426.58,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.369999510099088,CC1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
1073,CHEMBL350878,GMNSEVXCXMPGAC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,<,10000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.0,C1=CC=C(C=C1)CCCCC2=NC=C(N2)CCN
1075,CHEMBL36715,GMZVRMREEHBGGF-UHFFFAOYSA-N,PIRACETAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)N(C1)CC(=O)N
1076,CHEMBL36715,GMZVRMREEHBGGF-UHFFFAOYSA-N,PIRACETAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)N(C1)CC(=O)N
1077,CHEMBL256471,GNAFTHDBPJUMAT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803203,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)SC(=N5)C
1078,CHEMBL11553,GNBOIGBQIBQOIA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,400.0,NM,,,,,,,,,,,,,,,,,,,,6.3979400086720375,CN(C)CCC1=CN=C(N1)CCC(C2=CC=CC=C2)C3=CC=CC=C3
1079,CHEMBL304027,GNMIPEYDMWERLO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1023.29,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.990001269951939,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3=C(C(=CC=C3)F)F
1080,CHEMBL1201117,GNXFOGHNGIVQEH-UHFFFAOYSA-N,METHOCARBAMOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCC(COC(=O)N)O
1081,CHEMBL1201117,GNXFOGHNGIVQEH-UHFFFAOYSA-N,METHOCARBAMOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCC(COC(=O)N)O
1082,CHEMBL642,GOEMGAFJFRBGGG-UHFFFAOYSA-N,ACEBUTOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C
1083,CHEMBL642,GOEMGAFJFRBGGG-UHFFFAOYSA-N,ACEBUTOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C
1084,CHEMBL64124,GOVWCMLTQFJSCR-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,45708.82,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.339999990132752,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC#N)N
1085,CHEMBL2205819,GOYQRMVWIWPDFU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC7=CC=CC=C7)O
1086,CHEMBL7568,GPKJTRJOBQGKQK-UHFFFAOYSA-N,QUINACRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC
1087,CHEMBL7568,GPKJTRJOBQGKQK-UHFFFAOYSA-N,QUINACRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC
1088,CHEMBL191703,GPLGAQQQNWMVMM-MYAJQUOBSA-N,CONESSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18683917.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor,The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.0,C[C@H]1[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)N(C)C)C)CN1C
1089,CHEMBL1730,GPRBEKHLDVQUJE-QSWIMTSFSA-N,CEFOTAXIME,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3=CSC(=N3)N)SC1)C(=O)O
1090,CHEMBL1730,GPRBEKHLDVQUJE-QSWIMTSFSA-N,CEFOTAXIME,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3=CSC(=N3)N)SC1)C(=O)O
1092,CHEMBL2208427,GPRHHSZIXIDKDN-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,63.1,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755866,COC1=C(C=CC(=C1)C(=O)NC[C@H](CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)O)N
1093,CHEMBL96429,GPVDPKZTACUYNW-IPKCRJEZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,2.36,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.627087997029893,C1COCCN1CC2C[C@H]3[C@H](O2)C4=CC=CC=C4CC5=CC=CC=C35
1094,CHEMBL1276947,GPWMNUXSJDSCAV-NZICPMOKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.50003813440381,C1C[C@@]2(CC1N3C[C@@H]4C[C@@]4(C3)C(=O)O)CC5=CC=CC=C5CC6=CC=CC=C26
1095,CHEMBL2031737,GPZMWOXSIRVXQW-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313227.0,Ki,=,7055.0,NM,,,,,,,,,,,,,,,Binding affinity to human recombinant H1 receptor,Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.,J. Med. Chem.,PUBLICATION,,5.151502981909633,C[C@@H]1CCCN1CCC2=CC3=C(O2)C=CC(=C3)C(=O)C4=CC=C(C=C4)[N+](=O)[O-]
1099,CHEMBL1767167,GQWSXILTLUTBAJ-PGUFJCEWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.899974269892137,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCCN3CCC[C@@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl
1100,CHEMBL514,GQYIWUVLTXOXAJ-UHFFFAOYSA-N,LOMUSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)NC(=O)N(CCCl)N=O
1101,CHEMBL514,GQYIWUVLTXOXAJ-UHFFFAOYSA-N,LOMUSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)NC(=O)N(CCCl)N=O
1102,CHEMBL303369,GRAGHFIYRPTBJY-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,16595.87,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.779999975777493,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](C(C)C)N
1103,CHEMBL62592,GRAGHFIYRPTBJY-QHCPKHFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,19054.61,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.719999935717911,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@H](C(C)C)N
1104,CHEMBL1910380,GREREVYRUNFCTM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,602.56,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.219999701663429,COC1=CC=C(C=C1)CN(CCN2CCN(CC2)C(=O)C3=NC4=CC=CC=C4N3)C5=CC=CC=N5
1105,CHEMBL485958,GRHNPETZKNATKG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,7000.0,NM,,,,,,,,,,,,,,,,,,,,5.154901959985743,C1CCC(CC1)CC(=O)NC(=NCCCC2=CN=CN2)N
1107,CHEMBL102452,GRJGKRWJSKONHR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3548.13,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.450000476425332,C1CN(CCC1N)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
1108,CHEMBL594138,GRKYNTKPAFRLLZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,386.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,6.413412695328245,CNCCCC(C1=CC=CC=C1)C2=CC=CC=C2
1110,CHEMBL303824,GRWARSULWXLZOY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12798320.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Compound was tested for its binding affinity towards human H1 receptor,"A new class of histamine H(3)-receptor antagonists: synthesis and structure-activity relationships of 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN1CCCC1CCNC2=C3CCCCCC3=NC4=CC=CC=C42
1111,CHEMBL81977,GSCPDZHWVNUUFI-UHFFFAOYSA-N,3-AMINOBENZAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC(=C1)N)C(=O)N
1112,CHEMBL81977,GSCPDZHWVNUUFI-UHFFFAOYSA-N,3-AMINOBENZAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC(=C1)N)C(=O)N
1113,CHEMBL33,GSDSWSVVBLHKDQ-JTQLQIEISA-N,LEVOFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
1114,CHEMBL33,GSDSWSVVBLHKDQ-JTQLQIEISA-N,LEVOFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
1115,CHEMBL4,GSDSWSVVBLHKDQ-UHFFFAOYSA-N,OFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
1116,CHEMBL4,GSDSWSVVBLHKDQ-UHFFFAOYSA-N,OFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
1117,CHEMBL2171041,GSQPHXFZLYFUQD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934842,CN(C)C1=CC=CC=C1S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
1118,CHEMBL1277491,GSUXFSXZSCBDQK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,199.53,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.699991797446187,C1CC2(CC1N3CCC(CC3)C(=O)O)C4=CC=CC=C4SC5=C(C2=O)C=C(C=C5)F
1122,CHEMBL434785,GUDHMDVRURNAHL-SNVBAGLBSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,10715.19,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.970000123715015,C1C(CC2=CC=CC=C21)[C@H](C(=O)O)N
1124,CHEMBL303454,GUGOEEXESWIERI-SSEXGKCCSA-N,R-TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,3.16,NM,,,,,,,,,,,,,,,,,,,,8.500312917381596,CC(C)(C)C1=CC=C(C=C1)[C@@H](CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O
1125,CHEMBL303454,GUGOEEXESWIERI-SSEXGKCCSA-N,R-TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,,,,,,8.698970004336019,CC(C)(C)C1=CC=C(C=C1)[C@@H](CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O
1126,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12747773.0,Ki,=,58.0,NM,,,,,,,,,,,,,,,Binding affinity towards histamine H1 receptor,Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.,J. Med. Chem.,PUBLICATION,,7.236572006437063,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O
1127,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,40.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O
1128,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25494650.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),CNS drug design: balancing physicochemical properties for optimal brain exposure.,J. Med. Chem.,PUBLICATION,,9.0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O
1129,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,22.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.657577319177793,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O
1130,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,563.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.249491605148654,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O
1131,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,2.59,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.586700235918748,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O
1132,CHEMBL1091782,GUNAZEDORZMWRN-LBPRGKRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,4.6,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.337242168318426,C[C@@H](C1=CSC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C
1133,CHEMBL1940412,GUOQPFNLBAXWIZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,62.9,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,7.201349354554731,C1CN(CCN1CCCOC2=CC=C(C=C2)F)C3=CC=CC=C3
1135,CHEMBL360202,GUUFVYCRQBZPLO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,50.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,C1CC2=C(C=CC(=C2)Cl)C(=C3CCN(CC3)CCCCOC4=CC=C(C=C4)C#CCCN(C(=O)N)O)C5=C1C=CC=N5
1137,CHEMBL1774492,GUYGSIXDIXLGLA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,255.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.5934598195660445,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCN3C4=CC=CC=C4COC5=C3C=C(C=C5)CC(=O)O
1139,CHEMBL345185,GVDNUYAKHMLSKZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1995.26,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1=C(NC=N1)CCCCCCCCCN
1140,CHEMBL345185,GVDNUYAKHMLSKZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,50118723362727.1,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.699999999999999,C1=C(NC=N1)CCCCCCCCCN
1141,CHEMBL1096430,GVGOZYJHWUIVHV-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,=,89.13,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0499760934766735,C[C@H](CC(=O)NC(=NCCCC1=CN=CN1)N)C2CCCCC2
1143,CHEMBL486965,GVGOZYJHWUIVHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,280.0,NM,,,,,,,,,,,,,,,,,,,,6.552841968657781,CC(CC(=O)NC(=NCCCC1=CN=CN1)N)C2CCCCC2
1144,CHEMBL486965,GVGOZYJHWUIVHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,910.0,NM,,,,,,,,,,,,,,,,,,,,6.040958607678906,CC(CC(=O)NC(=NCCCC1=CN=CN1)N)C2CCCCC2
1145,CHEMBL486965,GVGOZYJHWUIVHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,5300.0,NM,,,,,,,,,,,,,,,,,,,,5.275724130399211,CC(CC(=O)NC(=NCCCC1=CN=CN1)N)C2CCCCC2
1147,CHEMBL1096431,GVGOZYJHWUIVHV-ZDUSSCGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,=,66.07,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.179995693191682,C[C@@H](CC(=O)NC(=NCCCC1=CN=CN1)N)C2CCCCC2
1149,CHEMBL47,GVJHHUAWPYXKBD-IEOSBIPESA-N,VITAMIN E,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C
1150,CHEMBL47,GVJHHUAWPYXKBD-IEOSBIPESA-N,VITAMIN E,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C
1151,CHEMBL561690,GWLKWIJXTVRQMT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,IC50,=,80.5,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.094204119632131,CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=CC=CC=C5
1153,CHEMBL1078240,GWSJPOPJXLJSLF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,1013.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.994390554639719,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=CC(=C(C=C4O3)S(=O)(=O)N)Cl)OC
1154,CHEMBL13341,GWUSZQUVEVMBPI-UHFFFAOYSA-N,NIMETAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3
1155,CHEMBL13341,GWUSZQUVEVMBPI-UHFFFAOYSA-N,NIMETAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3
1156,CHEMBL2207657,GWVFJNPANMKQSY-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,2.51,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.600326278518962,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC=C4F)O
1159,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,0.8,NM,,,,,,,,,,,,,,,,,,,,9.096910013008056,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
1160,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12747773.0,Ki,=,3.0,NM,,,,,,,,,,,,,,,Binding affinity towards histamine H1 receptor,Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.,J. Med. Chem.,PUBLICATION,,8.522878745280337,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
1161,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,2.09,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.679853713888946,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
1162,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,14.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.853871964321762,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
1163,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.61,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.79317412396815,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
1164,CHEMBL239975,GXILWBIQFGWJQN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F
1167,CHEMBL408,GXPHKUHSUJUWKP-UHFFFAOYSA-N,TROGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C
1168,CHEMBL408,GXPHKUHSUJUWKP-UHFFFAOYSA-N,TROGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C
1170,CHEMBL3290012,GXZWKZAOGQRNTL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24805037.0,Ki,=,69.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant H1 receptor expressed in HEK293 cells,Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia.,J. Med. Chem.,PUBLICATION,,7.161150909262744,C1CN(CCC1C2=NOC3=C2C=CC(=C3)F)CCCCNS(=O)(=O)C4=CC5=CC=CC=C5S4
1171,CHEMBL293033,GYCWHNUGCXMJDF-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,16218.1,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.790000026071145,CC(C)(C)OC[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N
1172,CHEMBL877,GYDJEQRTZSCIOI-LJGSYFOKSA-N,TRANEXAMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1CN)C(=O)O
1173,CHEMBL877,GYDJEQRTZSCIOI-LJGSYFOKSA-N,TRANEXAMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1CN)C(=O)O
1176,CHEMBL25688,GZAZQKHMIYBBFL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,5011.87,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.300000202445418,C1CCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
1177,CHEMBL62312,GZGINHDPANJTJY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,398.11,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.399996913372259,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=CO3
1178,CHEMBL12713,GZKLJWGUPQBVJQ-UHFFFAOYSA-N,SERTINDOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,130.0,NM,,,,,,,,,,,,,,,,,,,,6.886056647693163,C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O
1179,CHEMBL12713,GZKLJWGUPQBVJQ-UHFFFAOYSA-N,SERTINDOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,320.0,NM,,,,,,,,,,,,,,,,,,,,6.494850021680094,C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O
1180,CHEMBL12713,GZKLJWGUPQBVJQ-UHFFFAOYSA-N,SERTINDOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,130.0,NM,,,,,,,,,,,,,,,,,,,,6.886056647693163,C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O
1181,CHEMBL12713,GZKLJWGUPQBVJQ-UHFFFAOYSA-N,SERTINDOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,570.0,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,6.2441251443275085,C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O
1182,CHEMBL12713,GZKLJWGUPQBVJQ-UHFFFAOYSA-N,SERTINDOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,0.51,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,9.292429823902063,C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O
1183,CHEMBL81,GZUITABIAKMVPG-UHFFFAOYSA-N,RALOXIFENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
1184,CHEMBL81,GZUITABIAKMVPG-UHFFFAOYSA-N,RALOXIFENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O
1185,CHEMBL1910382,GZUNLKUPHLSRKX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,100.0,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CN(CCN1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)Cl)CCN(CC4=CC=C(C=C4)OC)C5=CC=CC=N5
1186,CHEMBL257536,HAJIPROMBKTILW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OCC(=O)N5
1187,CHEMBL696,HAPOVYFOVVWLRS-UHFFFAOYSA-N,ETHOSUXIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCC1(CC(=O)NC1=O)C
1188,CHEMBL696,HAPOVYFOVVWLRS-UHFFFAOYSA-N,ETHOSUXIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(CC(=O)NC1=O)C
1189,CHEMBL696,HAPOVYFOVVWLRS-UHFFFAOYSA-N,ETHOSUXIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(CC(=O)NC1=O)C
1190,CHEMBL433257,HAVJATCHLFRDHY-KSZYUSJVSA-N,HARRINGTONINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(CC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O
1191,CHEMBL433257,HAVJATCHLFRDHY-KSZYUSJVSA-N,HARRINGTONINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(CC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O
1194,CHEMBL90997,HBMJQYDGBNSZMC-UHFFFAOYSA-N,S-34324,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771448.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to Histamine H1 receptor,Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.,J. Med. Chem.,PUBLICATION,,6.0,C1C(CC2=C1C=CC(=C2)F)CC3CN=CN3
1195,CHEMBL129,HBOMLICNUCNMMY-XLPZGREQSA-N,ZIDOVUDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-]
1196,CHEMBL129,HBOMLICNUCNMMY-XLPZGREQSA-N,ZIDOVUDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-]
1197,CHEMBL352375,HBRHULDGKNIFGB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,218.78,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.659992382003327,CC(C)N(CCC1=C(C2=CC=CC=C2C1)C(C)C3=CC=CC=N3)C(C)C
1198,CHEMBL352375,HBRHULDGKNIFGB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,2454.71,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.6099998081597775,CC(C)N(CCC1=C(C2=CC=CC=C2C1)C(C)C3=CC=CC=N3)C(C)C
1200,CHEMBL1568,HBUBKKRHXORPQB-FJFJXFQQSA-N,FLUDARABINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N
1201,CHEMBL1568,HBUBKKRHXORPQB-FJFJXFQQSA-N,FLUDARABINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N
1202,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,120.0,NM,,,,,,,,,,,,,,,,,,,,6.920818753952375,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
1203,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,60.0,NM,,,,,,,,,,,,,,,,,,,,7.221848749616356,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
1204,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
1205,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31
1206,CHEMBL1168,HDACQVRGBOVJII-JBDAPHQKSA-N,RAMIPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O
1207,CHEMBL1168,HDACQVRGBOVJII-JBDAPHQKSA-N,RAMIPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O
1208,CHEMBL1277769,HDDLHPPRMNRBQB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.299988937677887,CC1(CCN(CC1)C2CCC3(C2)CC4=CC=CC=C4CC5=CC=CC=C35)C(=O)O
1210,CHEMBL37161,HDDSHPAODJUKPD-UHFFFAOYSA-N,FENBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)SC3=CC=CC=C3
1211,CHEMBL37161,HDDSHPAODJUKPD-UHFFFAOYSA-N,FENBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)SC3=CC=CC=C3
1213,CHEMBL1349,HDOVUKNUBWVHOX-QMMMGPOBSA-N,VALACYCLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N
1214,CHEMBL1349,HDOVUKNUBWVHOX-QMMMGPOBSA-N,VALACYCLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N
1215,CHEMBL285802,HDOZVRUNCMBHFH-UHFFFAOYSA-N,ZOTEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,0.62,NM,,,,,,,,,,,,,,,,,,,,9.207608310501746,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl
1216,CHEMBL285802,HDOZVRUNCMBHFH-UHFFFAOYSA-N,ZOTEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,3.3,NM,,,,,,,,,,,,,,,,,,,,8.481486060122112,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl
1217,CHEMBL285802,HDOZVRUNCMBHFH-UHFFFAOYSA-N,ZOTEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11170639.0,Ki,=,0.62,NM,,,,,,,,,,,,,,,Binding affinity towards human H1 receptor,Current and novel approaches to the drug treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,9.207608310501746,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl
1218,CHEMBL285802,HDOZVRUNCMBHFH-UHFFFAOYSA-N,ZOTEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,3.4,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,8.468521082957745,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl
1219,CHEMBL237087,HDRIBIYPLKZUDQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19524331.0,Ki,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Displacement of [3H]N-alpha-methylhistamine from histamine H1 receptor expressed in SK-N-MC cells,Diamine-based human histamine H3 receptor antagonists: (4-aminobutyn-1-yl)benzylamines.,Eur. J. Med. Chem.,PUBLICATION,,5.0,C1CCN(CC1)CCC#CC2=CC=CC(=C2)CN3CCOCC3
1220,CHEMBL2205820,HDZWTAJVYGVJEQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC7=CC(=CC=C7)F)O
1221,CHEMBL2205820,HDZWTAJVYGVJEQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC7=CC(=CC=C7)F)O
1222,CHEMBL44618,HEDRZPFGACZZDS-UHFFFAOYSA-N,CHLOROFORM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(Cl)(Cl)Cl
1223,CHEMBL44618,HEDRZPFGACZZDS-UHFFFAOYSA-N,CHLOROFORM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(Cl)(Cl)Cl
1224,CHEMBL561489,HEFAAVYYGFTJLY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,75.2,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.123782159408358,CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC=N5
1225,CHEMBL175,HEFNNWSXXWATRW-JTQLQIEISA-N,DEXIBUPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O
1226,CHEMBL175,HEFNNWSXXWATRW-JTQLQIEISA-N,DEXIBUPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O
1227,CHEMBL427526,HEFNNWSXXWATRW-SNVBAGLBSA-N,(R)-IBUPROPHEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)O
1228,CHEMBL427526,HEFNNWSXXWATRW-SNVBAGLBSA-N,(R)-IBUPROPHEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)O
1229,CHEMBL521,HEFNNWSXXWATRW-UHFFFAOYSA-N,IBUPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
1230,CHEMBL521,HEFNNWSXXWATRW-UHFFFAOYSA-N,IBUPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
1231,CHEMBL457,HEMJJKBWTPKOJG-UHFFFAOYSA-N,GEMFIBROZIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O
1232,CHEMBL457,HEMJJKBWTPKOJG-UHFFFAOYSA-N,GEMFIBROZIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O
1233,CHEMBL34139,HFGZFHCWKKQGIS-NOZJJQNGSA-N,GENACONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)S(=O)(=O)C
1234,CHEMBL34139,HFGZFHCWKKQGIS-NOZJJQNGSA-N,GENACONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)S(=O)(=O)C
1235,CHEMBL1230813,HFHDHCJBZVLPGP-RWMJIURBSA-N,ALFADEX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@H](O2)[C@@H]([C@H]7O)O)CO)CO)CO)CO)CO)O)O)O
1236,CHEMBL1230813,HFHDHCJBZVLPGP-RWMJIURBSA-N,ALFADEX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@H](O2)[C@@H]([C@H]7O)O)CO)CO)CO)CO)CO)O)O)O
1239,CHEMBL1091791,HFLPUFFCCFMOMB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,390.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4089353929735005,CC1=CC(=NC=C1)C(C)C2=C(SC3=CC=CC=C32)CCN(C)C
1240,CHEMBL2171047,HFWLILWGBZWYRI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=C(C(=C(C=C4)Cl)C)Cl
1241,CHEMBL1669421,HGLDEVLFUAEPJC-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,162.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.790484985457369,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CO4
1242,CHEMBL1243394,HGLGWLWXYRAXPK-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20690643.0,Ki,=,280.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,6.552841968657781,C1CNCCC1[C@H](CSC2=CC=C(C=C2)C(F)(F)F)C3=CN=CN3
1243,CHEMBL1243395,HGLGWLWXYRAXPK-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20690643.0,Ki,=,48.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,7.318758762624412,C1CNCCC1[C@@H](CSC2=CC=C(C=C2)C(F)(F)F)C3=CN=CN3
1245,CHEMBL2391541,HGRHWEAUHXYNNP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23602445.0,Ki,=,936.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting analysis,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.028724151261895,COC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C
1246,CHEMBL2391541,HGRHWEAUHXYNNP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23602445.0,Ki,=,1258.93,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting analysis,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198648,COC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C
1247,CHEMBL2391541,HGRHWEAUHXYNNP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C
1248,CHEMBL2391541,HGRHWEAUHXYNNP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,COC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C
1250,CHEMBL401777,HGTGAIQIJPCZMF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)CCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)C
1251,CHEMBL30327,HGUFODBRKLSHSI-UHFFFAOYSA-N,"2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl
1252,CHEMBL30327,HGUFODBRKLSHSI-UHFFFAOYSA-N,"2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl
1253,CHEMBL29808,HGWVDBLPHYBBTH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CC1=CC=C(C=C1)N2CCN(CC2)CC3=CNC4=C3C=CC=N4
1254,CHEMBL219146,HHJUWIANJFBDHT-KOTLKJBCSA-N,VINDESINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O
1255,CHEMBL219146,HHJUWIANJFBDHT-KOTLKJBCSA-N,VINDESINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O
1258,CHEMBL748,HIGSLXSBYYMVKI-UHFFFAOYSA-N,PRALIDOXIME CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1=CC=CC=C1/C=N/O.[Cl-]
1259,CHEMBL748,HIGSLXSBYYMVKI-UHFFFAOYSA-N,PRALIDOXIME CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1=CC=CC=C1/C=N/O.[Cl-]
1260,CHEMBL563920,HILDNLJIJXAVHA-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,0.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,9.045757490560675,C[C@@H](C1=CC=CC=N1)C2=C(OC3=CC=CC=C32)CCN(C)C
1262,CHEMBL11584,HJHFHKLECBMBFW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,125892541179417.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.100000000000001,C1=CC=C(C=C1)C(CC2=NC=C(N2)CCN)C3=CC=CC=C3
1264,CHEMBL1779058,HJKLOGARPBXZTP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21555222.0,Ki,=,2372.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,"Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (s) receptor ligands modulates off-target activity and subtype selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.624885315307775,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC(=O)C7=CC=C(C=C7)F)O
1265,CHEMBL1779058,HJKLOGARPBXZTP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,=,2372.0,NM,,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.624885315307775,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC(=O)C7=CC=C(C=C7)F)O
1266,CHEMBL1220,HJLSLZFTEKNLFI-UHFFFAOYSA-N,TINIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C
1267,CHEMBL1220,HJLSLZFTEKNLFI-UHFFFAOYSA-N,TINIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C
1268,CHEMBL1669408,HJNGVQMITVXZEN-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,13.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.886056647693163,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CCF
1269,CHEMBL2030623,HJOLMLNXMCFYQQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CC3=CC(=CC=C3)F
1270,CHEMBL1783969,HJSAIEMTRYMFMF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,>,10000.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)C(=O)O
1271,CHEMBL1783969,HJSAIEMTRYMFMF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)C(=O)O
1272,CHEMBL456807,HKOOXMFOFWEVGF-UHFFFAOYSA-N,PHENYLHYDRAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NN
1273,CHEMBL456807,HKOOXMFOFWEVGF-UHFFFAOYSA-N,PHENYLHYDRAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NN
1275,CHEMBL446885,HKYLTVCKKUPKSQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,436.52,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.359995853468939,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)OC(F)(F)F
1277,CHEMBL11879,HKZSTMPUPMSPLU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,398107170553497.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.6,C1CCN(C1)CCC2=CN=C(N2)CCC(C3=CC=CC=C3)C4=CC=CC=C4
1279,CHEMBL238456,HLBPILNTTPELKS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,3162.28,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.499999678657065,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.C(=O)O
1282,CHEMBL1454,HLFSDGLLUJUHTE-SNVBAGLBSA-N,LEVAMISOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CSC2=N[C@H](CN21)C3=CC=CC=C3
1283,CHEMBL1454,HLFSDGLLUJUHTE-SNVBAGLBSA-N,LEVAMISOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CSC2=N[C@H](CN21)C3=CC=CC=C3
1292,CHEMBL2158782,HLXZPGHNFUSVMT-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=C(C=CC(=C1)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=C(C=C4)F)C(=O)O)Cl
1293,CHEMBL3221637,HMPMHACJMYGXPE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,>,4000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,,MedChemComm,PUBLICATION,,5.3979400086720375,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)C3(CCOCC3)C(=O)N
1294,CHEMBL64775,HMRCFAPWUJGFPW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,275.42,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.560004526046192,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCC(C)C
1295,CHEMBL348302,HMWYNGSUVFCIHB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,3.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,8.522878745280337,CNCCCC1C2=CC=CC=C2CC3=CC=CC=C13
1296,CHEMBL189676,HMXDWDSNPRNUKI-UHFFFAOYSA-N,SURINABANT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15131245.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,,,,,,6.0,CCC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Br
1299,CHEMBL28997,HNCAIEASLRMRKM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)F
1300,CHEMBL2207632,HNCOLMVXXZHGHT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC=CC=C1N2CCN(CC2)CC3=CC(=C4C3=CC=CC=C4)C#C
1301,CHEMBL317524,HNDKQQSKDXJMDG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,204.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.690369832574102,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC8=C(C=C7)OCO8.CS(=O)(=O)O
1302,CHEMBL1411979,HNJJXZKZRAWDPF-UHFFFAOYSA-N,METHAPYRILENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,16.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.795880017344075,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2
1303,CHEMBL1411979,HNJJXZKZRAWDPF-UHFFFAOYSA-N,METHAPYRILENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.8,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.744727494896694,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2
1304,CHEMBL1767157,HNLNXYUSMGCHFW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,63.1,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.199970640755866,CN1CCCC1CCN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
1305,CHEMBL1024,HOMGKSMUEGBAAB-UHFFFAOYSA-N,IFOSFAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(P(=O)(OC1)NCCCl)CCCl
1306,CHEMBL1024,HOMGKSMUEGBAAB-UHFFFAOYSA-N,IFOSFAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(P(=O)(OC1)NCCCl)CCCl
1308,CHEMBL1092813,HOUUGSUKNBXWNT-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,17.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.769551078621726,CC1=C(C=CC=N1)[C@@H](C)C2=C(SC3=CC=CC=C32)CCN(C)C
1309,CHEMBL1669413,HOXVEGPFZJNLIG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,2.8,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.55284196865778,C1CCN(C1)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4
1310,CHEMBL483400,HOYKNPXNYUOCRM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18841880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human histamine H1 receptor,Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.,J. Med. Chem.,PUBLICATION,,5.0,CC1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5
1311,CHEMBL1444,HPJKCIUCZWXJDR-UHFFFAOYSA-N,LETROZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3
1312,CHEMBL1444,HPJKCIUCZWXJDR-UHFFFAOYSA-N,LETROZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3
1313,CHEMBL866,HPNSFSBZBAHARI-RUDMXATFSA-N,MYCOPHENOLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O
1314,CHEMBL866,HPNSFSBZBAHARI-RUDMXATFSA-N,MYCOPHENOLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O
1315,CHEMBL2323582,HPRWHXGAJGUOCP-UHFFFAOYSA-N,BODILISANT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1662.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells,,ACS Med. Chem. Lett.,PUBLICATION,,5.779368980551908,[B-]1(N2C(=CC(=C2C(=C3[N+]1=C(C=C3C)C)C4=CC=C(C=C4)OCCCN5CCCCC5)C)C)(F)F
1316,CHEMBL1092651,HPVUAGMZZRSSHI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,0.8,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.096910013008056,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NC=CN=C3OC
1317,CHEMBL493677,HQZBFDAIHIKVRO-CXAGYDPISA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18817368.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,"Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.",J. Med. Chem.,PUBLICATION,,5.221848749616356,CC(C)(C)CCN1CC[C@@H]([C@@H](C1)F)CNC(=O)C2=CC(=CC(=C2)Cl)Cl
1318,CHEMBL271844,HRBGKICNPOCYPZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC=N6
1319,CHEMBL2207637,HRHSURDPAJFNRA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,=,2600.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,CN(C)CC1=C2C=CC=CC=C2C(=C1)CN3CCN(CC3)C4=CC=CC=C4OC
1320,CHEMBL534737,HRQFLVPRFGMKJO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4CC4.Cl
1322,CHEMBL2146805,HRSYZRFBUGIVHN-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.34700000000000003,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.459670525209127,CN1CCC[C@@H]1CN2C(=O)C3=C(C=NC=C3)C(=N2)CC4=CC=C(C=C4)Cl
1323,CHEMBL270227,HRUTWQCXFHLYSD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C(C(F)(F)F)(F)F
1324,CHEMBL980,HSRJKNPTNIJEKV-UHFFFAOYSA-N,GUAIFENESIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCC(CO)O
1325,CHEMBL980,HSRJKNPTNIJEKV-UHFFFAOYSA-N,GUAIFENESIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCC(CO)O
1326,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
1327,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC
1328,CHEMBL272511,HTADTAUIMFMPFI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,794.33,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)OC(=N6)C
1329,CHEMBL239101,HTCLEEXSMMUUES-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1584.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.800000874803203,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC(=CC(=C5)F)F.C(=O)O
1330,CHEMBL1767141,HTHMMDLGLVQHEM-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.2,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.698970004336019,CC1=CC=C(C=C1)CC2=NN(C(=O)C3=CC=CC=C32)C[C@H]4CCCN4C
1331,CHEMBL1491,HTIQEAQVCYTUBX-UHFFFAOYSA-N,AMLODIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
1332,CHEMBL1491,HTIQEAQVCYTUBX-UHFFFAOYSA-N,AMLODIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
1333,CHEMBL2376803,HTLDHQKBLGJBRF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23558237.0,Ki,=,16595.87,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human histamine H1 receptor expressed in HEK cells,"A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.779999975777493,CNC1CN(C1)C2=NC(=NC3=C2N=CC(=C3)C4CCCC4)N
1334,CHEMBL1016,HTQMVQVXFRQIKW-UHFFFAOYSA-N,CANDESARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O
1335,CHEMBL1016,HTQMVQVXFRQIKW-UHFFFAOYSA-N,CANDESARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O
1337,CHEMBL403815,HULQLOOBDVQQSC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803203,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(C=C6C(=C5CC4)N=C(O6)C)Cl
1338,CHEMBL1521,HUNXMJYCHXQEGX-UHFFFAOYSA-N,ZALEPLON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C
1339,CHEMBL1521,HUNXMJYCHXQEGX-UHFFFAOYSA-N,ZALEPLON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C
1340,CHEMBL898,HUPFGZXOMWLGNK-UHFFFAOYSA-N,DIFLUNISAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O
1341,CHEMBL898,HUPFGZXOMWLGNK-UHFFFAOYSA-N,DIFLUNISAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O
1342,CHEMBL1669427,HUPZZDHJGMFMTN-SFHVURJKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,15.2,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.818156412055227,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4CCOCC4
1343,CHEMBL129198,HUQJRYMLJBBEDO-UHFFFAOYSA-N,JNJ-7777120,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14722321.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)Cl
1344,CHEMBL129198,HUQJRYMLJBBEDO-UHFFFAOYSA-N,JNJ-7777120,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18983139.0,Ki,=,977.24,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.",J. Med. Chem.,PUBLICATION,,6.009998764965339,CN1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)Cl
1345,CHEMBL129198,HUQJRYMLJBBEDO-UHFFFAOYSA-N,JNJ-7777120,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,46773.51,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.330000038335378,CN1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)Cl
1346,CHEMBL1084132,HVBAGGJDXDXSAY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20153647.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Activity at histamine H1 receptor,"The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,C1CCNC(C1)CN2CCN(C2)C3=CC=CC=C3
1347,CHEMBL2207641,HVGNYVOUQOKFLU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,=,1000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,COC1=CC=CC=C1N2CCN(CC2)CC3=CC(=C4C3=CC=CC=C4)CN5CCN(CC5)C6=CC=CC=C6OC
1348,CHEMBL516088,HVJOIRMQZXEGPW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19329329.0,Ki,=,944.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned histamine H1 receptor by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,6.025028005701931,COC1=C(C=CC=C1OCCF)C(=O)C2CCN(CC2)CCC3=CC=C(C=C3)F
1349,CHEMBL1085672,HVSRNYNPOUFDNJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20153647.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Activity at histamine H1 receptor,"The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,C1CCNC(C1)CN2CCN(C2=O)C3=CC(=CC=C3)Cl
1350,CHEMBL1490,HWHLPVGTWGOCJO-UHFFFAOYSA-N,TRIHEXYPHENIDYL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O
1351,CHEMBL1490,HWHLPVGTWGOCJO-UHFFFAOYSA-N,TRIHEXYPHENIDYL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O
1352,CHEMBL398812,HWRLDLIRHAWZST-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O
1353,CHEMBL239963,HWSMMNKRBIFEDV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CCC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)F.C(=O)O
1354,CHEMBL1527608,HWXIGFIVGWUZAO-UHFFFAOYSA-N,DOXOFYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3
1355,CHEMBL1527608,HWXIGFIVGWUZAO-UHFFFAOYSA-N,DOXOFYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3
1356,CHEMBL106545,HWYZEJDWSUNZPS-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3715.35,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.430000267796054,CN[C@@H]1CCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
1357,CHEMBL309904,HXBMOXWVYIRYHK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,151.36,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.819988880942282,CC(C)N(CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1)C(C)C
1358,CHEMBL1483,HXHWSAZORRCQMX-UHFFFAOYSA-N,ALBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
1359,CHEMBL1483,HXHWSAZORRCQMX-UHFFFAOYSA-N,ALBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
1360,CHEMBL1824784,HXOMGUPFBWZKBK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21788137.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of H1 receptor by NIMH PDSP,N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (s) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2CC3CC1CC(C2)N3CC4=CC=CC=C4.Cl
1363,CHEMBL74355,HXTGXYRHXAGCFP-OAQYLSRUSA-N,VOLINANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.0,COC1=CC=CC(=C1OC)[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O
1364,,HXTGXYRHXAGCFP-UHFFFAOYSA-N,MDL 100907,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15999145.0,Ki,=,66.7,NM,,,,,,,,,,,,,,,,,,,,7.175874166083451,COC1=CC=CC(=C1OC)C(C2CCN(CC2)CCC3=CC=C(C=C3)F)O
1365,CHEMBL595,HYAFETHFCAUJAY-UHFFFAOYSA-N,PIOGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
1366,CHEMBL595,HYAFETHFCAUJAY-UHFFFAOYSA-N,PIOGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
1367,CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
1368,CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
1369,CHEMBL56367,HYWYRSMBCFDLJT-UHFFFAOYSA-N,NIMESULIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2
1370,CHEMBL56367,HYWYRSMBCFDLJT-UHFFFAOYSA-N,NIMESULIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2
1372,CHEMBL686,HYYBABOKPJLUIN-UHFFFAOYSA-N,MEFENAMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C
1373,CHEMBL686,HYYBABOKPJLUIN-UHFFFAOYSA-N,MEFENAMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C
1374,CHEMBL64100,HZCFDQSTHWNXEC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,354.81,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.450004148469349,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3CCC3
1376,CHEMBL568400,HZPGVFKYDDQWIZ-GASCZTMLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,390.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4089353929735005,CC1=CC(=NC(=N1)NC2CCC(CC2)NC(=O)C3=CC(=C(C=C3)Cl)Cl)N(C)C
1379,CHEMBL107,IAKHMKGGTNLKSZ-INIZCTEOSA-N,COLCHICINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
1380,CHEMBL107,IAKHMKGGTNLKSZ-INIZCTEOSA-N,COLCHICINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
1382,CHEMBL504,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,DIMETHYL SULFOXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)C
1383,CHEMBL504,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,DIMETHYL SULFOXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)C
1384,CHEMBL239099,IBEQZETWFPHMMF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)C#N.C(=O)O
1385,CHEMBL1090527,IBILQKIYEWGQDQ-GFCCVEGCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,0.3,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.522878745280337,C[C@H](C1=C(CC2=C1C=CC(=C2)F)CCN(C)C)C3=NC=CS3
1386,CHEMBL3215298,IBSREHMXUMOFBB-JFUDTMANSA-N,ABAMECTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1/C=C/C=C/2\CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](C/C=C(/[C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)\C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C(C)C)C)O
1387,CHEMBL3215298,IBSREHMXUMOFBB-JFUDTMANSA-N,ABAMECTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1/C=C/C=C/2\CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](C/C=C(/[C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)\C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C(C)C)C)O
1388,CHEMBL2207660,IBTMKWBYOYIWBF-GFCCVEGCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415902,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=C(NN=C3)C(F)(F)F)O)Cl
1389,CHEMBL592752,IBUHDDLETPJVGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,40.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=CC=C4
1390,CHEMBL592752,IBUHDDLETPJVGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,146.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as reduction of histamine-induced intracellular calcium spike at phase 2 treated 20 to 30 seconds after histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.835647144215563,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=CC=C4
1391,CHEMBL104994,IBVAFMSEJOGFLC-RDJZCZTQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,43000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.366531544420414,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)[C@H](CO)N
1392,CHEMBL608151,IBZJKEOJOGAMGJ-COPLHBTASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20170186.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.0,CCOC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl
1393,CHEMBL595180,ICAQZJCLBRKWBG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773175.0,Ki,>,1000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in Sf9 cells co-expressing RGS4,"2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CN1CCN(CC1)C2=NC(=NC(=C2)NCC3=C(C=CC=C3Cl)Cl)N
1394,CHEMBL101748,ICDXLEXUWOLRPG-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,8900.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.050609993355088,C1CN(C[C@H]1NS(=O)(=O)C2=CC=CC(=C2)C#N)CCCOC3=CC=C(C=C3)C(=O)C4CC4
1396,CHEMBL1935573,ICIGFIHEQAKGAX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153663.0,Ki,=,6422.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human H1 receptor expressed in HEK cell membranes,Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.192329698769516,CN1CCN(CC1)C2=NC(=NC3=C2C=CC(=C3)C4=CC=CO4)N
1398,CHEMBL1200585,ICMWWNHDUZJFDW-DHODBPELSA-N,OXYMETHOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C
1399,CHEMBL1200585,ICMWWNHDUZJFDW-DHODBPELSA-N,OXYMETHOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C
1401,CHEMBL435949,IDBBDQXTEVOOKW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC=CC=C1N2CCN(CC2)CC3=CNC4=C3C=CC=N4
1403,CHEMBL1910383,IDNLJMLLYBSJEB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,223.87,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.650004100737144,C1CN(CCN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)C4=CC5=CC=CC=C5N4
1405,CHEMBL826,IDYZIJYBMGIQMJ-UHFFFAOYSA-N,ENOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O
1406,CHEMBL826,IDYZIJYBMGIQMJ-UHFFFAOYSA-N,ENOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O
1407,CHEMBL2106399,IEMDOFXTVAPVLX-YWQHLDGFSA-N,KITASAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O
1408,CHEMBL2106399,IEMDOFXTVAPVLX-YWQHLDGFSA-N,KITASAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O
1409,CHEMBL85735,IEMJYQZKJFERDW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,5.89,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.229884705212898,CC1=CC2=C(CC3=CC=CC=C3C4N2OC(C4)CN(C)C)C=C1
1410,CHEMBL2,IENZQIKPVFGBNW-UHFFFAOYSA-N,PRAZOSIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC
1411,CHEMBL2,IENZQIKPVFGBNW-UHFFFAOYSA-N,PRAZOSIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC
1412,CHEMBL1940419,IESJRUUOIHDONG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,212.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,6.673664139071248,C1CN(CCN1CCCSC2=CC=C(C=C2)F)C3=CC=CC=N3
1413,CHEMBL591568,IESQFAFNQAYROM-SDNWHVSQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,345.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.462180904926726,CN1CCC2C(C1)C3=CC=CC=C3N2/C=C/C4=CC=CC=C4
1414,CHEMBL591568,IESQFAFNQAYROM-SDNWHVSQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,2130.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as reduction of histamine-induced intracellular calcium spike at phase 2 treated 20 to 30 seconds after histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.671620396561262,CN1CCC2C(C1)C3=CC=CC=C3N2/C=C/C4=CC=CC=C4
1416,CHEMBL153062,IGFHQQFPSIBGKE-UHFFFAOYSA-N,4-NONYLPHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCCCCC1=CC=C(C=C1)O
1417,CHEMBL153062,IGFHQQFPSIBGKE-UHFFFAOYSA-N,4-NONYLPHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCCCCC1=CC=C(C=C1)O
1418,CHEMBL2171038,IGLADUDHPDHSRD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,CC1=CC=CC=C1S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
1419,CHEMBL1935441,IGUBZXXWVQQSPY-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2[C@H]4CNCCO4
1420,CHEMBL2171048,IGXXJZSHANKJAD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934842,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=C(C=C(C=C4)Cl)C
1421,CHEMBL2207658,IGYNNXYCDMNULT-LLVKDONJSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.79997073344623,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=C(NN=C3)C(F)(F)F)O
1422,CHEMBL1767151,IGZMIXBCHNOMPG-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.100015437450609,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4CCCCC4
1423,CHEMBL179166,IHIXIJGXTJIKRB-UHFFFAOYSA-N,SODIUM ORTHOVANAD,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,[O-][V](=O)([O-])[O-].[Na+].[Na+].[Na+]
1424,CHEMBL179166,IHIXIJGXTJIKRB-UHFFFAOYSA-N,SODIUM ORTHOVANAD,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,[O-][V](=O)([O-])[O-].[Na+].[Na+].[Na+]
1425,CHEMBL264374,IIBYAHWJQTYFKB-UHFFFAOYSA-N,BEZAFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl
1426,CHEMBL264374,IIBYAHWJQTYFKB-UHFFFAOYSA-N,BEZAFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl
1427,CHEMBL923,IIDJRNMFWXDHID-UHFFFAOYSA-N,RISEDRONIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
1428,CHEMBL923,IIDJRNMFWXDHID-UHFFFAOYSA-N,RISEDRONIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
1429,CHEMBL1222692,IIRIKFXWBJTDCC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,63.1,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755866,C1CC(CCC1C(=O)O)N2CCN(CC2)C3=CC4=CC=CC=C4CN5C3=NC=C5
1430,CHEMBL1222692,IIRIKFXWBJTDCC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,125.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455316,C1CC(CCC1C(=O)O)N2CCN(CC2)C3=CC4=CC=CC=C4CN5C3=NC=C5
1431,CHEMBL418971,IISBACLAFKSPIT-UHFFFAOYSA-N,BISPHENOL A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O
1432,CHEMBL418971,IISBACLAFKSPIT-UHFFFAOYSA-N,BISPHENOL A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O
1434,CHEMBL1669414,IIVFRUJVDGTOEB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,49.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.309803919971486,C1C(CN1CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4)F
1435,CHEMBL1669424,IJFPVAYNHAMKAK-SFHVURJKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,13.9,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.856985199745905,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=CC=N4
1437,CHEMBL138458,IJKYJDDNDXAREJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11784148.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of mepyramine binding to Histamine H1 receptor,Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.,J. Med. Chem.,PUBLICATION,,5.096910013008056,COC1CC2=CC=CC=C2C3(O1)CCN(CC3)CCCC4=CC=CC=C4
1438,CHEMBL264418,IJMPFBJUROFOGZ-NVXWUHKLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18387300.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,C1CO[C@H](CN1)[C@@H](C2=CC=CC=C2)OC3=C(C(=CC=C3)F)F
1440,CHEMBL589147,IJQSFAYWVZPICY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,66.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.180456064458132,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=C(C=C4)OC
1441,CHEMBL2207279,IKBGPCPPFWCFRO-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892137,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC(=C4)F)O
1442,CHEMBL255566,IKHRYIGPRIAKFA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C(C)(C)C
1444,CHEMBL2208424,IKNJHFAJDYZLNM-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,0.316,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.500312917381596,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)CC[C@@H](COC3=CC=CC(=C3)C#N)O
1445,CHEMBL257525,ILAPINSYTQOSTH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCC(C)N4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C(F)(F)F
1446,CHEMBL274525,ILLGYRJAYAAAEW-QMMMGPOBSA-N,ABT-418,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7518514.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC1=NOC(=C1)[C@@H]2CCCN2C
1447,CHEMBL595449,ILPANLYEJQKXKY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19646882.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.,Bioorg. Med. Chem.,PUBLICATION,,5.0,CC(C)(C)C1=CC=C(C=C1)C2=NC(=NN2C3=CC(=CC=C3)O)CN(C)C
1448,CHEMBL476934,ILSADQLMJBGMFK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2CN(C1CN2C3=CC=C(C=C3)Cl)CCCC(=O)C4=CC=C(C=C4)F
1449,CHEMBL255220,IMFZWBPHAPCFAZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)N=C(S5)C
1452,CHEMBL1767166,IMKMPTLRTHMERW-MGBGTMOVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.899974269892137,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)O
1453,CHEMBL1201146,IMONTRJLAWHYGT-ZCPXKWAGSA-N,NORETHINDRONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C
1454,CHEMBL1201146,IMONTRJLAWHYGT-ZCPXKWAGSA-N,NORETHINDRONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C
1455,CHEMBL1201151,IMSSROKUHAOUJS-MJCUULBUSA-N,MESTRANOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC
1456,CHEMBL1201151,IMSSROKUHAOUJS-MJCUULBUSA-N,MESTRANOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC
1457,CHEMBL428880,IMZMKUWMOSJXDT-UHFFFAOYSA-N,CROMOLYN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O
1458,CHEMBL428880,IMZMKUWMOSJXDT-UHFFFAOYSA-N,CROMOLYN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O
1459,CHEMBL506,INDBQLZJXZLFIT-UHFFFAOYSA-N,PRIMAQUINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2
1460,CHEMBL506,INDBQLZJXZLFIT-UHFFFAOYSA-N,PRIMAQUINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2
1462,CHEMBL862,INJOMKTZOLKMBF-UHFFFAOYSA-N,GUANFACINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl
1463,CHEMBL862,INJOMKTZOLKMBF-UHFFFAOYSA-N,GUANFACINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl
1464,CHEMBL1923523,INKZIWWVJYBNOA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,426.58,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,6.369999510099088,C1=CC=C(C=C1)C2N=C(NC3=NC4=CC=CC=C4N23)N
1465,CHEMBL101691,INULYJUFVOFQOR-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,9100.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.040958607678906,C1CN(C[C@H]1NS(=O)(=O)C2=CC=CC=C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
1466,CHEMBL1087,INWLQCZOYSRPNW-UHFFFAOYSA-N,MEPIVACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C
1467,CHEMBL1087,INWLQCZOYSRPNW-UHFFFAOYSA-N,MEPIVACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C
1468,CHEMBL3094214,IOCXEAYYBZJHHK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,=,1000.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CCN(CC1)CCCOC2=CC3=C(CCN(CC3)C4=CC=CC=C4)C=C2
1469,CHEMBL2207638,IOFOPIMDJBEBFZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,=,5500.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.259637310505756,COC1=CC=CC=C1N2CCN(CC2)CC3=C4C=CC=CC=C4C(=C3)CN5CCCCC5
1470,CHEMBL429132,IOJIPFCHEXMFMJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,5011.87,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.300000202445418,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C(C)(C)C
1472,CHEMBL614,IPEHBUMCGVEMRF-UHFFFAOYSA-N,PYRAZINAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=C(C=N1)C(=O)N
1473,CHEMBL614,IPEHBUMCGVEMRF-UHFFFAOYSA-N,PYRAZINAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=C(C=N1)C(=O)N
1476,CHEMBL1201346,IPOKCKJONYRRHP-FMQUCBEESA-N,BALSALAZID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
1477,CHEMBL1201346,IPOKCKJONYRRHP-FMQUCBEESA-N,BALSALAZID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O
1478,CHEMBL93556,IPQSEKMUUNQIQD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,IC50,=,309.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,6.510041520575165,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)F)OC
1479,CHEMBL93556,IPQSEKMUUNQIQD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.48,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.188424994129406,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)F)OC
1480,CHEMBL93556,IPQSEKMUUNQIQD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,309.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.510041520575165,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)F)OC
1482,CHEMBL155188,IPTWWGFBGODTAQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.0,C1=C(NC=N1)CCCCCCCCCCCCN
1483,CHEMBL155188,IPTWWGFBGODTAQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,1000000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-6.0,C1=C(NC=N1)CCCCCCCCCCCCN
1484,CHEMBL64608,IPWACKIXHGZBDD-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,1513.56,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.820000358220839,C[C@@H](CN)C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3
1485,CHEMBL61288,IPWACKIXHGZBDD-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,1737.8,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.760000207113128,C[C@H](CN)C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3
1486,CHEMBL255158,IQFXDOJWHPEPAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=C(C=CC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(F)(F)F
1487,CHEMBL1277311,IQNSUCJNGFOYPQ-JNDNBTNTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,125.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.900008766455316,C1C[C@H](CN(C1)C2CCC3(C2)CC4=CC=CC=C4OC5=CC=CC=C35)C(=O)O
1488,CHEMBL1502,IQPSEEYGBUAQFF-UHFFFAOYSA-N,PANTOPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC
1489,CHEMBL1502,IQPSEEYGBUAQFF-UHFFFAOYSA-N,PANTOPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC
1490,CHEMBL1091775,IQWBKNWLBVZZLG-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,3.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.4089353929735,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN4CCC4
1491,CHEMBL1277312,IRGGYSVFJCBILG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.299988937677887,C1CC2(CC1N3CC(C3)C(=O)O)CC4=CC=CC=C4OC5=CC=CC=C25
1492,CHEMBL313604,IRIGJBAWLKWASO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,15.49,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.809948582240794,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C(=CC=C4)Cl
1493,CHEMBL182,IRSCQMHQWWYFCW-UHFFFAOYSA-N,GANCICLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
1494,CHEMBL182,IRSCQMHQWWYFCW-UHFFFAOYSA-N,GANCICLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
1495,CHEMBL695,IRYJRGCIQBGHIV-UHFFFAOYSA-N,TRIMETHADIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(C(=O)N(C(=O)O1)C)C
1496,CHEMBL695,IRYJRGCIQBGHIV-UHFFFAOYSA-N,TRIMETHADIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(C(=O)N(C(=O)O1)C)C
1498,CHEMBL14060,ISWSIDIOOBJBQZ-UHFFFAOYSA-N,PHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)O
1499,CHEMBL14060,ISWSIDIOOBJBQZ-UHFFFAOYSA-N,PHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)O
1500,CHEMBL592753,ITLPFSDCSSQVPC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,30.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=C(C=C4)F
1501,CHEMBL1774491,ITNVSKVARAVDNB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,41.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.3872161432802645,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4COC5=C3C=C(C=C5)C(=O)O
1502,CHEMBL1650,ITRJWOMZKQRYTA-RFZYENFJSA-N,CORTISONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O
1503,CHEMBL1650,ITRJWOMZKQRYTA-RFZYENFJSA-N,CORTISONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O
1504,CHEMBL272480,ITTGLZWHTWLHSG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)C(=O)N(C6)C
1505,CHEMBL2030622,ITUMTGGIBOPIJQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CC3=CC=CC=C3
1506,CHEMBL13,IUBSYMUCCVWXPE-UHFFFAOYSA-N,METOPROLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O
1507,CHEMBL13,IUBSYMUCCVWXPE-UHFFFAOYSA-N,METOPROLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O
1508,CHEMBL499815,IUCNQFHEWLYECJ-CXCSZTQTSA-L,ATRACTYLOSIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC(=O)O[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2C[C@H]([C@H]3CC[C@@]45C[C@@H](CCC4[C@@]3(C2)C)C(=C)[C@H]5O)C(=O)O)CO)OS(=O)(=O)[O-])OS(=O)(=O)[O-].[K+].[K+]
1509,CHEMBL499815,IUCNQFHEWLYECJ-CXCSZTQTSA-L,ATRACTYLOSIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC(=O)O[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2C[C@H]([C@H]3CC[C@@]45C[C@@H](CCC4[C@@]3(C2)C)C(=C)[C@H]5O)C(=O)O)CO)OS(=O)(=O)[O-])OS(=O)(=O)[O-].[K+].[K+]
1511,CHEMBL2158837,IUIGATKKQCOBAF-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=CC=C4Cl)C(=O)O
1512,CHEMBL127516,IUWVALYLNVXWKX-UHFFFAOYSA-N,BUTAMBEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC(=O)C1=CC=C(C=C1)N
1513,CHEMBL127516,IUWVALYLNVXWKX-UHFFFAOYSA-N,BUTAMBEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC(=O)C1=CC=C(C=C1)N
1514,CHEMBL702,IVBHGBMCVLDMKU-GXNBUGAJSA-N,PIPERACILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
1515,CHEMBL702,IVBHGBMCVLDMKU-GXNBUGAJSA-N,PIPERACILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
1516,CHEMBL59715,IVCVMDSHKKVJIF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,524.81,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.279997898282849,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CN=CN3
1517,CHEMBL421026,IVRXDSYEBGHJBD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,2884.03,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.540000226349733,C1C2CN(CC2CN1)CCCOC3=CC=C(C=C3)C4=CC=C(C=C4)C#N
1518,CHEMBL1088882,IVVSQFRLZUQKBC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,12.0,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.920818753952375,CC1=CN=CC(=N1)CC2=C(CC3=CC=CC=C32)CCN(C)C
1519,CHEMBL589148,IWEWIZBBORJKBV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,40.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=C4)C=CC(=C3)F
1520,CHEMBL589148,IWEWIZBBORJKBV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,131.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as reduction of histamine-induced intracellular calcium spike at phase 2 treated 20 to 30 seconds after histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.882728704344236,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=C4)C=CC(=C3)F
1523,CHEMBL1643,IWUCXVSUMQZMFG-AFCXAGJDSA-N,RIBAVIRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
1524,CHEMBL1643,IWUCXVSUMQZMFG-AFCXAGJDSA-N,RIBAVIRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
1525,CHEMBL1517,IWVCMVBTMGNXQD-PXOLEDIWSA-N,OXYTETRACYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O
1526,CHEMBL1517,IWVCMVBTMGNXQD-PXOLEDIWSA-N,OXYTETRACYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O
1527,CHEMBL256488,IWYNZVSUMFYFCF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803203,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)N=C(O6)C(C)(F)F
1528,CHEMBL1201237,IXHBTMCLRNMKHZ-LBPRGKRZSA-N,LEVOBUNOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O
1529,CHEMBL1201237,IXHBTMCLRNMKHZ-LBPRGKRZSA-N,LEVOBUNOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O
1531,CHEMBL90063,IXZDLPYKIIELLK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,3162.28,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.499999678657065,C1=C(NC=N1)CCCCCCCCN
1532,CHEMBL90063,IXZDLPYKIIELLK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,25118864315095.8,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.4,C1=C(NC=N1)CCCCCCCCN
1533,CHEMBL1277679,IYAJUPFWKMPDJJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.299988937677887,C1CC2(CC1N3CCC(CC3)(C(=O)O)O)CC4=CC=CC=C4CC5=CC=CC=C25
1534,CHEMBL1278116,IYDOAHOHMRQFTJ-QWAKEFERSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,3.98,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,8.400116927926312,CN(C)C1CC[C@@]2(C1)CC3=CC=CC=C3CC4=CC=CC=C24
1535,CHEMBL60189,IYDTWLIGTRMAPG-SSEXGKCCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,12022.64,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920000156997057,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CC=C(C=C4)C5=CC=CC=C5)N
1536,CHEMBL327497,IYGHJULMISLCJX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.62,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.1791420105603,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC=CC=C3)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)F)OC
1537,CHEMBL327497,IYGHJULMISLCJX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,240.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.619788758288394,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC=CC=C3)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)F)OC
1538,CHEMBL417990,IYGYMKDQCDOMRE-ZWKOTPCHSA-N,BICUCULLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN1CCC2=CC3=C(C=C2[C@H]1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3
1539,CHEMBL633,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,AMIODARONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
1540,CHEMBL633,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,AMIODARONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I
1541,CHEMBL559147,IYOZTVGMEWJPKR-IJLUTSLNSA-N,Y-27632,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](C1CCC(CC1)C(=O)NC2=CC=NC=C2)N
1542,CHEMBL559147,IYOZTVGMEWJPKR-IJLUTSLNSA-N,Y-27632,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](C1CCC(CC1)C(=O)NC2=CC=NC=C2)N
1543,CHEMBL1743259,IZBNNCFOBMGTQX-UHFFFAOYSA-N,ETOPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,3100.0,NM,,,,,,,,,,,,,,,,,,,,5.508638306165727,CCC1=NN(C(=O)N1CC)CCCN2CCN(CC2)C3=CC(=CC=C3)Cl
1544,CHEMBL932,IZEKFCXSFNUWAM-UHFFFAOYSA-N,DIPYRIDAMOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
1545,CHEMBL932,IZEKFCXSFNUWAM-UHFFFAOYSA-N,DIPYRIDAMOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
1548,CHEMBL11603,IZVUQTNTFFLRBB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,<,10000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.0,C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=NC=C(N3)CCN
1551,CHEMBL1172,JAUOIFJMECXRGI-UHFFFAOYSA-N,DESLORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,16000.0,NM,,,,binding,,,,,,,,,,,,,,,,4.795880017344075,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4
1552,CHEMBL1172,JAUOIFJMECXRGI-UHFFFAOYSA-N,DESLORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,0.97,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.013228265733755,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4
1553,CHEMBL1172,JAUOIFJMECXRGI-UHFFFAOYSA-N,DESLORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,9.98,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.000869458712629,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4
1554,CHEMBL1172,JAUOIFJMECXRGI-UHFFFAOYSA-N,DESLORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.16,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.935542010773082,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4
1555,CHEMBL440864,JAUZYQXKUMRTOO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,208.93,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.679999195735272,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)F
1556,CHEMBL1222694,JAWGTZDKZCZPKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,CC1=CN2CC3=CC=CC=C3C=C(C2=N1)N4CCN(CC4)CC(C)(C)C(=O)O
1558,CHEMBL152122,JAXLDMXXLBSGOC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1258.93,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.899998417198648,C1=CC(=CN=C1)CCCCCCCCCCCCN
1559,CHEMBL152122,JAXLDMXXLBSGOC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,251188643150958.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.4,C1=CC(=CN=C1)CCCCCCCCCCCCN
1560,CHEMBL153479,JBDGDEWWOUBZPM-XYPYZODXSA-N,AMBROXOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O
1561,CHEMBL153479,JBDGDEWWOUBZPM-XYPYZODXSA-N,AMBROXOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O
1562,CHEMBL1381098,JBDOSUUXMYMWQH-UHFFFAOYSA-N,1-NAPHTHYLISOTHIOCYANATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC=C2N=C=S
1563,CHEMBL1381098,JBDOSUUXMYMWQH-UHFFFAOYSA-N,1-NAPHTHYLISOTHIOCYANATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC=C2N=C=S
1564,CHEMBL1433,JBIWCJUYHHGXTC-AKNGSSGZSA-N,DOXYCYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
1565,CHEMBL1433,JBIWCJUYHHGXTC-AKNGSSGZSA-N,DOXYCYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
1566,CHEMBL272899,JCCIEQKRVYXDHE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,311.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 (unknown origin),,Med Chem Res,PUBLICATION,,6.507239610973162,CCCC1=CC2=C(C=C1)N(C(=O)S2)CCN3CCCCCC3
1567,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,1500000.0,NM,,,,binding,,,,,,,,,,,,,,,,2.8239087409443187,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
1568,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,414.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.382999658879101,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
1569,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771458.0,Ki,=,37.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for H1 histamine receptor expressed in CHO cells,"Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines.",J. Med. Chem.,PUBLICATION,,7.431798275933005,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
1570,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,IC50,=,290.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,6.537602002101044,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
1571,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,311.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,6.507239610973162,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
1572,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,170.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.769551078621726,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
1573,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,20.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.698970004336019,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
1574,CHEMBL571391,JCHIUKROMYHWKE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,64.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.1938200260161125,CC1=CC=C(C=C1)CCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
1575,CHEMBL515,JCKYGMPEJWAADB-UHFFFAOYSA-N,CHLORAMBUCIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
1576,CHEMBL515,JCKYGMPEJWAADB-UHFFFAOYSA-N,CHLORAMBUCIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
1577,CHEMBL567791,JCSAJCBJJWFNIO-CALCHBBNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008056,CC1=CC(=NC(=N1)NC2CCC(CC2)NC(=O)C3=CC=C(C=C3)Cl)N(C)C
1578,CHEMBL256651,JCUBTYXXBDFOHF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CCC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CC(=C(C=C5)F)F
1579,CHEMBL101168,JCXKHYLLVKZPKE-UHFFFAOYSA-N,1-AMINOBENZOTRIAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)N=NN2N
1580,CHEMBL101168,JCXKHYLLVKZPKE-UHFFFAOYSA-N,1-AMINOBENZOTRIAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)N=NN2N
1583,CHEMBL302445,JDYFFOLXVFGXNI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,6025.6,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.219999701663429,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCNCC2
1584,CHEMBL1455766,JEJWQCTZDAJWOX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24690494.0,Ki,<,1000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),Antagonists of the kappa opioid receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=CC=C(C=C1)S(=O)(=O)NCC2=CC=C(C=C2)C(=O)NCCN(CC3=CC=CC=C3)C(C)C
1588,CHEMBL290106,JFIOVJDNOJYLKP-UHFFFAOYSA-N,BITHIONOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C=C(C(=C1SC2=C(C(=CC(=C2)Cl)Cl)O)O)Cl)Cl
1589,CHEMBL290106,JFIOVJDNOJYLKP-UHFFFAOYSA-N,BITHIONOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C=C(C(=C1SC2=C(C(=CC(=C2)Cl)Cl)O)O)Cl)Cl
1590,CHEMBL589389,JGJNEIOIBJGSFV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,104.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.982966660701219,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=C4)C=CC(=C3)OC
1591,CHEMBL353846,JGOAIQNSOGZNBX-UHFFFAOYSA-N,ADIPHENINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,112201.85,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,3.949999982311873,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2
1592,CHEMBL240187,JGPLBVWXJOJNGO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,CS(=O)(=O)C1=CC=C(C=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OCCCN4CCCCC4
1593,CHEMBL252556,JGPMMRGNQUBGND-UHFFFAOYSA-N,IDEBENONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO
1594,CHEMBL252556,JGPMMRGNQUBGND-UHFFFAOYSA-N,IDEBENONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO
1596,CHEMBL102925,JGRFHTWWWXEAHZ-QFIPXVFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,2300.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.638272163982407,CCC1=CC=C(C=C1)S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
1597,CHEMBL29,JGSARLDLIJGVTE-MBNYWOFBSA-N,BENZYLPENICILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C
1598,CHEMBL29,JGSARLDLIJGVTE-MBNYWOFBSA-N,BENZYLPENICILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C
1603,CHEMBL2158820,JHJPBZPNRYMQKP-DEOSSOPVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,25.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934842,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](C4=CC=CC=C4)C(=O)O
1604,CHEMBL2158819,JHJPBZPNRYMQKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(C4=CC=CC=C4)C(=O)O
1605,CHEMBL2158821,JHJPBZPNRYMQKP-XMMPIXPASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@H](C4=CC=CC=C4)C(=O)O
1608,CHEMBL394144,JHRLWHBYMHILPR-FSRHSHDFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O
1609,CHEMBL239300,JHRLWHBYMHILPR-FYZYNONXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C[C@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O
1610,CHEMBL1200679,JIAARYAFYJHUJI-UHFFFAOYSA-L,ZINC CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,[Cl-].[Cl-].[Zn+2]
1611,CHEMBL1200679,JIAARYAFYJHUJI-UHFFFAOYSA-L,ZINC CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,[Cl-].[Cl-].[Zn+2]
1612,CHEMBL1055,JIVPVXMEBJLZRO-UHFFFAOYSA-N,CHLORTHALIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O
1613,CHEMBL1055,JIVPVXMEBJLZRO-UHFFFAOYSA-N,CHLORTHALIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O
1614,CHEMBL516,JJCFRYNCJDLXIK-UHFFFAOYSA-N,CYPROHEPTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,0.06,NM,,,,,,,,,,,,,,,,,,,,10.221848749616356,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1
1616,CHEMBL516,JJCFRYNCJDLXIK-UHFFFAOYSA-N,CYPROHEPTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,3.7,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.431798275933005,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1
1617,CHEMBL516,JJCFRYNCJDLXIK-UHFFFAOYSA-N,CYPROHEPTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.43,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.366531544420413,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1
1618,CHEMBL326263,JJKPSOUEWPDPFS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,795.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,6.0996328713435295,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)OCCC4=CC=C(C=C4)C#N
1619,CHEMBL2030627,JJTSIVODPMDGBG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CCC3=CC=CC=C3
1620,CHEMBL1006,JKOQGQFVAUAYPM-UHFFFAOYSA-N,AMIFOSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CN)CNCCSP(=O)(O)O
1621,CHEMBL1006,JKOQGQFVAUAYPM-UHFFFAOYSA-N,AMIFOSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CN)CNCCSP(=O)(O)O
1622,CHEMBL443,JLKIGFTWXXRPMT-UHFFFAOYSA-N,SULFAMETHOXAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N
1623,CHEMBL443,JLKIGFTWXXRPMT-UHFFFAOYSA-N,SULFAMETHOXAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N
1625,CHEMBL2208428,JMGBVGDZPLNFAE-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,199.53,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446187,CS(=O)(=O)C1=CC=CC=C1C(=O)NC[C@H](CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)O
1626,CHEMBL12131,JMPFSEBWVLAJKM-UHFFFAOYSA-N,CLOSANTEL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)I)I)O)Cl)C(C#N)C3=CC=C(C=C3)Cl
1627,CHEMBL12131,JMPFSEBWVLAJKM-UHFFFAOYSA-N,CLOSANTEL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)I)I)O)Cl)C(C#N)C3=CC=C(C=C3)Cl
1628,CHEMBL437,JNMRHUJNCSQMMB-UHFFFAOYSA-N,SULFATHIAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1N)S(=O)(=O)NC2=NC=CS2
1629,CHEMBL437,JNMRHUJNCSQMMB-UHFFFAOYSA-N,SULFATHIAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1N)S(=O)(=O)NC2=NC=CS2
1630,CHEMBL589390,JNODQFNWMXFMEV-UHFFFAOYSA-N,LATREPIRDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,160.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.795880017344075,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C
1631,CHEMBL589390,JNODQFNWMXFMEV-UHFFFAOYSA-N,LATREPIRDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,1580.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.801342913045578,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C
1632,CHEMBL589390,JNODQFNWMXFMEV-UHFFFAOYSA-N,LATREPIRDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,158.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.801342913045577,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C
1633,CHEMBL589390,JNODQFNWMXFMEV-UHFFFAOYSA-N,LATREPIRDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,1580.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as reduction of histamine-induced intracellular calcium spike at phase 2 treated 20 to 30 seconds after histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.801342913045578,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C
1634,CHEMBL1540,JNTOCHDNEULJHD-UHFFFAOYSA-N,PENCICLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N
1635,CHEMBL1540,JNTOCHDNEULJHD-UHFFFAOYSA-N,PENCICLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N
1636,CHEMBL255567,JNTWHFOMVSHHKK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CCC1=NC2=C(S1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C(N=CO5)C
1637,CHEMBL590241,JNUCCWMHZZUFKE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20045641.0,Ki,=,242.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human cloned histamine H1 receptor,"9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.616184634019569,C1C2=CC=CC=C2C(C3=CC=CC=C31)CNCCC4=CC=CC=C4
1638,CHEMBL418666,JOFVFDZMGRFHQG-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,4677.35,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.330000131185909,CC[C@@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N
1639,CHEMBL302829,JOFVFDZMGRFHQG-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,2089.3,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.679999195735272,CC[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N
1640,CHEMBL302829,JOFVFDZMGRFHQG-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,70794.58,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.149999990420336,CC[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N
1641,CHEMBL2204360,JOJYHYRCIYAVHN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21486038.0,Ki,=,180.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,6.7447274948966935,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C.Cl
1642,CHEMBL560517,JONUVZHQXKYZDL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,>,500.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=C(C=CC=C53)C(=O)O
1643,CHEMBL462547,JOYRKODLDBILNP-UHFFFAOYSA-N,URETHANE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N
1644,CHEMBL462547,JOYRKODLDBILNP-UHFFFAOYSA-N,URETHANE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N
1645,CHEMBL271909,JOZMHQIYXRYITJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,251.19,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)N=C(S6)C
1646,CHEMBL2207286,JPDUMUHTXIBGHJ-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892137,CN(C)S(=O)(=O)C1=CC2=C(C=C1)C(=CNC2=O)C(=O)NC[C@H](CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl)O
1647,CHEMBL1940404,JPTSMZMSIACDAD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,698.6,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.155771418698372,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCOC3=CC=C(C=C3)F
1648,CHEMBL96141,JPUGXAMECQJERZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.47,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.1890957193313,CCOCCN1C2=CC=CC=C2N=C1C(=O)C3CCN(CC3)CCC4(CCN(C4)C(=O)C5=CC(=C(C(=C5)OC)OC)OC)C6=CC(=C(C=C6)Cl)Cl
1649,CHEMBL271066,JQEQULOLEPTBRS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,158.49,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593398,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OCC(=O)N6
1650,CHEMBL392713,JQJNQYUMEBRJKC-FERBBOLQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C[C@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC(=CC(=C4)F)F.C(=O)O
1651,CHEMBL239081,JQJNQYUMEBRJKC-GMUIIQOCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC(=CC(=C4)F)F.C(=O)O
1654,CHEMBL270852,JQVYPXIHEOFUGD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCCN4CCC5=CC6=C(C=C5CC4)C(=O)N(C6)C(C)C
1655,CHEMBL374478,JQXXHWHPUNPDRT-WLSIYKJHSA-N,RIFAMPICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C
1656,CHEMBL374478,JQXXHWHPUNPDRT-WLSIYKJHSA-N,RIFAMPICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C
1657,CHEMBL926,JRWZLRBJNMZMFE-UHFFFAOYSA-N,DOBUTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O
1658,CHEMBL926,JRWZLRBJNMZMFE-UHFFFAOYSA-N,DOBUTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O
1659,CHEMBL1592,JSDRRTOADPPCHY-HSQYWUDLSA-N,QUINAPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O
1660,CHEMBL1592,JSDRRTOADPPCHY-HSQYWUDLSA-N,QUINAPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O
1661,CHEMBL323517,JSPIFTWKMOPKHZ-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,37000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.431798275933005,C1CN(C[C@H]1NC(=O)C2=CSC(=N2)C3=CN=CC=C3)CCCOC4=CC=C(C=C4)C(=O)C5CC5
1662,CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C
1663,CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C
1665,CHEMBL258930,JTCQOAITNDJYSA-IEBWSBKVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18387300.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,C1COC2=C1C=CC=C2O[C@@H]([C@H]3CNCCO3)C4=CC=CC=C4
1666,CHEMBL141,JTEGQNOMFQHVDC-NKWVEPMBSA-N,LAMIVUDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N
1667,CHEMBL141,JTEGQNOMFQHVDC-NKWVEPMBSA-N,LAMIVUDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N
1668,CHEMBL315772,JTLCTTWVUAIQHD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,2.34,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.630784142589857,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=C(C=C4)Cl
1669,CHEMBL315772,JTLCTTWVUAIQHD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12443779.0,IC50,=,2.34,NM,,,,,,,,,,,,,,,Binding affinity against Histamine H1 receptor,2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT(2C) antagonist with potential anxiolytic properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.630784142589857,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=C(C=C4)Cl
1670,CHEMBL84158,JTVPZMFULRWINT-UHFFFAOYSA-N,TIAPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC
1671,CHEMBL84158,JTVPZMFULRWINT-UHFFFAOYSA-N,TIAPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC
1672,CHEMBL1537,JTWOMNBEOCYFNV-NFFDBFGFSA-N,AZLOCILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C
1673,CHEMBL1537,JTWOMNBEOCYFNV-NFFDBFGFSA-N,AZLOCILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C
1675,CHEMBL102984,JUQYDUYFGBPURU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3467.37,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4599998126889995,CC1CCCCN1CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
1676,CHEMBL255417,JURMKPGGUGOQIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)C(C)CCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)Br
1677,CHEMBL429023,JUVIOZPCNVVQFO-HBGVWJBISA-N,ROTENONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC
1678,CHEMBL429023,JUVIOZPCNVVQFO-HBGVWJBISA-N,ROTENONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC
1680,CHEMBL2203551,JUWUZLUBIRHYMM-LBPRGKRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor after 1.5 hrs by microbeta scintillation counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,C1C[C@H](NC1)COC2=NOC(=C2)COC3=CC=CC=C3
1681,CHEMBL236610,JVCJWEYSNNCGKX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,266.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.575118363368933,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=CC=CC=C4O3)Cl
1682,CHEMBL2158832,JVDFBAQLTSMMBQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)CC4=CC(=CC=C4)C(=O)O
1684,CHEMBL1783968,JVIRLKXDBNCSGU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,220.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.657577319177793,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)C(F)(F)F
1685,CHEMBL1783968,JVIRLKXDBNCSGU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)C(F)(F)F
1688,CHEMBL591803,JVPBPESGJIUWIZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,35.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.455931955649724,CN1CCC2=C(C1)C3=C(N2CCC4=CC=C(C=C4)C(F)(F)F)C=CC(=C3)F
1689,CHEMBL1200559,JVTAAEKCZFNVCJ-UHFFFAOYSA-N,LACTIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C(=O)O)O
1690,CHEMBL1200559,JVTAAEKCZFNVCJ-UHFFFAOYSA-N,LACTIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C(=O)O)O
1691,CHEMBL1670,JWBOIMRXGHLCPP-UHFFFAOYSA-N,MITOTANE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl
1692,CHEMBL1670,JWBOIMRXGHLCPP-UHFFFAOYSA-N,MITOTANE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl
1693,CHEMBL1767147,JWDZDXFXHWMSGR-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,2.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.698970004336019,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC(=CC=C4)OC
1694,CHEMBL631,JWHAUXFOSRPERK-UHFFFAOYSA-N,PROPAFENONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O
1695,CHEMBL631,JWHAUXFOSRPERK-UHFFFAOYSA-N,PROPAFENONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O
1696,CHEMBL240395,JWVDVKRDYUKSCG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C(=O)N5CCC5.C(=O)O
1697,CHEMBL103828,JWVSNNPXFZNTNU-APWZRJJASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,56000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.251811972993799,C[C@H](C(=O)N[C@H]1CCN(C1)CCCOC2=CC=C(C=C2)C(=O)C)NC(=O)OC(C)(C)C
1698,CHEMBL320174,JWVSNNPXFZNTNU-LPHOPBHVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,60000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.221848749616356,C[C@@H](C(=O)N[C@H]1CCN(C1)CCCOC2=CC=C(C=C2)C(=O)C)NC(=O)OC(C)(C)C
1699,CHEMBL91157,JWYUBODPEUBFLH-FSTMKDAKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771448.0,Ki,=,113.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to Histamine H1 receptor,Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.,J. Med. Chem.,PUBLICATION,,6.94692155651658,C/C(=C\C1=CC=CC=C1)/CN2CCN(CC2)C[C@H]3[C@@H]4COC5=CC(=C(C=C5C4=NO3)OC)OC
1700,CHEMBL434,JWZZKOKVBUJMES-UHFFFAOYSA-N,ISOPROTERENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC(=C(C=C1)O)O)O
1701,CHEMBL434,JWZZKOKVBUJMES-UHFFFAOYSA-N,ISOPROTERENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC(=C(C=C1)O)O)O
1702,CHEMBL159,JXLYSJRDGCGARV-CFWMRBGOSA-N,VINBLASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
1703,CHEMBL159,JXLYSJRDGCGARV-CFWMRBGOSA-N,VINBLASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
1704,CHEMBL305338,JXOCVUPTHGIJET-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,56.23,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.250031916490597,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)CC3=CC=CC=C3
1705,CHEMBL389621,JYGXADMDTFJGBT-VWUMJDOOSA-N,HYDROCORTISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O
1706,CHEMBL389621,JYGXADMDTFJGBT-VWUMJDOOSA-N,HYDROCORTISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O
1708,CHEMBL1090197,JYRXHQCPLUTCMM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,7.7,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.113509274827518,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NN=CC=C3
1709,CHEMBL63323,JZFPYUNJRRFVQU-UHFFFAOYSA-N,NIFLUMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F
1710,CHEMBL63323,JZFPYUNJRRFVQU-UHFFFAOYSA-N,NIFLUMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F
1711,CHEMBL64461,JZOQPCYGADPKSS-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,37153.52,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.430000034012231,C1C[C@@H](NC1)C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
1712,CHEMBL117405,JZQKKSLKJUAGIC-NSHDSACASA-N,S(-)-PINDOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@@H](COC1=CC=CC2=C1C=CN2)O
1713,CHEMBL117405,JZQKKSLKJUAGIC-NSHDSACASA-N,S(-)-PINDOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@@H](COC1=CC=CC2=C1C=CN2)O
1714,CHEMBL500,JZQKKSLKJUAGIC-UHFFFAOYSA-N,PINDOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O
1715,CHEMBL500,JZQKKSLKJUAGIC-UHFFFAOYSA-N,PINDOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O
1716,CHEMBL435,JZUFKLXOESDKRF-UHFFFAOYSA-N,HYDROCHLOROTHIAZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl
1717,CHEMBL435,JZUFKLXOESDKRF-UHFFFAOYSA-N,HYDROCHLOROTHIAZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl
1718,CHEMBL1091778,KAWDUHFGBOIYCO-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,79000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.102372908709558,C[C@@H](C1=CN=CC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C
1719,CHEMBL1091777,KAWDUHFGBOIYCO-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,IC50,=,3500.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,C[C@H](C1=CN=CC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C
1720,CHEMBL1091776,KAWDUHFGBOIYCO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,10000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C1=CN=CC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C
1721,CHEMBL42335,KAXNWVHHUKHNDK-JOCHJYFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,91.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.040958607678906,CC1=C([C@H](CC(=O)N1)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)(C#N)C4=C(C=C(C=C4)F)C#N
1723,CHEMBL408208,KBAMXOZNCXYSJT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCN4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C(F)(F)F
1728,CHEMBL272588,KCFSZIDRLPEDRQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)N5C=CC(=CC5=N4)C(F)(F)F
1729,CHEMBL1196,KCLANYCVBBTKTO-UHFFFAOYSA-N,PROPARACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N
1730,CHEMBL1196,KCLANYCVBBTKTO-UHFFFAOYSA-N,PROPARACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N
1731,CHEMBL271729,KCLMHEWINSXASY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)N6C=C(C=CC6=N5)C(F)(F)F
1732,CHEMBL2158838,KCLONPRRKHVPLU-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,31.62,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.50003813440381,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=C(C=C4)Cl)C(=O)O
1733,CHEMBL1092494,KCSVGYHUQTUHTM-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,8.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.096910013008056,C[C@H](C1=C(SC2=CC=CC=C21)CCN(C)C)C3=C(C=CC=N3)Cl
1735,CHEMBL1753,KDLRVYVGXIQJDK-AWPVFWJPSA-N,CLINDAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl
1736,CHEMBL1753,KDLRVYVGXIQJDK-AWPVFWJPSA-N,CLINDAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl
1737,CHEMBL1092118,KEDAYBZXXNOGOP-LBPRGKRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,5.2,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.2839966563652,C[C@@H](C1=CN=CS1)C2=C(SC3=CC=CC=C32)CCN(C)C
1738,CHEMBL1259187,KEEXCUUQRQNRNF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,64.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,7.1938200260161125,CC(=O)NCC1=CC2=C(C=C1)N(C=C2C3CCN(CC3)CCN4CCNC4=O)C5=CC=C(C=C5)F
1740,CHEMBL400612,KENVEDVQQZAGDU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CCCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.C(=O)O
1742,CHEMBL392532,KEQCAAQBOMIVCB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O
1745,CHEMBL351231,KFHYZKCRXNRKRC-MRXNPFEDSA-N,ABT-239,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15608078.0,Ki,=,1621.81,NM,,,,,,,,,,,,,,,,,,,,5.790000026071145,C[C@@H]1CCCN1CCC2=CC3=C(O2)C=CC(=C3)C4=CC=C(C=C4)C#N
1746,CHEMBL273166,KFMDKMLEGDZMCX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)CC7CC7
1747,CHEMBL101692,KGDAOALFCOEYFT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CNC=C3
1748,CHEMBL256474,KGDPFNITOFAOLP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)C(C)(F)F
1750,CHEMBL287671,KGZWRXWYLPRJCF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)C5=CC=CC=C5
1751,CHEMBL942,KHOITXIGCFIULA-UHFFFAOYSA-N,BISACODYL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3
1752,CHEMBL942,KHOITXIGCFIULA-UHFFFAOYSA-N,BISACODYL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3
1753,CHEMBL272297,KHTUQDQSUXMHQA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=NN(C(=C1)C2=NC3=C(O2)C=CC4=C3CCN(CC4)CCCSC5=NN=C(N5C)C6=C(N=CO6)C)C
1754,CHEMBL175782,KIAVPENCSGKVQP-UHFFFAOYSA-N,METHIMEPIP,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771452.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine binding to COS-7 cell membranes expressing human histamine H1 receptor,N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist.,J. Med. Chem.,PUBLICATION,,5.0,CN1CCC(CC1)CC2=CN=CN2
1755,CHEMBL2376804,KICLSPYVVBSUFF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23558237.0,Ki,=,20892.96,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human histamine H1 receptor expressed in HEK cells,"A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.68000002720016,CNC1CN(C1)C2=NC(=NC3=C2N=CC(=C3)C4CC4)N
1756,CHEMBL26880,KINYVKAOICLKCC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12657274.0,Ki,<,1905.46,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine (H1) receptor,Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.720000163638921,C1CCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N4CCCC4
1757,CHEMBL609579,KISZTEOELCMZPY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,2758.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,5.559405738160169,C1=CC=C(C=C1)C(CCN)C2=CC=CC=C2
1758,CHEMBL64120,KIUNCIUUHAZFFW-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,46773.51,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.330000038335378,CC(C)(C)OC(=O)N1CCC[C@@H]1C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
1759,,KIWQWJKWBHZMDT-GSVOUGTGSA-N,D-HOMOCYSTEINE THIOLACTONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CSC(=O)[C@@H]1N
1760,CHEMBL568892,KIZHXXNZJUOENQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,20.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.698970004336019,COC(=O)C1=CC=C(C=C1)CCCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
1764,CHEMBL13209,KJONHKAYOJNZEC-UHFFFAOYSA-N,NITRAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3
1765,CHEMBL13209,KJONHKAYOJNZEC-UHFFFAOYSA-N,NITRAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3
1766,CHEMBL13209,KJONHKAYOJNZEC-UHFFFAOYSA-N,NITRAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3
1767,CHEMBL293492,KJPRLNWUNMBNBZ-QPJJXVBHSA-N,CINNAMALDEHYDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)/C=C/C=O
1768,CHEMBL293492,KJPRLNWUNMBNBZ-QPJJXVBHSA-N,CINNAMALDEHYDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)/C=C/C=O
1769,CHEMBL1092126,KJQCJXUDPPZASI-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,9.3,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.031517051446064,CC1=C(N=CC=C1)[C@H](C)C2=C(SC3=CC=CC=C32)CCN(C)C
1772,CHEMBL63631,KJWJYNTUXOGLFR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,11220.18,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.950000175844591,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)S(=O)(=O)C(C)C
1773,CHEMBL14192,KKKDZZRICRFGSD-UHFFFAOYSA-N,BENZYLIMIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CN2C=CN=C2
1774,CHEMBL14192,KKKDZZRICRFGSD-UHFFFAOYSA-N,BENZYLIMIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CN2C=CN=C2
1777,CHEMBL58,KKZJGLLVHKMTCM-UHFFFAOYSA-N,MITOXANTRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
1778,CHEMBL58,KKZJGLLVHKMTCM-UHFFFAOYSA-N,MITOXANTRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO
1779,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,16.12,NM,,,,,,,,,,,,,,,,,,,,7.792634962530928,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
1780,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,16.0,NM,,,,,,,,,,,,,,,,,,,,7.795880017344075,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
1781,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,19.0,NM,,,,,,,,,,,,,,,,,,,,7.721246399047171,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
1782,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,72.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.142667503568732,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
1783,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,8.41,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.075204004202087,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC
1784,CHEMBL1092765,KLFVGKSTNOVPOR-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,1.7,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.769551078621726,C[C@H](C1=C(N=CC=C1)F)C2=C(SC3=CC=CC=C32)CCN(C)C
1786,CHEMBL321709,KLHSXAZZKUOFFG-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,1500.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,C1CN(C[C@H]1NS(=O)(=O)C2=CC=C(C=C2)Br)CCCOC3=CC=C(C=C3)C(=O)C4CC4
1788,CHEMBL2207668,KLPJSXVRXSMWBK-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,501.19,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,C1CN(CCC1OC2=CC=C(C=C2)C#N)C[C@@H](CNC(=O)C3=CNC(=O)C4=CC=CC=C43)O
1789,CHEMBL460,KLPWJLBORRMFGK-UHFFFAOYSA-N,MOLINDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C
1790,CHEMBL460,KLPWJLBORRMFGK-UHFFFAOYSA-N,MOLINDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C
1791,CHEMBL460,KLPWJLBORRMFGK-UHFFFAOYSA-N,MOLINDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C
1792,CHEMBL460,KLPWJLBORRMFGK-UHFFFAOYSA-N,MOLINDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,2130.0,NM,,,,,,,,,,,,,,,,,,,,5.671620396561262,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C
1793,CHEMBL2030635,KLUCWWVQVUXBSE-UHFFFAOYSA-N,N-(2-PHENYLETHYL)PYRROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CCC2=CC=CC=C2
1794,CHEMBL64896,KMEARAZYHMRMGA-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN[C@@H]1C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
1795,CHEMBL305144,KMEARAZYHMRMGA-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,12589.25,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.900000142057633,C1CN[C@H]1C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
1796,CHEMBL2146803,KMFDXNUGIFDFHQ-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.513,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.289882634888183,COCCN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
1797,CHEMBL2207633,KMVWYPYWHLOVLW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC=CC=C1N2CCN(CC2)CC3=CC(=C4C3=CC=CC=C4)C#CC5=CC=CC=C5
1798,CHEMBL1518,KNAHARQHSZJURB-UHFFFAOYSA-N,PROPYLTHIOURACIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1=CC(=O)NC(=S)N1
1799,CHEMBL1518,KNAHARQHSZJURB-UHFFFAOYSA-N,PROPYLTHIOURACIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1=CC(=O)NC(=S)N1
1800,CHEMBL2432046,KNBHNNRMMAKKFI-SEDVZXITSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,=,1359.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.866780543267506,COC1=C(C=C(C=C1)CN[C@H]2C3C4CC5C2C6C3CC4C56)OC
1802,CHEMBL565,KNHUKKLJHYUCFP-UHFFFAOYSA-N,CLOFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl
1803,CHEMBL565,KNHUKKLJHYUCFP-UHFFFAOYSA-N,CLOFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl
1804,CHEMBL105952,KNMJAZUTBMPTPA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,162.18,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.790002703917631,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=CC=C3[N+](=O)[O-]
1806,CHEMBL429136,KNZNKJDEMHGXSO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18023344.0,Ki,=,18.3,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.73754891026957,CC1C2=C(C=CC(=C2Cl)Cl)NC(=NCC(F)F)N1
1807,CHEMBL256694,KNZNKJDEMHGXSO-YFKPBYRVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18023344.0,Ki,=,2.6,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.585026652029182,C[C@H]1C2=C(C=CC(=C2Cl)Cl)NC(=NCC(F)F)N1
1809,CHEMBL2208417,KOACYGPEOVSJCA-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,501.19,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,C1CN(CCC1NC[C@@H](COC2=CC=C(C=C2)C#N)O)CC3=CC(=C(C=C3)Cl)Cl
1814,CHEMBL2208435,KOUMCBHTVFDPSI-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892137,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CN=NC4=CC=CC=C43)O
1815,CHEMBL1065,KPJZHOPZRAFDTN-ZRGWGRIASA-N,METHYSERGIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C
1816,CHEMBL1065,KPJZHOPZRAFDTN-ZRGWGRIASA-N,METHYSERGIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C
1817,CHEMBL498847,KPQZUUQMTUIKBP-UHFFFAOYSA-N,SECNIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=C(N1CC(C)O)[N+](=O)[O-]
1818,CHEMBL498847,KPQZUUQMTUIKBP-UHFFFAOYSA-N,SECNIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=C(N1CC(C)O)[N+](=O)[O-]
1819,CHEMBL557555,KPSRODZRAIWAKH-UHFFFAOYSA-N,CIPROFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl
1820,CHEMBL557555,KPSRODZRAIWAKH-UHFFFAOYSA-N,CIPROFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl
1821,CHEMBL62804,KPXVCGPCRXEDLT-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,53703.18,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.2699999970646445,C[C@@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N
1822,CHEMBL302196,KPXVCGPCRXEDLT-OAHLLOKOSA-N,A-304121,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,69183.1,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.159999981744464,C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N
1823,CHEMBL302196,KPXVCGPCRXEDLT-OAHLLOKOSA-N,A-304121,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12606603.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N
1824,CHEMBL701,KPYSYYIEGFHWSV-UHFFFAOYSA-N,BACLOFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(CC(=O)O)CN)Cl
1825,CHEMBL701,KPYSYYIEGFHWSV-UHFFFAOYSA-N,BACLOFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(CC(=O)O)CN)Cl
1826,CHEMBL141343,KPZQRBACZSLMPH-UHFFFAOYSA-N,U-78517F,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,14791.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,4.83000246293343,CC1=C(C2=C(CCC(O2)(C)CN3CCN(CC3)C4=NC(=NC(=C4)N5CCCC5)N6CCCC6)C(=C1O)C)C
1827,CHEMBL141343,KPZQRBACZSLMPH-UHFFFAOYSA-N,U-78517F,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1718.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.764976840504777,CC1=C(C2=C(CCC(O2)(C)CN3CCN(CC3)C4=NC(=NC(=C4)N5CCCC5)N6CCCC6)C(=C1O)C)C
1828,CHEMBL128,KQKPFRSPSRPDEB-UHFFFAOYSA-N,SUMATRIPTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C
1829,CHEMBL128,KQKPFRSPSRPDEB-UHFFFAOYSA-N,SUMATRIPTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C
1832,CHEMBL447,KQPKPCNLIDLUMF-UHFFFAOYSA-N,SECOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C
1833,CHEMBL447,KQPKPCNLIDLUMF-UHFFFAOYSA-N,SECOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C
1834,CHEMBL1208572,KQXDHUJYNAXLNZ-XQSDOZFQSA-N,SALINOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]([C@H]1CC[C@@H]([C@@H](O1)[C@@H](C)[C@@H]([C@H](C)C(=O)[C@H](CC)[C@@H]2[C@H](C[C@H]([C@]3(O2)C=C[C@H]([C@@]4(O3)CC[C@@](O4)(C)[C@H]5CC[C@@]([C@@H](O5)C)(CC)O)O)C)C)O)C)C(=O)O
1835,CHEMBL1208572,KQXDHUJYNAXLNZ-XQSDOZFQSA-N,SALINOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]([C@H]1CC[C@@H]([C@@H](O1)[C@@H](C)[C@@H]([C@H](C)C(=O)[C@H](CC)[C@@H]2[C@H](C[C@H]([C@]3(O2)C=C[C@H]([C@@]4(O3)CC[C@@](O4)(C)[C@H]5CC[C@@]([C@@H](O5)C)(CC)O)O)C)C)O)C)C(=O)O
1837,CHEMBL1261,KRKNYBCHXYNGOX-UHFFFAOYSA-N,CITRIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)C(CC(=O)O)(C(=O)O)O
1838,CHEMBL1261,KRKNYBCHXYNGOX-UHFFFAOYSA-N,CITRIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)C(CC(=O)O)(C(=O)O)O
1839,CHEMBL1669423,KRLJKEOQHOYBSK-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,28.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.552841968657781,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CN4C
1840,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,0.67,NM,,,,,,,,,,,,,,,,,,,,9.173925197299173,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
1841,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,0.95,NM,,,,,,,,,,,,,,,,,,,,9.022276394711152,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
1842,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,1.12,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.950781977329818,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
1843,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,4.78,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.320572103387882,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
1844,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.555,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.255707016877324,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
1845,CHEMBL605081,KRPHBUMURAALTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,112.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.950781977329818,CC1=CC=C(C=C1)CCN2C3=C(CN(CC3)C)C4=C2C=CC(=C4)C
1846,CHEMBL1752,KSCFJBIXMNOVSH-UHFFFAOYSA-N,DYPHYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O
1847,CHEMBL1752,KSCFJBIXMNOVSH-UHFFFAOYSA-N,DYPHYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O
1848,CHEMBL32749,KSEBMYQBYZTDHS-HWKANZROSA-N,FERULIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=CC(=C1)/C=C/C(=O)O)O
1849,CHEMBL32749,KSEBMYQBYZTDHS-HWKANZROSA-N,FERULIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=CC(=C1)/C=C/C(=O)O)O
1850,CHEMBL540445,KTEXNACQROZXEV-SLXBATTESA-N,PARTHENOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CCC[C@@]2([C@@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C
1851,CHEMBL540445,KTEXNACQROZXEV-SLXBATTESA-N,PARTHENOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CCC[C@@]2([C@@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C
1852,CHEMBL941,KTUFNOKKBVMGRW-UHFFFAOYSA-N,IMATINIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
1853,CHEMBL941,KTUFNOKKBVMGRW-UHFFFAOYSA-N,IMATINIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
1854,CHEMBL82635,KTWZXHKXAGXWOB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,6.03,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.219682687859848,CC1=C2CC3=CC=CC=C3C4CC(ON4C2=CC=C1)CN(C)C
1856,CHEMBL330719,KUAJFMGQGXJNCK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.55,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.183758700008218,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=NC=C6)C7=CC=CC=C7
1857,CHEMBL330719,KUAJFMGQGXJNCK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,285.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.54515513999149,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=NC=C6)C7=CC=CC=C7
1858,CHEMBL96158,KUCRPWOVGMMXDP-FDMCOVCTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,14.0,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.853871964321762,CN(C)CC1C[C@H]2[C@H](O1)C3=CC=CC=C3OC4=CC=CC=C24
1859,CHEMBL330713,KUCRPWOVGMMXDP-MRJVUNAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,32.6,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.486782399932061,CN(C)CC1C[C@@H]2[C@H](O1)C3=CC=CC=C3OC4=CC=CC=C24
1861,CHEMBL61396,KUPWVSPABUWQQB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,104.71,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.980011840408715,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=C(C=CO3)C
1862,CHEMBL24944,KVSKGMLNBAPGKH-UHFFFAOYSA-N,TRIBROMSALAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1NC(=O)C2=C(C(=CC(=C2)Br)Br)O)Br
1863,CHEMBL24944,KVSKGMLNBAPGKH-UHFFFAOYSA-N,TRIBROMSALAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1NC(=O)C2=C(C(=CC(=C2)Br)Br)O)Br
1864,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,0.65,NM,,,,,,,,,,,,,,,,,,,,9.187086643357144,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
1865,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,0.087,NM,,,,,,,,,,,,,,,,,,,,10.060480747381382,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
1866,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11170639.0,Ki,=,5.6,NM,,,,,,,,,,,,,,,Binding affinity towards human H1 receptor,Current and novel approaches to the drug treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,8.2518119729938,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
1867,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,,,,,,8.698970004336019,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
1868,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,3.5,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,8.455931955649724,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
1869,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,1.2,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.920818753952375,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
1870,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,2.8,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,8.55284196865778,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
1872,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24559051.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,J. Med. Chem.,PUBLICATION,,8.698970004336019,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
1873,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,13.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.886056647693163,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
1874,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.47,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.832682665251824,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
1875,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,7.0,NM,,,,,,,,,,,,,,,In vitro binding affinity of compound against histamine H1 neuronal receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.154901959985743,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
1876,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,10.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay,,MedChemComm,PUBLICATION,,8.0,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
1877,CHEMBL94788,KVYXGCNCFPIESF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,5.0,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.301029995663981,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCCC(=O)O)C6=CC(=C(C=C6)Cl)Cl
1879,CHEMBL327306,KWUQZAPLAOREKL-FDMCOVCTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,4.3,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.366531544420413,CN(C)CC1C[C@H]2[C@H](O1)C3=CC=CC=C3SC4=CC=CC=C24
1881,CHEMBL3409256,KWZBJWOQFABHPF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25557493.0,Ki,=,160.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in HEK-293 cells,Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.,Eur. J. Med. Chem.,PUBLICATION,,6.795880017344075,C1CN(CCN1CCCOC2=CC=CC=C2C(=O)N)C3=CC=CC4=C3C=CN4S(=O)(=O)C5=CC=CC=C5
1884,CHEMBL2208437,KXSMUDWNWWFRRE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,1258.93,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198648,CS(=O)(=O)C1=CC=CC=C1C(=O)NCC(CNC2CCN(CC2)CC3=CC(=C(C=C3)Cl)Cl)O
1885,CHEMBL9514,KYRVNWMVYQXFEU-UHFFFAOYSA-N,NOCODAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CS3
1886,CHEMBL9514,KYRVNWMVYQXFEU-UHFFFAOYSA-N,NOCODAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CS3
1888,CHEMBL1118,KYYIDSXMWOZKMP-UHFFFAOYSA-N,DESVENLAFAXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16675639.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
1889,CHEMBL304714,KZBINGTZAGPLQP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,741.31,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.130000141365475,CCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCC
1890,CHEMBL1910384,KZGYBDPASGTNOZ-QHCPKHFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,457.09,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.339998279897117,COC1=CC=C(C=C1)CN(CCN[C@H]2CCN(C2)C(=O)C3=CC4=CC=CC=C4N3)C5=CC=CC=N5
1892,CHEMBL468176,KZPYBMNBUZPMKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18640038.0,EC50,>,50000.0,NM,,,,,,,,,,,,,,,Agonist activity at histamine H1 receptor,Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,C1CN(CCC1C2=NC(=NO2)C3=C(C=C(C=C3)F)Cl)C4=CN=C5C=CC(=CC5=C4)Cl
1893,CHEMBL468176,KZPYBMNBUZPMKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18640038.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,C1CN(CCC1C2=NC(=NO2)C3=C(C=C(C=C3)F)Cl)C4=CN=C5C=CC(=CC5=C4)Cl
1895,CHEMBL293802,KZZIVOLMJPSDEP-UHFFFAOYSA-N,ARPROMIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,353.0,NM,,,,,,,,,,,,,,,,,,,,6.452225294612178,C1=CC=NC(=C1)C(CCNC(=NCCCC2=CN=CN2)N)C3=CC=C(C=C3)F
1896,CHEMBL3094130,LABRWGKKPFQRIQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,=,1258.93,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198648,C1CCN(CC1)CCCOC2=CC3=C(CCNCC3)C=C2
1897,CHEMBL258090,LAGGNVKIMAMGMQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)CC(F)(F)F
1899,CHEMBL1910378,LAKQJOXTAMPPOO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,169.82,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.770011163455189,COC1=CC=C(C=C1)CN(CCN2CCN(CC2)C(=O)C3=CC4=CC=CC=C4N3)C5=CC=CC=N5
1900,CHEMBL2031884,LBAKRWRQQGNMEB-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313242.0,Ki,=,7230.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 receptor,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.140861702705469,CCNC(=O)C1=CC=C(C=C1)C2=CC3=C(C=C2)C(=O)N(CC3)CCN4CCC[C@H]4C
1901,CHEMBL64321,LBCXFPZCIKKGSB-RUZDIDTESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,3311.31,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.480000159330324,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](CC3=CC=NC=C3)N
1902,CHEMBL62808,LBCXFPZCIKKGSB-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,2290.87,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.639999555020352,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@H](CC3=CC=NC=C3)N
1903,CHEMBL2030630,LCBQDWKMNGEPLD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CCCC3=CC(=CC=C3)F
1904,CHEMBL1088899,LCEUDZGEEHIOMS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,35.0,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.455931955649724,CC1=CN=C(C=N1)CC2=C(CC3=CC=CC=C32)CCN(C)C
1909,CHEMBL81485,LCKBEOTXTNWYRG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,10.72,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.969805214643249,CNCC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1
1910,CHEMBL179590,LDAIZSJPULESPS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,5.89,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human Histamine H1 receptor in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.229884705212898,CCOC(=O)N(CCC#CC1=CC=C(C=C1)OCCCCN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)O
1911,CHEMBL1094510,LDKQFEPUPKIHCG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,0.8,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.096910013008056,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CCOC4=CC=CC=C4
1912,CHEMBL549599,LDMXQNXCFMLIER-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.619788758288394,CNC1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
1913,CHEMBL360666,LDPRUJUFFYEDJC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,17.8,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human Histamine H1 receptor in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.749579997691106,C1CN(CCN1CCCCOC2=CC=C(C=C2)C#CCCN(C(=O)OCC3=CC=CC=C3)O)C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
1914,CHEMBL85155,LDUDMYAXGOQOGO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,15.85,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.79997073344623,CC1=CC2=C(C=C1)C3CC(ON3C4=CC=CC=C4C2)CN(C)C
1915,CHEMBL1201193,LEBVLXFERQHONN-INIZCTEOSA-N,LEVOBUPIVACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C
1916,CHEMBL1201193,LEBVLXFERQHONN-INIZCTEOSA-N,LEVOBUPIVACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C
1917,CHEMBL340816,LECUUDCCVOYUHG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,973.5,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.0116640441439495,C1CC2CC(CC1N2CCCC(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4
1918,CHEMBL2158792,LEHDCEDFGAFVGX-NDEPHWFRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,CC1=C(C=CC(=C1)OC2CCN(CC2)CC3CCN(CC3)[C@@](C)(CC4=CC=C(C=C4)F)C(=O)O)Cl
1921,CHEMBL1200391,LENZDBCJOHFCAS-UHFFFAOYSA-N,TROMETHAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(CO)(CO)N)O
1922,CHEMBL1200391,LENZDBCJOHFCAS-UHFFFAOYSA-N,TROMETHAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(CO)(CO)N)O
1923,CHEMBL61231,LESFXMYDPQCDFJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,933.25,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.030002001401658,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)CC(C)C
1924,CHEMBL43594,LEVRYVCMBBJQLU-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,616.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.210419287835575,CC1=C([C@H](CC(=O)N1C)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)(C#N)C4=C(C=C(C=C4)F)C#N
1925,CHEMBL437002,LEVTWCPGXIVKEH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3F
1926,CHEMBL437002,LEVTWCPGXIVKEH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3F
1927,CHEMBL366563,LEVWYRKDKASIDU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(C(C(=O)O)N)SSCC(C(=O)O)N
1928,CHEMBL808,LEZWWPYKPKIXLL-UHFFFAOYSA-N,ECONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl
1929,CHEMBL808,LEZWWPYKPKIXLL-UHFFFAOYSA-N,ECONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl
1930,CHEMBL63036,LFKNMWWWQLOXKE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,416.87,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3799993576999325,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=CC=N3
1931,CHEMBL545,LFQSCWFLJHTTHZ-UHFFFAOYSA-N,ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCO
1932,CHEMBL545,LFQSCWFLJHTTHZ-UHFFFAOYSA-N,ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCO
1933,CHEMBL557210,LFSBNTMFCXGIEC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,3.2,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.494850021680094,CN(CCO)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
1934,CHEMBL18797,LFWHFZJPXXOYNR-MFOYZWKCSA-N,SULINDAC SULFIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)SC)C=CC(=C2)F)CC(=O)O
1935,CHEMBL18797,LFWHFZJPXXOYNR-MFOYZWKCSA-N,SULINDAC SULFIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)SC)C=CC(=C2)F)CC(=O)O
1936,CHEMBL102390,LGBGBJRXINUEFH-AZUAARDMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,80000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.096910013008056,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)[C@@H](CO)NC(=O)OC(C)(C)C
1937,CHEMBL316968,LGBGBJRXINUEFH-ICSRJNTNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,75000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.1249387366083,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)[C@H](CO)NC(=O)OC(C)(C)C
1938,CHEMBL194659,LGHLMADLDHUIJY-MQSINFNDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,7.5,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.1249387366083,CN(C)C[C@H]1CC2[C@H](O1)C3=C(C=CC(=C3)F)OC4=CC=CC=C24
1939,CHEMBL195706,LGHLMADLDHUIJY-SHZHJNINSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,33.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,7.481486060122113,CN(C)C[C@@H]1CC2[C@H](O1)C3=C(C=CC(=C3)F)OC4=CC=CC=C24
1940,CHEMBL593988,LGIIUKGHECNJNZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,6.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,8.221848749616356,CN(C)CCC1C2=CC=CC=C2CC3=CC=CC=C13
1941,CHEMBL2171029,LGNOCEJCJLXMEA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415902,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC=C(C=C4)C5=NN(N=N5)CCCCC(=O)O
1944,CHEMBL156455,LGXVIGDEPROXKC-UHFFFAOYSA-N,"1,1-DICHLOROETHENE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=C(Cl)Cl
1945,CHEMBL156455,LGXVIGDEPROXKC-UHFFFAOYSA-N,"1,1-DICHLOROETHENE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=C(Cl)Cl
1946,CHEMBL1643902,LGZPNSXZRKGUES-DKSPCFMDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21146989.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor at 10 uM,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(CCC1=CC(=CC=C1)F)[C@H]2C3C4CC5C2C6C3CC4C56
1947,CHEMBL1643902,LGZPNSXZRKGUES-DKSPCFMDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.0,CN(CCC1=CC(=CC=C1)F)[C@H]2C3C4CC5C2C6C3CC4C56
1948,CHEMBL3233142,LHAPOGAFBLSJJQ-GUTACTQSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24559051.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,J. Med. Chem.,PUBLICATION,,6.0,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F
1950,CHEMBL82966,LHTXSHOSMCEFFX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,2.29,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.640164517660113,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C(=CC=C3)F
1951,CHEMBL293762,LHVRFUVVRXGZPV-UHFFFAOYSA-N,AMTHAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,EC50,=,15848.93,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.800000052738446,CC1=C(SC(=N1)N)CCN
1952,CHEMBL1090176,LHYWGVZKOTTYSZ-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,2.7,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.568636235841012,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)[C@@H](C)C3=NC=CN=C3OC
1953,CHEMBL1090176,LHYWGVZKOTTYSZ-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20800486.0,Ki,=,2.7,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.568636235841012,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)[C@@H](C)C3=NC=CN=C3OC
1954,CHEMBL2037604,LIEAKONJVOLXFZ-LSDHHAIUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22578490.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,5.0,C[C@@H]1CCCN1C[C@H](C)COC2=CC=C(C=C2)C3=CC(=O)NN=C3
1956,CHEMBL271631,LJDQESSYTJNKOI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CCC1=NC2=C(S1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C
1958,CHEMBL440512,LJVNYCDXBXGQIK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,87.0,NM,,,,,,,,,,,,,,,In vitro binding affinity of compound against histamine H1 neuronal receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.060480747381382,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CC[N+](CC4)(C)[O-]
1959,CHEMBL2079587,LKAJKIOFIWVMDJ-IYRCEVNGSA-N,STANOZOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=C(C4)NN=C5)C
1960,CHEMBL2079587,LKAJKIOFIWVMDJ-IYRCEVNGSA-N,STANOZOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=C(C4)NN=C5)C
1961,CHEMBL177,LKCWBDHBTVXHDL-RMDFUYIESA-N,AMIKACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N
1962,CHEMBL177,LKCWBDHBTVXHDL-RMDFUYIESA-N,AMIKACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N
1965,CHEMBL2171035,LKFICSFQSQYFJF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC=C(C=C4)Cl
1967,CHEMBL63560,LKJPYSCBVHEWIU-KRWDZBQOSA-N,(R)-BICALUTAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
1968,CHEMBL63560,LKJPYSCBVHEWIU-KRWDZBQOSA-N,(R)-BICALUTAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
1969,CHEMBL1910386,LLBZLFNYOYVBFX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,5.5,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.259637310505756,C1CN(CCC1NC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)CCN5CCN(CC5)C(=O)C6=CC7=CC=CC=C7N6
1970,CHEMBL2158793,LLEJNWFSXZIFMW-NDEPHWFRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450609,CC1=C(C=CC(=C1)F)OC2CCN(CC2)CC3CCN(CC3)[C@@](C)(CC4=CC=C(C=C4)F)C(=O)O
1973,CHEMBL1088898,LLKGAHXEIBHUNC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,63.0,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.200659450546418,CC1=NC=CN=C1CC2=C(CC3=CC=CC=C32)CCN(C)C
1974,CHEMBL1542,LMEKQMALGUDUQG-UHFFFAOYSA-N,AZATHIOPRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
1975,CHEMBL1542,LMEKQMALGUDUQG-UHFFFAOYSA-N,AZATHIOPRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
1976,CHEMBL302231,LMFNLINKCDGRTE-NTSWFWBYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@H]([C@@H]1C2=CN=CN2)CN
1977,CHEMBL292924,LMFNLINKCDGRTE-PHDIDXHHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@@H]([C@@H]1C2=CN=CN2)CN
1978,CHEMBL292558,LMFNLINKCDGRTE-RITPCOANSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@@H]([C@H]1C2=CN=CN2)CN
1979,CHEMBL305135,LMFNLINKCDGRTE-WDSKDSINSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@H]([C@H]1C2=CN=CN2)CN
1980,CHEMBL1054,LMJSLTNSBFUCMU-UHFFFAOYSA-N,TRICHLORMETHIAZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl
1981,CHEMBL1054,LMJSLTNSBFUCMU-UHFFFAOYSA-N,TRICHLORMETHIAZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl
1982,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,1886.79,NM,,,,,,,,,,,,,,,,,,,,5.724276434183983,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1983,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,1700.0,NM,,,,,,,,,,,,,,,,,,,,5.769551078621726,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1984,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,1900.0,NM,,,,,,,,,,,,,,,,,,,,5.721246399047171,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1985,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,790.0,NM,,,,,,,,,,,,,,,,,,,,6.102372908709558,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1986,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,260.0,NM,,,,,,,,,,,,,,,,,,,,6.585026652029182,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1987,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,1800.0,NM,,,,,,,,,,,,,,,,,,,,5.7447274948966935,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1988,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,730.0,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,6.136677139879544,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1989,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,440.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.356547323513812,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1990,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,440.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,6.356547323513812,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1991,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,440.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.356547323513812,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1992,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,2781.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.55579901113584,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1993,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,323.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.490797477668897,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F
1994,CHEMBL865,LNPDTQAFDNKSHK-UHFFFAOYSA-N,VALDECOXIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N
1995,CHEMBL865,LNPDTQAFDNKSHK-UHFFFAOYSA-N,VALDECOXIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N
1998,CHEMBL1744448,LOLFAJUUOFBGSF-KYIYJVAASA-N,BLEOMYCIN A2,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]([C@H]([C@@H](C)NC(=O)[C@H](C(C1=CN=CN1)O[C@H]2[C@H]([C@H]([C@@H]([C@@H](O2)CO)O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)OC(=O)N)O)NC(=O)C4=CC(=NC(=N4)C(CC(=O)N)NCC(C(=O)N)N)N)O)C(=O)N[C@@H](C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C.[Br-]
1999,CHEMBL1744448,LOLFAJUUOFBGSF-KYIYJVAASA-N,BLEOMYCIN A2,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]([C@H]([C@@H](C)NC(=O)[C@H](C(C1=CN=CN1)O[C@H]2[C@H]([C@H]([C@@H]([C@@H](O2)CO)O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)OC(=O)N)O)NC(=O)C4=CC(=NC(=N4)C(CC(=O)N)NCC(C(=O)N)N)N)O)C(=O)N[C@@H](C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C.[Br-]
2001,CHEMBL1824778,LPAMOYXJLQSGRI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21788137.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of H1 receptor by NIMH PDSP,N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (s) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2CC3CC1CC(C2)(N3CC4=CC(=CC=C4)F)O.Cl
2002,CHEMBL2171013,LPHIWCBAJGQIIF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,2.51,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.600326278518962,CC1=CC=C(C=C1)S(=O)(=O)N(C)C(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
2003,CHEMBL441687,LPLVUJXQOOQHMX-QWBHMCJMSA-N,GLYCYRRHIZIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O
2004,CHEMBL441687,LPLVUJXQOOQHMX-QWBHMCJMSA-N,GLYCYRRHIZIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O
2005,CHEMBL222863,LPMXVESGRSUGHW-HBYQJFLCSA-N,OUABAIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O
2006,CHEMBL222863,LPMXVESGRSUGHW-HBYQJFLCSA-N,OUABAIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O
2007,CHEMBL404,LPQZKKCYTLCDGQ-WEDXCCLWSA-N,TAZOBACTAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3
2008,CHEMBL404,LPQZKKCYTLCDGQ-WEDXCCLWSA-N,TAZOBACTAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3
2009,CHEMBL111861,LPYXTAPPNYMYOP-XDBTXSBWSA-N,CORTISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O
2010,CHEMBL111861,LPYXTAPPNYMYOP-XDBTXSBWSA-N,CORTISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O
2011,CHEMBL2207672,LQCZDIMQFUOGJG-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC(=C4)S(=O)(=O)C)O)Cl
2012,CHEMBL2207636,LQGNDHYNCHVOGU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC=CC=C1N2CCN(CC2)CC3=CC(=C4C3=CC=CC=C4)C#N
2013,CHEMBL94480,LQNLNHOIPAAEJI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.25,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.204119982655925,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CC=N6)C7=CC=C(C=C7)F
2014,CHEMBL891,LQOLIRLGBULYKD-JKIFEVAISA-N,CLOXACILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
2015,CHEMBL891,LQOLIRLGBULYKD-JKIFEVAISA-N,CLOXACILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O
2019,CHEMBL506247,LRBQNJMCXXYXIU-PPKXGCFTSA-N,TANNIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O
2020,CHEMBL506247,LRBQNJMCXXYXIU-PPKXGCFTSA-N,TANNIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O
2023,CHEMBL346230,LRTHKJMSTYBFFO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,0.5,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,9.301029995663981,CN(C)CCCC1C2=CC=CC=C2CC3=CC=CC=C13
2026,CHEMBL2207659,LSHDMKHXFDYKLP-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934842,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=C(NN=C3)C(F)(F)F)O
2027,CHEMBL158595,LSLKPVQOFVGVSL-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14741266.0,Ki,=,890.0,NM,,,,,,,,,,,,,,,Binding affinity towards histamine H1 receptor of human colon cells was determined,"Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.050609993355088,C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC(=C(C=C2)C3=NOC(=N3)CC4CCCC4)F)NC(=O)C5=CC=C(C=C5)N(C)C
2028,CHEMBL1566249,LSNWBKACGXCGAJ-UHFFFAOYSA-N,AMPIROXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3
2029,CHEMBL1566249,LSNWBKACGXCGAJ-UHFFFAOYSA-N,AMPIROXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3
2030,CHEMBL549598,LSOVNGNFKVHURS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,IC50,=,4.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.356547323513812,CN(CC1CCCCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
2031,CHEMBL1082,LSQZJLSUYDQPKJ-NJBDSQKTSA-N,AMOXICILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C
2032,CHEMBL1082,LSQZJLSUYDQPKJ-NJBDSQKTSA-N,AMOXICILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C
2033,CHEMBL62949,LSVDVSGWHKKGEU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CCCCCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCC
2035,CHEMBL1751,LTMHDMANZUZIPE-PUGKRICDSA-N,DIGOXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O
2036,CHEMBL1751,LTMHDMANZUZIPE-PUGKRICDSA-N,DIGOXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O
2039,CHEMBL1935435,LUFOXAFMTZDQHJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,8.1,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.09151498112135,C1CC(CN(C1)CC2=NC=CO2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
2040,CHEMBL1935435,LUFOXAFMTZDQHJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,13.1,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.882728704344236,C1CC(CN(C1)CC2=NC=CO2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
2041,CHEMBL1909051,LUHHARLTABWBTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3C(F)(F)F
2042,CHEMBL1909051,LUHHARLTABWBTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3C(F)(F)F
2043,CHEMBL165,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,RESVERATROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O
2044,CHEMBL165,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,RESVERATROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O
2045,CHEMBL54126,LULNWZDBKTWDGK-UHFFFAOYSA-M,NEOSTIGMINE BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C.[Br-]
2046,CHEMBL54126,LULNWZDBKTWDGK-UHFFFAOYSA-M,NEOSTIGMINE BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C.[Br-]
2048,CHEMBL552026,LUSFVKKEBIMJTI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,6.6,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.18045606445813,C1CCN(C(=O)C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
2049,CHEMBL1732,LUZRJRNZXALNLM-JGRZULCMSA-N,DIHYDROERGOTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
2050,CHEMBL1732,LUZRJRNZXALNLM-JGRZULCMSA-N,DIHYDROERGOTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
2051,CHEMBL64259,LVCDOFXANXULSM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,309.03,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.509999358109048,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OC(C)C
2052,CHEMBL1231107,LVQDKIWDGQRHTE-UHFFFAOYSA-N,CYROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1NC2=NC(=NC(=N2)N)N
2053,CHEMBL1231107,LVQDKIWDGQRHTE-UHFFFAOYSA-N,CYROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1NC2=NC(=NC(=N2)N)N
2054,CHEMBL560061,LVQDPXHGLLUJTK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,69.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.161150909262744,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CCC(=O)O
2055,CHEMBL105967,LVTJCSTYQPNIJJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3890.45,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.410000161858408,C1CNCCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
2056,CHEMBL1672288,LVXAMCKZCLWWTF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21207959.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging.,J. Med. Chem.,PUBLICATION,,5.0,C1=C(C=C(C=C1C#N)F)C#CC2=CSC(=N2)F
2059,CHEMBL187264,LWOMEPYLSGEMDX-SSEXGKCCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,9.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.045757490560675,C1CN(CCN1CCCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl
2060,CHEMBL325372,LXCFILQKKLGQFO-UHFFFAOYSA-N,METHYLPARABEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)C1=CC=C(C=C1)O
2061,CHEMBL325372,LXCFILQKKLGQFO-UHFFFAOYSA-N,METHYLPARABEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)C1=CC=C(C=C1)O
2062,CHEMBL1908355,LXIKEPCNDFVJKC-QXMHVHEDSA-N,TENIDAP,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)C(=O)C2=C(N(C3=C2C=C(C=C3)Cl)C(=O)N)O
2063,CHEMBL1908355,LXIKEPCNDFVJKC-QXMHVHEDSA-N,TENIDAP,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)C(=O)C2=C(N(C3=C2C=C(C=C3)Cl)C(=O)N)O
2064,CHEMBL1393,LXMSZDCAJNLERA-ZHYRCANASA-N,SPIRONOLACTONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C
2065,CHEMBL1393,LXMSZDCAJNLERA-ZHYRCANASA-N,SPIRONOLACTONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C
2066,CHEMBL1935443,LXOHJARDVFSOPS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.721246399047171,CC1=C(C=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCO4)C
2067,CHEMBL1935443,LXOHJARDVFSOPS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,365.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.437707135543525,CC1=C(C=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCO4)C
2068,CHEMBL457299,LYCAIKOWRPUZTN-UHFFFAOYSA-N,ETHYLENE GLYCOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CO)O
2069,CHEMBL457299,LYCAIKOWRPUZTN-UHFFFAOYSA-N,ETHYLENE GLYCOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CO)O
2073,CHEMBL59931,LYZKHJXQSGMRGZ-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,10232.93,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.989999996723885,CC(C)(C)C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N
2074,CHEMBL302795,LZNWYQJJBLGYLT-UHFFFAOYSA-N,TENOXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=C(C2=C(S1(=O)=O)C=CS2)O)C(=O)NC3=CC=CC=N3
2075,CHEMBL302795,LZNWYQJJBLGYLT-UHFFFAOYSA-N,TENOXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=C(C2=C(S1(=O)=O)C=CS2)O)C(=O)NC3=CC=CC=N3
2076,CHEMBL1935434,LZTBBMYTELVXQM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,16.6,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.779891911959945,C1CC(CN(C1)CC(=O)N2CCOCC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
2077,CHEMBL2112451,LZZBODFOSOSLCF-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,20000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,C1CN(C[C@H]1NS(=O)(=O)C2=CC=C(C=C2)C#N)CCCOC3=CC=C(C=C3)C(=O)C4CC4
2078,CHEMBL593734,MAAQGZFMFXQVOG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,1670.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,5.777283528852417,C1=CC=C(C=C1)C(CCCN)C2=CC=CC=C2
2079,CHEMBL2158840,MANRLQSCJCTMOZ-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,125.89,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455316,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC(=CC=C4)F)C(=O)O
2081,CHEMBL2208434,MAWNODXTLNGOAA-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,3.98,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CC(=O)NC4=CC=CC=C43)O
2082,CHEMBL313493,MBABOKRGFJTBAE-UHFFFAOYSA-N,METHANESULFONIC ACID METHYL ESTER,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COS(=O)(=O)C
2083,CHEMBL313493,MBABOKRGFJTBAE-UHFFFAOYSA-N,METHANESULFONIC ACID METHYL ESTER,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COS(=O)(=O)C
2085,CHEMBL832,MBGGBVCUIVRRBF-UHFFFAOYSA-N,SULFINPYRAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4
2086,CHEMBL832,MBGGBVCUIVRRBF-UHFFFAOYSA-N,SULFINPYRAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4
2087,CHEMBL2207670,MBMAQWYADJFPMU-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,251.19,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,CS(=O)(=O)C1=CC2=C(C=C1)C(=CNC2=O)C(=O)NC[C@H](CN3CCC(CC3)OC4=CC(=C(C=C4)C#N)Cl)O
2088,CHEMBL186125,MBQMCWRJVSGZMF-WJOKGBTCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,30.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,C1CN(CCN1CCCCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl
2091,CHEMBL639,MBUVEWMHONZEQD-UHFFFAOYSA-N,AZELASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,1.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.899629454882437,CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
2093,CHEMBL639,MBUVEWMHONZEQD-UHFFFAOYSA-N,AZELASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,1.2,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,8.920818753952375,CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
2094,CHEMBL1767137,MBVVVQZOMZFVJF-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.1,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,10.0,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)OC
2098,CHEMBL1222623,MCEBFAPNLMTKDG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,CC(C)(CN1CCCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC=C4)C(=O)O
2099,CHEMBL310555,MCJGNVYPOGVAJF-UHFFFAOYSA-N,OXYQUINOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C1)O)N=CC=C2
2100,CHEMBL310555,MCJGNVYPOGVAJF-UHFFFAOYSA-N,OXYQUINOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C1)O)N=CC=C2
2101,CHEMBL1923729,MCNAJLPLCULBOJ-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22014551.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Synthesis and evaluation of pyridone-phenoxypropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=CN(C(=O)C=C3)C
2105,CHEMBL1935444,MCVGJQYUOLRXOM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.3,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693163,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4
2106,CHEMBL1935444,MCVGJQYUOLRXOM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.5,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.823908740944319,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4
2107,CHEMBL1935444,MCVGJQYUOLRXOM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,63.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.200659450546418,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4
2108,CHEMBL1091790,MDTGYTUAMOVSAG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,IC50,=,23000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.638272163982407,CC(C1=CC=NC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C
2109,CHEMBL272702,MDWSQWMMLXSJIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OCCN6C(=O)C
2111,CHEMBL1536,MECHNRXZTMCUDQ-RKHKHRCZSA-N,ERGOCALCIFEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
2112,CHEMBL1536,MECHNRXZTMCUDQ-RKHKHRCZSA-N,ERGOCALCIFEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
2113,CHEMBL2413154,MEKSQRMXWZHFIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17221184.0,Ki,=,1030.0,NM,,,,,,,,,,,,,,,,,,,,5.987162775294828,CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=CC=CC=C3OC
2114,CHEMBL2413154,MEKSQRMXWZHFIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23816046.0,Ki,=,1030.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),"Synthesis and in vivo evaluation of [(18)F]2-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione ([(18)F]FECUMI-101) as an imaging probe for 5-HT1A receptor agonist in nonhuman primates.",Bioorg. Med. Chem.,PUBLICATION,,5.987162775294828,CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=CC=CC=C3OC
2115,CHEMBL24,METKIMKYRPQLGS-UHFFFAOYSA-N,ATENOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O
2116,CHEMBL24,METKIMKYRPQLGS-UHFFFAOYSA-N,ATENOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O
2117,CHEMBL1222626,MEWLTRGECZFZDU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892137,C1CN(CCN1C2CC(C2)C(=O)O)C3=CC4=CC=CC=C4CN5C3=NC=C5
2118,CHEMBL1222626,MEWLTRGECZFZDU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934842,C1CN(CCN1C2CC(C2)C(=O)O)C3=CC4=CC=CC=C4CN5C3=NC=C5
2119,CHEMBL972,MEZLKOACVSPNER-GFCCVEGCSA-N,SELEGILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CC1=CC=CC=C1)N(C)CC#C
2120,CHEMBL972,MEZLKOACVSPNER-GFCCVEGCSA-N,SELEGILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CC1=CC=CC=C1)N(C)CC#C
2121,CHEMBL569,MFDFERRIHVXMIY-UHFFFAOYSA-N,PROCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N
2122,CHEMBL569,MFDFERRIHVXMIY-UHFFFAOYSA-N,PROCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N
2124,CHEMBL2171033,MFJWXRIWIGLCGD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.50003813440381,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC=CC=C4
2125,CHEMBL2030624,MFKYGKXYJBKSQN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=C(C=C1)CN2C3CCC2CC3)OC
2126,CHEMBL289469,MFWNKCLOYSRHCJ-UHFFFAOYSA-N,GRANISETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
2127,CHEMBL289469,MFWNKCLOYSRHCJ-UHFFFAOYSA-N,GRANISETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C
2128,CHEMBL1086105,MGPIMNVSULKFFK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20452213.0,EC50,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in human SK-N-MC cells,Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=CC(=C1)OCCCN2CCC3=C(C2)NC=N3)C4=NC5=C(N4)C=CC(=C5C)F
2131,CHEMBL2207667,MHAQTEBGBYFXKL-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,251.19,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,C1CN(CCC1OC2=C(C(=C(C=C2)Cl)Cl)C(=O)N)C[C@@H](CNC(=O)C3=CNC(=O)C4=CC=CC=C43)O
2132,CHEMBL268258,MHPMXTGKTXJIDI-IBGZPJMESA-N,A-80426,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771448.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to Histamine H1 receptor,Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.,J. Med. Chem.,PUBLICATION,,6.0,CN(CCC1=CC2=C(C=C1)C=CO2)C[C@@H]3CCCC4=C3C=CC=C4OC
2133,CHEMBL1687,MHXYWXHKLBMJKL-QBYKQQEBSA-N,TUBOCURARINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC.[Cl-]
2134,CHEMBL1687,MHXYWXHKLBMJKL-QBYKQQEBSA-N,TUBOCURARINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC.[Cl-]
2135,CHEMBL407030,MIFVTYPADKEWAV-HGRQBIKSSA-N,GAMMA-CYCLODEXTRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](OC([C@@H]([C@H]5O)O)OC6[C@H](OC([C@@H]([C@H]6O)O)C7[C@H](OC([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8O)O)O[C@@H]9[C@H](O[C@H](O2)[C@@H]([C@H]9O)O)CO)CO)CO)CO)CO)CO)CO)O)O)O
2136,CHEMBL407030,MIFVTYPADKEWAV-HGRQBIKSSA-N,GAMMA-CYCLODEXTRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](OC([C@@H]([C@H]5O)O)OC6[C@H](OC([C@@H]([C@H]6O)O)C7[C@H](OC([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8O)O)O[C@@H]9[C@H](O[C@H](O2)[C@@H]([C@H]9O)O)CO)CO)CO)CO)CO)CO)CO)O)O)O
2137,CHEMBL340978,MITFXPHMIHQXPI-UHFFFAOYSA-N,BENOXAPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O
2138,CHEMBL340978,MITFXPHMIHQXPI-UHFFFAOYSA-N,BENOXAPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O
2139,CHEMBL2030633,MIZXZRHARATZMK-UHFFFAOYSA-N,"N-(3,4-DIMETHOXYBENZYL)PYRROLIDINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=C(C=C1)CN2CCCC2)OC
2141,CHEMBL480,MJIHNNLFOKEZEW-UHFFFAOYSA-N,LANSOPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
2142,CHEMBL480,MJIHNNLFOKEZEW-UHFFFAOYSA-N,LANSOPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
2143,CHEMBL305660,MJJALKDDGIKVBE-UHFFFAOYSA-N,EBASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,28.3,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.548213564475709,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4
2144,CHEMBL305660,MJJALKDDGIKVBE-UHFFFAOYSA-N,EBASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,3.29,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.482804102050025,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4
2145,CHEMBL322873,MJKGHXXXMDVBEW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,275.42,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.560004526046192,CC1CCCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
2146,CHEMBL476839,MJKRYUCQHJLOIV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19329329.0,Ki,=,439.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned histamine H1 receptor by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,6.357535479757878,CC1=CC=C(C=C1)CCN2CCC(CC2)C(C3=C(C(=CC=C3)OCCF)OC)O
2147,CHEMBL402087,MJLHCRFMFPSGBF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803203,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C(C)(C)C
2152,CHEMBL563647,MKKJPIHSAMRGEO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,41.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3872161432802645,CCC(C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCCN(CC4)C5=CC(=O)N(C(=O)N5C)C)C(=O)O
2153,CHEMBL184,MKUXAQIIEYXACX-UHFFFAOYSA-N,ACYCLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1COCCO)N=C(NC2=O)N
2154,CHEMBL184,MKUXAQIIEYXACX-UHFFFAOYSA-N,ACYCLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1COCCO)N=C(NC2=O)N
2155,CHEMBL806,MKXKFYHWDHIYRV-UHFFFAOYSA-N,FLUTAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F
2156,CHEMBL806,MKXKFYHWDHIYRV-UHFFFAOYSA-N,FLUTAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F
2157,CHEMBL52440,MKXZASYAUGDDCJ-NJAFHUGGSA-N,DEXTROMETHORPHAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
2158,CHEMBL52440,MKXZASYAUGDDCJ-NJAFHUGGSA-N,DEXTROMETHORPHAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC
2159,CHEMBL271072,MLGRCKZMFCALCK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCCN4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C
2160,CHEMBL15770,MLKXDPUZXIRXEP-MFOYZWKCSA-N,SULINDAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O
2161,CHEMBL15770,MLKXDPUZXIRXEP-MFOYZWKCSA-N,SULINDAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O
2163,CHEMBL256473,MMAVGOXTOMTHGO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C(C)(F)F
2164,CHEMBL83073,MMEQHMVQEKIHIG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,37.15,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.430041181903406,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C(=CC=C3)C(F)(F)F
2166,CHEMBL561377,MMKZIPYPZZNRTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,53.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.275724130399211,CN1C(=CC(=O)N(C1=O)C)N(C)CCCN2CCC(CC2)CN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(=O)O
2168,CHEMBL238871,MMRPNJJCBOGWTP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CCCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC(=CC(=C4)F)F.C(=O)O
2169,CHEMBL1923531,MMWJPRSBOSCWBE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,4168.69,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.380000399499541,C1CCN(CC1)CCN2C3=CC=CC=C3N4C2=NC=N4
2170,CHEMBL560120,MMXKXXGRZUAQGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,28.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.552841968657781,CN1C(=CC(=O)N(C1=O)C)NCCCN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl
2171,CHEMBL560120,MMXKXXGRZUAQGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,58.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.236572006437063,CN1C(=CC(=O)N(C1=O)C)NCCCN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl
2174,CHEMBL93645,MNIPYSSQXLZQLJ-UHFFFAOYSA-N,ACECLOFENAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl
2175,CHEMBL93645,MNIPYSSQXLZQLJ-UHFFFAOYSA-N,ACECLOFENAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl
2176,CHEMBL539093,MNOZJGDIRIYZSQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,3162.28,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.499999678657065,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)Cl.Cl
2177,CHEMBL2158828,MNSGCVNHLLGCDG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,15.85,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.79997073344623,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=CC=C4OCC(=O)O
2178,CHEMBL2207643,MNVDCQLMHFFYCU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC=CC=C1N2CCN(CC2)CC3=C4C=CC=CC=C4C=C3
2180,CHEMBL2208418,MNXRFTOYSSFEST-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,316.23,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.499996931948306,C1CN(CCC1NC[C@@H](COC2=CC3=C(C=C2)N=CS3)O)CC4=CC(=C(C=C4)Cl)Cl
2181,CHEMBL3357041,MOFVGVFZWIHAPO-DUXPYHPUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,153.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,6.815308569182402,C/C=C/C(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
2182,CHEMBL2158780,MOHMWXTYADLKCG-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450609,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=C(C=C4)F)C(=O)O
2186,CHEMBL3321790,MPWWGTFDWDZHRM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,977.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.010105436281227,C1CC2CC(CC1N2CCCSC3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O
2187,CHEMBL1632411,MQAUVLYNYCPXHD-ICFOKQHNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,Ki,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Binding affinity to human recombinant histamine H1 receptor expressed in human SK-N-MC cells by radioligand displacement assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC(CC1)/C(=N/O)/C2=CC3=CC=CC=C3N2
2188,CHEMBL529,MQTOSJVFKKJCRP-BICOPXKESA-N,AZITHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O
2189,CHEMBL529,MQTOSJVFKKJCRP-BICOPXKESA-N,AZITHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O
2190,CHEMBL597,MRBDMNSDAVCSSF-UHFFFAOYSA-N,PHENTOLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,4000.0,NM,,,,,,,,,,,,,,,,,,,,5.3979400086720375,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O
2191,CHEMBL597,MRBDMNSDAVCSSF-UHFFFAOYSA-N,PHENTOLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,316227.77,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,3.4999999945296856,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O
2192,CHEMBL597,MRBDMNSDAVCSSF-UHFFFAOYSA-N,PHENTOLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O
2193,CHEMBL597,MRBDMNSDAVCSSF-UHFFFAOYSA-N,PHENTOLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O
2195,CHEMBL62066,MRYDVIQPLWEQDJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1659.59,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.779999190713337,CCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCC
2196,CHEMBL330367,MRZJFWSFVDADTA-WLHGVMLRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,158.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.801342913045577,CCOC1=CC(=CC(=C1OCC)OCC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC(=C(C=C7)OC)OC.C(=C/C(=O)O)\C(=O)O
2197,CHEMBL1669418,MSDXVUCMHKOWGT-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,8.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.09151498112135,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=CO4
2200,CHEMBL1669406,MSMKOTVNTGCTFQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,41.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3872161432802645,CCCN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3
2201,CHEMBL65849,MSNSHZJXNNLNOS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12798320.0,Ki,=,7696.0,NM,,,,,,,,,,,,,,,Compound was tested for its binding affinity towards human H1 receptor,"A new class of histamine H(3)-receptor antagonists: synthesis and structure-activity relationships of 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.113734940970243,CN(C)CCCNC1=C2CCCCCC2=NC3=CC=CC=C31
2202,CHEMBL1093607,MSPFRPWEGPBFTC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,122.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.913640169325252,CC(C1=C(SC2=CC=CC=C21)CCN(C)C)N3C=CN=C3
2203,CHEMBL84931,MSQRTETUBFIHMP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,2.57,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.590066876668706,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=C(C=C4)F
2208,CHEMBL116735,MUAYITOFLINYIL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,1660.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,5.779891911959945,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)CCC4=CC=C(C=C4)F
2209,CHEMBL386630,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,TESTOSTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C
2210,CHEMBL386630,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,TESTOSTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C
2211,CHEMBL2207282,MUPZZNZQFUCJBT-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC(=C4)S(=O)(=O)N)O
2212,CHEMBL1200845,MUQNGPZZQDCDFT-JNQJZLCISA-N,HALCINONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F
2213,CHEMBL1200845,MUQNGPZZQDCDFT-JNQJZLCISA-N,HALCINONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F
2214,CHEMBL2037608,MURCULVYVOMYIO-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22578490.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,5.0,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=CC(=O)N(N=C3)COC
2215,CHEMBL1194,MVFGUOIZUNYYSO-UHFFFAOYSA-N,PRILOCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNC(C)C(=O)NC1=CC=CC=C1C
2216,CHEMBL1194,MVFGUOIZUNYYSO-UHFFFAOYSA-N,PRILOCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNC(C)C(=O)NC1=CC=CC=C1C
2217,CHEMBL488025,MVGSNCBCUWPVDA-MFOYZWKCSA-N,EXISULIND,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O
2218,CHEMBL488025,MVGSNCBCUWPVDA-MFOYZWKCSA-N,EXISULIND,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O
2219,CHEMBL476108,MVKKLGNVARQKRP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,188.6,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.72445831159869,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCC(=O)C3=CC=C(C=C3)F
2220,CHEMBL564226,MVMQESMQSYOVGV-HNNXBMFYSA-N,(S)-(+)-DIMETHINDENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,0.43700000000000006,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,9.359518563029578,C[C@@H](C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C
2221,CHEMBL564226,MVMQESMQSYOVGV-HNNXBMFYSA-N,(S)-(+)-DIMETHINDENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,0.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,9.397940008672037,C[C@@H](C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C
2222,CHEMBL1493369,MVMQESMQSYOVGV-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,69.18,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.160019442321658,C[C@H](C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C
2223,CHEMBL22108,MVMQESMQSYOVGV-UHFFFAOYSA-N,DIMETHINDENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,0.6920000000000001,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,9.159893905543242,CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C
2224,CHEMBL708,MVWVFYHBGMAFLY-UHFFFAOYSA-N,ZIPRASIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,15.0,NM,,,,,,,,,,,,,,,,,,,,7.823908740944319,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
2225,CHEMBL708,MVWVFYHBGMAFLY-UHFFFAOYSA-N,ZIPRASIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,4.6,NM,,,,,,,,,,,,,,,,,,,,8.337242168318426,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
2226,CHEMBL708,MVWVFYHBGMAFLY-UHFFFAOYSA-N,ZIPRASIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11170639.0,Ki,=,510.0,NM,,,,,,,,,,,,,,,Binding affinity towards human H1 receptor,Current and novel approaches to the drug treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,6.292429823902063,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
2227,CHEMBL708,MVWVFYHBGMAFLY-UHFFFAOYSA-N,ZIPRASIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,43.0,NM,,,,,,,,,,,,,,,,,,,,7.366531544420414,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
2228,CHEMBL708,MVWVFYHBGMAFLY-UHFFFAOYSA-N,ZIPRASIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,5.3,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,8.275724130399212,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
2229,CHEMBL708,MVWVFYHBGMAFLY-UHFFFAOYSA-N,ZIPRASIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,47.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,7.327902142064283,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
2232,CHEMBL93,MWLSOWXNZPKENC-UHFFFAOYSA-N,ZILEUTON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,,,,Not Determined,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells; not tested,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O
2233,CHEMBL93,MWLSOWXNZPKENC-UHFFFAOYSA-N,ZILEUTON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O
2234,CHEMBL93,MWLSOWXNZPKENC-UHFFFAOYSA-N,ZILEUTON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O
2237,CHEMBL3238447,MXRUKGSLFINORK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,=,2238.72,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,5.650000220873455,C1CCN(CC1)CCCOC2=CC=C(C=C2)CN3C(=O)C(NC3=O)(C4=CC=CC=C4)C5=CC=CC=C5
2238,CHEMBL271632,MXYJVPGKILUPBU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)SC(=N6)C
2239,CHEMBL2103769,MXYUKLILVYORSK-HKBOAZHASA-N,LOBELINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,44668.36,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,4.349999992368662,CN1[C@H](CCC[C@H]1CC(=O)C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O
2240,CHEMBL600325,MYEJFUXQJGHEQK-ALRJYLEOSA-N,PROSCILLARIDIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O
2241,CHEMBL600325,MYEJFUXQJGHEQK-ALRJYLEOSA-N,PROSCILLARIDIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O
2242,CHEMBL262777,MYPYJXKWCTUITO-LYRMYLQWSA-N,VANCOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O
2243,CHEMBL262777,MYPYJXKWCTUITO-LYRMYLQWSA-N,VANCOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O
2244,CHEMBL8,MYSWGUAQZAJSOK-UHFFFAOYSA-N,CIPROFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
2245,CHEMBL8,MYSWGUAQZAJSOK-UHFFFAOYSA-N,CIPROFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O
2247,CHEMBL417215,MYYDLAXWFPHASV-XMMPIXPASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,9332.54,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.030000139977383,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CC=C(C=C4)F)N
2250,CHEMBL2205815,MYZBXDLMEOAPIJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC8=C(C=C7)OCO8)O
2251,CHEMBL2158788,MYZGZNJBQOQRTJ-DEOSSOPVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755866,CC1=C(C=CC(=C1Cl)Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=CC=C4)C(=O)O
2252,CHEMBL1095699,MZZGOOYMKKIOOX-VKHMYHEASA-N,AZASERINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H](C(=O)O)N)OC(=O)C=[N+]=[N-]
2253,CHEMBL1095699,MZZGOOYMKKIOOX-VKHMYHEASA-N,AZASERINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H](C(=O)O)N)OC(=O)C=[N+]=[N-]
2254,CHEMBL257717,NAFIXABLSKOHPB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=CC2=NC3=C(N2C=C1)CCN(CC3)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C
2255,CHEMBL558339,NAGKIWFBALBSMD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,59.3,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.226945306635738,C1CN(CCC1N2C=CC=C2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
2256,CHEMBL564144,NANQRVOKMXDMNL-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,4.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,8.397940008672037,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C
2257,CHEMBL564144,NANQRVOKMXDMNL-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,4000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C
2258,CHEMBL564144,NANQRVOKMXDMNL-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20800486.0,Ki,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C
2259,CHEMBL1090433,NANQRVOKMXDMNL-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,IC50,=,256000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.5917600346881504,C[C@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C
2260,CHEMBL1090432,NANQRVOKMXDMNL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,12.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.920818753952375,CC(C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C
2262,CHEMBL157328,NAQBCIUOBUOYRD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,79432823472428.2,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.9,C1=CC(=CC(=C1)C(F)(F)F)C2=NC(=CS2)CCN
2264,CHEMBL62115,NAVVYTVXMQUKNO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,2041.74,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.689999562814496,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=NC=CN=C3
2266,CHEMBL1586,NBMKJKDGKREAPL-DVTGEIKXSA-N,BECLOMETHASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C
2267,CHEMBL1586,NBMKJKDGKREAPL-DVTGEIKXSA-N,BECLOMETHASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C
2268,CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
2269,CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
2270,CHEMBL421,NCEXYHBECQHGNR-QZQOTICOSA-N,SULFASALAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
2271,CHEMBL421,NCEXYHBECQHGNR-QZQOTICOSA-N,SULFASALAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
2274,CHEMBL1200656,NCXMLFZGDNKEPB-FFPOYIOWSA-N,NATAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)/C=C/C(=O)O1)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O
2275,CHEMBL1200656,NCXMLFZGDNKEPB-FFPOYIOWSA-N,NATAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)/C=C/C(=O)O1)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O
2276,CHEMBL714,NDAUXUAQIAJITI-UHFFFAOYSA-N,ALBUTEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
2277,CHEMBL714,NDAUXUAQIAJITI-UHFFFAOYSA-N,ALBUTEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
2278,CHEMBL406,NDDAHWYSQHTHNT-UHFFFAOYSA-N,INDAPAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N
2279,CHEMBL406,NDDAHWYSQHTHNT-UHFFFAOYSA-N,INDAPAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N
2281,CHEMBL475621,NDEWHFAPFGGMKU-UHFFFAOYSA-N,UR-PI294,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19317445.0,EC50,=,3467.37,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in insect Sf9 cells co-expressing RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting,N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.,J. Med. Chem.,PUBLICATION,,5.4599998126889995,CCC(=O)NC(=NCCCC1=CN=CN1)N
2284,CHEMBL187637,NDNBZMHADGKSLT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,295.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.530177984021837,C1CN(CCN1CCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
2285,CHEMBL578170,NDWXGJDJKXDMOV-HDICACEKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.769551078621726,CC1=CC=C(C=C1)C(=O)NC2CCC(CC2)NC3=NC=C(C(=N3)N(C)C)C
2286,CHEMBL2207661,NDXPOARUSJMOJN-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892137,C1CC1C2=C(C=NN2)C(=O)NC[C@H](CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl)O
2287,CHEMBL214312,NESASFDNMLPZIR-KBPBESRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,EC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in 293-EBNA cells by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,5.0,C1CCC(CC1)CNCC[C@H]2C[C@@H]2C3=CN=CN3
2288,CHEMBL214312,NESASFDNMLPZIR-KBPBESRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human H1 receptor expressed in 293-EBNA cells assessed as inhibition of histamine agonist activity by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,5.0,C1CCC(CC1)CNCC[C@H]2C[C@@H]2C3=CN=CN3
2289,CHEMBL895,NETZHAKZCGBWSS-CEDHKZHLSA-N,NALBUPHINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O
2290,CHEMBL895,NETZHAKZCGBWSS-CEDHKZHLSA-N,NALBUPHINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O
2291,CHEMBL325516,NEUFWHZAVWYYSZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,1280.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,5.892790030352131,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)OCCC4=CC=C(C=C4)F
2292,CHEMBL711,NFBAXHOPROOJAW-UHFFFAOYSA-N,PHENINDIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
2293,CHEMBL711,NFBAXHOPROOJAW-UHFFFAOYSA-N,PHENINDIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
2294,CHEMBL113956,NFBNIRNKYJTDIE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,1820.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,5.739928612014925,CCOC1=CC=C(C=C1)CCNC(=O)N2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
2296,CHEMBL1200406,NFLLKCVHYJRNRH-UHFFFAOYSA-N,DIMENHYDRINATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,319.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.496209316942819,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
2297,CHEMBL1200406,NFLLKCVHYJRNRH-UHFFFAOYSA-N,DIMENHYDRINATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,37.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.431798275933005,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
2298,CHEMBL577904,NFQWOMAFZMZYOX-FZNQNYSPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,920.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.036212172654444,CC1=CN=C(N=C1N(C)C)NC2CCC(CC2)CNC(=O)C3=CC(=C(C=C3)F)F
2300,CHEMBL24665,NFUYVKMAGIJYKB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.0,C1=CC(=CC(=C1)C(F)(F)F)C2=NC=C(N2)CCN
2301,CHEMBL24665,NFUYVKMAGIJYKB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,251188643150958.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.4,C1=CC(=CC(=C1)C(F)(F)F)C2=NC=C(N2)CCN
2302,CHEMBL24665,NFUYVKMAGIJYKB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,EC50,=,251.19,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,C1=CC(=CC(=C1)C(F)(F)F)C2=NC=C(N2)CCN
2304,CHEMBL1148,NGBFQHCMQULJNZ-UHFFFAOYSA-N,TORSEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C
2305,CHEMBL1148,NGBFQHCMQULJNZ-UHFFFAOYSA-N,TORSEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C
2306,CHEMBL2158779,NHOMRPYETSURDH-DEOSSOPVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CN(CCC1CN2CCC(CC2)OC3=C(C=C(C=C3)Cl)Cl)[C@@H](CC4=CC=C(C=C4)F)C(=O)O
2307,CHEMBL1200862,NHTGHBARYWONDQ-JTQLQIEISA-N,METYROSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N
2308,CHEMBL1200862,NHTGHBARYWONDQ-JTQLQIEISA-N,METYROSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N
2309,CHEMBL453,NHUHCSRWZMLRLA-UHFFFAOYSA-N,SULFISOXAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N
2310,CHEMBL453,NHUHCSRWZMLRLA-UHFFFAOYSA-N,SULFISOXAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N
2313,CHEMBL109,NIJJYAXOARWZEE-UHFFFAOYSA-N,VALPROIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(CCC)C(=O)O
2314,CHEMBL109,NIJJYAXOARWZEE-UHFFFAOYSA-N,VALPROIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(CCC)C(=O)O
2315,CHEMBL1774501,NIKHLOHBEKSSNM-LIMNOBDPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,540.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.267606240177032,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CC/C=C/3\C4=CC=CC=C4COC5=C3C=C(C=C5)CC(=O)O
2316,CHEMBL1774500,NIKHLOHBEKSSNM-NYAPKIOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,84.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.075720713938118,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CC/C=C\3/C4=CC=CC=C4COC5=C3C=C(C=C5)CC(=O)O
2321,CHEMBL486962,NJDNYPJEXDZZKT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=CC=C(C=C1)CCCC(=O)NC(=NCCCC2=CN=CN2)N
2323,CHEMBL406678,NJIAHBGDDDILFN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)N6C=CC=CC6=N5
2324,CHEMBL322678,NJOYBVVACVXAAZ-SFHVURJKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,91000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.040958607678906,CN1C=C(N=C1)S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
2325,CHEMBL83,NKANXQFJJICGDU-QPLCGJKRSA-N,TAMOXIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
2326,CHEMBL83,NKANXQFJJICGDU-QPLCGJKRSA-N,TAMOXIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
2328,CHEMBL1946126,NLEQSFUEJXECJY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,509.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,6.293282217663242,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCOC3=CC=C(C=C3)F
2330,CHEMBL1747,NLVFBUXFDBBNBW-PBSUHMDJSA-N,TOBRAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N
2331,CHEMBL1747,NLVFBUXFDBBNBW-PBSUHMDJSA-N,TOBRAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N
2332,CHEMBL563055,NMEALLMQARPNTN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,14.1,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.85078088734462,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2N4CCC(CC4)NCC5CCOCC5
2334,CHEMBL2158777,NMLHPAJBQUFHAV-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,158.49,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593398,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC(=CC=C4)C(F)(F)F)C(=O)O
2335,CHEMBL104808,NMOWFTXQHLZDDV-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,9200.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.036212172654444,C1CN(C[C@H]1NS(=O)(=O)C2=CC=C(C=C2)F)CCCOC3=CC=C(C=C3)C(=O)C4CC4
2336,CHEMBL59798,NMTPIRAMYOPHIO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,457.09,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.339998279897117,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)CC(C)C
2337,CHEMBL1489,NMUSYJAQQFHJEW-KVTDHHQDSA-N,AZACITIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N
2338,CHEMBL1489,NMUSYJAQQFHJEW-KVTDHHQDSA-N,AZACITIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N
2339,CHEMBL462605,NNACHAUCXXVJSP-UHFFFAOYSA-N,TIPROLISANT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,=,1148.15,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,5.940001369850308,C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl
2340,CHEMBL28607,NNGCXJPRHBHODU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC=C(C=C1)N2CCN(CC2)CC3=CNC4=C3C=CC=N4
2341,CHEMBL79,NNJVILVZKWQKPM-UHFFFAOYSA-N,LIDOCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C
2342,CHEMBL79,NNJVILVZKWQKPM-UHFFFAOYSA-N,LIDOCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C
2343,CHEMBL622,NNYBQONXHNTVIJ-UHFFFAOYSA-N,ETODOLAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O
2344,CHEMBL622,NNYBQONXHNTVIJ-UHFFFAOYSA-N,ETODOLAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O
2345,CHEMBL394015,NOBSINPJDRJYCC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(C1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC(=CC(=C4)F)F
2348,CHEMBL757,NPAGDVCDWIYMMC-IZPLOLCNSA-N,NANDROLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34
2349,CHEMBL757,NPAGDVCDWIYMMC-IZPLOLCNSA-N,NANDROLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34
2350,CHEMBL3039597,NPEFREDMMVQEPL-RWPARATISA-N,GENTAMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)N.CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC.C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O
2351,CHEMBL3039597,NPEFREDMMVQEPL-RWPARATISA-N,GENTAMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)N.CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC.C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O
2352,CHEMBL57,NQDJXKOVJZTUJA-UHFFFAOYSA-N,NEVIRAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
2353,CHEMBL57,NQDJXKOVJZTUJA-UHFFFAOYSA-N,NEVIRAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
2354,CHEMBL238503,NQEWRKQNDSWJNM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=NC=C4.C(=O)O
2355,CHEMBL418691,NQLCAHXYVYXKBG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,812.83,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.090000275786018,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)OC
2357,CHEMBL2171026,NQTXEWZDVUMZDO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.50003813440381,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC=C(C=C4)C5=NNN=N5
2358,CHEMBL62050,NQVNEFLFZVEJSK-RUZDIDTESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,13489.63,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.869999962200743,CN[C@H](CC1=CC=CC=C1)C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
2359,CHEMBL291394,NQWIESOLCWAUTM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,478.63,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.32000008377078,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=NC=C3
2360,CHEMBL1177,NRNCYVBFPDDJNE-UHFFFAOYSA-N,PEMOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2C(=O)N=C(O2)N
2361,CHEMBL1177,NRNCYVBFPDDJNE-UHFFFAOYSA-N,PEMOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2C(=O)N=C(O2)N
2362,CHEMBL1092650,NRNPLYWFPSCQAF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.5,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.823908740944319,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)Cl)CC3=NC=CN=C3OC
2363,CHEMBL256015,NRQJARQPULKWBG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C(C)C
2365,CHEMBL1940418,NSMCYUMPIGJKHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,167.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,6.777283528852417,C1CN(CCN1CCCCC2=CC=C(C=C2)F)C3=CC=CC=N3
2366,CHEMBL256658,NSOOFJHAXVGHFH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=CN2C3=C(CCN(CC3)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)N=C2C=C1
2367,CHEMBL1222552,NSRMKMSTPLJNHM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,0.631,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.199970640755865,C1CN(CCN1)C2=CC3=CC=CC=C3CN4C2=NC=C4
2368,CHEMBL96471,NTBSVMCWAHSWAK-YLOCQQLVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,29.7,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.527243550682788,C1CN(CCC1C2=CC=CC=C2)CC3C[C@H]4[C@H](O3)C5=CC=CC=C5CC6=CC=CC=C46
2369,CHEMBL195437,NTDQQZYCCIDJRK-UHFFFAOYSA-N,4-OCTYLPHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCCCC1=CC=C(C=C1)O
2370,CHEMBL195437,NTDQQZYCCIDJRK-UHFFFAOYSA-N,4-OCTYLPHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCCCC1=CC=C(C=C1)O
2371,CHEMBL1096428,NTHUVTORAXKPJS-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,=,6165.95,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.210000001311122,C[C@H](CC(=O)NC(=NCCCC1=CN=CN1)N)C2=CC=CC=C2
2381,CHEMBL1096429,NTHUVTORAXKPJS-ZDUSSCGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,=,831.76,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0800019690359814,C[C@@H](CC(=O)NC(=NCCCC1=CN=CN1)N)C2=CC=CC=C2
2383,CHEMBL243712,NTJOBXMMWNYJFB-UHFFFAOYSA-N,AMISULPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19337725.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC
2384,CHEMBL534512,NTMBNTAWSSELPH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)Cl.Cl
2385,CHEMBL2205830,NTRDOPDLDNCOHJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC(=CC(=C1OC)OC)CN2C3C4C5CC6C4C2(C7C6C5C73)O
2386,CHEMBL2205830,NTRDOPDLDNCOHJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,COC1=CC(=CC(=C1OC)OC)CN2C3C4C5CC6C4C2(C7C6C5C73)O
2389,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=C(NC=N1)CCN
2390,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,1258.92,NM,,,,,,,,,,,,,,,,,,,,5.900001866923468,C1=C(NC=N1)CCN
2391,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8335064.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=C(NC=N1)CCN
2392,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,1258.92,NM,,,,,,,,,,,,,,,,,,,,5.900001866923468,C1=C(NC=N1)CCN
2393,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,1258.93,NM,,,,,,,,,,,,,,,,,,,,5.899998417198648,C1=C(NC=N1)CCN
2394,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=C(NC=N1)CCN
2395,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,2060.0,NM,,,,,,,,,,,,,,,,,,,,5.686132779630847,C1=C(NC=N1)CCN
2396,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,=,13.0,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,7.886056647693163,C1=C(NC=N1)CCN
2398,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,158.49,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.799998134593398,C1=C(NC=N1)CCN
2399,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,15848931924611.1,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.199999999999999,C1=C(NC=N1)CCN
2400,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15033391.0,Ki,=,7010.0,NM,,,,,,,,,,,,,,,,,,,,5.154281982033341,C1=C(NC=N1)CCN
2401,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16408006.0,Ki,=,79432.82,NM,,,cell_based,,,,,COS-7,,,,,,,Displacement of [3H]mepyramine from human wild-type histamine H1 receptor expressed in COS-7 cells by liquid scintillation counting,Linking agonist binding to histamine H1 receptor activation.,Nat. Chem. Biol.,PUBLICATION,,4.100000018985305,C1=C(NC=N1)CCN
2402,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,190.0,NM,,,,,,,,,,,,,,,,,,,,6.721246399047171,C1=C(NC=N1)CCN
2403,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,EC50,=,45.0,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in 293-EBNA cells by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,7.346787486224656,C1=C(NC=N1)CCN
2404,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18950149.0,EC50,=,190.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,"Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.",J. Med. Chem.,PUBLICATION,,6.721246399047171,C1=C(NC=N1)CCN
2405,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19317445.0,EC50,=,190.55,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in insect Sf9 cells co-expressing RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting,N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.,J. Med. Chem.,PUBLICATION,,6.719991046891814,C1=C(NC=N1)CCN
2406,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19791743.0,EC50,=,190.55,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase assay,Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.,J. Med. Chem.,PUBLICATION,,6.719991046891814,C1=C(NC=N1)CCN
2407,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,=,190.55,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.719991046891814,C1=C(NC=N1)CCN
2409,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,EC50,=,199.53,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446187,C1=C(NC=N1)CCN
2410,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25993395.0,Ki,=,6000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.,J. Med. Chem.,PUBLICATION,,5.221848749616356,C1=C(NC=N1)CCN
2411,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,EC50,=,190.0,NM,,,,,,,,,,,,,,,Agonist activity at human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 or RGS9 assessed as increase in 32Pi level incubated for 20 mins by liquid scintillation counting in presence of [gamma32P]GTP,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,6.721246399047171,C1=C(NC=N1)CCN
2412,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,EC50,=,190.55,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 preincubated for 2 mins before [gamma32P]GTP addition measured after 20 mins by steady-state GTPase activity assay,,MedChemComm,PUBLICATION,,6.719991046891814,C1=C(NC=N1)CCN
2413,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,~,1000.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1=C(NC=N1)CCN
2415,CHEMBL154047,NTZJIQAKZMLDFO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,79432823472428.2,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.9,C1=CC=NC(=C1)CCCCCCCCCCN
2417,CHEMBL2207635,NUTCIQIPIDPFOT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,=,1400.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321762,COC1=CC=CC=C1N2CCN(CC2)CC3=CC(=C4C3=CC=CC=C4)CO
2419,CHEMBL27769,NVKAWKQGWWIWPM-ABEVXSGRSA-N,STANOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C
2420,CHEMBL27769,NVKAWKQGWWIWPM-ABEVXSGRSA-N,STANOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C
2423,CHEMBL1278115,NWCYKTKORNLIRC-AVKWCDSFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.599980364934842,C1C[C@]2(CC1NCCC(=O)O)CC3=CC=CC=C3CC4=CC=CC=C24
2424,CHEMBL1278114,NWCYKTKORNLIRC-BPARTEKVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,10.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,8.0,C1C[C@@]2(CC1NCCC(=O)O)CC3=CC=CC=C3CC4=CC=CC=C24
2425,CHEMBL105,NWIBSHFKIJFRCO-WUDYKRTCSA-N,MITOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N
2426,CHEMBL105,NWIBSHFKIJFRCO-WUDYKRTCSA-N,MITOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N
2427,CHEMBL2171044,NWUBEEIEKUQVJL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC=CC(=C4)C#N
2429,CHEMBL155314,NWWFCAFBMXDHNK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1995.26,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1=C(NC=N1)CCCCCCCCCCCCCCN
2430,CHEMBL155314,NWWFCAFBMXDHNK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,3981071705534970.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-6.6,C1=C(NC=N1)CCCCCCCCCCCCCCN
2431,CHEMBL572,NXFQHRVNIOXGAQ-YCRREMRBSA-N,NITROFURANTOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]
2432,CHEMBL572,NXFQHRVNIOXGAQ-YCRREMRBSA-N,NITROFURANTOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]
2433,CHEMBL2171032,NXHYSNCNFYHMIU-NFBKMPQASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,199.53,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446187,CS(=O)(=O)C1=CC=CC(=C1)C(=O)N2CC[C@H]([C@@H](C2)C(=O)O)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
2434,CHEMBL3094216,NXSLQNZNLLDVBI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,=,1995.26,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC3=C(CCN(CC3)CC4CCCO4)C=C2
2435,CHEMBL393436,NYAIYQKWZFWRCU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,826.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.083019952679618,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=CC=CC=C4O3)F
2437,CHEMBL70586,NYKCGQQJNVPOLU-ONTIZHBOSA-N,SPIRADOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl
2438,CHEMBL70586,NYKCGQQJNVPOLU-ONTIZHBOSA-N,SPIRADOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl
2439,CHEMBL92401,NYMGNSNKLVNMIA-UHFFFAOYSA-N,IPRONIAZID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NNC(=O)C1=CC=NC=C1
2440,CHEMBL92401,NYMGNSNKLVNMIA-UHFFFAOYSA-N,IPRONIAZID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NNC(=O)C1=CC=NC=C1
2441,CHEMBL1079686,NYMPDEKHLLUZPU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,5000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,CCOC1=CC(=CC(=C1N2C=CC=C2)OCC)CN3CCC(CC3)NC4=NC5=C(O4)C=CC(=C5)S(=O)(=O)N(C)C
2442,CHEMBL1277126,NYWUAMYWDNANQG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.299988937677887,C1CC2(CC1N3CCC(=CC3)C(=O)O)CC4=CC=CC=C4OC5=CC=CC=C25
2443,CHEMBL2207654,NZFSPDVTABQASR-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,2.51,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.600326278518962,C1CN(C1)S(=O)(=O)C2=CC3=C(C=C2)C(=CNC3=O)C(=O)NC[C@H](CN4CCC(CC4)OC5=CC(=C(C=C5)Cl)Cl)O
2444,CHEMBL415324,NZHGWWWHIYHZNX-CSKARUKUSA-N,TRANILAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC
2445,CHEMBL415324,NZHGWWWHIYHZNX-CSKARUKUSA-N,TRANILAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC
2446,CHEMBL402853,NZPLLWYDJFVQEH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)OC(=N6)C7=CC(=NN7C)C
2447,CHEMBL1237174,OAKJQQAXSVQMHS-UHFFFAOYSA-N,HYDRAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,NN
2448,CHEMBL1237174,OAKJQQAXSVQMHS-UHFFFAOYSA-N,HYDRAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,NN
2449,CHEMBL59733,OBMUCKQULKBRME-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,100000.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=NC=CS4)N
2450,CHEMBL445332,OBSYBRPAKCASQB-AGQYDFLVSA-N,SALVINORIN A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12192085.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(=O)O[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC
2452,CHEMBL1774502,ODFDIJBCTCNYMX-OPVMPGTRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,92.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.036212172654444,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CC/C=C\3/C4=CC=CC=C4COC5=C3C=C(C=C5)CC(=O)O
2453,CHEMBL314968,ODJIGTDOQQQJKM-JKRBJUMTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,47.1,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.326979092871104,C1CN(CCC1C2=CC=CC=C2)CC3C[C@H]4[C@H](O3)C5=CC=CC=C5SC6=CC=CC=C46
2454,CHEMBL917,ODKNJVUHOIMIIZ-RRKCRQDMSA-N,FLOXURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)O
2455,CHEMBL917,ODKNJVUHOIMIIZ-RRKCRQDMSA-N,FLOXURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)O
2456,CHEMBL2207663,ODKRBJGIPOQDPJ-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,10.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C=C3C(F)(F)F)O
2457,CHEMBL1632174,ODMLUIATXKBXOW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21075638.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to Histamine receptor H1,Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CN2C3=CC=CC=C3C(=C2OC1)C(=O)NCC4CCN(CC4)CCCCCC(=O)O
2458,CHEMBL101740,ODQWQRRAPPTVAG-BOPFTXTBSA-N,CIDOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,0.49,NM,,,,,,,,,,,,,,,,,,,,9.309803919971486,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31
2459,CHEMBL101740,ODQWQRRAPPTVAG-BOPFTXTBSA-N,CIDOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,0.17,NM,,,,,,,,,,,,,,,,,,,,9.769551078621726,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31
2460,CHEMBL101740,ODQWQRRAPPTVAG-BOPFTXTBSA-N,CIDOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,0.09,NM,,,,,,,,,,,,,,,,,,,,10.045757490560675,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31
2461,CHEMBL101740,ODQWQRRAPPTVAG-BOPFTXTBSA-N,CIDOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,0.32,NM,,,,,,,,,,,,,,,,,,,,9.494850021680094,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31
2463,CHEMBL1628227,ODQWQRRAPPTVAG-UHFFFAOYSA-N,DOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,0.17800000000000002,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,9.749579997691106,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31
2464,CHEMBL1628227,ODQWQRRAPPTVAG-UHFFFAOYSA-N,DOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,0.57,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.244125144327509,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31
2465,CHEMBL1628227,ODQWQRRAPPTVAG-UHFFFAOYSA-N,DOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.066,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,10.18045606445813,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31
2466,CHEMBL514217,ODRJZKUJAYVKSJ-VVOJOOEHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18768318.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Synthesis and evaluation of a spiro-isobenzofuranone class of histamine H3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(CCN1CCCCC1)C(=O)C2CCC3(CC2)C4=CC=CC=C4C(=O)O3
2467,CHEMBL167911,OEBRKCOSUFCWJD-UHFFFAOYSA-N,DICHLORVOS,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COP(=O)(OC)OC=C(Cl)Cl
2468,CHEMBL167911,OEBRKCOSUFCWJD-UHFFFAOYSA-N,DICHLORVOS,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COP(=O)(OC)OC=C(Cl)Cl
2469,CHEMBL327888,OEJHRMYSNOPXGZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.2,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.207608310501746,CCOCCN1C2=CC=CC=C2N=C1C(=O)C3CCN(CC3)CCC4(CCN(C4)C(=O)C5=CC(=C(C(=C5)OC)OC)OC)C6=CC(=C(C=C6)OC)OC
2470,CHEMBL783,OELFLUMRDSZNSF-BRWVUGGUSA-N,NATEGLINIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O
2471,CHEMBL783,OELFLUMRDSZNSF-BRWVUGGUSA-N,NATEGLINIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O
2473,CHEMBL1767158,OEYDBWKMXFZENQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,2.51,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.600326278518962,CN1CCCCC(C1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
2474,CHEMBL407,OFBIFZUFASYYRE-UHFFFAOYSA-N,FLUMAZENIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C
2475,CHEMBL407,OFBIFZUFASYYRE-UHFFFAOYSA-N,FLUMAZENIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C
2476,CHEMBL1467,OFCNXPDARWKPPY-UHFFFAOYSA-N,ALLOPURINOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NNC2=C1C(=O)NC=N2
2477,CHEMBL1467,OFCNXPDARWKPPY-UHFFFAOYSA-N,ALLOPURINOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NNC2=C1C(=O)NC=N2
2478,CHEMBL236788,OFGZKSUTEKHHAS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,2600.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,CCOC1=CC(=CC(=C1N)OCC)CN2CCC(CC2)NC3=NC4=C(O3)C=CC(=C4)S(=O)(=O)N
2479,CHEMBL1601669,OFHCOWSQAMBJIW-AVJTYSNKSA-N,ALFACALCIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C
2480,CHEMBL1601669,OFHCOWSQAMBJIW-AVJTYSNKSA-N,ALFACALCIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C
2483,CHEMBL95029,OFMHVSNETOZSQH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.0,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.221848749616356,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCCCOC6=CC=CC=C6C(=O)OC)C7=CC=CC=C7
2484,CHEMBL1071,OFPXSFXSNFPTHF-UHFFFAOYSA-N,OXAPROZIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3
2485,CHEMBL1071,OFPXSFXSNFPTHF-UHFFFAOYSA-N,OXAPROZIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3
2486,CHEMBL1440,OFVLGDICTFRJMM-WESIUVDSSA-N,TETRACYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
2487,CHEMBL1440,OFVLGDICTFRJMM-WESIUVDSSA-N,TETRACYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O
2488,CHEMBL936,OGAKLTJNUQRZJU-UHFFFAOYSA-N,DIPHENIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O
2489,CHEMBL936,OGAKLTJNUQRZJU-UHFFFAOYSA-N,DIPHENIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O
2491,CHEMBL70598,OGEAASSLWZDQBM-UHFFFAOYSA-N,TEMELASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8335064.0,Ki,=,3.2,NM,,,,,,,,,,,,,,,,,,,,8.494850021680094,CC1=NC=C(C=C1)CC2=CN=C(NC2=O)NCCCCC3=NC=C(C=C3C)Br
2492,CHEMBL723,OGHNVEJMJSYVRP-UHFFFAOYSA-N,CARVEDILOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
2493,CHEMBL723,OGHNVEJMJSYVRP-UHFFFAOYSA-N,CARVEDILOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O
2494,CHEMBL267014,OGJGQVFWEPNYSB-UHFFFAOYSA-N,L-745870,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)Cl
2495,CHEMBL9,OGJPXUAPXNRGGI-UHFFFAOYSA-N,NORFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O
2496,CHEMBL9,OGJPXUAPXNRGGI-UHFFFAOYSA-N,NORFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O
2497,CHEMBL264761,OGLKHSQISDJZCG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,977.24,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.009998764965339,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C(=C)C
2498,CHEMBL1669416,OGQADGYHVAQLNE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,249.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.603800652904264,C1CN(CC1(F)F)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4
2499,CHEMBL870,OGSPWJRAVKPPFI-UHFFFAOYSA-N,ALENDRONIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
2500,CHEMBL870,OGSPWJRAVKPPFI-UHFFFAOYSA-N,ALENDRONIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN
2501,CHEMBL1669409,OGTGPRXXTIEASF-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,32.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.494850021680094,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC#N
2502,CHEMBL372453,OGWAJJGAXANYMJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=C(C=C4)Cl)OC
2503,CHEMBL90555,OGWKCGZFUXNPDA-XQKSVPLYSA-N,VINCRISTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
2504,CHEMBL90555,OGWKCGZFUXNPDA-XQKSVPLYSA-N,VINCRISTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
2506,CHEMBL181085,OHBPVXVMMZZMKM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,7.59,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human Histamine H1 receptor in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.119758224104519,CC(C)COC(=O)N(CCC#CC1=CC=C(C=C1)OCCCCN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)O
2507,CHEMBL370128,OHBRURMYVYWCLY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=CC=C4Cl)OC
2508,CHEMBL444307,OHFUDGRGQOZMIF-IZZDOVSWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,426.58,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.369999510099088,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)/C=C/C3=CN=CC=C3
2509,CHEMBL1783965,OHKBLWVRXBNICP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,160.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.795880017344075,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=NC=C4
2510,CHEMBL1783965,OHKBLWVRXBNICP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,3980.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.400116927926312,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=NC=C4
2512,CHEMBL131,OIGNJSKKLXVSLS-VWUMJDOOSA-N,PREDNISOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O
2513,CHEMBL131,OIGNJSKKLXVSLS-VWUMJDOOSA-N,PREDNISOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O
2516,CHEMBL3609372,OINGHOPGNMYCAB-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26191365.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human histamine H1 receptor,,ACS Med. Chem. Lett.,PUBLICATION,,4.522878745280337,CC(C)NC(=O)N1CC[C@@H](C1)N=C2C3=C(C=CC(=C3)Cl)N(C4=C(N2)C=C(C=C4)F)CC(F)F
2517,CHEMBL2178580,OIXSYJAHIPQFMO-RUZDIDTESA-N,YM-344484,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22931505.0,Ki,=,47.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at histamine H1 receptor expressed in human PC3 cells inhibition of histamine-induced calcium influx by cell based assay,Chemokine receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.327902142064283,CC1=NN=C(C=C1)C(=O)N2CCC(=CC(=O)N[C@@H]3CCN(C3)CC4=CC5=C(C=C4)C=C(C=C5)F)CC2
2518,CHEMBL1767155,OIZYYUJMNZAXNN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,6.31,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.199970640755867,CN1CCC(C1)CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
2519,CHEMBL253376,OJGDCBLYJGHCIH-UHFFFAOYSA-N,BROMHEXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CC1=C(C(=CC(=C1)Br)Br)N)C2CCCCC2
2520,CHEMBL253376,OJGDCBLYJGHCIH-UHFFFAOYSA-N,BROMHEXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CC1=C(C(=CC(=C1)Br)Br)N)C2CCCCC2
2522,CHEMBL1447,OJMMVQQUTAEWLP-KIDUDLJLSA-N,LINCOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O
2523,CHEMBL1447,OJMMVQQUTAEWLP-KIDUDLJLSA-N,LINCOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O
2524,CHEMBL94739,OJSFTALXCYKKFQ-YLJYHZDGSA-N,FEMOXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,4200.0,NM,,,,,,,,,,,,,,,,,,,,5.376750709602099,CN1CC[C@@H]([C@H](C1)COC2=CC=C(C=C2)OC)C3=CC=CC=C3
2527,CHEMBL598753,OKSDPUBPIUWZPV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20045641.0,Ki,=,2640.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human cloned histamine H1 receptor,"9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.578396073130169,COC1=CC2=C(C=C1)C3=C(CC4=CC=CC=C4C3CN)C=C2
2529,CHEMBL526,OLBCVFGFOZPWHH-UHFFFAOYSA-N,PROPOFOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=CC=C1)C(C)C)O
2530,CHEMBL526,OLBCVFGFOZPWHH-UHFFFAOYSA-N,PROPOFOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=CC=C1)C(C)C)O
2531,CHEMBL452847,OLJSGKYQYTWQNJ-UHFFFAOYSA-N,VUF-10497,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19053770.0,Ki,=,19.95,NM,,,cell_based,,,,,NIH3T3,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in NIH3T3 cells,Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach.,J. Med. Chem.,PUBLICATION,,7.700057099977233,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)C(=N2)NCC4=CC=CS4
2532,CHEMBL452847,OLJSGKYQYTWQNJ-UHFFFAOYSA-N,VUF-10497,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,549.54,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.260000690598032,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)C(=N2)NCC4=CC=CS4
2535,CHEMBL85606,OLWRVVHPJFLNPW-LSNLESRRSA-N,SB-277011,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,630.96,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.199998172182031,C1CC(CCC1CCN2CCC3=C(C2)C=CC(=C3)C#N)NC(=O)C4=CC=NC5=CC=CC=C45
2536,CHEMBL85606,OLWRVVHPJFLNPW-LSNLESRRSA-N,SB-277011,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,630.96,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.199998172182031,C1CC(CCC1CCN2CCC3=C(C2)C=CC(=C3)C#N)NC(=O)C4=CC=NC5=CC=CC=C45
2538,CHEMBL3233067,ONISVGVNTCDONI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,=,6165.95,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,5.210000001311122,C1CCN(CC1)CCCN2C(=O)C(NC2=O)(C3=CC=CC=C3)C4=CC=CC=C4
2539,CHEMBL1200624,ONKUMRGIYFNPJW-KIEAKMPYSA-N,ETHYNODIOL DIACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C
2540,CHEMBL1200624,ONKUMRGIYFNPJW-KIEAKMPYSA-N,ETHYNODIOL DIACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C
2542,CHEMBL1617548,ONRXABULYAHOMS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,10715.19,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,4.970000123715015,C=CCN1C2=CC=CC=C2N(C1=N)CC(=O)C3=CC=CC=C3
2543,CHEMBL565833,ONUBXRCAOBQBRS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19632840.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,CCCNCC1=CN=C(C=C1)CCN2C=CC(=CC2=O)OCC3=CC=C(C=C3)F
2544,CHEMBL311231,ONUZLDLDGNZGFE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CN(CCN1)CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2
2546,CHEMBL282424,OOKNJSVAHXTYKL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=CC=C4F
2547,CHEMBL1783956,OORNIOGZQUYGRW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,610.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.214670164989233,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)F
2548,CHEMBL1783956,OORNIOGZQUYGRW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,940.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.026872146400302,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)F
2549,CHEMBL566075,OOUPDYBXVFKJRL-UJKQEGAGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CN=C(N=C1N(C)C)NC2CCC(CC2)CNC(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
2550,CHEMBL287367,OPICWPJAKDPOOB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,1760.0,NM,,,,,,,,,,,,,,,,,,,,5.7544873321858505,C1=CC(=CC(=C1)I)C2=NC=C(N2)CCN
2551,CHEMBL685,OPXLLQIJSORQAM-UHFFFAOYSA-N,MEBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3
2552,CHEMBL685,OPXLLQIJSORQAM-UHFFFAOYSA-N,MEBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3
2554,CHEMBL1697694,OQIQSTLJSLGHID-WNWIJWBNSA-N,AFLATOXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1
2555,CHEMBL1697694,OQIQSTLJSLGHID-WNWIJWBNSA-N,AFLATOXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1
2557,CHEMBL1669415,OQSOOFROGDVPSV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,4605.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.336770365467133,C1C2=CC=CC=C2C(=C1CCN3CC(C3)(F)F)CC4=NC=CN=C4
2559,CHEMBL97240,ORBDOXUKPRMJQT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.26,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.20342566678957,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCN6CCOCC6)C7=CC(=C(C=C7)Cl)Cl
2561,CHEMBL410270,ORMPNUUVYNSLES-WLHGVMLRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,500.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,COC1=CC=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=CC=N7.C(=C/C(=O)O)\C(=O)O
2563,CHEMBL398440,OSDLLIBGSJNGJE-UHFFFAOYSA-N,CHLOROXYLENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC(=C1Cl)C)O
2564,CHEMBL398440,OSDLLIBGSJNGJE-UHFFFAOYSA-N,CHLOROXYLENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC(=C1Cl)C)O
2565,CHEMBL64317,OSENGOVQGXZHHZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,575.44,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2399999527072705,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCCCC
2567,CHEMBL1909072,OSJJYEUEJRVVOD-UHFFFAOYSA-N,PIPAMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,9.94,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.002613615602687,C1CN(CCC1C(=O)N)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
2568,CHEMBL1909072,OSJJYEUEJRVVOD-UHFFFAOYSA-N,PIPAMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.15,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.939302159646388,C1CN(CCC1C(=O)N)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
2569,CHEMBL2171039,OSUVEVWOPQLILG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC=CC=C4Cl
2570,CHEMBL1277401,OSWDQWCAAIWPDM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.0,C1CC2(CC1N3CCC(CC3)C(=O)O)C4=CC=CC=C4OC5=C(C2=O)C=C(C=C5)Cl
2571,CHEMBL108545,OSWPMRLSEDHDFF-UHFFFAOYSA-N,METHYL SALICYLATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)C1=CC=CC=C1O
2572,CHEMBL108545,OSWPMRLSEDHDFF-UHFFFAOYSA-N,METHYL SALICYLATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)C1=CC=CC=C1O
2573,CHEMBL418470,OTBYLNCJHFPRTL-NKWVEPMBSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@@H]([C@@H]1C2=CN=CN2)CCN
2574,CHEMBL60716,OTBYLNCJHFPRTL-RQJHMYQMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@H]([C@H]1C2=CN=CN2)CCN
2575,CHEMBL1236282,OTVAEFIXJLOWRX-NXEZZACHSA-N,THIAMPHENICOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O
2576,CHEMBL1236282,OTVAEFIXJLOWRX-NXEZZACHSA-N,THIAMPHENICOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O
2577,CHEMBL597528,OUBNFHMJUXSZKL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20045641.0,Ki,=,964.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human cloned histamine H1 receptor,"9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.015922966097169,C1C2=CC=CC=C2C(C3=CC=CC=C31)CNCCCCC4=CC=CC=C4
2578,CHEMBL817,OUDSBRTVNLOZBN-UHFFFAOYSA-N,TOLAZAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2
2579,CHEMBL817,OUDSBRTVNLOZBN-UHFFFAOYSA-N,TOLAZAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2
2581,CHEMBL2146809,OUEZWZJJIKBFFV-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.316,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.500312917381596,CN1CCC[C@@H]1CN2C(=O)C3=C(C(=N2)CC4=CC=C(C=C4)Cl)N=CC=C3
2582,CHEMBL26260,OUGIDAPQYNCXRA-UHFFFAOYSA-N,BETA-NAPHTHOFLAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC4=CC=CC=C43
2583,CHEMBL26260,OUGIDAPQYNCXRA-UHFFFAOYSA-N,BETA-NAPHTHOFLAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC4=CC=CC=C43
2584,CHEMBL3358509,OURPZJJZFFKVJH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25343529.0,Ki,=,110.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies.",J. Med. Chem.,PUBLICATION,,6.958607314841775,C1CN(CCN1CCCCNC(=O)C2=CC3=C(C=C2)N=CC=C3)C4=CC=CC=C4
2585,CHEMBL1946255,OUSOPIMSKOMYQI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,665.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,6.1771783546968955,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCC3=NC4=CC=CC=C4S3
2587,CHEMBL157264,OUVNPGHJCOISPW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,100000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.0,C1CCC(CC1)C(CCC2=NC=C(N2)CCN)C3=CC=CC=C3
2590,CHEMBL1092767,OVTUKEYYZWXZMJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,35.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.455931955649724,CC(C1=C(SC2=CC=CC=C21)CCN(C)C)C3=NC=CS3
2591,CHEMBL1092663,OWMBYQVIMDTSAW-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,4.2,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.3767507096021,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)[C@@H](C)C3=NC=CN=C3
2592,CHEMBL476933,OWMYGKYXZFSRMD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,,C1CC2CN(CC1N2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F
2593,CHEMBL160893,OWPHKTVZEZNCMB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,137.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,6.863279432843593,C1C2=CC=CC=C2C(C3=CC=CC=C31)CCN
2594,CHEMBL77675,OWRCNXZUPFZXOS-UHFFFAOYSA-N,"N,N'-DIPHENYL-GUANIDINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NC(=NC2=CC=CC=C2)N
2595,CHEMBL77675,OWRCNXZUPFZXOS-UHFFFAOYSA-N,"N,N'-DIPHENYL-GUANIDINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NC(=NC2=CC=CC=C2)N
2596,CHEMBL59389,OWWNABDDYQLERE-CRCLSJGQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@@H]([C@@H]1N)C2=CN=CN2
2597,CHEMBL13559,OWWNABDDYQLERE-RFZPGFLSSA-N,VUF-5296,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@H]([C@@H]1N)C2=CN=CN2
2598,CHEMBL294061,OWWNABDDYQLERE-UHNVWZDZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@H]([C@H]1N)C2=CN=CN2
2599,CHEMBL13795,OWWNABDDYQLERE-WHFBIAKZSA-N,VUF-5297,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,=,864.0,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,6.063486257521107,C1[C@@H]([C@H]1N)C2=CN=CN2
2600,CHEMBL188921,OWYLAEYXIQKAOL-UHFFFAOYSA-N,BUFLOMEDIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC
2601,CHEMBL188921,OWYLAEYXIQKAOL-UHFFFAOYSA-N,BUFLOMEDIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC
2602,CHEMBL429458,OXAGECQHLDNVCY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CCN(C1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O
2603,CHEMBL270595,OXEFHEYEQUISKC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CCC2=CC=CC=N2
2604,CHEMBL455288,OXJGPZFAZUEPIX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,390.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4089353929735005,C1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)OCCN3CCN(CC3)CCCN4C5=CC=CC=C5SC6=C4C=C(C=C6)C(F)(F)F
2605,CHEMBL392354,OXLSTDPYCCQCDK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CCC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=C(C=C(C=C5)F)F.C(=O)O
2606,CHEMBL564168,OYGQVRYZRZJCQY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,124.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.906578314837765,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(=O)O
2609,CHEMBL255827,OYUFXMRRZYKKDL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)C
2610,CHEMBL79838,OZETYYSIKGRYTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CN(CCN1CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2)C6=CC(=CC=C6)Cl
2611,CHEMBL1935425,OZMRAMSUYZLMIG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153342.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC(C1)N2CCC3(CCC4=C(O3)C=CC(=C4)OC5CCS(=O)(=O)CC5)CC2
2612,CHEMBL1923535,OZUNHSMQAVTNLW-UHFFFAOYSA-N,2-(2-PHENOXYPHENYL)ETHANAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,10964.78,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,4.960000077688649,C1=CC=C(C=C1)OC2=CC=CC=C2CCN
2613,CHEMBL493,OZVBMTJYIDMWIL-AYFBDAFISA-N,BROMOCRIPTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O
2614,CHEMBL493,OZVBMTJYIDMWIL-AYFBDAFISA-N,BROMOCRIPTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O
2615,CHEMBL469,OZWKMVRBQXNZKK-UHFFFAOYSA-N,KETOROLAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O
2616,CHEMBL469,OZWKMVRBQXNZKK-UHFFFAOYSA-N,KETOROLAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O
2617,CHEMBL257946,OZZLMZAQJKSGCB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)ON=C6C
2618,CHEMBL431850,PARRBDIQICRPTM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,437.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.359518563029578,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CC=N6)C7=CC(=C(C=C7)Cl)Cl.CS(=O)(=O)O
2619,CHEMBL1243,PBCZLFBEBARBBI-UHFFFAOYSA-N,SULFABENZAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)NS(=O)(=O)C2=CC=C(C=C2)N
2620,CHEMBL1243,PBCZLFBEBARBBI-UHFFFAOYSA-N,SULFABENZAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)NS(=O)(=O)C2=CC=C(C=C2)N
2621,CHEMBL1259172,PBYSLXLVOFLVAY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,64.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,7.1938200260161125,C1CN(CCC1C2=CN(C3=C2C=C(C=C3)CN)C4=CC=C(C=C4)F)CCN5CCNC5=O
2623,CHEMBL2208425,PCRWWFINVOSHRN-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.79997073344623,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CN4C=C(C=CC4=N3)F)O
2624,CHEMBL503,PCZOHLXUXFIOCF-BXMDZJJMSA-N,LOVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
2625,CHEMBL503,PCZOHLXUXFIOCF-BXMDZJJMSA-N,LOVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
2627,CHEMBL2171027,PDJBLXDNFLXACI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450609,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC(=CC=C4)S(=O)(=O)CCCC(=O)O
2628,CHEMBL18701,PDMUULPVBYQBBK-UHFFFAOYSA-N,RO-201724,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC1=C(C=CC(=C1)CC2CNC(=O)N2)OC
2629,CHEMBL18701,PDMUULPVBYQBBK-UHFFFAOYSA-N,RO-201724,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC1=C(C=CC(=C1)CC2CNC(=O)N2)OC
2630,,PDNJLMZEGXHSCU-GSVOUGTGSA-N,D-HOMOCYSTEINE SULFINIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(CS(=O)O)[C@H](C(=O)O)N
2631,CHEMBL1516176,PDNJLMZEGXHSCU-VKHMYHEASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(CS(=O)O)[C@@H](C(=O)O)N
2633,CHEMBL291166,PEDXQUUSXXYPJU-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,355.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.449771646944906,CC1=C([C@H](CC(=O)N1C)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)(C#N)C4=CC=C(C=C4)F
2634,CHEMBL106483,PFEJJOZKVMFZED-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3235.94,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.489999539566098,C1COCCN1CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
2635,CHEMBL107293,PFSYJJKLBNXBAA-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,5500.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.259637310505756,CC1=CC=C(C=C1)S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
2636,CHEMBL196169,PGAUZNVGTNAJSV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=CC=C4F)OC
2637,CHEMBL184618,PGBHMTALBVVCIT-VCIWKGPPSA-N,NEOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N
2638,CHEMBL184618,PGBHMTALBVVCIT-VCIWKGPPSA-N,NEOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N
2639,CHEMBL426317,PGGCRGAETLNAJC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16458504.0,Ki,=,839.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor by radioligand binding assay,"Synthesis, in vitro and in vivo evaluation of [O-methyl-11C] 2-{4-[4-(3-methoxyphenyl)piperazin-1-yl]-butyl}-4-methyl-2H-[1,2,4]-triazine-3,5-dione: a novel agonist 5-HT1A receptor PET ligand.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0762380391713,CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=CC(=CC=C3)OC
2642,CHEMBL1201190,PGLIUCLTXOYQMV-GHVWMZMZSA-N,LEVOCETIRIZINE DIHYDROCHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771458.0,Ki,=,50.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for H1 histamine receptor expressed in CHO cells,"Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines.",J. Med. Chem.,PUBLICATION,,7.301029995663981,C1CN(CCN1CCOCC(=O)O)[C@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl
2643,CHEMBL1221512,PGOKBMWPBDRDGN-IBXSQZDTSA-N,L-744832,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H](CO[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)OC(C)C)NC[C@H](CS)N
2644,CHEMBL1221512,PGOKBMWPBDRDGN-IBXSQZDTSA-N,L-744832,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H](CO[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)OC(C)C)NC[C@H](CS)N
2645,CHEMBL2171042,PHHPFXWDLDXLPN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.50003813440381,CC1=CC(=CC=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
2646,CHEMBL1149,PHIQHXFUZVPYII-ZCFIWIBFSA-N,LEVOCARNITINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)C[C@@H](CC(=O)[O-])O
2647,CHEMBL1149,PHIQHXFUZVPYII-ZCFIWIBFSA-N,LEVOCARNITINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)C[C@@H](CC(=O)[O-])O
2648,CHEMBL1105,PHJFLPMVEFKEPL-UHFFFAOYSA-N,6-METHOXY-2-NAPHTHYLACETIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC2=C(C=C1)C=C(C=C2)CC(=O)O
2649,CHEMBL1105,PHJFLPMVEFKEPL-UHFFFAOYSA-N,6-METHOXY-2-NAPHTHYLACETIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC2=C(C=C1)C=C(C=C2)CC(=O)O
2650,CHEMBL621,PHLBKPHSAVXXEF-UHFFFAOYSA-N,TRAZODONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,1100.0,NM,,,,,,,,,,,,,,,,,,,,5.958607314841775,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl
2651,CHEMBL621,PHLBKPHSAVXXEF-UHFFFAOYSA-N,TRAZODONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,361.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.442492798094342,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl
2652,CHEMBL621,PHLBKPHSAVXXEF-UHFFFAOYSA-N,TRAZODONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,42.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.376750709602099,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl
2653,CHEMBL41543,PHNLCHMJDSSPDQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N
2654,CHEMBL41543,PHNLCHMJDSSPDQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N
2655,CHEMBL319231,PHNZBVSSQHIXIP-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,90000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.045757490560675,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)N
2656,CHEMBL319231,PHNZBVSSQHIXIP-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,100000.0,NM,,,,,,,,,,,,,,,Binding affinity towards human Histamine H1 receptor (For compound 11),Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)N
2658,CHEMBL445,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NORTRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,8.4,NM,,,,,,,,,,,,,,,,,,,,8.075720713938118,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
2659,CHEMBL445,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NORTRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,6.3,NM,,,,,,,,,,,,,,,,,,,,8.200659450546418,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
2660,CHEMBL445,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NORTRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,50.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.301029995663981,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
2661,CHEMBL445,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NORTRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,5.86,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.232102383981909,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
2662,CHEMBL833,PHWBOXQYWZNQIN-UHFFFAOYSA-N,TICLOPIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl
2663,CHEMBL833,PHWBOXQYWZNQIN-UHFFFAOYSA-N,TICLOPIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl
2664,CHEMBL1090175,PIHREWZGYZJCNQ-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,3.1,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.508638306165727,C[C@@H](C1=NC=CN=C1)C2=C(CC3=C2C=CC(=C3)OC)CCN(C)C
2665,CHEMBL302468,PIIKAHNRVYTSPK-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,4570.88,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3400001801593495,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](C4=CC=CC=C4)N
2666,CHEMBL94,PIJVFDBKTWXHHD-HIFRSBDPSA-N,PHYSOSTIGMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C
2667,CHEMBL94,PIJVFDBKTWXHHD-HIFRSBDPSA-N,PHYSOSTIGMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C
2668,CHEMBL47244,PIMZUZSSNYHVCU-YKWPQBAZSA-N,PICROTOXININ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C
2669,CHEMBL47244,PIMZUZSSNYHVCU-YKWPQBAZSA-N,PICROTOXININ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C
2672,CHEMBL534958,PJJQGSLLJOVYBM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.Cl
2673,CHEMBL1712923,PJLVTVAIERNDEQ-BTJKTKAUSA-N,IRSOGLADINE MALEATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)C2=NC(=NC(=N2)N)N)Cl.C(=C\C(=O)O)\C(=O)O
2674,CHEMBL1712923,PJLVTVAIERNDEQ-BTJKTKAUSA-N,IRSOGLADINE MALEATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)C2=NC(=NC(=N2)N)N)Cl.C(=C\C(=O)O)\C(=O)O
2675,CHEMBL349543,PJLWLZAKVLPHRL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20045641.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human cloned histamine H1 receptor,"9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2=CC=CC=C2C(C3=CC=CC=C31)CNCC4=CC=CC=C4
2676,CHEMBL596,PJMPHNIQZUBGLI-UHFFFAOYSA-N,FENTANYL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,147910.84,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,3.8299999965259595,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3
2677,CHEMBL1539,PJSFRIWCGOHTNF-UHFFFAOYSA-N,SULFADOXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N
2678,CHEMBL1539,PJSFRIWCGOHTNF-UHFFFAOYSA-N,SULFADOXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N
2679,CHEMBL1464,PJVWKTKQMONHTI-UHFFFAOYSA-N,WARFARIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
2680,CHEMBL1464,PJVWKTKQMONHTI-UHFFFAOYSA-N,WARFARIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O
2682,CHEMBL1090528,PKONXOYDGGORHO-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,2.2,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.657577319177793,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)[C@@H](C)C3=NC=CS3
2683,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,20.83,NM,,,,,,,,,,,,,,,,,,,,7.681310730052254,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
2684,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,21.0,NM,,,,,,,,,,,,,,,,,,,,7.6777807052660805,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
2685,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,21.0,NM,,,,,,,,,,,,,,,,,,,,7.6777807052660805,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
2686,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,40.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3979400086720375,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
2687,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,40.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.3979400086720375,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
2688,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,4.66,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.331614083309999,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO
2689,CHEMBL1103,PLHJDBGFXBMTGZ-WEVVVXLNSA-N,FURAZOLIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]
2690,CHEMBL1103,PLHJDBGFXBMTGZ-WEVVVXLNSA-N,FURAZOLIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-]
2691,CHEMBL126224,PLIGPBGDXASWPX-UHFFFAOYSA-N,IPRINDOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,120.0,NM,,,,,,,,,,,,,,,,,,,,6.920818753952375,CN(C)CCCN1C2=C(CCCCCC2)C3=CC=CC=C31
2693,CHEMBL2207640,PLYQWXWXIUOYQJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)CC2=CC(=C3C2=CC=CC=C3)CN4CCN(CC4)C5=CC=CC=C5OC
2694,CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
2695,CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C
2699,CHEMBL1783954,PMLYIGFXJXRZKK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,500.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=CC=N4
2700,CHEMBL1783954,PMLYIGFXJXRZKK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,10000.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=CC=N4
2701,CHEMBL270387,PMOFOATUAABMTD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1258.93,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198648,CN1C(=NN=C1SCCCN2CCC3=C(CC2)C4=C(C=C3)OC(=N4)C(F)(F)F)C5=CC=CC=C5
2702,CHEMBL1515,PMRYVIKBURPHAH-UHFFFAOYSA-N,METHIMAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=CNC1=S
2703,CHEMBL1515,PMRYVIKBURPHAH-UHFFFAOYSA-N,METHIMAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=CNC1=S
2704,CHEMBL1729417,PMTIWRPLQBVEMR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24690494.0,Ki,<,1000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),Antagonists of the kappa opioid receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=C2C(=NC=C1)N(C(=O)C3=CC=CN32)CC(=O)NCCCN4CCN(CC4)C5=CC=C(C=C5)OC
2707,CHEMBL1621,PMXMIIMHBWHSKN-UHFFFAOYSA-N,PALIPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,32.0,NM,,,,,,,,,,,,,,,,,,,,7.494850021680094,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
2708,CHEMBL1621,PMXMIIMHBWHSKN-UHFFFAOYSA-N,PALIPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,3.4,NM,,,,,,,,,,,,,,,,,,,,8.468521082957745,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
2711,CHEMBL1669407,PNSJAJNXVSKCBP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,24.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.619788758288394,CN(CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3)CCF
2712,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
2713,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11750180.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
2714,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
2715,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O
2717,CHEMBL141209,POOPPNNSPMKABZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11784148.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of mepyramine binding to Histamine H1 receptor,Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.,J. Med. Chem.,PUBLICATION,,5.0,COC1CC2=CC=CC=C2C3(O1)CCN(CC3)CC4=CC=CC=C4
2718,CHEMBL1201012,POPFMWWJOGLOIF-XWCQMRHXSA-N,FLURANDRENOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F
2719,CHEMBL1201012,POPFMWWJOGLOIF-XWCQMRHXSA-N,FLURANDRENOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F
2722,CHEMBL1091874,POXFWGOYGQTRMD-SECBINFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20299215.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Identification and hit-to-lead exploration of a novel series of histamine H4 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.522878745280337,CN[C@@H]1CCN(C1)C2=NC(=NC3=C2OC4=C3C=C(C=C4)Cl)N
2723,CHEMBL1479,POZRVZJJTULAOH-LHZXLZLDSA-N,DANAZOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5
2724,CHEMBL1479,POZRVZJJTULAOH-LHZXLZLDSA-N,DANAZOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5
2725,CHEMBL372588,PPABRKQHBMJESP-VYYCAZPPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,Ki,=,20.0,NM,,,,,,,,,,,,,,,Inhibition constant against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,7.698970004336019,C1CN(CCC1CC2=CC=CC=C2)C/C=C\3/C4=CC=CC=C4COC5=C3C=C(C=C5)CC(=O)O
2726,CHEMBL551457,PPLDJNZKOFVZGW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,37.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.431798275933005,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(=O)O
2727,CHEMBL40583,PPQNQXQZIWHJRB-UHFFFAOYSA-N,3-METHYLCHOLANTHRENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1
2728,CHEMBL40583,PPQNQXQZIWHJRB-UHFFFAOYSA-N,3-METHYLCHOLANTHRENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1
2729,CHEMBL431172,PPWTZQUEISGLGF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,26302.68,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.579999998661813,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)S(=O)(=O)C
2730,CHEMBL490632,PPXOTGGYVKBLCQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19329329.0,Ki,=,665.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned histamine H1 receptor by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,6.1771783546968955,CC1=CC=C(C=C1)CCN2CCC(CC2)C(=O)C3=C(C(=CC=C3)OCCF)OC
2731,CHEMBL1098230,PQPVHIHIJVIEQG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20384344.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.,J. Med. Chem.,PUBLICATION,,6.0,CC(C)(C)C1=CC=C(C=C1)SCCC2=CN=CN2
2732,CHEMBL1098230,PQPVHIHIJVIEQG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20541426.0,Ki,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]rilamine from human histamine H1 receptor expressed in CHO cells after 1 hr by liquid scintillation counting,Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor.,Bioorg. Med. Chem.,PUBLICATION,,6.0,CC(C)(C)C1=CC=C(C=C1)SCCC2=CN=CN2
2736,CHEMBL261551,PQQUQVYOCGJWAX-UHFFFAOYSA-N,VUF-10148,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18357976.0,Ki,=,741.31,NM,,,cell_based,,,,,NIH3T3,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in NIH3T3 cells,Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo.,J. Med. Chem.,PUBLICATION,,6.130000141365475,CN1CCN(CC1)C2=NC3=CC=CC=C3N=C2CC4=CC=CC=C4
2738,CHEMBL3289656,PQVQCEDGSJVHMK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24800940.0,Ki,=,724.44,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor by PDSP assay,Identification of a new selective dopamine D4 receptor ligand.,Bioorg. Med. Chem.,PUBLICATION,,6.139997578098902,C1CN(CCN1CCCC2=NC3=CC=CC=C3S2)C4=NC=CC=N4
2739,CHEMBL3289656,PQVQCEDGSJVHMK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24800940.0,Ki,=,730.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor by PDSP assay,Identification of a new selective dopamine D4 receptor ligand.,Bioorg. Med. Chem.,PUBLICATION,,6.136677139879544,C1CN(CCN1CCCC2=NC3=CC=CC=C3S2)C4=NC=CC=N4
2740,CHEMBL2207669,PREVLKLSVWYCAY-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,125.89,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455316,C1CN(CCC1OC2=CC(=C(C=C2)C#N)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=CC=CC=C43)O
2741,CHEMBL2376800,PREVTMRNRJIUDH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23558237.0,Ki,=,33884.42,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human histamine H1 receptor expressed in HEK cells,"A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.469999943783888,CCC1=CC2=C(C(=NC(=N2)N)N3CC(C3)NC)N=C1
2742,CHEMBL2030632,PRKCBGIXZFUCEF-UHFFFAOYSA-N,N-(3-FLUOROBENZYL)PYRROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CC2=CC(=CC=C2)F
2743,CHEMBL193482,PROQIPRRNZUXQM-ZXXIGWHRSA-N,ESTRIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O
2744,CHEMBL193482,PROQIPRRNZUXQM-ZXXIGWHRSA-N,ESTRIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O
2745,CHEMBL488248,PRPSMPHMELIHFQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553110.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Development of a selective and potent radioactive ligand for histamine H(3) receptors: A compound potentially useful for receptor occupancy studies.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1C(=NC2=CC=CC=C2C1=O)C3=CC=C(C=C3)OCCCN4CCCC4
2746,CHEMBL1783967,PRSVXRUERNSVCI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,120.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)F
2747,CHEMBL1783967,PRSVXRUERNSVCI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,470.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.327902142064283,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)F
2748,CHEMBL1935572,PRWLDKKWXOINJS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153663.0,Ki,=,2800.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human H1 receptor expressed in HEK cell membranes,Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.552841968657781,CN1CCN(CC1)C2=NC(=NC3=C2C=CC(=C3)C4=CSC=C4)N
2749,CHEMBL2205836,PSBBAGWMKGXQRW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,=,3727.0,NM,,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.428640607246161,COC1=CC=CC=C1CCN2C3C4C5CC6C4C2(C7C6C5C73)O
2750,CHEMBL717,PSGAAPLEWMOORI-PEINSRQWSA-N,MEDROXYPROGESTERONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C
2751,CHEMBL717,PSGAAPLEWMOORI-PEINSRQWSA-N,MEDROXYPROGESTERONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C
2752,CHEMBL191,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,LOSARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
2753,CHEMBL191,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,LOSARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
2754,CHEMBL255621,PSMOCFUMBCKOPV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,5011.87,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.300000202445418,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC=N5
2755,CHEMBL402377,PSTMOSWQMHZABO-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18077160.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by [35S]GTP-gamma-S binding assay,In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C[C@H]1CCCN1CCC2=CC3=CC=CC=C3C=C2
2757,CHEMBL84081,PSVLBKXIZLIMQR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,1.29,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.88941028970075,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=CC(=C4)F
2763,CHEMBL1909078,PTLRDCMBXHILCL-UHFFFAOYSA-M,SODIUM ARSENITE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,[O-][As]=O.[Na+]
2764,CHEMBL1909078,PTLRDCMBXHILCL-UHFFFAOYSA-M,SODIUM ARSENITE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,[O-][As]=O.[Na+]
2765,CHEMBL1619,PTOAARAWEBMLNO-KVQBGUIXSA-N,CLADRIBINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
2766,CHEMBL1619,PTOAARAWEBMLNO-KVQBGUIXSA-N,CLADRIBINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
2767,CHEMBL328662,PTZUOUKVZMOWMQ-NFOSLFKVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,1.9,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.721246399047171,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CC3C[C@H]4[C@H](O3)C5=CC=CC=C5CC6=CC=CC=C46
2769,CHEMBL562894,PUYPQZLPNDWKQC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,7.1,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.148741651280925,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)OC
2770,CHEMBL475534,PVHUJELLJLJGLN-UHFFFAOYSA-N,NITRENDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C
2771,CHEMBL475534,PVHUJELLJLJGLN-UHFFFAOYSA-N,NITRENDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C
2772,CHEMBL408868,PVISFTMIHRDVDS-QZTJIDSGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18387300.0,Ki,=,26.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.585026652029182,COC1=C(C=CC(=C1)Cl)O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3
2774,CHEMBL94454,PVLJETXTTWAYEW-UHFFFAOYSA-N,MIZOLASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.7,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.568636235841012,CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(=O)N5
2775,CHEMBL573,PVNIIMVLHYAWGP-UHFFFAOYSA-N,NIACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)C(=O)O
2776,CHEMBL573,PVNIIMVLHYAWGP-UHFFFAOYSA-N,NIACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)C(=O)O
2777,CHEMBL264007,PVOZTVLKZYEWDB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.36,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.196542884351587,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=C(C=C(C=C7)F)F
2778,CHEMBL264007,PVOZTVLKZYEWDB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,436.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.360513510731414,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=C(C=C(C=C7)F)F
2779,CHEMBL256482,PVPUOHNCMSOAEE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)CCCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)Br
2781,CHEMBL595158,PVWQFOKNAQZORV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,48.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,7.318758762624412,CNCCC1C2=CC=CC=C2CC3=CC=CC=C13
2782,CHEMBL3238445,PWBFJEIJPADHLX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,=,10471.29,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,4.97999981255505,CC1=NN=C(N1C2=CC=C(C=C2)OCCCN3CCCCC3)C4=CN=CC=C4
2785,CHEMBL443896,PWESNUDCWDBFNS-UHFFFAOYSA-N,UR-PI288,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19317445.0,EC50,=,12882.5,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in insect Sf9 cells co-expressing RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting,N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.,J. Med. Chem.,PUBLICATION,,4.889999848866887,CC(=O)NC(=NCCCC1=CN=CN1)N
2786,CHEMBL314885,PWJDUASUWRTROR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,3.8,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.42021640338319,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC(=C3)F
2787,CHEMBL317900,PWKIXUGLRAVBKW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,181.97,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.740000204918113,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)Br
2788,CHEMBL2391166,PWLRRJAFPMHNQH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23591112.0,Ki,>,9300.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.031517051446065,CC1CCCN1C2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=CC=CC=C4F)C
2789,CHEMBL643,PWWVAXIEGOYWEE-UHFFFAOYSA-N,PROMETHAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23919353.0,IC50,=,5.4,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by radioligand binding assay,Polypharmacology - foe or friend?,J. Med. Chem.,PUBLICATION,,8.267606240177031,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
2790,CHEMBL643,PWWVAXIEGOYWEE-UHFFFAOYSA-N,PROMETHAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,2.87,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.542118103266008,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
2791,CHEMBL643,PWWVAXIEGOYWEE-UHFFFAOYSA-N,PROMETHAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.33399999999999996,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.476253533188435,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
2792,CHEMBL589150,PWXLJFASAVPIDI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,32.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.494850021680094,CN1CCC2=C(C1)C3=C(N2CCC4=CC=C(C=C4)OC)C=CC(=C3)F
2793,CHEMBL2030636,PXBKRGXXBYALIH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CCC2=CC(=CC=C2)F
2794,CHEMBL66660,PXCSHWXWJPYMAD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12798320.0,Ki,=,15733.0,NM,,,,,,,,,,,,,,,Compound was tested for its binding affinity towards human H1 receptor,"A new class of histamine H(3)-receptor antagonists: synthesis and structure-activity relationships of 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.803188457337323,C1CCC2=C(C3=CC=CC=C3N=C2CC1)C#CCCN4CCCCC4
2795,CHEMBL1277855,PXJLHYOGLFJGQN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.400007822415902,C1CN(CC(=C1)C(=O)O)C2CCC3(C2)CC4=C(CC5=CC=CC=C35)C=CC(=C4)F
2797,CHEMBL401728,PXMXBPLOQSHMBE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=NN(C(=C1)C2=NC3=C(O2)C=C4CCN(CCC4=C3)CCCSC5=NN=C(N5C)C6=C(N=CO6)C)C
2799,CHEMBL2208423,PXQMPHKMJWQPRD-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CC=CC(=C3)C#N)O
2800,CHEMBL1946125,PXQSRAWVKJTJBP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,800.2,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,6.096801452957021,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCSC3=CC=C(C=C3)F
2805,CHEMBL3609328,PYSIAKZWZJNMNM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26191365.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human histamine H1 receptor,,ACS Med. Chem. Lett.,PUBLICATION,,9.0,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)F)NC4=C2C=C(C=C4)F
2808,CHEMBL741,PYZRQGJRPPTADH-UHFFFAOYSA-N,LAMOTRIGINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N
2809,CHEMBL741,PYZRQGJRPPTADH-UHFFFAOYSA-N,LAMOTRIGINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N
2813,CHEMBL189,PZRHRDRVRGEVNW-UHFFFAOYSA-N,MILRINONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2
2814,CHEMBL189,PZRHRDRVRGEVNW-UHFFFAOYSA-N,MILRINONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2
2815,CHEMBL309981,PZVJEHWECRAJMM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CN(CCN1CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2)C6=CC=CC=C6
2816,CHEMBL584,QAGYKUNXZHXKMR-HKWSIXNMSA-N,NELFINAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O
2817,CHEMBL584,QAGYKUNXZHXKMR-HKWSIXNMSA-N,NELFINAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O
2818,CHEMBL103027,QAPJOZONDSMYPF-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,6600.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.180456064458132,CC1=CC(=CC=C1)S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
2819,CHEMBL16068,QARVLSVVCXYDNA-UHFFFAOYSA-N,BROMOBENZENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)Br
2820,CHEMBL16068,QARVLSVVCXYDNA-UHFFFAOYSA-N,BROMOBENZENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)Br
2821,CHEMBL2171025,QAXGZLPJWOSHHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.79997073344623,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC=C(C=C4)C5=NOC(=O)N5
2822,CHEMBL536991,QBEYTQZMQMRCRI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,CC1=CC=C(C=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OCCCN4CCCCC4.Cl
2824,CHEMBL315834,QBPDZEVGAGDUQY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,1.74,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.7594507517174,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=CC=C4F
2826,CHEMBL551888,QBUBIPIOMZYFEI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,3.6,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.443697499232712,CN(CC1=CC=CC=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
2827,CHEMBL3357027,QCAINJLOQVFTKT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,5.0,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=C(C=C4)C(=O)OC)C=C(C=C3)Cl)CC1
2828,CHEMBL1779059,QCBXRMVDVAHCPR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21555222.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,"Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (s) receptor ligands modulates off-target activity and subtype selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=C(C=C1)CCN2C3C4C5CC6C4C2(C7C6C5C73)O)OCCC8=CC=CC=C8
2829,CHEMBL1779059,QCBXRMVDVAHCPR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=C(C=C1)CCN2C3C4C5CC6C4C2(C7C6C5C73)O)OCCC8=CC=CC=C8
2830,CHEMBL515472,QCFZUTYIUYQTPW-JOCHJYFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19329329.0,Ki,=,509.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned histamine H1 receptor by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,6.293282217663242,COC1=C(C=CC=C1OCCF)[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O
2831,CHEMBL402143,QCFZUTYIUYQTPW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19329329.0,Ki,=,374.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned histamine H1 receptor by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,6.42712839779952,COC1=C(C=CC=C1OCCF)C(C2CCN(CC2)CCC3=CC=C(C=C3)F)O
2836,CHEMBL554031,QDMPFGBUXBHFTH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,1995262314968.88,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-3.3,C1=C(NC=N1)CCCCCCN
2838,CHEMBL2376801,QEDDBMMRWNQKSG-SNVBAGLBSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23558237.0,Ki,=,11220.18,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human histamine H1 receptor expressed in HEK cells,"A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.950000175844591,CCC1=CC2=C(C(=NC(=N2)N)N3CC[C@H](C3)NC)N=C1
2839,CHEMBL290916,QELUYTUMUWHWMC-UHFFFAOYSA-N,EDARAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN(C(=O)C1)C2=CC=CC=C2
2840,CHEMBL290916,QELUYTUMUWHWMC-UHFFFAOYSA-N,EDARAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN(C(=O)C1)C2=CC=CC=C2
2841,CHEMBL2113241,QENBLMVKRYFDIR-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16821797.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,"(R)-3'-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5'-oxazolidin]-2'-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties.",J. Med. Chem.,PUBLICATION,,5.0,CC1=COC2=C1C=C(C=C2)N3C[C@@]4(CN5CCC4CC5)OC3=O
2842,CHEMBL772,QEVHRUUCFGRFIF-MDEJGZGSSA-N,RESERPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC
2843,CHEMBL772,QEVHRUUCFGRFIF-MDEJGZGSSA-N,RESERPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC
2844,CHEMBL1935416,QEWJHGKQGHFKCH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153342.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CS(=O)(=O)CCCOC1=CC2=C(C=C1)OC3(CC2)CCN(CC3)C4CCC4
2845,CHEMBL413,QFJCIRLUMZQUOT-HPLJOQBZSA-N,SIROLIMUS,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
2846,CHEMBL413,QFJCIRLUMZQUOT-HPLJOQBZSA-N,SIROLIMUS,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
2847,CHEMBL1098441,QFKNUCVKOWGNCX-GFCCVEGCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,>,10000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(SC(=N1)N)CCCN=C(N)NC(=O)C[C@@H](C)C2=CC=CC=C2
2848,CHEMBL1098442,QFKNUCVKOWGNCX-LBPRGKRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,>,10000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(SC(=N1)N)CCCN=C(N)NC(=O)C[C@H](C)C2=CC=CC=C2
2849,CHEMBL1098110,QFKNUCVKOWGNCX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,>,10000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(SC(=N1)N)CCCN=C(N)NC(=O)CC(C)C2=CC=CC=C2
2850,CHEMBL2205834,QFMGHZDEZHDVJJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC=NC=C7)O
2851,CHEMBL2436555,QFNMPNWOYBWECY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24035337.0,Ki,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor expressed in HEK cells after 90 mins by scintillation counting analysis,"2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2=C(C=CC(=C2)Cl)NC(=N1)N.Cl
2852,CHEMBL420108,QFTNRJFCJNHEPW-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,6200.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2076083105017466,C1CN(C[C@H]1NS(=O)(=O)C2=CC=CC=C2C#N)CCCOC3=CC=C(C=C3)C(=O)C4CC4
2853,CHEMBL240565,QGFBWPZGQZAHLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,CS(=O)(=O)C1=CC=CC(=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OC4CCN(CC4)C5CCCC5.C(=O)O
2858,CHEMBL87285,QGXBDMJGAMFCBF-HLUDHZFRSA-N,ANDROSTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O
2859,CHEMBL87285,QGXBDMJGAMFCBF-HLUDHZFRSA-N,ANDROSTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O
2860,CHEMBL3321792,QHLAPIQLWATZKM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,1009.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.996108833763089,C1CC2CC(CC1N2CCCSC3=CC=CC=C3F)(C4=CC=C(C=C4)Cl)O
2864,CHEMBL430502,QIPPGLRRKJCTOV-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,13000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)C3=CC=C(C=C3)C#N
2865,CHEMBL2158770,QIUVHPATBGGVRR-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,25.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934842,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC(=CC=C4)C#N)C(=O)O
2866,CHEMBL105762,QJFIAPPKZLXTPP-QZTJIDSGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,562.34,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2500010234416505,C[C@@H]1CC[C@H](N1CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N)C
2867,CHEMBL269732,QJJXYPPXXYFBGM-LFZNUXCKSA-N,TACROLIMUS,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC
2868,CHEMBL269732,QJJXYPPXXYFBGM-LFZNUXCKSA-N,TACROLIMUS,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC
2869,CHEMBL594731,QJNCEPWQQYZJCX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773175.0,Ki,>,1000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in Sf9 cells co-expressing RGS4,"2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC1=CC=CC=C1CNC2=CC(=NC(=N2)N)N3CCN(CC3)C
2870,CHEMBL437792,QJNRRDWLNVGLID-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803203,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(C)(F)F
2871,CHEMBL292195,QJPBTFRGWJLPSI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,Ki,=,7.0,NM,,,,,,,,,,,,,,,Inhibition constant against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,8.154901959985743,CN(CCCCC1=CN=CN1)CCC(C2=CC=C(C=C2)Cl)C3=CC=CC=N3
2872,CHEMBL292195,QJPBTFRGWJLPSI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21062081.0,Ki,=,7.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Histamine H3 receptor as a drug discovery target.,J. Med. Chem.,PUBLICATION,,8.154901959985743,CN(CCCCC1=CN=CN1)CCC(C2=CC=C(C=C2)Cl)C3=CC=CC=N3
2873,CHEMBL330430,QJSGTTMHFKBELN-WLHGVMLRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,124.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.906578314837765,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC(=C(C=C7)Cl)Cl.C(=C/C(=O)O)\C(=O)O
2874,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3
2875,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12606603.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3
2876,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15033391.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3
2877,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18683917.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor,The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.0,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3
2879,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,5.0,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3
2881,CHEMBL277100,QKDHBVNJCZBTMR-UHFFFAOYSA-N,TEMAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F
2882,CHEMBL277100,QKDHBVNJCZBTMR-UHFFFAOYSA-N,TEMAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F
2883,CHEMBL1088900,QKNADAQNYDFJFJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,2.2,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.657577319177793,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3OC
2884,CHEMBL2031877,QKNQLRSRULGFBA-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313242.0,Ki,=,7010.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 receptor,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.154281982033341,C[C@H]1CCCN1C(=O)C2=CC=C(C=C2)C3=CC4=C(C=C3)C(=O)N(CC4)CCN5CCCC5
2885,CHEMBL2031876,QKNQLRSRULGFBA-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313242.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 receptor,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,C[C@@H]1CCCN1C(=O)C2=CC=C(C=C2)C3=CC4=C(C=C3)C(=O)N(CC4)CCN5CCCC5
2886,CHEMBL1669426,QLDMAQDSTHZTSU-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,24.7,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.607303046740334,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CN=C4
2887,CHEMBL2158774,QLGIWKYNMSCERQ-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450609,CC1=CC=C(C=C1)C[C@@H](C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
2888,CHEMBL1669410,QLIYPKVJEXOVDM-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,109.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.962573502059376,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CCC#N
2889,CHEMBL9419,QLNWXBAGRTUKKI-UHFFFAOYSA-N,METACETAMOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC(=CC=C1)O
2890,CHEMBL9419,QLNWXBAGRTUKKI-UHFFFAOYSA-N,METACETAMOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC(=CC=C1)O
2891,CHEMBL1767161,QLOCEFPHCAKSLE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.700057099977233,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCCC(CC3)N4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl
2892,CHEMBL1946257,QLTASWSCCMMISJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,129.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,6.889410289700751,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCCC(=O)C3=NC4=CC=CC=C4S3
2893,CHEMBL110691,QMBJSIBWORFWQT-DFXBJWIESA-N,CHLORMADINONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)CC[C@]34C)Cl)C)OC(=O)C
2894,CHEMBL110691,QMBJSIBWORFWQT-DFXBJWIESA-N,CHLORMADINONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)CC[C@]34C)Cl)C)OC(=O)C
2895,CHEMBL227934,QMGVPVSNSZLJIA-FVWCLLPLSA-N,STRYCHNINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75
2896,CHEMBL227934,QMGVPVSNSZLJIA-FVWCLLPLSA-N,STRYCHNINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75
2897,CHEMBL157548,QMLVECGLEOSESV-RYUDHWBXSA-N,DANOFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C[C@@H]2C[C@H]1CN2C3=C(C=C4C(=C3)N(C=C(C4=O)C(=O)O)C5CC5)F
2898,CHEMBL157548,QMLVECGLEOSESV-RYUDHWBXSA-N,DANOFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C[C@@H]2C[C@H]1CN2C3=C(C=C4C(=C3)N(C=C(C4=O)C(=O)O)C5CC5)F
2899,CHEMBL64235,QMUNKLLETTWTBJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1096.48,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.95999928552668,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)CSCC
2902,CHEMBL366925,QNNXKPSMUIHGIZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,5.01,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human Histamine H1 receptor in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,COC(=O)N(CCC#CC1=CC=C(C=C1)OCCCCN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)O
2904,CHEMBL3321791,QOECKZUXJGSVMP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,1207.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.91829272990265,C1CC2CC(CC1N2CCCSC3=CC=CC(=C3)F)(C4=CC=C(C=C4)Cl)O
2905,CHEMBL1669425,QORUSIWOKHYRCP-SFHVURJKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,4.9,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.309803919971486,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=NC=C4
2906,CHEMBL46516,QOYHHIBFXOOADH-UHFFFAOYSA-N,FLUSPIRILENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,12.0,NM,,,,,,,,,,,,,,,,,,,,7.920818753952375,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
2907,CHEMBL96466,QPFYLKDZMPQIPZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.89,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.161780778092375,C1CN(CCC1C(=O)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)CCC5(CCN(C5)C(=O)C6=C(C=C(C=C6)Cl)Cl)C7=CC8=C(C=C7)OCO8
2909,CHEMBL438,QPPBRPIAZZHUNT-UHFFFAOYSA-N,SULFAMERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N
2910,CHEMBL438,QPPBRPIAZZHUNT-UHFFFAOYSA-N,SULFAMERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N
2912,CHEMBL1767163,QQERDUJEEYWVED-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.400007822415902,CN(CCCCC1=CC=C(C=C1)OCCCN2CCCCCC2)CCN3C(=O)C4=CC=CC=C4C(=N3)CC5=CC=C(C=C5)Cl
2913,CHEMBL318320,QQJIHDLIMPSIHG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,81.28,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.090016305060156,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)[N+](=O)[O-]
2914,CHEMBL515914,QQOBRRFOVWGIMD-OJAKKHQRSA-N,AZARIBINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=O)NC(=O)C=N2)OC(=O)C)OC(=O)C
2915,CHEMBL515914,QQOBRRFOVWGIMD-OJAKKHQRSA-N,AZARIBINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=O)NC(=O)C=N2)OC(=O)C)OC(=O)C
2916,CHEMBL2207655,QQODNMGQNZBOAF-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934842,CC1(CN(C1)S(=O)(=O)C2=CC3=C(C=C2)C(=CNC3=O)C(=O)NC[C@H](CN4CCC(CC4)OC5=CC(=C(C=C5)Cl)Cl)O)O
2918,CHEMBL331077,QQWLSTBNUSPPGV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12443779.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Binding affinity against Histamine H1 receptor,2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT(2C) antagonist with potential anxiolytic properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=NC=C4
2919,CHEMBL1774497,QQXGHFOKGJXCOQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,70.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.154901959985743,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4CCC5=C3C=C(C=C5)C(=O)O
2920,CHEMBL1262,QRJJEGAJXVEBNE-HKOYGPOVSA-N,OXICONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)Cl)CO/N=C(\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl
2921,CHEMBL1262,QRJJEGAJXVEBNE-HKOYGPOVSA-N,OXICONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)Cl)CO/N=C(\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl
2922,CHEMBL28833,QRQZDZPCRVUFNL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCCC1=CC=C(C=C1)N2CCN(CC2)CC3=CNC4=C3C=CC=N4
2923,CHEMBL271096,QRWDBCPLADXSGV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CCC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CC=C(C=C5)C(F)(F)F
2924,CHEMBL64,QRXWMOHMRWLFEY-UHFFFAOYSA-N,ISONIAZID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=CC=C1C(=O)NN
2925,CHEMBL64,QRXWMOHMRWLFEY-UHFFFAOYSA-N,ISONIAZID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=CC=C1C(=O)NN
2927,CHEMBL413965,QRZAKQDHEVVFRX-UHFFFAOYSA-N,FELBINAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)O
2928,CHEMBL413965,QRZAKQDHEVVFRX-UHFFFAOYSA-N,FELBINAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)O
2929,CHEMBL21731,QSLMDECMDJKHMQ-UHFFFAOYSA-N,MAPROTILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,0.79,NM,,,,,,,,,,,,,,,,,,,,9.102372908709558,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24
2930,CHEMBL21731,QSLMDECMDJKHMQ-UHFFFAOYSA-N,MAPROTILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,1.67,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.777283528852417,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24
2931,CHEMBL21731,QSLMDECMDJKHMQ-UHFFFAOYSA-N,MAPROTILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,8.79,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.056011124926227,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24
2932,CHEMBL21731,QSLMDECMDJKHMQ-UHFFFAOYSA-N,MAPROTILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.02,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.991399828238082,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24
2933,CHEMBL30713,QSQQQURBVYWZKJ-UHFFFAOYSA-N,ALPHA-METHYLTRYPTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23602445.0,Ki,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting analysis,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(CC1=CNC2=CC=CC=C21)N
2934,CHEMBL1200748,QTAOMKOIBXZKND-PPHPATTJSA-N,CARBIDOPA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O
2935,CHEMBL1200748,QTAOMKOIBXZKND-PPHPATTJSA-N,CARBIDOPA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O
2936,CHEMBL3099716,QTAONPFQLNZKSD-XJABCFGWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,48500.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.314258261397736,CC1([C@@H](N(C(=O)O1)C2CCC(CC2)C3=CC(=C(N=C3)N)C4=NC=CC=N4)C5=CC=CC=C5)C
2937,CHEMBL434063,QTQMRBZOBKYXCG-MHZLTWQESA-N,GW1929,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CCOC1=CC=C(C=C1)C[C@@H](C(=O)O)NC2=CC=CC=C2C(=O)C3=CC=CC=C3)C4=CC=CC=N4
2938,CHEMBL434063,QTQMRBZOBKYXCG-MHZLTWQESA-N,GW1929,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CCOC1=CC=C(C=C1)C[C@@H](C(=O)O)NC2=CC=CC=C2C(=O)C3=CC=CC=C3)C4=CC=CC=N4
2941,CHEMBL2205828,QUMVESOWCHBEEV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC(=CC(=C1)CN2C3C4C5CC6C4C2(C7C6C5C73)O)OC
2942,CHEMBL1774506,QUPFMAXRMLKPQC-WMDMUMDLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,135.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.8696662315049934,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CC/C=C\3/C4=CC=CC=C4CCC5=C3C=C(C=C5)CC(=O)O
2943,,QUROTGLADLKIIK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,1778.28,NM,,,,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.749999855918706,C1CCN(CC1)CCN2C(=CC3=C2N=CC=C3)C4CCCO4
2946,CHEMBL238504,QUXZAXNZEZALDL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,3162.28,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.499999678657065,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C5N=CC=CN5N=C4.C(=O)O
2948,CHEMBL2158814,QVLZVRFIGXNZMN-UHFFFAOYSA-N,AZD-3778,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22931505.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Chemokine receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.3979400086720375,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
2949,CHEMBL2158814,QVLZVRFIGXNZMN-UHFFFAOYSA-N,AZD-3778,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,31.62,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.50003813440381,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
2950,CHEMBL2158814,QVLZVRFIGXNZMN-UHFFFAOYSA-N,AZD-3778,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.50003813440381,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
2951,CHEMBL900,QVYRGXJJSLMXQH-UHFFFAOYSA-N,ORPHENADRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,97723.72,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,4.010000009312982,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C
2952,CHEMBL900,QVYRGXJJSLMXQH-UHFFFAOYSA-N,ORPHENADRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,1241.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.90622821850127,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C
2953,CHEMBL900,QVYRGXJJSLMXQH-UHFFFAOYSA-N,ORPHENADRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,144.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.841637507904751,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C
2956,CHEMBL114,QWAXKHKRTORLEM-UGJKXSETSA-N,SAQUINAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O
2957,CHEMBL114,QWAXKHKRTORLEM-UGJKXSETSA-N,SAQUINAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O
2958,CHEMBL1109,QWCJHSGMANYXCW-UHFFFAOYSA-N,SULFAPHENAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N
2959,CHEMBL1109,QWCJHSGMANYXCW-UHFFFAOYSA-N,SULFAPHENAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N
2960,CHEMBL49,QWCRAEMEVRGPNT-UHFFFAOYSA-N,BUSPIRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4
2961,CHEMBL49,QWCRAEMEVRGPNT-UHFFFAOYSA-N,BUSPIRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4
2963,CHEMBL1113,QWGDMFLQWFTERH-UHFFFAOYSA-N,AMOXAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,99.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.00436480540245,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
2964,CHEMBL1113,QWGDMFLQWFTERH-UHFFFAOYSA-N,AMOXAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,11.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.958607314841775,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
2966,CHEMBL105268,QWIRSRRDSYVSEG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,380.19,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.41999931041096,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=CC(=C3)C#N
2967,CHEMBL411293,QWMBVXDLQBRGEQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,794.33,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)N6C=CC(=CC6=N5)C(F)(F)F
2968,CHEMBL255826,QWRZAQFQULNINP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)N7CCCCC7
2969,CHEMBL551340,QWTQKWHOWDAFRM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,75.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,7.1249387366083,CN(C)CCC1=C(C2=CC=CC=C2S1)CC3=NC=CN=C3
2970,CHEMBL1365675,QXAITBQSYVNQDR-ZIOPAAQOSA-N,AMITRAZ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C
2971,CHEMBL1365675,QXAITBQSYVNQDR-ZIOPAAQOSA-N,AMITRAZ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C
2972,CHEMBL416,QXKHYNVANLEOEG-UHFFFAOYSA-N,METHOXSALEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2
2973,CHEMBL416,QXKHYNVANLEOEG-UHFFFAOYSA-N,METHOXSALEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2
2974,CHEMBL1767159,QYAXGGUCDQSHIT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.299988937677887,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CN3CCCC(CC3)N4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl
2978,CHEMBL527,QYSPLQLAKJAUJT-UHFFFAOYSA-N,PIROXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3
2979,CHEMBL527,QYSPLQLAKJAUJT-UHFFFAOYSA-N,PIROXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3
2980,CHEMBL1042,QYSXJUFSXHHAJI-YRZJJWOYSA-N,CHOLECALCIFEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
2981,CHEMBL1042,QYSXJUFSXHHAJI-YRZJJWOYSA-N,CHOLECALCIFEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C
2982,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,EC50,=,0.4,NM,,inverse_agonist,,binding,,,,,,,,,,,,,,,,9.397940008672037,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2983,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,2.77,NM,,,,,,,,,,,,,,,,,,,,8.557520230935552,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2984,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,1.2,NM,,,,,,,,,,,,,,,,,,,,8.920818753952375,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2985,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,2.8,NM,,,,,,,,,,,,,,,,,,,,8.55284196865778,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2986,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,0.23,NM,,,,,,,,,,,,,,,,,,,,9.638272163982407,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2987,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,3.1,NM,,,,,,,,,,,,,,,,,,,,8.508638306165727,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2988,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11170639.0,Ki,=,17.0,NM,,,,,,,,,,,,,,,Binding affinity against histamine H1 receptor,Current and novel approaches to the drug treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,7.769551078621726,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2989,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.54,NM,,,,,,,,,,,,,,,,,,,,8.812479279163536,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2990,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.63,NM,,,,,,,,,,,,,,,,,,,,8.787812395596042,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2991,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,1.2,NM,,,,,,,,,,,,,,,,,,,,8.920818753952375,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2992,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,2.1,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,8.67778070526608,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2993,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,1.1,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.958607314841775,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2994,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,1.8,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,8.744727494896694,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2995,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,2.38,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.623423042943488,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2997,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,1.8,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,8.744727494896694,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2998,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24559051.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,J. Med. Chem.,PUBLICATION,,9.0,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
2999,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,4.91,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.308918507877031,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
3000,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.5710000000000001,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.243363891754152,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
3001,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,10.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay,,MedChemComm,PUBLICATION,,8.0,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42
3003,CHEMBL153994,QZYRMAITXZSSGA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,316227766016838.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.5,CC1=CC=C(C=C1)C(CCC2=NC=C(N2)CCN)C3=CC=CC=C3
3005,CHEMBL240185,RAGNKICHAZGMOB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O
3006,CHEMBL105385,RAHWSYMHXYDXJB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,354.81,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.450004148469349,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)Cl
3007,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27639363.0,Ki,=,42.6,NM,,,,,,,,,,,,,,,,,,,,7.370590400897281,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
3008,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,27.0,NM,,,,,,,,,,,,,,,,,,,,7.568636235841013,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
3009,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,5.2,NM,,,,,,,,,,,,,,,,,,,,8.2839966563652,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
3010,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11170639.0,Ki,=,88.0,NM,,,,,,,,,,,,,,,Binding affinity towards human H1 receptor,Current and novel approaches to the drug treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,7.055517327849832,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
3011,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,15.0,NM,,,,,,,,,,,,,,,,,,,,7.823908740944319,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
3012,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,2.6,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,8.585026652029182,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
3013,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,33.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,7.481486060122113,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
3014,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,19.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,7.721246399047171,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
3015,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27173799.0,IC50,=,868.0,NM,,,,,,,,,,,,,,,Antagonistic activity at histamine1 receptor (unknown origin) after 10 mins by FLIPR assay,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.061480274823508,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
3016,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,25.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.6020599913279625,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
3017,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,2.87,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.542118103266008,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
3018,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay,,MedChemComm,PUBLICATION,,7.0,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F
3019,CHEMBL1909048,RBCUCXILXJXLTB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3Cl
3020,CHEMBL1909048,RBCUCXILXJXLTB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3Cl
3021,CHEMBL95243,RBJZEZVXAVEQFQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.02,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.220403508742175,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)C(=O)OC)OC
3022,CHEMBL1630578,RBKASMJPSJDQKY-RBFSKHHSSA-N,TIRILIZAD,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@H]1C(=O)CN5CCN(CC5)C6=NC(=NC(=C6)N7CCCC7)N8CCCC8)C)C
3023,CHEMBL1630578,RBKASMJPSJDQKY-RBFSKHHSSA-N,TIRILIZAD,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@H]1C(=O)CN5CCN(CC5)C6=NC(=NC(=C6)N7CCCC7)N8CCCC8)C)C
3024,CHEMBL270209,RBZIHZIBFQXVQY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5CCOCC5
3025,CHEMBL311350,RCIMBBZXSXFZBV-UHFFFAOYSA-N,PIROMIDIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CN=C(N=C21)N3CCCC3)C(=O)O
3026,CHEMBL311350,RCIMBBZXSXFZBV-UHFFFAOYSA-N,PIROMIDIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CN=C(N=C21)N3CCCC3)C(=O)O
3027,CHEMBL428647,RCINICONZNJXQF-MZXODVADSA-N,PACLITAXEL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
3028,CHEMBL428647,RCINICONZNJXQF-MZXODVADSA-N,PACLITAXEL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
3030,CHEMBL102331,RDGBZPAYYHGGML-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,7400.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.130768280269024,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)C3=CN=CC=C3
3032,CHEMBL1297,RDJGLLICXDHJDY-UHFFFAOYSA-N,FENOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O
3033,CHEMBL1297,RDJGLLICXDHJDY-UHFFFAOYSA-N,FENOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O
3034,CHEMBL841,RDOIQAHITMMDAJ-UHFFFAOYSA-N,LOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4
3035,CHEMBL841,RDOIQAHITMMDAJ-UHFFFAOYSA-N,LOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4
3036,CHEMBL1200993,REEUVFCVXKWOFE-UHFFFAOYSA-K,GALLAMINE TRIETHIODIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC.[I-].[I-].[I-]
3037,CHEMBL1200993,REEUVFCVXKWOFE-UHFFFAOYSA-K,GALLAMINE TRIETHIODIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC.[I-].[I-].[I-]
3039,CHEMBL2158833,REJVZJBLJWRHQL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,125.89,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455316,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)CC4=CC=C(C=C4)C(=O)O
3040,CHEMBL640,REQCZEXYDRLIBE-UHFFFAOYSA-N,PROCAINAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N
3041,CHEMBL640,REQCZEXYDRLIBE-UHFFFAOYSA-N,PROCAINAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N
3043,CHEMBL2146801,REXDQAIKTDDWAC-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.251,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.600326278518962,COCCN1CCC[C@@H]1CN2C(=O)C3=C(C=NC=C3)C(=N2)CC4=CC=C(C=C4)Cl
3044,CHEMBL1767160,REXVRCXDIWIKGL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.79997073344623,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCN3CCCC(CC3)N4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl
3045,CHEMBL28079,REZGGXNDEMKIQB-UHFFFAOYSA-N,ZAPRINAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2
3046,CHEMBL28079,REZGGXNDEMKIQB-UHFFFAOYSA-N,ZAPRINAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2
3047,CHEMBL179234,REZSROOERNUDJU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15634025.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human H1 histamine receptor,2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.0,C1CC1C(=O)C2=CC3=C(C=C2)N=C(C=C3)N4CCN(CC4)C5CC5
3048,CHEMBL320178,RFDSGHNJJQPTLS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,158.49,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593398,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
3049,CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O
3050,CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O
3052,CHEMBL1201216,RFWZESUMWJKKRN-UHFFFAOYSA-N,DAPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4
3053,CHEMBL1201216,RFWZESUMWJKKRN-UHFFFAOYSA-N,DAPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4
3054,CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,8.33,NM,,,,,,,,,,,,,,,,,,,,8.079354998593212,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
3055,CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,8.0,NM,,,,,,,,,,,,,,,,,,,,8.096910013008056,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
3056,CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,8.0,NM,,,,,,,,,,,,,,,,,,,,8.096910013008056,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
3057,CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
3058,CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO
3059,CHEMBL1923525,RGFBLHAWTZMUAK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,707.95,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,6.149997413907539,CN(C)CCSC1=NC2=CC=CC=C2C3=NN=NN31
3060,CHEMBL572034,RGGWURWNJUDTIH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,121.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.91721462968355,CC1=CC=C(C=C1)CCCCN2CCC(CC2)C(C3=CC=CC=C3)O
3061,CHEMBL411,RGLYKWWBQGJZGM-ISLYRVAYSA-N,DIETHYLSTILBESTROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O
3062,CHEMBL411,RGLYKWWBQGJZGM-ISLYRVAYSA-N,DIETHYLSTILBESTROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O
3064,CHEMBL2208429,RGQXJYRGDMABLT-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,7.94,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=NNC4=CC=CC=C43)O
3065,CHEMBL105515,RGULNTQENHHTRC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3981.07,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,CC1CCCC(N1CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N)C
3067,CHEMBL2208422,RHDOFWFMSRHNFN-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450609,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNS(=O)(=O)C3=CC=CC(=C3)C#N)O
3068,CHEMBL65518,RHEMXJFXAARMOY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,4168.69,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.380000399499541,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)N3CCOCC3
3071,CHEMBL435301,RHPCETHLGGFAQB-MQSINFNDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,4.3,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.366531544420413,CN(C)C[C@H]1CC2[C@H](O1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24
3072,CHEMBL364270,RHPCETHLGGFAQB-SHZHJNINSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,14.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,7.853871964321762,CN(C)C[C@@H]1CC2[C@H](O1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24
3073,CHEMBL2171023,RIEFZSRXHBEIFW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934842,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC=CC=C4C(=O)O
3074,CHEMBL1308,RIKMMFOAQPJVMX-UHFFFAOYSA-N,FOMEPIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CNN=C1
3075,CHEMBL1308,RIKMMFOAQPJVMX-UHFFFAOYSA-N,FOMEPIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CNN=C1
3076,CHEMBL560917,RIUIDVINUPJOQH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,105.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.978810700930062,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CCC(=O)O
3078,CHEMBL154068,RIXQVRQUELEXES-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,50118.72,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,4.300000029139089,C1=CC(=C(C=C1C2=NC=C(N2)CCN)Cl)Cl
3079,CHEMBL154068,RIXQVRQUELEXES-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,50118723362727.1,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.699999999999999,C1=CC(=C(C=C1C2=NC=C(N2)CCN)Cl)Cl
3080,CHEMBL1092652,RJAXVZUSTIFVGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,2.1,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.67778070526608,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)Cl)CC3=NN=CC=C3
3081,CHEMBL103,RJKFOVLPORLFTN-LEKSSAKUSA-N,PROGESTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
3082,CHEMBL103,RJKFOVLPORLFTN-LEKSSAKUSA-N,PROGESTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
3083,CHEMBL1554,RJURFGZVJUQBHK-IIXSONLDSA-N,DACTINOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C
3084,CHEMBL1554,RJURFGZVJUQBHK-IIXSONLDSA-N,DACTINOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C
3085,CHEMBL83777,RJYJDEQXOIQEGZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC=C3F
3086,CHEMBL271097,RKDBVDKLNHXCIZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCCN4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C(F)(F)F
3087,CHEMBL185825,RKEGNNLTPLWIIC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,109.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.962573502059376,C1CN(CCN1CCCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
3089,CHEMBL517712,RKUNBYITZUJHSG-SPUOUPEWSA-N,ATROPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
3090,CHEMBL517712,RKUNBYITZUJHSG-SPUOUPEWSA-N,ATROPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
3091,CHEMBL9751,RKUNBYITZUJHSG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,1600.0,NM,,,,,,,,,,,,,,,,,,,,5.795880017344075,CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
3092,CHEMBL498,RKWGIWYCVPQPMF-UHFFFAOYSA-N,CHLORPROPAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl
3093,CHEMBL498,RKWGIWYCVPQPMF-UHFFFAOYSA-N,CHLORPROPAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl
3094,CHEMBL1237,RLAWWYSOJDYHDC-BZSNNMDCSA-N,LISINOPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O
3095,CHEMBL1237,RLAWWYSOJDYHDC-BZSNNMDCSA-N,LISINOPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O
3096,CHEMBL295001,RLMGUPUESXPDFJ-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,108.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.966576244513051,CC1=C([C@H](CC(=O)N1)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)(C#N)C4=C(C=C(C=C4)F)F
3097,CHEMBL62803,RLVMZEQCHVFJEJ-UHFFFAOYSA-N,A-923,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,275.42,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.560004526046192,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCC
3098,CHEMBL272478,RLYPJRVMOKDHBV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)C(=O)N(C6)C(C)C
3099,CHEMBL273199,RLZDEABBOHACIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,794.33,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,CC1=CC2=C(C=CC=C2C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C=C(C=C5)C6=CC(=NN6C)C)C=N1
3101,CHEMBL2207639,RMDQSWIVOHIFNT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,=,6500.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.187086643357144,COC1=CC=CC=C1N2CCN(CC2)CC3=CC(=C4C3=CC=CC=C4)CN5CCOCC5
3102,CHEMBL1108,RMEDXOLNCUSCGS-UHFFFAOYSA-N,DROPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,4519.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.344957658668799,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F
3103,CHEMBL1108,RMEDXOLNCUSCGS-UHFFFAOYSA-N,DROPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,525.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.279840696594043,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F
3104,CHEMBL2207280,RMQXJQUUIKBXMM-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,6.31,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.199970640755867,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=C(C=C4)F)O
3105,CHEMBL2158776,RMSWKUOSOVPFPF-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755866,COC1=CC=C(C=C1)C[C@@H](C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
3106,CHEMBL1089,RMUCZJUITONUFY-UHFFFAOYSA-N,PHENELZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CCNN
3107,CHEMBL1089,RMUCZJUITONUFY-UHFFFAOYSA-N,PHENELZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CCNN
3108,CHEMBL1923526,RMZULTRHWHVHDS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,707.95,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,6.149997413907539,C1CN(CCN1CCO)C2=C3C=CSC3=NC=N2
3109,CHEMBL12856,RNLQIBCLLYYYFJ-UHFFFAOYSA-N,INAMRINONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=CC=C1C2=CNC(=O)C(=C2)N
3110,CHEMBL12856,RNLQIBCLLYYYFJ-UHFFFAOYSA-N,INAMRINONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=CC=C1C2=CNC(=O)C(=C2)N
3112,CHEMBL1632158,RNXYMZNGMNWKMC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21075638.0,Ki,=,1258.93,NM,,,,,,,,,,,,,,,Binding affinity to Histamine receptor H1,Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,5.899998417198648,COC(=O)CCCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42
3113,CHEMBL488,ROBVIMPUHSLWNV-UHFFFAOYSA-N,AMINOGLUTETHIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
3114,CHEMBL488,ROBVIMPUHSLWNV-UHFFFAOYSA-N,AMINOGLUTETHIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N
3115,CHEMBL184238,ROFVXGGUISEHAM-UHFFFAOYSA-N,URB597,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16352709.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CCC(CC1)NC(=O)OC2=CC=CC(=C2)C3=CC(=CC=C3)C(=O)N
3116,CHEMBL476935,ROKAKGMAWJNFEN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,157.6,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.802443786846464,C1CN(CCN1CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl
3117,CHEMBL654,RONZAEMNMFQXRA-UHFFFAOYSA-N,MIRTAZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,1.6,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.795880017344075,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4
3118,CHEMBL2158834,ROQGCKBWSKAVEH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=C(C=CC=N4)C(=O)O
3119,CHEMBL276832,RPTUSVTUFVMDQK-UHFFFAOYSA-N,HYDRALAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=NN=C2NN
3120,CHEMBL276832,RPTUSVTUFVMDQK-UHFFFAOYSA-N,HYDRALAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=NN=C2NN
3121,CHEMBL167223,RPUXCIYWJSVFFV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,0.813,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,9.089909454405932,CC(C1=CC=CC=N1)C2=C(CC3=C2C=CC(=C3)Cl)CCN(C)C
3122,CHEMBL1794855,RPZYOWNZYQHSLJ-SPIKMXEPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15203136.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards histamine H1 receptor,"(+/-)8-Amino-5,6,7,8-tetrahydroisoquinolines as novel antinociceptive agents.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(C1C2=C(C=CN=C2)CCC1)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O
3123,CHEMBL3104092,RQBRUGMHSQYCNU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,=,47.86,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.320027305722581,CN1CCC2=C(C1)C3=CC=CC4=C3N2CC5=CC=CC=C5C4
3124,CHEMBL3104092,RQBRUGMHSQYCNU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,=,48.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.318758762624412,CN1CCC2=C(C1)C3=CC=CC4=C3N2CC5=CC=CC=C5C4
3126,CHEMBL43491,RQTZTSPFFYDZKA-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,58.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.236572006437063,CC1=C([C@H](CC(=O)N1)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)C4=C(C=C(C=C4)F)C#N
3127,CHEMBL1201139,RQZAXGRLVPAYTJ-GQFGMJRRSA-N,MEGESTROL ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C
3128,CHEMBL1201139,RQZAXGRLVPAYTJ-GQFGMJRRSA-N,MEGESTROL ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C
3129,CHEMBL42710,RRAFCDWBNXTKKO-UHFFFAOYSA-N,EUGENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=CC(=C1)CC=C)O
3130,CHEMBL42710,RRAFCDWBNXTKKO-UHFFFAOYSA-N,EUGENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=CC(=C1)CC=C)O
3132,CHEMBL2205831,RRBNCHNWWUXYEM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCC(CC1)CN2C3C4C5CC6C4C2(C7C6C5C73)O
3133,CHEMBL2205831,RRBNCHNWWUXYEM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1CCC(CC1)CN2C3C4C5CC6C4C2(C7C6C5C73)O
3134,CHEMBL105267,RRBSCZCNYAJFEJ-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,13803.84,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.860000083248981,C1CN(C[C@@H]1N)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
3135,CHEMBL799,RRGUKTPIGVIEKM-UHFFFAOYSA-N,CILOSTAZOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
3136,CHEMBL799,RRGUKTPIGVIEKM-UHFFFAOYSA-N,CILOSTAZOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4
3138,CHEMBL2207634,RSTJJQONPRJAIE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCCC#CC1=C2C=CC=CC=C2C(=C1)CN3CCN(CC3)C4=CC=CC=C4OC
3139,CHEMBL1909076,RSTSYGXUDMJEFP-SECBINFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CNC(=S)SC[C@H](C(=O)O)N
3140,CHEMBL1909076,RSTSYGXUDMJEFP-SECBINFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CNC(=S)SC[C@H](C(=O)O)N
3142,CHEMBL315044,RTEBNFQOFLORPE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,14.45,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.840132152907433,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC(=C3)OC
3143,CHEMBL1456,RTGDFNSFWBGLEC-SYZQJQIISA-N,MYCOPHENOLATE MOFETIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O
3144,CHEMBL1456,RTGDFNSFWBGLEC-SYZQJQIISA-N,MYCOPHENOLATE MOFETIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O
3145,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,1100.0,NM,,,,,,,,,,,,,,,,,,,,5.958607314841775,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F
3146,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,5400.0,NM,,,,,,,,,,,,,,,,,,,,5.267606240177032,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F
3148,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F
3149,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F
3150,CHEMBL403181,RTMHXVRCXRAHLV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,125.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455316,CCC1=NOC2=C1C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C
3151,CHEMBL2391167,RTNOWHVTNCEMDM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23591112.0,Ki,>,9300.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.031517051446065,CC1CCCN1C2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=C(C=CC(=C4)F)C)C
3152,CHEMBL361355,RTRADBQSZJIRMT-GOSISDBHSA-N,A-317920,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12606603.0,Ki,=,3981.07,NM,,,,,,,,,,,,,,,,,,,,5.40000018605658,C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)NC(=O)C4=CC=CO4
3153,CHEMBL430471,RTZKLQYXUHBGFX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,5.04,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.297569463554474,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCCCOC6=CC=CC=C6C(=O)O)C7=CC=CC=C7
3154,CHEMBL329685,RUKTXHCGSFMYLO-JCNKGUCWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,9.3,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.031517051446064,CNCC1C[C@H]2[C@H](O1)C3=CC=CC=C3CC4=CC=CC=C24
3155,CHEMBL2112371,RUKTXHCGSFMYLO-SNRMKQJTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,3.5,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.455931955649724,CNC[C@@H]1C[C@@H]2[C@@H](O1)C3=CC=CC=C3CC4=CC=CC=C24
3156,CHEMBL2171049,RUMOWLXMMCFECC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,125.89,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455316,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC=C(C=C4)Cl
3157,CHEMBL79568,RUNAWWHMBJYHQQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CCCCC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1
3159,CHEMBL60360,RURVOBDSGULLAW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,60.26,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.219970872662662,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)CC3=NC=CS3
3161,CHEMBL315308,RUWZQSJWDUNAEU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,7.94,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=C(C=C4)C5=CC=CC=C5
3162,CHEMBL707,RUZYUOTYCVRMRZ-UHFFFAOYSA-N,DOXAZOSIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC
3163,CHEMBL707,RUZYUOTYCVRMRZ-UHFFFAOYSA-N,DOXAZOSIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC
3164,CHEMBL189118,RVSLLQIPFFIMSB-KPKJPENVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16134937.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against Histamine H1 receptor,"6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode.",J. Med. Chem.,PUBLICATION,,5.0,CC1=CC(=NC2=C1C=C(C=C2)NC(=O)/C=C/C3=CC=C(C=C3)OC(F)(F)F)N(C)CCN(C)C
3165,CHEMBL1946258,RWCQKGYXYLNOEC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCC(=O)C3=NC4=CC=CC=C4S3
3166,CHEMBL1256017,RWTGFMPOODRXIM-UHFFFAOYSA-N,ARCAINE SULFATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCN=C(N)N)CN=C(N)N.OS(=O)(=O)O
3167,CHEMBL1256017,RWTGFMPOODRXIM-UHFFFAOYSA-N,ARCAINE SULFATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCN=C(N)N)CN=C(N)N.OS(=O)(=O)O
3168,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,,,,,,8.0,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
3169,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,78.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.107905397309519,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
3170,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,78.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.107905397309519,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
3171,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,27.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.568636235841013,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
3172,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,78.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.107905397309519,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
3173,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25494650.0,IC50,=,15.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),CNS drug design: balancing physicochemical properties for optimal brain exposure.,J. Med. Chem.,PUBLICATION,,7.823908740944319,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
3174,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
3175,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O
3176,CHEMBL1909065,RWVUEZAROXKXRT-VQLSFVLHSA-N,LYSERGOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C
3177,CHEMBL1909065,RWVUEZAROXKXRT-VQLSFVLHSA-N,LYSERGOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C
3180,CHEMBL10780,RXMTUVIKZRXSSM-UHFFFAOYSA-N,"2,2-DIPHENYLETHYLAMINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1=CC=C(C=C1)C(CN)C2=CC=CC=C2
3181,CHEMBL469912,RXWNCPJZOCPEPQ-NVWDDTSBSA-N,PUROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)NC(=O)[C@H](CC4=CC=C(C=C4)OC)N)O
3182,CHEMBL469912,RXWNCPJZOCPEPQ-NVWDDTSBSA-N,PUROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)NC(=O)[C@H](CC4=CC=C(C=C4)OC)N)O
3183,CHEMBL1214185,RXZBMPWDPOLZGW-XMRMVWPWSA-N,ROXITHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
3184,CHEMBL1214185,RXZBMPWDPOLZGW-XMRMVWPWSA-N,ROXITHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
3187,CHEMBL1064,RYMZZMVNJRMUDD-HGQWONQESA-N,SIMVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
3188,CHEMBL1064,RYMZZMVNJRMUDD-HGQWONQESA-N,SIMVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
3189,CHEMBL113,RYYVLZVUVIJVGH-UHFFFAOYSA-N,CAFFEINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=NC2=C1C(=O)N(C(=O)N2C)C
3190,CHEMBL113,RYYVLZVUVIJVGH-UHFFFAOYSA-N,CAFFEINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=NC2=C1C(=O)N(C(=O)N2C)C
3192,CHEMBL2146804,RZBPSXCZVILRNE-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.6920000000000001,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.159893905543242,CN1CCC[C@@H]1CN2C(=O)C3=C(C=CN=C3)C(=N2)CC4=CC=C(C=C4)Cl
3193,CHEMBL118,RZEKVGVHFLEQIL-UHFFFAOYSA-N,CELECOXIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
3194,CHEMBL118,RZEKVGVHFLEQIL-UHFFFAOYSA-N,CELECOXIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
3195,CHEMBL45245,RZFVLEJOHSLEFR-UHFFFAOYSA-N,PHENANTHRIDIN-6(5H)-ONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C3=CC=CC=C3NC2=O
3196,CHEMBL45245,RZFVLEJOHSLEFR-UHFFFAOYSA-N,PHENANTHRIDIN-6(5H)-ONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C3=CC=CC=C3NC2=O
3197,CHEMBL122,RZJQGNCSTQAWON-UHFFFAOYSA-N,ROFECOXIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3
3198,CHEMBL122,RZJQGNCSTQAWON-UHFFFAOYSA-N,ROFECOXIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3
3199,CHEMBL1480,RZTAMFZIAATZDJ-UHFFFAOYSA-N,FELODIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C
3200,CHEMBL1480,RZTAMFZIAATZDJ-UHFFFAOYSA-N,FELODIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C
3201,CHEMBL112,RZVAJINKPMORJF-UHFFFAOYSA-N,ACETAMINOPHEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC=C(C=C1)O
3202,CHEMBL112,RZVAJINKPMORJF-UHFFFAOYSA-N,ACETAMINOPHEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC=C(C=C1)O
3203,CHEMBL138809,RZZAEVQHACUOGI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11784148.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of mepyramine binding to Histamine H1 receptor,Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.,J. Med. Chem.,PUBLICATION,,5.0,COC1C2=CC=CC=C2C3(O1)CCN(CC3)CC4=CC=CC=C4
3204,CHEMBL1767135,SAKVKDBLCRHLAV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,10.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.0,CN(C)CCCN1C(=O)C2=CC=CC=C2C(=N1)CC3=CC=C(C=C3)Cl
3205,CHEMBL2146811,SAMYTBZVLLYSKN-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.537,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.270025714300445,COCCN1CCC[C@@H]1CN2C(=O)C3=C(C(=N2)CC4=CC=C(C=C4)Cl)N=CC=C3
3206,CHEMBL87708,SAPNXPWPAUFAJU-UHFFFAOYSA-N,LOFEPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,360.0,NM,,,,,,,,,,,,,,,,,,,,6.443697499232713,CN(CCCN1C2=CC=CC=C2CCC3=CC=CC=C31)CC(=O)C4=CC=C(C=C4)Cl
3211,CHEMBL509,SBDNJUWAMKYJOX-UHFFFAOYSA-N,MECLOFENAMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl
3212,CHEMBL509,SBDNJUWAMKYJOX-UHFFFAOYSA-N,MECLOFENAMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl
3213,CHEMBL95127,SBMCXVUSNRZQAG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.53,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.185086818724926,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CO6)C7=CC=CC=C7
3214,CHEMBL95127,SBMCXVUSNRZQAG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,293.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.533132379645891,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CO6)C7=CC=CC=C7
3215,CHEMBL31354,SBPRIAGPYFYCRT-UHFFFAOYSA-N,"WAY-100,635",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16915381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)C(=O)C4CCCCC4
3216,CHEMBL1384,SBUJHOSQTJFQJX-NOAMYHISSA-N,KANAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N
3217,CHEMBL1384,SBUJHOSQTJFQJX-NOAMYHISSA-N,KANAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N
3218,CHEMBL104700,SCDKHPSUXHBJDJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CC3=CN=CC=C3
3219,CHEMBL1413,SCKYRAXSEDYPSA-UHFFFAOYSA-N,CICLOPIROX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)N(C(=C1)C2CCCCC2)O
3220,CHEMBL1413,SCKYRAXSEDYPSA-UHFFFAOYSA-N,CICLOPIROX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)N(C(=C1)C2CCCCC2)O
3221,CHEMBL551347,SDEZSIUXMXPOCO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,18.3,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.73754891026957,C1CN(CCC1N2C=CC=N2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
3222,CHEMBL2171015,SDPQHMHFTWVGGO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,100.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)S(=O)(=O)NC(=O)C4=CC=CC=C4
3223,CHEMBL888,SDUQYLNIPVEERB-QPPQHZFASA-N,GEMCITABINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F
3224,CHEMBL888,SDUQYLNIPVEERB-QPPQHZFASA-N,GEMCITABINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F
3225,CHEMBL1923530,SDYJUASJEOPULH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,3235.94,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.489999539566098,C1CCC(C1)N2CCN(CC2)C3=NC=NC4=CC=CC=C43
3226,CHEMBL1277034,SECVFAJWTWEYDD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,316.23,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.499996931948306,C1CC2(CC1N3CC(C3)CC(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25
3227,CHEMBL439,SEEPANYCNGTZFQ-UHFFFAOYSA-N,SULFADIAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N
3228,CHEMBL439,SEEPANYCNGTZFQ-UHFFFAOYSA-N,SULFADIAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N
3229,CHEMBL1477,SEERZIQQUAZTOL-ANMDKAQQSA-N,CERIVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O
3230,CHEMBL1477,SEERZIQQUAZTOL-ANMDKAQQSA-N,CERIVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O
3231,CHEMBL2158783,SEIOTCVWLCUESB-DEOSSOPVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,39.81,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415902,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=C(C=C4)F)C(=O)O)Cl
3233,CHEMBL165790,SFBODOKJTYAUCM-UHFFFAOYSA-N,IPRIFLAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3
3234,CHEMBL165790,SFBODOKJTYAUCM-UHFFFAOYSA-N,IPRIFLAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3
3235,CHEMBL1946123,SFPSQBFPUCFLEZ-AIZNXBIQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,1719.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,5.764724123312948,C1C[C@H]2CC(C[C@@H]1N2CCCCC3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O
3236,CHEMBL3321788,SFPSQBFPUCFLEZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,1719.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.764724123312948,C1CC2CC(CC1N2CCCCC3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O
3240,CHEMBL852,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,MELPHALAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl
3241,CHEMBL852,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,MELPHALAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl
3242,CHEMBL360953,SGFIBQBVOOVDSS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771458.0,Ki,=,22.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for H1 histamine receptor expressed in CHO cells,"Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines.",J. Med. Chem.,PUBLICATION,,7.657577319177793,CN1C=CC2=C1CCN3C=CN=C3C2=C4CCNCC4
3243,CHEMBL2432052,SGFPDDMJMPKKTB-RAOGCBAWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.0,CN(CCC1=CC(=CC=C1)F)[C@H]2C3C4CC5C3C(=O)C6C2C4C56
3244,CHEMBL1946744,SGGMEYGWAJEGIP-WPUZRXDDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,,C1C[C@H]2CC(C[C@@H]1N2CCCCC(=O)C3=NC4=CC=CC=C4S3)(C5=CC=C(C=C5)Cl)O
3247,CHEMBL282468,SGMZJAMFUVOLNK-UHFFFAOYSA-M,CHOLINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCO.[Cl-]
3248,CHEMBL282468,SGMZJAMFUVOLNK-UHFFFAOYSA-M,CHOLINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCO.[Cl-]
3252,CHEMBL273915,SGSDMASCYPMWHE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,4.56,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.341035157335565,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)C(=O)O)OC
3253,CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
3254,CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
3255,CHEMBL429,SGUAFYQXFOLMHL-UHFFFAOYSA-N,LABETALOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O
3256,CHEMBL429,SGUAFYQXFOLMHL-UHFFFAOYSA-N,LABETALOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O
3259,CHEMBL653,SGXXNSQHWDMGGP-IZZDOVSWSA-N,NIZATIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C
3260,CHEMBL653,SGXXNSQHWDMGGP-IZZDOVSWSA-N,NIZATIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C
3261,CHEMBL547,SHGAZHPCJJPHSC-XFYACQKRSA-N,ISOTRETINOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\C(=O)O)/C)/C
3262,CHEMBL547,SHGAZHPCJJPHSC-XFYACQKRSA-N,ISOTRETINOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\C(=O)O)/C)/C
3263,CHEMBL38,SHGAZHPCJJPHSC-YCNIQYBTSA-N,TRETINOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C
3264,CHEMBL38,SHGAZHPCJJPHSC-YCNIQYBTSA-N,TRETINOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C
3265,CHEMBL316438,SHNQYDFOONPSKV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,3.02,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.51999305704285,C1CCN(C1)CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2
3267,CHEMBL2171215,SHRVEEBUQYOBLS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)CC4=CC=CC=C4
3268,CHEMBL1259190,SHVCHMGRIYXVAY-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,5.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,8.301029995663981,CC(C)C(=O)NCC1=CC2=C(C=C1)SC3=CC=CC=C3C[C@@H]2N4CCN(CC4)C
3269,CHEMBL1259189,SHVCHMGRIYXVAY-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,4.5,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,8.346787486224656,CC(C)C(=O)NCC1=CC2=C(C=C1)SC3=CC=CC=C3C[C@H]2N4CCN(CC4)C
3270,CHEMBL1259145,SHVCHMGRIYXVAY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,,,,Non-toxic,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,,CC(C)C(=O)NCC1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCN(CC4)C
3271,CHEMBL1767143,SHXAAVWRLZPGKQ-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,630.96,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,6.199998172182031,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)C(=O)OC
3272,CHEMBL43048,SHXWCVYOXRDMCX-UHFFFAOYSA-N,METHYLENEDIOXYMETHAMPHETAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12761331.0,Ki,=,2138.0,NM,,,,,,,,,,,,,,,,,,,,5.669992299127241,CC(CC1=CC2=C(C=C1)OCO2)NC
3273,CHEMBL1200396,SIEYLFHKZGLBNX-UHFFFAOYSA-N,BUPIVACAINE HYDROCHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl
3274,CHEMBL1200396,SIEYLFHKZGLBNX-UHFFFAOYSA-N,BUPIVACAINE HYDROCHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl
3275,CHEMBL303737,SIFNBTNSQZZNNX-XMMPIXPASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,14454.4,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.8399999311187,C1CCC(CC1)C[C@H](C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4)N
3276,CHEMBL102384,SJDGVHQTEPPTSY-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,4500.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.346787486224656,C1CN(C[C@H]1NS(=O)(=O)C2=CC=CC=C2Cl)CCCOC3=CC=C(C=C3)C(=O)C4CC4
3277,CHEMBL1946745,SJEXSMOVRPPLBZ-VXMMSVGHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,187.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,6.728158393463501,C1C[C@H]2CC(C[C@@H]1N2CCCCC3=NC4=CC=CC=C4S3)(C5=CC=C(C=C5)Cl)O
3278,CHEMBL291338,SJQBHPJLLIJASD-UHFFFAOYSA-N,"3,3',4',5-TETRACHLOROSALICYLANILIDE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)Cl)Cl)O)Cl)Cl
3279,CHEMBL291338,SJQBHPJLLIJASD-UHFFFAOYSA-N,"3,3',4',5-TETRACHLOROSALICYLANILIDE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)Cl)Cl)O)Cl)Cl
3280,CHEMBL60401,SJQFNVCRPKMBTI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,100000.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CNCC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3
3283,CHEMBL2432050,SJWCMFMHVZULSJ-DKSPCFMDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3CC4C2[C@@H](C5C1C3C45)NCCCC6=CC(=CC=C6)F
3284,CHEMBL62741,SKDLGPGMOATMSN-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,14454.4,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.8399999311187,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](CC(C)C)N
3285,CHEMBL291847,SKDLGPGMOATMSN-QHCPKHFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,9772.37,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.010000098195094,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@H](CC(C)C)N
3286,CHEMBL1278021,SKOALCKWENTDHG-NRWPOFLRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,158.49,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.799998134593398,C1CN(CC(=C1)C(=O)O)C2CC[C@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35
3287,CHEMBL1277935,SKOALCKWENTDHG-TUXUZCGSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.700057099977233,C1CN(CC(=C1)C(=O)O)C2CC[C@@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35
3288,CHEMBL1277935,SKOALCKWENTDHG-TUXUZCGSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.599980364934842,C1CN(CC(=C1)C(=O)O)C2CC[C@@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35
3289,CHEMBL115280,SKVXOYIMICHFPV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,496.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,6.304518323509803,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CC4=CC(=CC=C4)OC5=CC=CC=C5
3290,CHEMBL2207662,SKXJKSJHHFLVAP-GFCCVEGCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,3.98,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C=C3C(F)(F)F)O
3291,CHEMBL27577,SKZKKFZAGNVIMN-UHFFFAOYSA-N,SALICYLAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)N)O
3292,CHEMBL27577,SKZKKFZAGNVIMN-UHFFFAOYSA-N,SALICYLAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)N)O
3293,CHEMBL412873,SLRCCWJSBJZJBV-TUVASFSCSA-N,SPARTEINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN2C[C@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4
3294,CHEMBL412873,SLRCCWJSBJZJBV-TUVASFSCSA-N,SPARTEINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN2C[C@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4
3295,CHEMBL1088,SLVMESMUVMCQIY-UHFFFAOYSA-N,MESORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,1.81,NM,,,,,,,,,,,,,,,,,,,,8.742321425130816,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C
3296,CHEMBL1088,SLVMESMUVMCQIY-UHFFFAOYSA-N,MESORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,1.8,NM,,,,,,,,,,,,,,,,,,,,8.744727494896694,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C
3297,CHEMBL1046,SLXKOJJOQWFEFD-UHFFFAOYSA-N,AMINOCAPROIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCC(=O)O)CCN
3298,CHEMBL1046,SLXKOJJOQWFEFD-UHFFFAOYSA-N,AMINOCAPROIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCC(=O)O)CCN
3299,CHEMBL30008,SMANXXCATUTDDT-QPJJXVBHSA-N,FLUNARIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,158.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.801342913045577,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
3300,CHEMBL30008,SMANXXCATUTDDT-QPJJXVBHSA-N,FLUNARIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,18.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.7447274948966935,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
3302,CHEMBL1201195,SNBUBQHDYVFSQF-HIFRSBDPSA-N,CEFMETAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O
3303,CHEMBL1201195,SNBUBQHDYVFSQF-HIFRSBDPSA-N,CEFMETAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O
3304,CHEMBL3,SNICXCGAKADSCV-JTQLQIEISA-N,NICOTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC[C@H]1C2=CN=CC=C2
3305,CHEMBL3,SNICXCGAKADSCV-JTQLQIEISA-N,NICOTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC[C@H]1C2=CN=CC=C2
3306,CHEMBL1090198,SNPICWUEPVAZAM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,15.0,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.823908740944319,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CC=N3
3307,CHEMBL1371937,SNPLKNRPJHDVJA-UHFFFAOYSA-N,PANTHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(CO)C(C(=O)NCCCO)O
3308,CHEMBL1371937,SNPLKNRPJHDVJA-UHFFFAOYSA-N,PANTHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(CO)C(C(=O)NCCCO)O
3309,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
3310,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
3311,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C
3312,CHEMBL1774493,SNSVDJAVYWDAAX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,128.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.892790030352131,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4COC5=C3C=C(C=C5)CC(=O)O
3314,CHEMBL1222693,SOXIOTAVNTWQJT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415902,CC1=C(N2CC3=CC=CC=C3C=C(C2=N1)N4CCN(CC4)CC(C)(C)C(=O)O)C
3316,CHEMBL1201353,SOYKEARSMXGVTM-HNNXBMFYSA-N,DEXCHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.29,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.201349354554731,CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2
3317,CHEMBL1201353,SOYKEARSMXGVTM-HNNXBMFYSA-N,DEXCHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.73,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.136677139879545,CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2
3318,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,30.0,NM,,,,,,,,,,,,,,,,,,,,7.522878745280337,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
3319,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,15.0,NM,,,,,,,,,,,,,,,,,,,,7.823908740944319,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
3320,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,2.51,NM,,,,,,,,,,,,,,,,,,,,8.600326278518962,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
3321,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,2.51,NM,,,,,,,,,,,,,,,,,,,,8.600326278518962,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
3322,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,2.67,NM,,,,,,,,,,,,,,,,,,,,8.573488738635424,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
3323,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,4.81,NM,,,,,,,,,,,,,,,,,,,,8.317854923626168,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
3324,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17846138.0,IC50,=,66.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine receptor subtype 1 expressed in CHO cells,"Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.",Antimicrob. Agents Chemother.,PUBLICATION,,7.180456064458132,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
3325,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,7.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.154901959985743,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
3326,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,=,0.92,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.036212172654444,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
3327,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,=,4.47,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.349692476868064,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2
3329,CHEMBL157842,SOZBJQHYMWHOEA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,2511.89,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1=CC(=CN=C1)CCCCCCCCCCN
3330,CHEMBL157842,SOZBJQHYMWHOEA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,125892541179417.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.100000000000001,C1=CC(=CN=C1)CCCCCCCCCCN
3331,CHEMBL1200633,SPBDXSGPUHCETR-JFUDTMANSA-N,IVERMECTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)O[C@@H]1C(C)C
3332,CHEMBL1200633,SPBDXSGPUHCETR-JFUDTMANSA-N,IVERMECTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)O[C@@H]1C(C)C
3333,CHEMBL15511,SPFYMRJSYKOXGV-UHFFFAOYSA-N,ENROFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F
3334,CHEMBL15511,SPFYMRJSYKOXGV-UHFFFAOYSA-N,ENROFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F
3335,CHEMBL1493,SPIUTQOUKAMGCX-UHFFFAOYSA-N,FLAVOXATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4
3336,CHEMBL1493,SPIUTQOUKAMGCX-UHFFFAOYSA-N,FLAVOXATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4
3337,CHEMBL2031885,SPKOQCHHYOCMGR-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313242.0,Ki,=,8750.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 receptor,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.057991946977687,C[C@@H]1CCCN1CCN2CCC3=C(C2=O)C=CC(=C3)C4=CC=C(C=C4)C(=O)N5CCCC5
3338,CHEMBL294519,SPQNXJVWMXXMNU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,288.4,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.540004743952609,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=CC=C3
3339,CHEMBL1255837,SPXACGZWWVIDGR-SPZWACKZSA-N,DIHYDROERGOCRISTINE MESYLATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O
3340,CHEMBL1255837,SPXACGZWWVIDGR-SPZWACKZSA-N,DIHYDROERGOCRISTINE MESYLATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O
3341,CHEMBL1774507,SPYSLLTXIWIQNL-MWYAZZEHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,153.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.815308569182402,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CC/C=C\3/C4=CC=CC=C4CCC5=C3C=C(C=C5)C(=O)O
3342,CHEMBL1092599,SQDIKQKCDLMHCF-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,3.1,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.508638306165727,CC1=CSC(=N1)[C@H](C)C2=C(CC3=CC=CC=C32)CCN(C)C
3343,CHEMBL1669411,SQGLQUFJVYRVPS-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,91.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.040958607678906,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CCC(F)(F)F
3345,CHEMBL1902981,SQUNAWUMZGQQJD-UHFFFAOYSA-N,EPERISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2
3346,CHEMBL1902981,SQUNAWUMZGQQJD-UHFFFAOYSA-N,EPERISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2
3348,CHEMBL1091069,SROGIGROUAOOFN-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,5.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.301029995663981,C[C@H](C1=C(SC2=CC=CC=C21)CCN(C)C)C3=C(C=CC=N3)OC
3349,CHEMBL40733,SRPXSILJHWNFMK-ZBEGNZNMSA-N,DESMETHYLSERTRALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,9000.0,NM,,,,,,,,,,,,,,,,,,,,5.045757490560675,C1C[C@@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N
3350,CHEMBL2030629,SRRZEMVAQOSBLB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CCC3=CC=CC=N3
3351,CHEMBL551394,SSIZXVUYAOUIQY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,41.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3872161432802645,CN1C(=CC(=O)N(C1=O)C)C2=CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CC(=O)O
3352,CHEMBL338790,SSMIFVHARFVINF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=CC3=C2C(=C1)C(=O)NC3=O)N
3353,CHEMBL338790,SSMIFVHARFVINF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=CC3=C2C(=C1)C(=O)NC3=O)N
3354,CHEMBL1902627,SSMSBSWKLKKXGG-UHFFFAOYSA-N,CLORPRENALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC=CC=C1Cl)O
3355,CHEMBL1902627,SSMSBSWKLKKXGG-UHFFFAOYSA-N,CLORPRENALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC=CC=C1Cl)O
3356,CHEMBL537027,SSNHYUGXRZNUCY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,3420.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.465973893943865,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)C(=O)O)C7=CC=CC=C7.Cl
3358,CHEMBL49080,STJMRWALKKWQGH-UHFFFAOYSA-N,CLENBUTEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O
3359,CHEMBL49080,STJMRWALKKWQGH-UHFFFAOYSA-N,CLENBUTEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O
3360,CHEMBL178,STQGQHZAVUOBTE-VGBVRHCVSA-N,DAUNORUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O
3361,CHEMBL178,STQGQHZAVUOBTE-VGBVRHCVSA-N,DAUNORUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O
3362,CHEMBL2171046,STXMJDYUJFBELE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.79997073344623,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=C(C=C(C=C4)Cl)Cl
3363,CHEMBL1503,SUBDBMMJDZJVOS-UHFFFAOYSA-N,OMEPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC
3364,CHEMBL1503,SUBDBMMJDZJVOS-UHFFFAOYSA-N,OMEPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC
3365,CHEMBL134423,SUBRNIMHHUWIJU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Binding affinity towards histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1C[Si](CC1N2CCN(CC2)C3=CC=CC=C3)(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
3366,,SUGVYNSRNKFXQM-ACSDJOOWSA-N,SR144528,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,9454810.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC1=CC=C(C=C1)CN2C(=CC(=N2)C(=O)NC3[C@]4(CCC(C4)C3(C)C)C)C5=CC(=C(C=C5)Cl)C
3367,CHEMBL2158823,SUHCNXHLKUQVER-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,5.01,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=CC(=C4)C(=O)O
3368,CHEMBL1567463,SUHOQUVVVLNYQR-MRVPVSSYSA-N,CHOLINE ALFOSCERATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOP(=O)([O-])OC[C@@H](CO)O
3369,CHEMBL1567463,SUHOQUVVVLNYQR-MRVPVSSYSA-N,CHOLINE ALFOSCERATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOP(=O)([O-])OC[C@@H](CO)O
3370,CHEMBL559061,SULKMHQPINMVTR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.537602002101044,CN(C)CCN(C)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
3372,CHEMBL346574,SUOANLAYTVIAIR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,<,10000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.0,C1=CC=C(C=C1)CCCCCC2=NC=C(N2)CCN
3374,CHEMBL272150,SUTBGEJWOOOUFT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)OC(=N6)C(F)(F)F
3375,CHEMBL2207656,SUYKBMCECCINPJ-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,2.51,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.600326278518962,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC=C4F)O
3376,CHEMBL401752,SVBOCVYSHIJYID-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)C
3378,CHEMBL1935447,SWDWBOARDFBZAD-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.4,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.853871964321762,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2[C@H]4CNCCS4
3379,CHEMBL1935448,SWDWBOARDFBZAD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,92.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.036212172654444,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4
3380,CHEMBL2431120,SWEOAXMICIJCQC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1420.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.847711655616943,COC1=CC=CC=C1N2CCN(CC2)C3=NC(=NC4=CC(=C(C=C43)OC)OC)C5CC5
3381,CHEMBL1935446,SWFSQSZMVIJILA-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.3,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693163,C1CS[C@H](CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
3382,CHEMBL1935445,SWFSQSZMVIJILA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,4.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,C1CSC(CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
3383,CHEMBL1935445,SWFSQSZMVIJILA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,95.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.022276394711152,C1CSC(CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
3384,CHEMBL313189,SWGWJQBPCJEQJC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,83.18,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.079981083971085,CN(C)CCC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1
3385,CHEMBL319244,SWUARLUWKZWEBQ-VQHVLOKHSA-N,CAFFEIC ACID PHENETHYL ESTER,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CCOC(=O)/C=C/C2=CC(=C(C=C2)O)O
3386,CHEMBL319244,SWUARLUWKZWEBQ-VQHVLOKHSA-N,CAFFEIC ACID PHENETHYL ESTER,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CCOC(=O)/C=C/C2=CC(=C(C=C2)O)O
3387,CHEMBL2413153,SXCVVYUSUGUSMW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23816046.0,Ki,=,512.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),"Synthesis and in vivo evaluation of [(18)F]2-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione ([(18)F]FECUMI-101) as an imaging probe for 5-HT1A receptor agonist in nonhuman primates.",Bioorg. Med. Chem.,PUBLICATION,,6.29073003902417,CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=CC=CC=C3OCCF
3389,CHEMBL2146484,SXNOWQCFHNZUIX-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.355,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.449771646944907,CN1CCC[C@@H]1CN2C(=O)C3=C(C=CC=N3)C(=N2)CC4=CC=C(C=C4)Cl
3391,CHEMBL566534,SXYIRMFQILZOAM-HVNFFKDJSA-N,ARTEMETHER,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C
3392,CHEMBL566534,SXYIRMFQILZOAM-HVNFFKDJSA-N,ARTEMETHER,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C
3393,CHEMBL1935433,SYDJFDHCVPRQIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,4.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.309803919971486,C1CCN(CC1)C(=O)CN2CCCC(C2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
3394,CHEMBL195927,SYERHDJULLPKRY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)C3CCN(CC3)C4=CC=CC=C4OC)OC
3395,CHEMBL393718,SYNXMLXHBZIEOT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,520.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2839966563652006,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=C(O3)C=CC(=C4)S(=O)(=O)N)OC
3396,CHEMBL62716,SYSBZXCPPMQIMC-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,21877.62,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.659999925349902,CC(C)(C)[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N
3397,CHEMBL563,SYTBZMRGLBWNTM-UHFFFAOYSA-N,FLURBIPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
3398,CHEMBL563,SYTBZMRGLBWNTM-UHFFFAOYSA-N,FLURBIPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
3399,CHEMBL1201010,SYWHXTATXSMDSB-GSLJADNHSA-N,FLUDROCORTISONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)O
3400,CHEMBL1201010,SYWHXTATXSMDSB-GSLJADNHSA-N,FLUDROCORTISONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)O
3401,CHEMBL61120,SZCLNIBNFBNHIY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,28183.83,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5499999894083,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)CCN
3402,CHEMBL1669405,SZKXEXNSYILRKM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,7.2,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.142667503568731,CCN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3
3403,CHEMBL295416,SZRPDCCEHVWOJX-UHFFFAOYSA-N,PIRINIXIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C
3404,CHEMBL295416,SZRPDCCEHVWOJX-UHFFFAOYSA-N,PIRINIXIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C
3405,CHEMBL86,TTWJBBZEZQICBI-UHFFFAOYSA-N,METOCLOPRAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl
3406,CHEMBL86,TTWJBBZEZQICBI-UHFFFAOYSA-N,METOCLOPRAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl
3408,CHEMBL1946124,TUSPVTWVRDALHT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCC3CC4=C(C3=O)C=CC(=C4)F
3409,CHEMBL271449,TUZSKSVCURDDOD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(F)(F)F
3410,CHEMBL1144,TUZYXOIXSAXUGO-PZAWKZKUSA-N,PRAVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O
3411,CHEMBL1144,TUZYXOIXSAXUGO-PZAWKZKUSA-N,PRAVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O
3412,CHEMBL63125,TVAKGPNWRYKDTE-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,6760.83,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.169999984192581,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](C)NC(=O)OC(C)(C)C
3413,CHEMBL1222762,TVBIHDSWRDFHAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415902,CC(C)(CN1CCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC=C4Cl)C(=O)O
3414,CHEMBL2205826,TVDFWGUKMIRJAD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC(=C(C=C1)CN2C3C4C5CC6C4C2(C7C6C5C73)O)OC
3415,CHEMBL558663,TVKCCIBAUDHHBL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,14.1,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.85078088734462,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)OC
3417,CHEMBL1237044,TVYLLZQTGLZFBW-UHFFFAOYSA-N,TRAMADOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O
3418,CHEMBL1237044,TVYLLZQTGLZFBW-UHFFFAOYSA-N,TRAMADOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O
3419,CHEMBL376180,TVZGACDUOSZQKY-LBPRGKRZSA-N,AMINOPTERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=NC(=N3)N)N
3420,CHEMBL376180,TVZGACDUOSZQKY-LBPRGKRZSA-N,AMINOPTERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=NC(=N3)N)N
3421,CHEMBL60620,TWDZILVPGOSJTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803203,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)NCC
3422,CHEMBL2205812,TWMXGXSGGIIQDM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,=,3839.0,NM,,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.415781887882595,COC1=CC=C(C=C1)CCN2C3C4C5CC6C4C2(C7C6C5C73)O
3424,CHEMBL683,TXCGAZHTZHNUAI-UHFFFAOYSA-N,CLOFIBRIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)Cl
3425,CHEMBL683,TXCGAZHTZHNUAI-UHFFFAOYSA-N,CLOFIBRIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)Cl
3426,CHEMBL1371125,TXVHTIQJNYSSKO-UHFFFAOYSA-N,BENZO[E]PYRENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C(C=CC=C25)C=C4
3427,CHEMBL1371125,TXVHTIQJNYSSKO-UHFFFAOYSA-N,BENZO[E]PYRENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C(C=CC=C25)C=C4
3431,CHEMBL28651,TYDSNTMUQPPTLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CSC1=CC=C(C=C1)N2CCN(CC2)CC3=CNC4=C3C=CC=N4
3432,CHEMBL2158789,TYDWSEQLTIBAPO-NDEPHWFRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,199.53,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446187,CC1=C(C=CC(=C1Cl)Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@](C)(CC4=CC=CC=C4)C(=O)O
3433,CHEMBL2220427,TYQXKHPOXXXCTP-CSLYCKPJSA-N,ERYTHROMYCIN ESTOLATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O
3434,CHEMBL2220427,TYQXKHPOXXXCTP-CSLYCKPJSA-N,ERYTHROMYCIN ESTOLATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O
3435,CHEMBL1783972,TZBFBARTOUGERH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,7160.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.145086977692144,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)C5=CN=CC=C5
3436,CHEMBL1783972,TZBFBARTOUGERH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)C5=CN=CC=C5
3437,CHEMBL44,TZBJGXHYKVUXJN-UHFFFAOYSA-N,GENISTEIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O
3438,CHEMBL44,TZBJGXHYKVUXJN-UHFFFAOYSA-N,GENISTEIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O
3439,CHEMBL1371,TZFWDZFKRBELIQ-UHFFFAOYSA-N,CHLORZOXAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=C1Cl)NC(=O)O2
3440,CHEMBL1371,TZFWDZFKRBELIQ-UHFFFAOYSA-N,CHLORZOXAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=C1Cl)NC(=O)O2
3443,CHEMBL256472,TZVRVTZSSPWUGF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)COC
3444,CHEMBL70927,TZXKOCQBRNJULO-UHFFFAOYSA-N,DEFERIPRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C=CN1C)O
3445,CHEMBL70927,TZXKOCQBRNJULO-UHFFFAOYSA-N,DEFERIPRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C=CN1C)O
3448,CHEMBL459350,TZZKWSLLNPOOCC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,79.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.102372908709558,CN(CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31)CC4=CC=C(C=C4)OCCCN5CCCCC5
3449,CHEMBL302886,UAFWEWMUOVIYPG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1778.28,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.749999855918706,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3CC3
3450,CHEMBL272546,UALAMQRWRIVLLQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CCC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C(N=CO5)C
3451,CHEMBL10602,UAUJDKBNVRSJBD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,5172.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,5.286341483791643,CN(C)CC(C1=CC=CC=C1)C2=CC=CC=C2
3452,CHEMBL959,UBCHPRBFMUDMNC-UHFFFAOYSA-N,RIMANTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C12CC3CC(C1)CC(C3)C2)N
3453,CHEMBL959,UBCHPRBFMUDMNC-UHFFFAOYSA-N,RIMANTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C12CC3CC(C1)CC(C3)C2)N
3454,CHEMBL322695,UBCZIICPWSGHLS-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)C3=NC=CN=C3
3455,CHEMBL1935574,UBEJREHBDACTGD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153663.0,Ki,=,10500.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human H1 receptor expressed in HEK cell membranes,Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.978810700930062,C1CN(CCN1)C2=NC(=NC3=C2C=CC(=C3)C4=CC=CO4)N
3456,CHEMBL43882,UBOXGVDOUJQMTN-UHFFFAOYSA-N,TRICHLOROETHANE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(Cl)Cl)Cl
3457,CHEMBL43882,UBOXGVDOUJQMTN-UHFFFAOYSA-N,TRICHLOROETHANE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(Cl)Cl)Cl
3459,CHEMBL14690,UCAIEVHKDLMIFL-UHFFFAOYSA-N,CLOBENPROPIT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12606603.0,Ki,=,2754.23,NM,,,,,,,,,,,,,,,,,,,,5.559999795538785,C1=CC(=CC=C1CN=C(N)SCCCC2=CN=CN2)Cl
3460,CHEMBL102929,UCAOEOZGCIGAIW-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,16000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344075,CC1=CC=CC=C1S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
3461,CHEMBL84,UCFGDBYHRUNTLO-QHCPKHFHSA-N,TOPOTECAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O
3462,CHEMBL84,UCFGDBYHRUNTLO-QHCPKHFHSA-N,TOPOTECAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O
3463,CHEMBL787,UCHDWCPVSPXUMX-TZIWLTJVSA-N,MONTELUKAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O
3464,CHEMBL787,UCHDWCPVSPXUMX-TZIWLTJVSA-N,MONTELUKAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O
3466,CHEMBL318235,UCNOTTVNPRSTFW-XSFNXXSESA-N,R-226161,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17407815.0,Ki,=,74.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human cloned histamine H1 receptor,Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-adrenoceptor antagonism.,Bioorg. Med. Chem.,PUBLICATION,,7.130768280269024,C/C(=C\C1=CC=C(C=C1)F)/CN2CCN(CC2)C[C@H]3[C@@H]4COC5=CC(=C(C=C5C4=NO3)OC)OC
3467,CHEMBL459373,UCQNMJXTWOYVNH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,205.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.688246138944246,CN(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)CC4=CC=C(C=C4)OCCCN5CCCCC5
3468,CHEMBL372795,UCSJYZPVAKXKNQ-HZYVHMACSA-N,STREPTOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O
3469,CHEMBL372795,UCSJYZPVAKXKNQ-HZYVHMACSA-N,STREPTOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O
3471,CHEMBL679,UCTWMZQNUQWSLP-VIFPVBQESA-N,EPINEPHRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNC[C@@H](C1=CC(=C(C=C1)O)O)O
3472,CHEMBL679,UCTWMZQNUQWSLP-VIFPVBQESA-N,EPINEPHRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNC[C@@H](C1=CC(=C(C=C1)O)O)O
3473,CHEMBL564370,UDCCWKBPMHTQIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,23.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.638272163982407,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(=O)O
3476,CHEMBL537218,UDGQQGZVMXRRQI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,CC(C)(C)C(=O)N1CCN(C(=O)C1)C2=CC=C(C=C2)OCCCN3CCCCC3.Cl
3478,CHEMBL558551,UEJJHQNACJXSKW-SECBINFHSA-N,(R)-THALIDOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)[C@@H]1N2C(=O)C3=CC=CC=C3C2=O
3479,CHEMBL558551,UEJJHQNACJXSKW-SECBINFHSA-N,(R)-THALIDOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)[C@@H]1N2C(=O)C3=CC=CC=C3C2=O
3480,CHEMBL468,UEJJHQNACJXSKW-UHFFFAOYSA-N,THALIDOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
3481,CHEMBL468,UEJJHQNACJXSKW-UHFFFAOYSA-N,THALIDOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O
3482,CHEMBL426123,UEJJHQNACJXSKW-VIFPVBQESA-N,(-)-THALIDOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)[C@H]1N2C(=O)C3=CC=CC=C3C2=O
3483,CHEMBL426123,UEJJHQNACJXSKW-VIFPVBQESA-N,(-)-THALIDOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)[C@H]1N2C(=O)C3=CC=CC=C3C2=O
3484,CHEMBL2171019,UEMKNKCKJCNUSX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,7.94,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,CS(=O)(=O)C1=CC=CC(=C1)C(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
3485,CHEMBL252719,UEQUQVLFIPOEMF-GOSISDBHSA-N,(S)-MIANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,0.36,NM,,,,,,,,,,,,,,,,,,,,9.443697499232712,CN1CCN2[C@H](C1)C3=CC=CC=C3CC4=CC=CC=C42
3486,CHEMBL6437,UEQUQVLFIPOEMF-UHFFFAOYSA-N,MIANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,3.39,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.469800301796917,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42
3487,CHEMBL6437,UEQUQVLFIPOEMF-UHFFFAOYSA-N,MIANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,1.7,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.769551078621726,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42
3488,CHEMBL6437,UEQUQVLFIPOEMF-UHFFFAOYSA-N,MIANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,1.51,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.821023052706831,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42
3489,CHEMBL6437,UEQUQVLFIPOEMF-UHFFFAOYSA-N,MIANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.175,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.756961951313706,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42
3490,CHEMBL60837,UFCWZCWTDINVOS-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,16982.44,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769999911123512,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](CO)NC(=O)OC(C)(C)C
3491,CHEMBL1277216,UFCXUUIZIMGORH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.100015437450609,C1CC2(CC1N3CCC(CC3)C(=O)O)CC4=CC=CC=C4OC5=CC=CC=C25
3493,CHEMBL1241,UFLGIAIHIAPJJC-UHFFFAOYSA-N,TRIPELENNAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,39.81,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.400007822415902,CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2
3494,CHEMBL1241,UFLGIAIHIAPJJC-UHFFFAOYSA-N,TRIPELENNAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,1e+17,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-8.0,CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2
3495,CHEMBL940,UGJMXCAKCUNAIE-UHFFFAOYSA-N,GABAPENTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)(CC(=O)O)CN
3496,CHEMBL940,UGJMXCAKCUNAIE-UHFFFAOYSA-N,GABAPENTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)(CC(=O)O)CN
3497,CHEMBL275443,UGYXPZQILZRKJJ-UHFFFAOYSA-N,4-METHYLHISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19791743.0,EC50,=,15848.93,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase assay,Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.,J. Med. Chem.,PUBLICATION,,4.800000052738446,CC1=C(N=CN1)CCN
3500,CHEMBL803,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,CYTARABINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
3501,CHEMBL803,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,CYTARABINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
3502,CHEMBL1092649,UHPLDFSEISHDBD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.4,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.853871964321762,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NC=CN=C3
3504,CHEMBL203266,UHWVSEOVJBQKBE-UHFFFAOYSA-N,TRIMETAZIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC
3505,CHEMBL203266,UHWVSEOVJBQKBE-UHFFFAOYSA-N,TRIMETAZIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC
3506,CHEMBL255806,UHZJBSJVGFOSSA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1258.93,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198648,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C
3507,CHEMBL1428,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,NIMODIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
3508,CHEMBL1428,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,NIMODIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC
3509,CHEMBL34431,UIAYVIIHMORPSJ-UHFFFAOYSA-N,CILOSTAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C1CCCCC1)C(=O)CCCOC2=CC3=C(C=C2)NC(=O)C=C3
3510,CHEMBL34431,UIAYVIIHMORPSJ-UHFFFAOYSA-N,CILOSTAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C1CCCCC1)C(=O)CCCOC2=CC3=C(C=C2)NC(=O)C=C3
3511,CHEMBL564446,UIDVVYFYTIPHHE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,IC50,=,3.3,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.481486060122112,CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5CCOCC5
3512,CHEMBL211501,UIFFUZWRFRDZJC-SBOOETFBSA-N,ANTIMYCIN A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCC[C@@H]1[C@H]([C@@H](OC(=O)[C@H]([C@H](OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C
3513,CHEMBL211501,UIFFUZWRFRDZJC-SBOOETFBSA-N,ANTIMYCIN A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCC[C@@H]1[C@H]([C@@H](OC(=O)[C@H]([C@H](OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C
3514,CHEMBL2158841,UJDYUOWUTALBPP-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=C(C=C4)F)C(=O)O
3515,CHEMBL1767138,UJMUXUJLIHKBEA-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.158,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.801342913045577,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)O
3517,CHEMBL1385840,UJYGDMFEEDNVBF-OGGGUQDZSA-N,ERGOCORNINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O
3518,CHEMBL1385840,UJYGDMFEEDNVBF-OGGGUQDZSA-N,ERGOCORNINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O
3519,CHEMBL402826,UKHPZHQUPSAUMR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CCCC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C
3520,CHEMBL64406,UKHVQZVXQRGRSL-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,8128.31,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.089999741487069,C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)NC(=O)OC(C)(C)C
3524,CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
3525,CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O
3528,CHEMBL2158822,UMSPPMMERAOIRT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,6.31,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.199970640755867,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=CC=C4C(=O)O
3529,CHEMBL1419,UNAANXDKBXWMLN-UHFFFAOYSA-N,SIBUTRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C
3530,CHEMBL1419,UNAANXDKBXWMLN-UHFFFAOYSA-N,SIBUTRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C
3531,CHEMBL1201356,UNBRKDKAWYKMIV-QWQRMKEZSA-N,METHYLERGONOVINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
3532,CHEMBL1201356,UNBRKDKAWYKMIV-QWQRMKEZSA-N,METHYLERGONOVINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
3533,CHEMBL1167,UNFWWIHTNXNPBV-WXKVUWSESA-N,SPECTINOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O
3534,CHEMBL1167,UNFWWIHTNXNPBV-WXKVUWSESA-N,SPECTINOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O
3535,CHEMBL59870,UNKGZIGUDPASTI-AREMUKBSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,4677.35,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.330000131185909,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](CC(C)C)NC(=O)OC(C)(C)C
3536,CHEMBL63112,UNKGZIGUDPASTI-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,8128.31,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.089999741487069,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@H](CC(C)C)NC(=O)OC(C)(C)C
3537,CHEMBL1243335,UNQMLUWBMWGIRY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20690643.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,5.0,CC(C)(C)C1=CC=C(C=C1)SCC(C2=CC=CC=N2)C3=CN=CN3
3538,CHEMBL1946254,UNTNFKPMHAXOEK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,61.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,7.214670164989233,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCCC3=NC4=CC=CC=C4S3
3541,CHEMBL84293,UOSUONQDJGNZCQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,13.49,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.869988050328096,CCN(CC)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1
3542,CHEMBL1278019,UOSUQZZICNGJPM-QNVARPAVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,794.33,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.0999990348465305,C1CC(CN(C1)C2CC[C@@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35)(C(=O)O)F
3543,CHEMBL2171040,UOWPMQNCLJZBEA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,COC1=CC=CC=C1S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
3544,CHEMBL1020,UPSPUYADGBWSHF-UHFFFAOYSA-N,TOLMETIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O
3545,CHEMBL1020,UPSPUYADGBWSHF-UHFFFAOYSA-N,TOLMETIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O
3551,CHEMBL552057,UQAJLTTZWHXNJH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,35.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.455931955649724,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(=O)O
3552,CHEMBL325258,UQMFUNLNAONENR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,6.552841968657781,C1CN(CCN1CCCC2=CC=CC=C2)C(=O)OCCC3=CC=C(C=C3)C#N
3553,CHEMBL1489254,URAYPUMNDPQOKB-UHFFFAOYSA-N,TRIACETIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(COC(=O)C)OC(=O)C
3554,CHEMBL1489254,URAYPUMNDPQOKB-UHFFFAOYSA-N,TRIACETIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(COC(=O)C)OC(=O)C
3555,CHEMBL384467,UREBDLICKHMUKA-CXSFZGCWSA-N,DEXAMETHASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
3556,CHEMBL384467,UREBDLICKHMUKA-CXSFZGCWSA-N,DEXAMETHASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
3557,CHEMBL632,UREBDLICKHMUKA-DVTGEIKXSA-N,BETAMETHASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
3558,CHEMBL632,UREBDLICKHMUKA-DVTGEIKXSA-N,BETAMETHASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
3559,CHEMBL221753,UREZNYTWGJKWBI-UHFFFAOYSA-M,BENZETHONIUM CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2.[Cl-]
3560,CHEMBL221753,UREZNYTWGJKWBI-UHFFFAOYSA-M,BENZETHONIUM CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2.[Cl-]
3561,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,2.2,NM,,,,,,,,,,,,,,,,,,,,8.657577319177793,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
3562,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,19.0,NM,,,,,,,,,,,,,,,,,,,,7.721246399047171,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
3563,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11170639.0,Ki,=,21.0,NM,,,,,,,,,,,,,,,Binding affinity towards human H1 receptor,Current and novel approaches to the drug treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,7.6777807052660805,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
3564,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,11.0,NM,,,,,,,,,,,,,,,,,,,,7.958607314841775,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
3565,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,19.0,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,7.721246399047171,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
3566,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,8.7,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,8.060480747381382,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
3567,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,39.6,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.402304814074488,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
3568,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,4.6,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.337242168318426,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
3569,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,10.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay,,MedChemComm,PUBLICATION,,8.0,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42
3570,CHEMBL2030628,URNOPSHFIGOPOJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CCC3=CC(=CC=C3)F
3571,CHEMBL1767139,URSKGEZFWCRYMD-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,5.01,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.300162274132754,CCOC1=CC=C(C=C1)CC2=NN(C(=O)C3=CC=CC=C32)C[C@H]4CCCN4C
3572,CHEMBL221886,URWAJWIAIPFPJE-YFMIWBNJSA-N,SISOMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N)N)O
3573,CHEMBL221886,URWAJWIAIPFPJE-YFMIWBNJSA-N,SISOMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N)N)O
3574,CHEMBL1923534,URWAMRSFMYPXOS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,8128.31,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.089999741487069,C1CCC(CC1)C2=NC(=NN2C3=CC=CC=C3)SCCN
3575,CHEMBL429914,URXBXRUUVSTMJM-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18077160.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by [35S]GTP-gamma-S binding assay,In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C[C@@H]1CCCN1CCC2=CC=C(C=C2)OCC3=CC=CC=C3
3576,CHEMBL318659,URZPDWAADSKBHJ-QENMJEOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,3.0,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.522878745280337,CN1CCN(CC1)CC2C[C@H]3[C@H](O2)C4=CC=CC=C4CC5=CC=CC=C35
3577,CHEMBL319352,USCDVFNXTCISHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,500.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,6.301029995663981,CN1N=C(N=N1)C2=CC3=C(C=C2)N(C=C3C4CCN(CC4)CCN5CCNC5=O)C6=CC=C(C=C6)F
3578,CHEMBL2037528,USGLWFZAXHASGB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22520153.0,Ki,=,46.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 histamine receptor by liquid scintillation assay,Benzothiazoles as probes for the 5HT(1A) receptor and the serotonin transporter (SERT): A search for new dual-acting agents as potential antidepressants.,Eur. J. Med. Chem.,PUBLICATION,,7.337242168318426,C1CN(CCN1CCCCC(=O)C2=NC3=CC=CC=C3S2)C4=CC=C(C=C4)Cl
3579,CHEMBL402015,USKZVJAZXRLUHK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803203,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCN4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C
3580,CHEMBL320002,USQNYIPSWUNBEC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.69,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.174573882232178,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC8=C(C=C7)OCO8
3582,CHEMBL502896,USROQQUKEBHOFF-SKKCDYJJSA-N,CETRAXATE HYDROCHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1CN)C(=O)OC2=CC=C(C=C2)CCC(=O)O.Cl
3583,CHEMBL502896,USROQQUKEBHOFF-SKKCDYJJSA-N,CETRAXATE HYDROCHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1CN)C(=O)OC2=CC=C(C=C2)CCC(=O)O.Cl
3584,CHEMBL305371,USVPOSBOAJRHOO-XMMPIXPASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,9772.37,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.010000098195094,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CC=C(C=C4)O)N
3585,CHEMBL502620,USZYSDMBJDPRIF-SVEJIMAYSA-N,ACLARUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O
3586,CHEMBL502620,USZYSDMBJDPRIF-SVEJIMAYSA-N,ACLARUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O
3587,CHEMBL1333512,UTGQNNCQYDRXCH-UHFFFAOYSA-N,"N,N'-DIPHENYL-P-PHENYLENEDIAMINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NC2=CC=C(C=C2)NC3=CC=CC=C3
3588,CHEMBL1333512,UTGQNNCQYDRXCH-UHFFFAOYSA-N,"N,N'-DIPHENYL-P-PHENYLENEDIAMINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NC2=CC=C(C=C2)NC3=CC=CC=C3
3593,CHEMBL569270,UTPGRZGMQVAYAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24147864.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor by PDSP assay,Synthesis and evaluation in monkey of [(18)F]4-fluoro-N-methyl-N-(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)benzamide ([(18)F]FIMX): a promising radioligand for PET imaging of brain metabotropic glutamate receptor 1 (mGluR1).,J. Med. Chem.,PUBLICATION,,5.0,CNC1=NC=NC(=C1)C2=CSC(=N2)N(C)C(=O)C3=CC=C(C=C3)F
3594,CHEMBL2171031,UTVOOLLPUMDSJS-IRLDBZIGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,>,5011.87,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.300000202445418,CC1=CC=C(C=C1)C(=O)N2CCC(CC2)N3CC[C@H](C[C@H]3C(=O)O)OC4=C(C(=C(C=C4)Cl)C)Cl
3595,CHEMBL2171030,UTVOOLLPUMDSJS-RBBKRZOGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,>,6309.57,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200000237109354,CC1=CC=C(C=C1)C(=O)N2CCC(CC2)N3CC[C@@H](C[C@@H]3C(=O)O)OC4=C(C(=C(C=C4)Cl)C)Cl
3596,CHEMBL609328,UTYFBWKQSXSRBL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20045641.0,Ki,=,725.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human cloned histamine H1 receptor,"9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.139661993429006,C1C2=CC=CC=C2C(C3=CC=CC=C31)CNCCCC4=CC=CC=C4
3597,CHEMBL13378,UUDAMDVQRQNNHZ-UHFFFAOYSA-N,"(R,S)-AMPA",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)NO1)CC(C(=O)O)N
3598,CHEMBL13378,UUDAMDVQRQNNHZ-UHFFFAOYSA-N,"(R,S)-AMPA",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)NO1)CC(C(=O)O)N
3599,CHEMBL1092259,UUEDQZRCAVWNIH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.4,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.853871964321762,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)Cl)CC3=NC=CN=C3
3600,CHEMBL357995,UUOJIACWOAYWEZ-UHFFFAOYSA-N,BOPINDOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3
3601,CHEMBL357995,UUOJIACWOAYWEZ-UHFFFAOYSA-N,BOPINDOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3
3602,CHEMBL24441,UUQMNUMQCIQDMZ-UHFFFAOYSA-N,BETAHISTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC1=CC=CC=N1
3603,CHEMBL24441,UUQMNUMQCIQDMZ-UHFFFAOYSA-N,BETAHISTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC1=CC=CC=N1
3604,CHEMBL570033,UURQFLKKSYYPEF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,203.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.692503962086787,C1CN(CCC1C(C2=CC=CC=C2)(C3=CC=CC=C3)O)CCCCC4=CC=C(C=C4)C(=O)O
3605,CHEMBL1172754,UUTLATQGKXUVDD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20541426.0,Ki,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]rilamine from human histamine H1 receptor expressed in CHO cells after 1 hr by liquid scintillation counting,Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor.,Bioorg. Med. Chem.,PUBLICATION,,6.0,C1CN(CCC1CC2=CN=CN2)C3=CC=C(C=C3)C(F)(F)F
3606,CHEMBL535631,UUVMYIPSOIHEGH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.Cl
3607,CHEMBL1455,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,ALTRETAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
3608,CHEMBL1455,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,ALTRETAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C
3609,CHEMBL1767162,UUYDLXMNWLLYQV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.400007822415902,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCNCCN3C(=O)C4=CC=CC=C4C(=N3)CC5=CC=C(C=C5)Cl
3610,CHEMBL62527,UVFIYINSVIEJKT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,3981.07,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C(C)C
3611,CHEMBL648,UVKZSORBKUEBAZ-UHFFFAOYSA-N,CYCLIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,38.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.42021640338319,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3
3612,CHEMBL648,UVKZSORBKUEBAZ-UHFFFAOYSA-N,CYCLIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,4.44,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.35261702988538,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3
3613,CHEMBL404811,UVYVLBIGDKGWPX-YCCXZQINSA-N,DIGITONIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)[C@H]([C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(C[C@H]([C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H](C([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)O)C)C)O)C)OC1
3614,CHEMBL404811,UVYVLBIGDKGWPX-YCCXZQINSA-N,DIGITONIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)[C@H]([C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(C[C@H]([C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H](C([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)O)C)C)O)C)OC1
3615,CHEMBL139835,UWFYSQMTEOIJJG-FDTZYFLXSA-N,CYPROTERONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C
3616,CHEMBL139835,UWFYSQMTEOIJJG-FDTZYFLXSA-N,CYPROTERONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C
3617,CHEMBL481,UWKQSNNFCGGAFS-XIFFEERXSA-N,IRINOTECAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
3618,CHEMBL481,UWKQSNNFCGGAFS-XIFFEERXSA-N,IRINOTECAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7
3620,CHEMBL2146807,UXQVMDVKHFQOEU-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.631,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.199970640755865,CCCCN1CCC[C@@H]1CN2C(=O)C3=C(C=CC=N3)C(=N2)CC4=CC=C(C=C4)Cl
3621,CHEMBL86754,UXZFQZANDVDGMM-UHFFFAOYSA-N,IODOQUINOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C(C=C2I)I)O)N=C1
3622,CHEMBL86754,UXZFQZANDVDGMM-UHFFFAOYSA-N,IODOQUINOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C(C=C2I)I)O)N=C1
3623,CHEMBL282575,UYIFTLBWAOGQBI-BZDYCCQFSA-N,ESTRADIOL BENZOATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC(=O)C5=CC=CC=C5
3624,CHEMBL282575,UYIFTLBWAOGQBI-BZDYCCQFSA-N,ESTRADIOL BENZOATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC(=O)C5=CC=CC=C5
3625,CHEMBL305187,UYNVMODNBIQBMV-UHFFFAOYSA-N,IFENPRODIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,1681106.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Compound was tested for the binding affinity against histamine H1 receptor by using [3H]mepyramine as radioligand,Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.,J. Med. Chem.,PUBLICATION,,6.0,CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3
3627,CHEMBL152126,UYZUQDLFLZXDNQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,630.96,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.199998172182031,C1CCN(C1)CCCCCCCCC2=CN=CN2
3628,CHEMBL152126,UYZUQDLFLZXDNQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,251188643150958.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.4,C1CCN(C1)CCCCCCCCC2=CN=CN2
3629,CHEMBL2151156,UZFUMFWJEGINFP-UHFFFAOYSA-N,GSK541636,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21062081.0,Ki,=,12.59,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Histamine H3 receptor as a drug discovery target.,J. Med. Chem.,PUBLICATION,,7.899974269892137,CC1(CCCN(C1)CCCOC2=CC=C(C=C2)C3CCN(CC3)C(=O)C4=CC=C(C5=CC=CC=C54)CCC(=O)O)C
3632,CHEMBL80,UZHSEJADLWPNLE-GRGSLBFTSA-N,NALOXONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O
3633,CHEMBL80,UZHSEJADLWPNLE-GRGSLBFTSA-N,NALOXONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O
3635,CHEMBL1191,VACCAVUAMIDAGB-UHFFFAOYSA-N,SULFAMETHIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N
3636,CHEMBL1191,VACCAVUAMIDAGB-UHFFFAOYSA-N,SULFAMETHIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N
3637,CHEMBL137,VAOCPAMSLUNLGC-UHFFFAOYSA-N,METRONIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=C(N1CCO)[N+](=O)[O-]
3638,CHEMBL137,VAOCPAMSLUNLGC-UHFFFAOYSA-N,METRONIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=C(N1CCO)[N+](=O)[O-]
3640,CHEMBL94249,VAPDJJGAJMZUCA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,501.19,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.299997602857746,C1=C(NC=N1)CCCCCCCCCCN
3641,CHEMBL94249,VAPDJJGAJMZUCA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,199526231496888.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.3,C1=C(NC=N1)CCCCCCCCCCN
3643,CHEMBL263881,VAYOSLLFUXYJDT-RDTXWAMCSA-N,LYSERGIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12213075.0,Ki,=,1540.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor,"Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).",J. Med. Chem.,PUBLICATION,,5.8124792791635365,CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
3645,CHEMBL2030637,VBKWQJLSFFFYLC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CCCC2=CC(=CC=C2)F
3646,CHEMBL95125,VBMKWPABKWXAOB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.36,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.196542884351587,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CC=N6)C7=CC(=C(C=C7)Cl)Cl
3647,,VBOQYPQEPHKASR-GSVOUGTGSA-N,D-HOMOCYSTEIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(CS(=O)(=O)O)[C@H](C(=O)O)N
3648,CHEMBL230951,VBOQYPQEPHKASR-VKHMYHEASA-N,L-HOMOCYSTEATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(CS(=O)(=O)O)[C@@H](C(=O)O)N
3650,CHEMBL454890,VCADIWSEVTZZOR-UHFFFAOYSA-N,VUF-10499,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19053770.0,Ki,=,97.72,NM,,,cell_based,,,,,NIH3T3,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in NIH3T3 cells,Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach.,J. Med. Chem.,PUBLICATION,,7.010016541698601,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)C(=N2)NCC4=COC=C4
3654,CHEMBL402215,VCJRZGBNXMAJCB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(C(F)(F)F)(F)F
3658,CHEMBL611,VCKUSRYTPJJLNI-UHFFFAOYSA-N,TERAZOSIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
3659,CHEMBL611,VCKUSRYTPJJLNI-UHFFFAOYSA-N,TERAZOSIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
3660,CHEMBL1277678,VCLTUEPMXZBALZ-FHZUCYEKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.400007822415902,C1C[C@@]2(CC1N3CCC(CC3)(C(=O)O)F)CC4=CC=CC=C4CC5=CC=CC=C25
3661,CHEMBL403804,VCXXQIVAVCLUOT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CCC1=NC2=C(S1)C3=C(CCN(CC3)CCCSC4=NN=C(N4C)C5=C(N=CO5)C)C=C2
3662,CHEMBL64059,VCYFASOCVKPRSB-RUZDIDTESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CCC4=CC=CC=C4)N
3663,CHEMBL98079,VDAMCZUHIJCJPK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.63,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.178486471595226,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC=CC=C7
3664,CHEMBL2207642,VDCBDIRJDJYCIZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,=,490.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.309803919971486,COC1=CC=CC=C1N2CCN(CC2)CC3=C4C=CC=CC=C4C(=C3)CN5CCN(CC5)C6=CC=C(C=C6)Cl
3666,CHEMBL2208421,VDFDTTRCUDMUDX-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,COC1=CC(=CC=C1)SC[C@H](CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)O
3667,CHEMBL2171028,VDNHGXHYXNDCOW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.79997073344623,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC=CC=C4NCCC(=O)O
3671,CHEMBL1093294,VDXIBLBHDRKGBK-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,2.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.537602002101044,C[C@H](C1=C(N=CC=C1)OC)C2=C(SC3=CC=CC=C32)CCN(C)C
3672,CHEMBL239321,VDZPNNUVDOABNY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=C(C=C(C=C5)F)F.C(=O)O
3673,CHEMBL419912,VECOVVSVBRZIJA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3715.35,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.430000267796054,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=NC=C3
3674,CHEMBL2031874,VEGKMRUZYWQMBZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313242.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 receptor,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,CN(C)C(=O)C1=CC=C(C=C1)C2=CC3=C(C=C2)C(=O)N(CC3)CCN4CCCC4
3675,CHEMBL119385,VEPKQEUBKLEPRA-UHFFFAOYSA-N,VX-745,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl
3676,CHEMBL119385,VEPKQEUBKLEPRA-UHFFFAOYSA-N,VX-745,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl
3677,CHEMBL1200629,VEPSYABRBFXYIB-PWXDFCLTSA-M,VECURONIUM BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-]
3678,CHEMBL1200629,VEPSYABRBFXYIB-PWXDFCLTSA-M,VECURONIUM BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-]
3679,CHEMBL277474,VEQOALNAAJBPNY-UHFFFAOYSA-N,ANTIPYRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)N(N1C)C2=CC=CC=C2
3680,CHEMBL277474,VEQOALNAAJBPNY-UHFFFAOYSA-N,ANTIPYRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)N(N1C)C2=CC=CC=C2
3681,CHEMBL571389,VFCNPRIWDSWJIG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,39.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.4089353929735005,CC1=CC=C(C=C1)CCCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
3683,CHEMBL2146806,VFIDGXZRONKQBZ-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.39799999999999996,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.400116927926312,CCCCN1CCC[C@@H]1CN2C(=O)C3=C(C=NC=C3)C(=N2)CC4=CC=C(C=C4)Cl
3684,CHEMBL1277854,VFKIKYZNUCGJGD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.400007822415902,C1CC2(CC1N3CCC(=CC3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25
3685,CHEMBL283196,VFMMPHCGEFXGIP-UHFFFAOYSA-N,ALPHA-NAPHTHOFLAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
3686,CHEMBL283196,VFMMPHCGEFXGIP-UHFFFAOYSA-N,ALPHA-NAPHTHOFLAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3
3687,CHEMBL117537,VGBOISIRCIDEGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,1930.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,5.714442690992226,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)CCCC4=CC=CC=C4
3688,,VGFZCFWVSYIXEK-UHFFFAOYSA-N,K604,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15798001.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC1CC(C2=CC=CC=C2N1C(=O)C3=CC=CC=C3)N(C4=CC=CC=C4)C(=O)C5CC5
3689,CHEMBL29292,VGGGPCQERPFHOB-RDBSUJKOSA-N,UBENIMEX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O
3690,CHEMBL29292,VGGGPCQERPFHOB-RDBSUJKOSA-N,UBENIMEX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O
3691,CHEMBL589388,VGJCKVYMMJXTIH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,68.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=C4)C=CC(=C3)C(F)(F)F
3692,CHEMBL809,VGKDLMBJGBXTGI-SJCJKPOMSA-N,SERTRALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
3693,CHEMBL809,VGKDLMBJGBXTGI-SJCJKPOMSA-N,SERTRALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
3694,CHEMBL284994,VGKDLMBJGBXTGI-YVEFUNNKSA-N,"(1R,4S)-TRANS-SERTRALINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN[C@@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
3695,CHEMBL555146,VGSYEFOBFMUWGO-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313227.0,Ki,=,5440.0,NM,,,,,,,,,,,,,,,Binding affinity to human recombinant H1 receptor,Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.,J. Med. Chem.,PUBLICATION,,5.2644011003018205,C[C@@H]1CCCN1CCC2=CC3=C(O2)C=CC(=C3)C(=O)C4=CC=C(C=C4)F
3698,CHEMBL2429890,VGYQUDBPYFLBLJ-PTCVETCVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,=,4178.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.37903156435571,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC6=CC7=C(C=C6)OCO7
3700,CHEMBL299052,VHGCDTVCOLNTBX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,5500.0,NM,,,,,,,,,,,,,,,,,,,,5.259637310505756,CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2
3701,CHEMBL299052,VHGCDTVCOLNTBX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12431845.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,,,,,,6.0,CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2
3702,CHEMBL1767152,VHHWNRROUCRXSK-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.50003813440381,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CCC4=CC=CC=C4
3703,CHEMBL250699,VHKBTPQDHDSBSP-UHFFFAOYSA-N,A-803467,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17483457.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from histamine H1 receptor,"A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.",Proc. Natl. Acad. Sci. U.S.A.,PUBLICATION,,5.0,COC1=CC(=CC(=C1)NC(=O)C2=CC=C(O2)C3=CC=C(C=C3)Cl)OC
3704,CHEMBL270299,VHKZGNPOHPFPER-ONNFQVAWSA-N,BAY-11-7085,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)/C=C/C#N
3705,CHEMBL270299,VHKZGNPOHPFPER-ONNFQVAWSA-N,BAY-11-7085,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)/C=C/C#N
3706,CHEMBL960,VHOGYURTWQBHIL-UHFFFAOYSA-N,LEFLUNOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F
3707,CHEMBL960,VHOGYURTWQBHIL-UHFFFAOYSA-N,LEFLUNOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F
3708,CHEMBL650,VHRSUDSXCMQTMA-PJHHCJLFSA-N,METHYLPREDNISOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
3709,CHEMBL650,VHRSUDSXCMQTMA-PJHHCJLFSA-N,METHYLPREDNISOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O
3710,CHEMBL22587,VHVPQPYKVGDNFY-ZPGVKDDISA-N,ITRACONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl
3711,CHEMBL22587,VHVPQPYKVGDNFY-ZPGVKDDISA-N,ITRACONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl
3712,CHEMBL1935437,VIEHHRQCEMIKCL-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.2,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.920818753952375,C1C[C@H](CNC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
3713,CHEMBL1162,VIKNJXKGJWUCNN-XGXHKTLJSA-N,NORETHINDRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
3714,CHEMBL1162,VIKNJXKGJWUCNN-XGXHKTLJSA-N,NORETHINDRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34
3715,CHEMBL1087493,VILNAIPEYFWQQH-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20347297.0,Ki,=,4.8,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.318758762624412,CCOCCN1C2=CC=CC=C2N=C1N3CC[C@@H](C3)N(C)C
3716,CHEMBL267894,VIROVYVQCGLCII-UHFFFAOYSA-N,AMOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NC(=O)NC1=O)CCC(C)C
3717,CHEMBL267894,VIROVYVQCGLCII-UHFFFAOYSA-N,AMOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NC(=O)NC1=O)CCC(C)C
3718,CHEMBL60383,VJAQRKGFVIGFJD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,97.72,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.010016541698601,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=C(S3)C
3719,CHEMBL44657,VJJPUSNTGOMMGY-MRVIYFEKSA-N,ETOPOSIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O
3720,CHEMBL44657,VJJPUSNTGOMMGY-MRVIYFEKSA-N,ETOPOSIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O
3721,CHEMBL565083,VKAAMGNCPQOWFB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,72.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.142667503568732,CC(C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCCN(CC4)C5=CC(=O)N(C(=O)N5C)C)C(=O)O
3722,CHEMBL1276308,VKHAHZOOUSRJNA-GCNJZUOMSA-N,MIFEPRISTONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O
3723,CHEMBL1276308,VKHAHZOOUSRJNA-GCNJZUOMSA-N,MIFEPRISTONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O
3724,CHEMBL12089,VKJGBAJNNALVAV-UHFFFAOYSA-M,BERBERINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.[Cl-]
3725,CHEMBL12089,VKJGBAJNNALVAV-UHFFFAOYSA-M,BERBERINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.[Cl-]
3728,CHEMBL1726,VKQFCGNPDRICFG-UHFFFAOYSA-N,NISOLDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
3729,CHEMBL1726,VKQFCGNPDRICFG-UHFFFAOYSA-N,NISOLDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC
3730,CHEMBL559557,VKVAJQSZVWNRMB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.619788758288394,CN(CCC1=CC=CC=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
3731,CHEMBL558,VLPIATFUUWWMKC-UHFFFAOYSA-N,MEXILETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)OCC(C)N
3732,CHEMBL558,VLPIATFUUWWMKC-UHFFFAOYSA-N,MEXILETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)OCC(C)N
3733,CHEMBL2158829,VLUYCVQWTQUWPI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,5.01,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC(=CC=C4)OCC(=O)O
3735,CHEMBL310183,VMLLHZVDHFWOOM-UHFFFAOYSA-N,R-95292,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,102.33,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.98999702587294,CN(C)CC1CC2C3=CC=CC=C3OC4=C(N2O1)C=C(C=C4)Cl
3736,CHEMBL1612004,VMPITZXILSNTON-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1N
3737,CHEMBL1612004,VMPITZXILSNTON-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1N
3738,CHEMBL1222763,VMTWXOTZXVFSPH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415902,CC(C)(CN1CCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC(=C4)F)C(=O)O
3739,CHEMBL1790041,VMXUWOKSQNHOCA-UHFFFAOYSA-N,RANITIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C
3740,CHEMBL1790041,VMXUWOKSQNHOCA-UHFFFAOYSA-N,RANITIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C
3741,CHEMBL512,VMXUWOKSQNHOCA-UKTHLTGXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C
3742,CHEMBL512,VMXUWOKSQNHOCA-UKTHLTGXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C
3743,CHEMBL1093044,VMZBJCIUNPGQKF-ZDUSSCGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,32000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.494850021680094,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCNC
3744,CHEMBL64247,VMZMMCADYHQFBW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,562.34,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2500010234416505,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)C(C)(C)C
3745,CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,29406.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,4.531564047103727,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4
3746,CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,3416.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.466482137983032,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4
3749,CHEMBL156071,VNMMBNWUESETSJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1258.93,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.899998417198648,C1=C(NC=N1)CCCCCCCCCCCCCN
3750,CHEMBL156071,VNMMBNWUESETSJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,2511886431509580.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-6.4,C1=C(NC=N1)CCCCCCCCCCCCCN
3751,CHEMBL1092597,VNNFGZRIODMCIW-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,C[C@H](C1=C(CC2=CC=CC=C21)CCN(C)C)C3=NC=CN=C3OC
3754,CHEMBL155328,VNRWRBJKPUBFDY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,<,10000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.0,C1=C(N=CS1)CCN
3756,CHEMBL257524,VNUWHBRXYDCOFA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)C(C)CCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)C
3758,CHEMBL2158771,VNYAKKUPVDUAEG-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,15.85,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.79997073344623,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=C(C=C4)C#N)C(=O)O
3761,CHEMBL1632412,VOIJIMTXMUBFDD-VLGSPTGOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,Ki,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Binding affinity to human recombinant histamine H1 receptor expressed in human SK-N-MC cells by radioligand displacement assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC2=C(C=C1)NC(=C2)/C(=N\O)/C3CCN(CC3)C
3762,CHEMBL2158775,VOPUEJLKUSXAOZ-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755866,COC1=CC=CC=C1C[C@@H](C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
3763,CHEMBL1082296,VORZMLWIEYTBEN-JPYJTQIMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20452213.0,EC50,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in human SK-N-MC cells,Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=CC(=C1)OCCCN2C[C@H]3CCCN[C@H]3C2)C4=NC5=C(N4)C=CC(=C5C)F
3764,CHEMBL2112461,VOSJYQCPCAXSLK-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3890.45,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.410000161858408,C[C@]1(CCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N)O
3765,CHEMBL1370,VOVIALXJUBGFJZ-KWVAZRHASA-N,BUDESONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
3766,CHEMBL1370,VOVIALXJUBGFJZ-KWVAZRHASA-N,BUDESONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
3767,CHEMBL135,VOXZDWNPVJITMN-ZBRFXRBCSA-N,ESTRADIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O
3768,CHEMBL135,VOXZDWNPVJITMN-ZBRFXRBCSA-N,ESTRADIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O
3769,CHEMBL239724,VPAXWNMEGKLSOJ-FERBBOLQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C[C@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O
3770,CHEMBL239299,VPAXWNMEGKLSOJ-GMUIIQOCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O
3772,CHEMBL1909073,VPUGSHLBERYQGC-UHFFFAOYSA-M,PIPERILATE ETHOBROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[N+]1(CCCCC1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Br-]
3773,CHEMBL1909073,VPUGSHLBERYQGC-UHFFFAOYSA-M,PIPERILATE ETHOBROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[N+]1(CCCCC1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Br-]
3774,CHEMBL331188,VPZDYZMLWKUTOB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12443779.0,IC50,=,16.6,NM,,,,,,,,,,,,,,,Binding affinity against Histamine H1 receptor,2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT(2C) antagonist with potential anxiolytic properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.779891911959945,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)N=CC=C3
3775,CHEMBL92333,VQILFXAHDTXCBG-KUOLHFIUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,471.0,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.326979092871103,C1CN(CCN1CC2C[C@H]3[C@H](O2)C4=CC=CC=C4CC5=CC=CC=C35)C6=CC(=CC=C6)Cl
3776,CHEMBL1201207,VQODGRNSFPNSQE-DVTGEIKXSA-N,BETAMETHASONE PHOSPHORIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,10060.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,4.997402019280091,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C
3777,CHEMBL1201207,VQODGRNSFPNSQE-DVTGEIKXSA-N,BETAMETHASONE PHOSPHORIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1169.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.93218548883816,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C
3778,CHEMBL229383,VQOXZBDYSJBXMA-VHFLTRTASA-N,NYSTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C/CC/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H]([C@@H](CC[C@H](C[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@@H]3[C@@H]([C@@H]([C@H]([C@@H](O3)C)O)N)O
3779,CHEMBL229383,VQOXZBDYSJBXMA-VHFLTRTASA-N,NYSTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C/CC/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H]([C@@H](CC[C@H](C[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@@H]3[C@@H]([C@@H]([C@H]([C@@H](O3)C)O)N)O
3781,CHEMBL623,VRBKIVRKKCLPHA-UHFFFAOYSA-N,NEFAZODONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl
3782,CHEMBL661,VREFGVBLTWBCJP-UHFFFAOYSA-N,ALPRAZOLAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
3783,CHEMBL661,VREFGVBLTWBCJP-UHFFFAOYSA-N,ALPRAZOLAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4
3784,CHEMBL1923533,VRGIOLYGCLOIJI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,6309.57,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.200000237109354,C1CC1NCC(CN2C3=CC=CC=C3C4=CC=CC=C42)O
3785,CHEMBL1323355,VRQVVMDWGGWHTJ-AWEZNQCLSA-N,DEXTROMEPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,0.58,NM,,,,,,,,,,,,,,,,,,,,9.236572006437063,C[C@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C
3786,CHEMBL1400945,VSBHRRMYCDQLJF-ZDNYCOCVSA-N,PREGNENOLONE CARBONITRILE ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C#N
3787,CHEMBL1400945,VSBHRRMYCDQLJF-ZDNYCOCVSA-N,PREGNENOLONE CARBONITRILE ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C#N
3788,CHEMBL3094217,VSGRIQNOEXFJLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,>,1995.26,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCOC2=CC3=C(CCN(CC3)CC4CC4)C=C2
3789,CHEMBL65,VSJKWCGYPAHWDS-FQEVSTJZSA-N,CAMPTOTHECIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O
3790,CHEMBL65,VSJKWCGYPAHWDS-FQEVSTJZSA-N,CAMPTOTHECIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O
3791,CHEMBL26116,VSKJPAMQPJDPLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,2220.0,NM,,,,,,,,,,,,,,,,,,,,5.653647025549361,C1=CC(=CC(=C1)Br)C2=NC=C(N2)CCN
3792,CHEMBL26116,VSKJPAMQPJDPLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,EC50,=,199.53,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446187,C1=CC(=CC(=C1)Br)C2=NC=C(N2)CCN
3794,CHEMBL467,VSNHCAURESNICA-UHFFFAOYSA-N,HYDROXYUREA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(N)NO
3795,CHEMBL467,VSNHCAURESNICA-UHFFFAOYSA-N,HYDROXYUREA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(N)NO
3797,CHEMBL3187365,VSWBSWWIRNCQIJ-UHFFFAOYSA-N,ASENAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,0.16,NM,,,,,,,,,,,,,,,,,,,,9.795880017344075,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24
3798,CHEMBL3187365,VSWBSWWIRNCQIJ-UHFFFAOYSA-N,ASENAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,9.3,NM,,,,,,,,,,,,,,,,,,,,8.031517051446064,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24
3799,CHEMBL570915,VTDHRHRPPVJGSU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,,,,Not Active,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC=C(C=C1)CCCCN2CCC(CC2)CO
3800,CHEMBL2158826,VTIFNIOOCLEWLJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,5.01,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=CC(=C4)CC(=O)O
3801,CHEMBL76904,VTJXFTPMFYAJJU-UHFFFAOYSA-N,TYRPHOSTIN 23,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C=C(C#N)C#N)O)O
3802,CHEMBL76904,VTJXFTPMFYAJJU-UHFFFAOYSA-N,TYRPHOSTIN 23,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C=C(C#N)C#N)O)O
3803,CHEMBL2205818,VTLZIWJSKWWYHL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC=NC=C7)O
3804,CHEMBL257369,VTSMNPQRBXHIOD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1258.93,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198648,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCCN4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C(F)(F)F
3805,CHEMBL62903,VTWBFMFJUOTCOL-MUUNZHRXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,16982.44,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769999911123512,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](CC3=CC=NC=C3)NC(=O)OC(C)(C)C
3806,CHEMBL62266,VTWBFMFJUOTCOL-NDEPHWFRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,9332.54,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.030000139977383,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@H](CC3=CC=NC=C3)NC(=O)OC(C)(C)C
3807,CHEMBL104947,VUNCADMBSQOCKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,1479.11,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.829999526735649,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CN=CN3
3810,CHEMBL272545,VURVNYUMSCKMDC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1258.93,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198648,CCC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C
3813,CHEMBL1669419,VVGNEGYIOFKVTA-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,6.7,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.173925197299173,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=CS4
3814,CHEMBL1222554,VVGXLRREHSRFOF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934842,CC(C)(CN1CCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC=C4)C(=O)O
3815,CHEMBL1679,VVIAGPKUTFNRDU-ABLWVSNPSA-N,LEUCOVORIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
3816,CHEMBL1679,VVIAGPKUTFNRDU-ABLWVSNPSA-N,LEUCOVORIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
3817,CHEMBL1091792,VVIWSBGDDVESJJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,59.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.229147988357856,CC(C1=NC(=CC=C1)OC)C2=C(SC3=CC=CC=C32)CCN(C)C
3818,CHEMBL1430,VVNCNSJFMMFHPL-VKHMYHEASA-N,PENICILLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)([C@H](C(=O)O)N)S
3819,CHEMBL1430,VVNCNSJFMMFHPL-VKHMYHEASA-N,PENICILLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)([C@H](C(=O)O)N)S
3820,CHEMBL1092258,VWGHJDXVTAUEQY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,8.9,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.050609993355087,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)OC)CC3=NC=CN=C3
3822,CHEMBL154566,VWLKACVZBHNAND-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,7943.28,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.100000128334196,C1=CC=NC(=C1)CCCCCCCCCN
3823,CHEMBL154566,VWLKACVZBHNAND-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,31622776601683.8,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.5,C1=CC=NC(=C1)CCCCCCCCCN
3824,CHEMBL649,VWPOSFSPZNDTMJ-UCWKZMIHSA-N,NADOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O
3825,CHEMBL649,VWPOSFSPZNDTMJ-UCWKZMIHSA-N,NADOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O
3826,CHEMBL1766,VWVSBHGCDBMOOT-IIEHVVJPSA-N,DESOXIMETASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C
3827,CHEMBL1766,VWVSBHGCDBMOOT-IIEHVVJPSA-N,DESOXIMETASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C
3828,CHEMBL1222553,VXQLVBTWUUQZBI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCN1CCC(=O)O)C2=CC3=CC=CC=C3CN4C2=NC=C4
3830,CHEMBL153919,VXSXTQRWBIOLHD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,31622776601683.8,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.5,C1=CC(=CC(=C1)Cl)CC2=NC(=CS2)CCN
3832,CHEMBL272086,VYGLNPIKDOAMBL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCC(C)N4CCC5=CC6=C(C=C5CC4)C(=O)N(C6)C(C)C
3833,CHEMBL101,VYMDGNCVAMGZFE-UHFFFAOYSA-N,PHENYLBUTAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3
3834,CHEMBL101,VYMDGNCVAMGZFE-UHFFFAOYSA-N,PHENYLBUTAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3
3835,CHEMBL1388,VYQNWZOUAUKGHI-UHFFFAOYSA-N,MONOBENZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)COC2=CC=C(C=C2)O
3836,CHEMBL1388,VYQNWZOUAUKGHI-UHFFFAOYSA-N,MONOBENZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)COC2=CC=C(C=C2)O
3837,CHEMBL1230333,VYTXLSQVYGNWLV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)CCCC(=O)O
3838,CHEMBL1230333,VYTXLSQVYGNWLV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)CCCC(=O)O
3839,CHEMBL255778,VYZFKCYKUBTWCJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,501.19,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)Br
3840,CHEMBL431458,VZFRWFDQRYRONC-WLHGVMLRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,233.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.632644078973981,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC=CC=C7.C(=C/C(=O)O)\C(=O)O
3841,CHEMBL44814,VZGDMQKNWNREIO-UHFFFAOYSA-N,CARBON TETRACHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(Cl)(Cl)(Cl)Cl
3842,CHEMBL44814,VZGDMQKNWNREIO-UHFFFAOYSA-N,CARBON TETRACHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(Cl)(Cl)(Cl)Cl
3843,CHEMBL241330,WAQMOZNGKRFENV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18020391.0,Ki,>,5000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling.,J. Med. Chem.,PUBLICATION,,5.301029995663981,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC(=O)C3=CC(=CC=C3)S(=O)(=O)C)Cl
3844,CHEMBL1259203,WAWSGWZTHJAPIA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,,CN1CCC(CC1)C2=CN(C3=C2C=C(C=C3)C4=CN=CN=C4)C5=CC=C(C=C5)F
3845,CHEMBL257900,WAWZDKTUQQRILI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCN4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C(F)(F)F
3847,CHEMBL2208433,WBCSOAILRDZMDJ-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,3.98,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,CN(C[C@H](CN1CCC(CC1)OC2=CC(=C(C=C2)Cl)Cl)O)C(=O)C3=CNC(=O)C4=CC=CC=C43
3848,CHEMBL164290,WBNQDOYYEUMPFS-UHFFFAOYSA-N,N-NITROSODIETHYLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)N=O
3849,CHEMBL164290,WBNQDOYYEUMPFS-UHFFFAOYSA-N,N-NITROSODIETHYLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)N=O
3850,CHEMBL1079180,WCUAFHYQNZBNRN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,1374.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.862013267276469,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=CC(=C(C=C4O3)S(=O)(=O)N)Cl)F
3851,CHEMBL2158769,WCXUWQZNCRRRDD-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,15.85,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.79997073344623,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=CC=C4C#N)C(=O)O
3852,CHEMBL107162,WCZJQEWLLYRYTJ-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,4400.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.356547323513812,COC1=CC=C(C=C1)S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4
3853,CHEMBL254219,WDJUZGPOPHTGOT-XUDUSOBPSA-N,DIGITOXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O
3854,CHEMBL254219,WDJUZGPOPHTGOT-XUDUSOBPSA-N,DIGITOXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O
3855,CHEMBL571174,WDNSSDFBUPTPTP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,61.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.214670164989233,CC1CCC(CC1)CCCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
3856,CHEMBL1660,WDZCUPBHRAEYDL-GZAUEHORSA-N,RIFAPENTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C
3857,CHEMBL1660,WDZCUPBHRAEYDL-GZAUEHORSA-N,RIFAPENTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C
3858,CHEMBL420,WDZVGELJXXEGPV-YIXHJXPBSA-N,GUANABENZ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl
3859,CHEMBL420,WDZVGELJXXEGPV-YIXHJXPBSA-N,GUANABENZ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl
3860,CHEMBL485259,WEEGYLXZBRQIMU-UHFFFAOYSA-N,EUCALYPTOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(C2CCC(O1)(CC2)C)C
3861,CHEMBL485259,WEEGYLXZBRQIMU-UHFFFAOYSA-N,EUCALYPTOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(C2CCC(O1)(CC2)C)C
3862,CHEMBL562676,WEFSNJOGTPXLGH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,123.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.910094888560602,CC(C)(C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCCN(CC4)C5=CC(=O)N(C(=O)N5C)C)C(=O)O
3863,CHEMBL140872,WEVJMQOBCRCIPF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,911.8,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.0401004121340565,C1CN(CCN1CCCC(=O)C2=CC=C(C=C2)F)C3=NC=CC=N3
3864,CHEMBL140872,WEVJMQOBCRCIPF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,912.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,6.0400051616715835,C1CN(CCN1CCCC(=O)C2=CC=C(C=C2)F)C3=NC=CC=N3
3865,CHEMBL559206,WEVNWEYCEGALHH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,1258.93,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.899998417198648,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=CC=C4.Cl
3866,CHEMBL448,WEXRUCMBJFQVBZ-UHFFFAOYSA-N,PENTOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC
3869,CHEMBL1278088,WFQOETMVYMINSA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20931963.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor,"Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.",J. Med. Chem.,PUBLICATION,,6.0,C1CCC2=C(C1)C(=O)N(C(=N2)CCCCN3CCN(CC3)C4=NC5=CC=CC=C5C=C4)N
3870,CHEMBL106602,WFRROHNULMGADM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,446.68,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.350003492533959,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=CS3
3871,CHEMBL20883,WFWLQNSHRPWKFK-UHFFFAOYSA-N,TEGAFUR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(OC1)N2C=C(C(=O)NC2=O)F
3872,CHEMBL20883,WFWLQNSHRPWKFK-UHFFFAOYSA-N,TEGAFUR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(OC1)N2C=C(C(=O)NC2=O)F
3875,CHEMBL1278112,WGNYIJNJSDBPLE-JVPYDEADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,63.1,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.199970640755866,C1C[C@@]2(CC1N3CCOC(C3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25
3876,CHEMBL415690,WHGYBXFWUBPSRW-FOUAGVGXSA-N,BETADEX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O
3877,CHEMBL415690,WHGYBXFWUBPSRW-FOUAGVGXSA-N,BETADEX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O
3878,CHEMBL402016,WHKXNUMKCCTWNI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803203,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C(F)(F)F
3880,CHEMBL388590,WHQCHUCQKNIQEC-UHFFFAOYSA-N,BENZBROMARONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br
3881,CHEMBL388590,WHQCHUCQKNIQEC-UHFFFAOYSA-N,BENZBROMARONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br
3882,CHEMBL1481,WIGIZIANZCJQQY-RUCARUNLSA-N,GLIMEPIRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C
3883,CHEMBL1481,WIGIZIANZCJQQY-RUCARUNLSA-N,GLIMEPIRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C
3885,CHEMBL244946,WIHMMKGUBDZGEG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,794.33,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C=C(C=C5)C6=CC(=NN6C)C
3886,CHEMBL130,WIIZWVCIJKGZOK-RKDXNWHRSA-N,CHLORAMPHENICOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-]
3887,CHEMBL130,WIIZWVCIJKGZOK-RKDXNWHRSA-N,CHLORAMPHENICOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-]
3888,CHEMBL1091793,WIKAXVDAJYMGCT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,38.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.42021640338319,CC(C1=NC(=CC=C1)F)C2=C(SC3=CC=CC=C32)CCN(C)C
3889,CHEMBL728,WIKYUJGCLQQFNW-UHFFFAOYSA-N,PROCHLORPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,18.86,NM,,,,,,,,,,,,,,,,,,,,7.72445831159869,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
3890,CHEMBL728,WIKYUJGCLQQFNW-UHFFFAOYSA-N,PROCHLORPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,19.0,NM,,,,,,,,,,,,,,,,,,,,7.721246399047171,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
3891,CHEMBL728,WIKYUJGCLQQFNW-UHFFFAOYSA-N,PROCHLORPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,24.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.619788758288394,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
3892,CHEMBL728,WIKYUJGCLQQFNW-UHFFFAOYSA-N,PROCHLORPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,2.79,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.554395796726402,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl
3893,CHEMBL465123,WIQRCHMSJFFONW-HNNXBMFYSA-N,SEPROXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=CC=C(C=C1)[C@H](CCN)OC2=CC=C(C=C2)C(F)(F)F
3895,CHEMBL295395,WIVOLWKUZIBRAF-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,302.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.519993057042849,CC1=C([C@H](CC(=O)N1C)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)(C#N)C4=C(C=C(C=C4)F)F
3896,CHEMBL2113738,WIVVHNDNAXIGIV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,446.68,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.350003492533959,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)SC
3897,CHEMBL625,WJCNZQLZVWNLKY-UHFFFAOYSA-N,THIABENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3
3898,CHEMBL625,WJCNZQLZVWNLKY-UHFFFAOYSA-N,THIABENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3
3899,CHEMBL97357,WJEAYMAHIVBPGF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.55,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.183758700008218,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC(=C(C=C7)Cl)Cl
3900,CHEMBL828,WJFKNYWRSNBZNX-UHFFFAOYSA-N,PHENOTHIAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)NC3=CC=CC=C3S2
3901,CHEMBL828,WJFKNYWRSNBZNX-UHFFFAOYSA-N,PHENOTHIAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)NC3=CC=CC=C3S2
3903,CHEMBL1501,WJOHZNCJWYWUJD-IUGZLZTKSA-N,FLUOCINONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C
3904,CHEMBL1501,WJOHZNCJWYWUJD-IUGZLZTKSA-N,FLUOCINONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C
3906,CHEMBL197408,WJYDVXOBGXFRGI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=C(C=C4)C5=CC=CC=C5)OC
3907,CHEMBL271511,WKIHYCMRGGUMCH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)N5C=C(C=CC5=N4)C(F)(F)F
3908,CHEMBL2158784,WKNWCTUFTMDACE-DEOSSOPVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,31.62,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.50003813440381,CC1=C(C=CC(=C1Cl)Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=C(C=C4)F)C(=O)O
3909,CHEMBL486746,WKXIZVSDLMORMY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,990.0,NM,,,,,,,,,,,,,,,,,,,,6.00436480540245,C1CCC(CC1)CCCC(=O)NC(=NCCCC2=CN=CN2)N
3911,CHEMBL188021,WLCVFIFUKJWBRL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,14.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.853871964321762,C1CC2=C(C=CC(=C2)Cl)C(=C3CCN(CC3)CCCOC4=CC=C(C=C4)C#CCCN(C(=O)N)O)C5=C1C=CC=N5
3912,CHEMBL288768,WLHRCQLHMHKOKG-JOCHJYFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,63.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.200659450546418,CC1=C([C@H](CC(=O)N1)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)(C#N)C4=CC=C(C=C4)F
3913,CHEMBL104809,WLLPQVLLLQINAX-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,5900.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.229147988357856,C1CN(C[C@H]1NS(=O)(=O)C2=CC=CC(=C2)F)CCCOC3=CC=C(C=C3)C(=O)C4CC4
3915,CHEMBL570961,WMENQMDKVSUACK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,,,,Not Active,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC=C(C=C1)CCCCC2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
3918,CHEMBL3238446,WMVDPHRVWOFAIP-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,=,31622.78,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,4.499999953328896,C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCCCN2CCCCC2
3919,CHEMBL1774505,WNMOZKUIGRNEMN-JAHAZDFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,195.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.709965388637482,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CC/C=C\3/C4=CC=CC=C4CCC5=C3C=C(C=C5)CC(=O)O
3920,CHEMBL58922,WOFSEDMIUMNYEJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,255.0,NM,,,,,,,,,,,,,,,,,,,,6.5934598195660445,C1=CC=NC(=C1)C(CCNC(=NCCCC2=CN=CN2)N)C3=CC(=CC=C3)Cl
3925,CHEMBL86091,WPLHYZJLPBROHU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC(=C3)C(F)(F)F
3927,CHEMBL19236,WPNJAUFVNXKLIM-UHFFFAOYSA-N,MOXONIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC
3928,CHEMBL19236,WPNJAUFVNXKLIM-UHFFFAOYSA-N,MOXONIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC
3929,CHEMBL1923532,WPPQAAJWSRLDOO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,4570.88,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.3400001801593495,CC(C)NCC1=CC=C(O1)C2=CC=CC=C2
3931,CHEMBL274768,WPUIFWUHNWGBNW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,630957344480194.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.800000000000001,C1=CC=C(C=C1)C(CCCC2=NC=C(N2)CCN)C3=CC=CC=C3
3933,CHEMBL541,WPYMKLBDIGXBTP-UHFFFAOYSA-N,BENZOIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)O
3934,CHEMBL541,WPYMKLBDIGXBTP-UHFFFAOYSA-N,BENZOIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)O
3935,CHEMBL2105807,WQGJEAMPBSZCIF-HKSLRPGUSA-N,MADURAMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C.N
3936,CHEMBL2105807,WQGJEAMPBSZCIF-HKSLRPGUSA-N,MADURAMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C.N
3937,CHEMBL307145,WQGWDDDVZFFDIG-UHFFFAOYSA-N,PYROGALLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)O)O)O
3938,CHEMBL307145,WQGWDDDVZFFDIG-UHFFFAOYSA-N,PYROGALLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)O)O)O
3939,CHEMBL105594,WQTAFNUFMGEGDM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,8912.51,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.049999969853415,C1CN(CCN1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
3940,CHEMBL1767134,WRGOSJVRKURGMQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.251,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.600326278518962,CN(C)CCN1C(=O)C2=CC=CC=C2C(=N1)CC3=CC=C(C=C3)Cl
3941,CHEMBL517140,WROHEWWOCPRMIA-UHFFFAOYSA-N,GSK189254,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24269482.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CNC(=O)C1=CN=C(C=C1)OC2=CC3=C(CCN(CC3)C4CCC4)C=C2
3942,CHEMBL328356,WSAMXDVPPULVBH-KCDYIMILSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,6.0,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.221848749616356,CN1C2=CC=CC=C2[C@H]3CC(O[C@@H]3C4=CC=CC=C41)CN(C)C
3943,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,3194.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.495665088197536,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
3944,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,371.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.430626090384954,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
3945,CHEMBL908,WSPOMRSOLSGNFJ-AUWJEWJLSA-N,CHLORPROTHIXENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,3.75,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.425968732272281,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
3946,CHEMBL908,WSPOMRSOLSGNFJ-AUWJEWJLSA-N,CHLORPROTHIXENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,1.0,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,9.0,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
3947,CHEMBL908,WSPOMRSOLSGNFJ-AUWJEWJLSA-N,CHLORPROTHIXENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,870.96,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,6.060001790087838,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
3948,CHEMBL272302,WSSKPYCMFWWDPQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CCC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CN=CC=C5
3949,CHEMBL467094,WSVWKHTVFGTTKJ-UHFFFAOYSA-N,NANTENINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19963380.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor,Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC2=CC(=C(C3=C2C1CC4=CC5=C(C=C43)OCO5)OC)OC
3950,CHEMBL239744,WSXMMXMXSWZQOD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1584.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.800000874803203,C1CCC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)Cl.C(=O)O
3951,CHEMBL1009,WTDRDQBEARUVNC-LURJTMIESA-N,LEVODOPA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O
3952,CHEMBL1009,WTDRDQBEARUVNC-LURJTMIESA-N,LEVODOPA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O
3953,CHEMBL229429,WTLBLIGPXACYET-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17571866.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography.,J. Med. Chem.,PUBLICATION,,5.0,C1=C(C=C(C=C1C#N)F)C#CC2=CSC(=N2)CF
3954,CHEMBL1783953,WTMKJZWIEBUUNH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,930.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.031517051446065,CN1CCC2=C(C1)C3=CC=CC=C3N2CCC4=CC=CC=N4
3955,CHEMBL1783953,WTMKJZWIEBUUNH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,1820.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.739928612014925,CN1CCC2=C(C1)C3=CC=CC=C3N2CCC4=CC=CC=N4
3956,CHEMBL307609,WTUOCEYWCJZOOS-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,4.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,C1CN(CCN1CC2=CC=C(O2)CN(C(=O)N)O)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl
3957,CHEMBL304888,WUAKHYKTJKHZOM-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,46773.51,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.330000038335378,C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)NC(C)C
3958,CHEMBL1169,WUBBRNOQWQTFEX-UHFFFAOYSA-N,AMINOSALICYLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1N)O)C(=O)O
3959,CHEMBL1169,WUBBRNOQWQTFEX-UHFFFAOYSA-N,AMINOSALICYLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1N)O)C(=O)O
3960,CHEMBL1598608,WUKZPHOXUVCQOR-UHFFFAOYSA-N,AZASETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4
3961,CHEMBL1598608,WUKZPHOXUVCQOR-UHFFFAOYSA-N,AZASETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4
3963,CHEMBL273348,WUWFMDMBOJLQIV-UHFFFAOYSA-N,TOSUFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC1N)C2=C(C=C3C(=O)C(=CN(C3=N2)C4=C(C=C(C=C4)F)F)C(=O)O)F
3964,CHEMBL273348,WUWFMDMBOJLQIV-UHFFFAOYSA-N,TOSUFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC1N)C2=C(C=C3C(=O)C(=CN(C3=N2)C4=C(C=C(C=C4)F)F)C(=O)O)F
3965,CHEMBL236587,WUXDFTYUVPKGCE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18020390.0,Ki,=,624.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,"Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach.",J. Med. Chem.,PUBLICATION,,6.204815410317576,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=CC=CC=C4O3)OC
3966,CHEMBL236587,WUXDFTYUVPKGCE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,624.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.204815410317576,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=CC=CC=C4O3)OC
3967,CHEMBL91397,WUZYKBABMWJHDL-UHFFFAOYSA-N,RUPATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,IC50,=,3.9,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,8.4089353929735,CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2
3968,CHEMBL558933,WVCNWPFTYDURBB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.8,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.55284196865778,CN(C1CCCCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
3969,CHEMBL720,WVDDGKGOMKODPV-UHFFFAOYSA-N,BENZYL ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CO
3970,CHEMBL720,WVDDGKGOMKODPV-UHFFFAOYSA-N,BENZYL ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CO
3971,CHEMBL1278202,WVFQWSQTENHWCH-MTQWGCILSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.899974269892137,CC1(CCN(C1)C2CC[C@@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35)C(=O)O
3973,CHEMBL1935432,WVNZODFRLMLDAL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,6.3,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.200659450546418,CCN(CC)C(=O)CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
3974,CHEMBL428,WVPSKSLAZQPAKQ-CDMJZVDBSA-N,TROVAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F
3975,CHEMBL428,WVPSKSLAZQPAKQ-CDMJZVDBSA-N,TROVAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F
3976,CHEMBL119443,WVVSZNPYNCNODU-XTQGRXLLSA-N,ERGONOVINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
3977,CHEMBL119443,WVVSZNPYNCNODU-XTQGRXLLSA-N,ERGONOVINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
3978,CHEMBL154111,WVYADZUPLLSGPU-UHFFFAOYSA-N,SALSALATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O
3979,CHEMBL154111,WVYADZUPLLSGPU-UHFFFAOYSA-N,SALSALATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O
3980,CHEMBL1094452,WWEBJYNVUIMDCZ-GFCCVEGCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,>,10000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(SC(=N1)N)CCCN=C(N)NC(=O)C[C@@H](C)C2CCCCC2
3981,CHEMBL1094144,WWEBJYNVUIMDCZ-LBPRGKRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,>,10000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(SC(=N1)N)CCCN=C(N)NC(=O)C[C@H](C)C2CCCCC2
3982,CHEMBL1094142,WWEBJYNVUIMDCZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,>,10000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(SC(=N1)N)CCCN=C(N)NC(=O)CC(C)C2CCCCC2
3984,CHEMBL2107797,WWYNJERNGUHSAO-CULCCENASA-N,NORGESTREL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@]12CC[C@H]3[C@H]([C@@H]1CCC2(C#C)O)CCC4=CC(=O)CC[C@H]34
3985,CHEMBL2107797,WWYNJERNGUHSAO-CULCCENASA-N,NORGESTREL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@]12CC[C@H]3[C@H]([C@@H]1CCC2(C#C)O)CCC4=CC(=O)CC[C@H]34
3987,CHEMBL10961,WXSURELOKDGQNF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,5.0,CNCC(C1=CC=CC=C1)C2=CC=CC=C2
3988,CHEMBL86715,WYDUSKDSKCASEF-UHFFFAOYSA-N,PROCYCLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,17782.79,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,4.750000100140428,C1CCC(CC1)C(CCN2CCCC2)(C3=CC=CC=C3)O
3989,CHEMBL250403,WYEGTIGJSHGEID-ZDUSSCGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17976986.0,Ki,>,2000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,CCCN1CCO[C@@H](C1)C2=CC(=CC=C2)O
3990,CHEMBL328511,WYLMUYOKAITMJI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,5.93,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.226945306635738,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)C(=O)OC)C7=CC=CC=C7
3991,CHEMBL328511,WYLMUYOKAITMJI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,1210.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.91721462968355,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)C(=O)OC)C7=CC=CC=C7
3992,CHEMBL1767154,WYRUGBCTQBZIHO-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.316,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.500312917381596,CN1CCC[C@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
3993,CHEMBL1767136,WYRUGBCTQBZIHO-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.158,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.801342913045577,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
3995,CHEMBL1767136,WYRUGBCTQBZIHO-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.162,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.790484985457368,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
3996,CHEMBL727,WYWHKKSPHMUBEB-UHFFFAOYSA-N,THIOGUANINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1)C(=S)N=C(N2)N
3997,CHEMBL727,WYWHKKSPHMUBEB-UHFFFAOYSA-N,THIOGUANINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1)C(=S)N=C(N2)N
3998,CHEMBL762,WYWIFABBXFUGLM-UHFFFAOYSA-N,OXYMETAZOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C
3999,CHEMBL762,WYWIFABBXFUGLM-UHFFFAOYSA-N,OXYMETAZOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C
4000,CHEMBL564201,WYXSYVWAUAUWLD-SHUUEZRQSA-N,6-AZAURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
4001,CHEMBL564201,WYXSYVWAUAUWLD-SHUUEZRQSA-N,6-AZAURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O
4002,CHEMBL2103774,WZDGZWOAQTVYBX-XOINTXKNSA-N,TIBOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O
4003,CHEMBL2103774,WZDGZWOAQTVYBX-XOINTXKNSA-N,TIBOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O
4004,CHEMBL2031873,WZHAQWFZACLGKI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313242.0,Ki,=,9620.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 receptor,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.016824927962187,C1CCC(C1)NC(=O)C2=CC=C(C=C2)C3=CC4=C(C=C3)C(=O)N(CC4)CCN5CCCC5
4005,CHEMBL1480987,WZHCOOQXZCIUNC-UHFFFAOYSA-N,CYCLANDELATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O
4006,CHEMBL1480987,WZHCOOQXZCIUNC-UHFFFAOYSA-N,CYCLANDELATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O
4008,CHEMBL19215,WZHJKEUHNJHDLS-QTGUNEKASA-N,METERGOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,4133.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.383734594718292,CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5
4009,CHEMBL19215,WZHJKEUHNJHDLS-QTGUNEKASA-N,METERGOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,480.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.318758762624412,CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5
4010,CHEMBL330366,WZMVQZJKOVPVGZ-XIFFEERXSA-N,MDL-105212,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,IC50,=,3.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,8.522878745280337,COC1=CC(=CC(=C1OC)OC)C(=O)N2CC[C@](C2)(CCN3CCC(CC3)(C4=CC=CC=C4)C(=O)N)C5=CC(=C(C=C5)Cl)Cl
4011,CHEMBL330366,WZMVQZJKOVPVGZ-XIFFEERXSA-N,MDL-105212,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Compound was evaluated for the antagonistic activity against H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC(=CC(=C1OC)OC)C(=O)N2CC[C@](C2)(CCN3CCC(CC3)(C4=CC=CC=C4)C(=O)N)C5=CC(=C(C=C5)Cl)Cl
4012,CHEMBL245416,WZNJWVWKTVETCG-YFKPBYRVSA-N,L-MIMOSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C=C(C1=O)O)C[C@@H](C(=O)O)N
4013,CHEMBL245416,WZNJWVWKTVETCG-YFKPBYRVSA-N,L-MIMOSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C=C(C1=O)O)C[C@@H](C(=O)O)N
4014,CHEMBL328114,WZOMJNATDSYQHS-ZPWQMVEJSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771448.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to Histamine H1 receptor,Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.,J. Med. Chem.,PUBLICATION,,6.0,COC1=C(C=C2C(=C1)C3=NO[C@H]([C@@H]3CO2)CN4CCN(CC4)C/C=C/C5=CC=CC=C5)OC
4015,CHEMBL158,WZPBZJONDBGPKJ-VEHQQRBSSA-N,AZTREONAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\OC(C)(C)C(=O)O)/C2=CSC(=N2)N
4016,CHEMBL158,WZPBZJONDBGPKJ-VEHQQRBSSA-N,AZTREONAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\OC(C)(C)C(=O)O)/C2=CSC(=N2)N
4017,CHEMBL1923524,WZYLEAJVJMZIFE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,537.03,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,6.270001452716577,CC1=C2C(=CC=C1)C(=CN2CC3=CC=CC=C3)CCN
4018,CHEMBL540633,XAMKLIVWXRZDBC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=CC=C5.Cl
4019,CHEMBL37858,XBHBWNFJWIASRO-UHFFFAOYSA-N,SARAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F
4020,CHEMBL37858,XBHBWNFJWIASRO-UHFFFAOYSA-N,SARAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F
4021,CHEMBL6273,XBJBPGROQZJDOJ-UHFFFAOYSA-N,FLEROXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F
4022,CHEMBL6273,XBJBPGROQZJDOJ-UHFFFAOYSA-N,FLEROXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F
4024,CHEMBL2208431,XBJQRDCFABQBGT-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,6.31,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.199970640755867,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=NNC(=O)C4=CC=CC=C43)O
4027,CHEMBL93519,XBURWGMHOIWDHZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.3,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.200659450546418,COC1=CC=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=CC=N7
4028,CHEMBL270567,XBWBWCMBNYVAKR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C7=CC(=NN7C)C
4029,CHEMBL79249,XCCCRVPCDJNFIY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,26.3,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.580044251510242,C1COCCN1CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2
4030,CHEMBL3545252,XCDIRYDKECHIPE-QHEQPUDQSA-N,DOCETAXEL HYDRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O
4031,CHEMBL3545252,XCDIRYDKECHIPE-QHEQPUDQSA-N,DOCETAXEL HYDRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O
4032,CHEMBL442,XCGSFFUVFURLIX-VFGNJEKYSA-N,ERGOTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C
4033,CHEMBL442,XCGSFFUVFURLIX-VFGNJEKYSA-N,ERGOTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C
4034,CHEMBL1774503,XCIDTTYEFDTNFF-UYOCIXKTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,325.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.488116639021126,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CC/C=C\3/C4=CC=CC=C4COC5=C3C=C(C=C5)C(=O)O
4035,CHEMBL1403257,XCVMKCYUNNAQAM-UHFFFAOYSA-N,BAS 03602647,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,1905.46,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.720000163638921,C1CCN(C1)C2=NC(=NC(=N2)N3CCNCC3)N4CCCC4
4036,CHEMBL95764,XDDAORKBJWWYJS-UHFFFAOYSA-N,GLYPHOSATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)NCP(=O)(O)O
4037,CHEMBL95764,XDDAORKBJWWYJS-UHFFFAOYSA-N,GLYPHOSATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)NCP(=O)(O)O
4038,CHEMBL12620,XDKYTXBAVJELDQ-UHFFFAOYSA-N,2-METHYLHISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,EC50,=,794.33,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,CC1=NC=C(N1)CCN
4040,CHEMBL55,XDRYMKDFEDOLFX-UHFFFAOYSA-N,PENTAMIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N
4041,CHEMBL55,XDRYMKDFEDOLFX-UHFFFAOYSA-N,PENTAMIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N
4042,CHEMBL1117,XDXDZDZNSLXDNA-TZNDIEGXSA-N,IDARUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O
4043,CHEMBL1117,XDXDZDZNSLXDNA-TZNDIEGXSA-N,IDARUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O
4044,CHEMBL60509,XDXVWRAGPFLSNP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,4265.8,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.369999510099088,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CN=CO3
4045,CHEMBL577912,XEOSDWIUBUJPES-CALCHBBNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,760.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.119186407719209,CC1=CN=C(N=C1N(C)C)NC2CCC(CC2)NC(=O)C3=CC=C(C=C3)Cl
4046,CHEMBL1754,XFDJYSQDBULQSI-UHFFFAOYSA-N,DOXAPRAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4
4047,CHEMBL1754,XFDJYSQDBULQSI-UHFFFAOYSA-N,DOXAPRAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4
4051,CHEMBL3094213,XFMAJARUDAULHP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,>,2511.89,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CC(C)N1CCC(CC1)OC2=CC3=C(CCNCC3)C=C2
4052,CHEMBL270177,XFMPGBXLGWZMQP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17998160.0,Ki,=,1100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.958607314841775,CC1C2=C(C=CC=C2Cl)NC(=N1)N
4053,CHEMBL1935442,XFQZALCRWJDNNK-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,0.8,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.096910013008056,C1CO[C@H](CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
4054,CHEMBL2103747,XFSBVAOIAHNAPC-FKHWODAVSA-N,ACONITINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C[C@@]2([C@@H](C[C@H]([C@@]34[C@@H]2[C@H]([C@@H]([C@@H]31)[C@@]5([C@@H]6[C@H]4C[C@@]([C@@H]6OC(=O)C7=CC=CC=C7)([C@H]([C@@H]5O)OC)O)OC(=O)C)OC)OC)O)COC
4055,CHEMBL2103747,XFSBVAOIAHNAPC-FKHWODAVSA-N,ACONITINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C[C@@]2([C@@H](C[C@H]([C@@]34[C@@H]2[C@H]([C@@H]([C@@H]31)[C@@]5([C@@H]6[C@H]4C[C@@]([C@@H]6OC(=O)C7=CC=CC=C7)([C@H]([C@@H]5O)OC)O)OC(=O)C)OC)OC)O)COC
4057,CHEMBL1172775,XGWXPMUNGMSGIF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20541426.0,Ki,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]rilamine from human histamine H1 receptor expressed in CHO cells after 1 hr by liquid scintillation counting,Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor.,Bioorg. Med. Chem.,PUBLICATION,,6.0,COC1=CC=C(C=C1)N2CCC(CC2)CC3=CN=CN3
4058,CHEMBL271280,XHDPHPBWQCZQAX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)C6CC6
4059,CHEMBL330499,XHIAYAAKBSHSOX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.3,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.200659450546418,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4)C6=CC=CC=C6
4060,CHEMBL330499,XHIAYAAKBSHSOX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,500.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4)C6=CC=CC=C6
4061,CHEMBL1940414,XHIUHIDIRNZTAW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,67.9,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,7.168130225719498,C1CN(CCN1CCCOC2=CC=CC=C2)C3=CC=CC=C3
4062,CHEMBL92860,XHLHZPFSBCZVEA-HOFKKMOUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771448.0,Ki,=,460.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to Histamine H1 receptor,Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.,J. Med. Chem.,PUBLICATION,,6.337242168318426,COC1=C(C=C2C(=C1)C3=NO[C@H]([C@@H]3CO2)CN4CCN(CC4)CC5=CC6=CC=CC=C6C=C5)OC
4064,CHEMBL474448,XHPXJEMBVQVQEF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19317445.0,EC50,=,1698.24,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in insect Sf9 cells co-expressing RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting,N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.,J. Med. Chem.,PUBLICATION,,5.770000934050708,C1=CC=C2C(=C1)C=C(N2)C(=O)NC(=NCCCC3=CN=CN3)N
4066,CHEMBL62726,XIDMFZPTPXURCO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,74.13,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.130005999878258,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=CS3
4068,CHEMBL1231,XIQVNETUBQGFHX-UHFFFAOYSA-N,OXYBUTYNIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
4069,CHEMBL1231,XIQVNETUBQGFHX-UHFFFAOYSA-N,OXYBUTYNIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
4070,CHEMBL3357024,XIUQXOBEGLVYPC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,1955.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,5.708853238268114,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC(=C4)OC)C=C(C=C3)Cl)CC1
4072,CHEMBL1909070,XJGBDJOMWKAZJS-UHFFFAOYSA-N,NAFENOPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CCCC3=CC=CC=C23
4073,CHEMBL1909070,XJGBDJOMWKAZJS-UHFFFAOYSA-N,NAFENOPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CCCC3=CC=CC=C23
4074,CHEMBL831,XJGVXQDUIWGIRW-UHFFFAOYSA-N,LOXAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,5.0,NM,,,,,,,,,,,,,,,,,,,,8.301029995663981,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
4075,CHEMBL831,XJGVXQDUIWGIRW-UHFFFAOYSA-N,LOXAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,4.9,NM,,,,,,,,,,,,,,,,,,,,8.309803919971486,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
4076,CHEMBL831,XJGVXQDUIWGIRW-UHFFFAOYSA-N,LOXAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,7.0,NM,,,,,,,,,,,,,,,,,,,,8.154901959985743,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl
4079,CHEMBL439065,XJLKTBWZJKVXJX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3981.07,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,CC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CC=C(C=C5)C(F)(F)F
4080,CHEMBL3104093,XKGPHJMKJBEURD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC2=C(C1)C3=C4N2CCC5=CC=CC=C5C4=CC=C3
4082,CHEMBL313703,XKZZKFWMYWZWDI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1C(ON2C1C3=CC=CC=C3CC4=CC=CC=C42)CN5CC6=CC=CC=C6C5
4083,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl
4084,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl
4085,CHEMBL64408,XMLVVFKBGQDKNU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1071.52,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.9699997184078955,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OC
4086,CHEMBL96441,XMRHEUULHFVWJE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,5.71,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.243363891754152,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5)OC
4087,CHEMBL1321154,XMVJITFPVVRMHC-UHFFFAOYSA-N,ROXARSONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1[As](=O)(O)O)[N+](=O)[O-])O
4088,CHEMBL1321154,XMVJITFPVVRMHC-UHFFFAOYSA-N,ROXARSONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1[As](=O)(O)O)[N+](=O)[O-])O
4089,CHEMBL14376,XMXHEBAFVSFQEX-UHFFFAOYSA-N,ILOPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,12.3,NM,,,,,,,,,,,,,,,,,,,,7.910094888560602,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC
4090,CHEMBL991,XNKLLVCARDGLGL-JGVFFNPUSA-N,STAVUDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO
4091,CHEMBL991,XNKLLVCARDGLGL-JGVFFNPUSA-N,STAVUDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO
4092,CHEMBL1277585,XNPQDIOALLTRKK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.599980364934842,C1CC2(CC1N3CCC(CC3)CC(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25
4095,CHEMBL1222764,XNVKJWRHFRDBHD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,125.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455316,CC(C)(CN1CCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC=C4OC)C(=O)O
4096,CHEMBL635,XOFYZVNMUHMLCC-ZPOLXVRWSA-N,PREDNISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C
4097,CHEMBL635,XOFYZVNMUHMLCC-ZPOLXVRWSA-N,PREDNISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C
4098,CHEMBL975,XOGTZOOQQBDUSI-UHFFFAOYSA-M,MESNA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CS(=O)(=O)[O-])S.[Na+]
4099,CHEMBL975,XOGTZOOQQBDUSI-UHFFFAOYSA-M,MESNA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CS(=O)(=O)[O-])S.[Na+]
4103,CHEMBL838,XPCFTKFZXHTYIP-PMACEKPBSA-N,BENAZEPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O
4104,CHEMBL838,XPCFTKFZXHTYIP-PMACEKPBSA-N,BENAZEPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O
4106,CHEMBL918,XPFRXWCVYUEORT-UHFFFAOYSA-N,PHENACEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CC(=O)NC(=O)N
4107,CHEMBL918,XPFRXWCVYUEORT-UHFFFAOYSA-N,PHENACEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CC(=O)NC(=O)N
4110,CHEMBL32813,XPQIPUZPSLAZDV-UHFFFAOYSA-N,2-(2-AMINOETHYL)PYRIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1258.93,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.899998417198648,C1=CC=NC(=C1)CCN
4111,CHEMBL32813,XPQIPUZPSLAZDV-UHFFFAOYSA-N,2-(2-AMINOETHYL)PYRIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,6309573444801.94,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-3.8000000000000007,C1=CC=NC(=C1)CCN
4112,CHEMBL562638,XPYYQHFSTUXSTG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN1C(=CC(=O)N(C1=O)C)NCCCN2CCC(CC2)OC3=C(C=C(C=C3)Cl)C(=O)O
4113,CHEMBL605405,XQDRWCFJBHLWPR-RAXLEYEMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,70.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.154901959985743,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)/C=C\C4=CC=CC=C4
4114,CHEMBL605405,XQDRWCFJBHLWPR-RAXLEYEMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,154.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as reduction of histamine-induced intracellular calcium spike at phase 2 treated 20 to 30 seconds after histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.812479279163537,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)/C=C\C4=CC=CC=C4
4115,CHEMBL788,XQFRJNBWHJMXHO-RRKCRQDMSA-N,IDOXURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)CO)O
4116,CHEMBL788,XQFRJNBWHJMXHO-RRKCRQDMSA-N,IDOXURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)CO)O
4118,CHEMBL269959,XQYFTHHWGHOOSS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C
4119,CHEMBL19224,XQYZDYMELSJDRZ-UHFFFAOYSA-N,PAPAVERINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC
4120,CHEMBL19224,XQYZDYMELSJDRZ-UHFFFAOYSA-N,PAPAVERINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC
4121,CHEMBL712,XRCFXMGQEVUZFC-UHFFFAOYSA-N,ANISINDIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
4122,CHEMBL712,XRCFXMGQEVUZFC-UHFFFAOYSA-N,ANISINDIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
4123,CHEMBL2179222,XRDVQWJPAZZLKN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23006002.0,Ki,=,586.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,6.23210238398191,CC1=CN(C2=C1C=C(C=N2)Cl)S(=O)(=O)C3=CC(=C(C=C3)OC)NC4CCN(CC4)C
4124,CHEMBL1463,XRECTZIEBJDKEO-UHFFFAOYSA-N,FLUCYTOSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=O)NC(=C1F)N
4125,CHEMBL1463,XRECTZIEBJDKEO-UHFFFAOYSA-N,FLUCYTOSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=O)NC(=C1F)N
4126,CHEMBL61792,XRPRRDYTGFENHV-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,95499.26,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.019999993643078,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CN=CN4)N
4127,CHEMBL303313,XRYLGRGAWQSVQW-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,15.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,7.823908740944319,CN1CCN(CC1)[C@H]2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl
4128,CHEMBL64875,XRYLGRGAWQSVQW-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,12.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,7.920818753952375,CN1CCN(CC1)[C@@H]2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl
4129,CHEMBL64249,XRYLGRGAWQSVQW-UHFFFAOYSA-N,CLOROTEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,0.19,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,9.721246399047171,CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl
4130,CHEMBL1935431,XRZMHKTZJWSXPQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,5.7,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.244125144327509,CN(C)C(=O)CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
4131,CHEMBL1935431,XRZMHKTZJWSXPQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,8.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.050609993355087,CN(C)C(=O)CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F
4133,CHEMBL945,XSDQTOBWRPYKKA-UHFFFAOYSA-N,AMILORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N
4134,CHEMBL945,XSDQTOBWRPYKKA-UHFFFAOYSA-N,AMILORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N
4135,CHEMBL1512,XSFJVAJPIHIPKU-XWCQMRHXSA-N,FLUNISOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O
4136,CHEMBL1512,XSFJVAJPIHIPKU-XWCQMRHXSA-N,FLUNISOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O
4137,CHEMBL294087,XSLVAIIZNFBGBI-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,34673.69,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.459999937940861,CC(C)[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)NC
4138,CHEMBL3357043,XSNLDSYJHLYUGZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,147.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,6.8326826652518236,CCCCC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
4139,CHEMBL240141,XSOFCOCSPTUCJQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CCN(C1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.C(=O)O
4140,CHEMBL259765,XSZZVXRYXJUWCA-QZTJIDSGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18387300.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,COC1=C(C=CC(=C1)F)O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3
4142,CHEMBL1783957,XTVVBTLUOSFTHO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,120.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)Br
4143,CHEMBL1783957,XTVVBTLUOSFTHO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)Br
4144,CHEMBL31,XUBOMFCQGDBHNK-UHFFFAOYSA-N,GATIFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
4145,CHEMBL31,XUBOMFCQGDBHNK-UHFFFAOYSA-N,GATIFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
4146,CHEMBL461727,XUCIJNAGGSZNQT-JHSLDZJXSA-N,AMYGDALIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)[C@H](C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O
4147,CHEMBL461727,XUCIJNAGGSZNQT-JHSLDZJXSA-N,AMYGDALIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)[C@H](C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O
4148,CHEMBL902,XUFQPHANEAPEMJ-UHFFFAOYSA-N,FAMOTIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N
4149,CHEMBL902,XUFQPHANEAPEMJ-UHFFFAOYSA-N,FAMOTIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N
4150,CHEMBL1566,XUFXOAAUWZOOIT-SXARVLRPSA-N,ACARBOSE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO
4151,CHEMBL1566,XUFXOAAUWZOOIT-SXARVLRPSA-N,ACARBOSE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO
4152,CHEMBL54943,XUJNEKJLAYXESH-UHFFFAOYSA-N,CYSTEINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(C(C(=O)O)N)S
4154,CHEMBL1487,XUKUURHRXDUEBC-KAYWLYCHSA-N,ATORVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
4155,CHEMBL1487,XUKUURHRXDUEBC-KAYWLYCHSA-N,ATORVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
4156,CHEMBL255618,XURXMJIMPKTNSF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,501.19,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCC(C)N4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C(F)(F)F
4157,CHEMBL1774495,XURYOEGYBXTQTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,150.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.823908740944319,CC(C)(C1=CC2=C(C=C1)OCC3=CC=CC=C3N2CCCN4CCCN(CC4)C5=CC(=O)N(C(=O)N5C)C)C(=O)O
4158,CHEMBL1910381,XUSZWVLIKIUVKA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,7.08,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.14996674231023,CN(CCN1CCN(CC1)C(=O)C2=CC3=CC=CC=C3N2)CCN(CC4=CC=C(C=C4)OC)C5=CC=CC=N5
4160,CHEMBL1171434,XVOYSCVBGLVSOL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(C(C(=O)O)N)S(=O)(=O)O
4162,CHEMBL465170,XVZKDKXYAADAMU-UHFFFAOYSA-N,UR-PI295,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19317445.0,EC50,=,2187.76,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in insect Sf9 cells co-expressing RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting,N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.,J. Med. Chem.,PUBLICATION,,5.660000322371772,CCCC(=O)NC(=NCCCC1=CN=CN1)N
4163,CHEMBL1235242,XWHHYOYVRVGJJY-QMMMGPOBSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)F
4164,CHEMBL1235242,XWHHYOYVRVGJJY-QMMMGPOBSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)F
4165,CHEMBL64253,XWOZMTAARRXLLU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,2238.72,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.650000220873455,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)CC3CC3
4166,CHEMBL1760,XWTYSIMOBUGWOL-UHFFFAOYSA-N,TERBUTALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O
4167,CHEMBL1760,XWTYSIMOBUGWOL-UHFFFAOYSA-N,TERBUTALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O
4168,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,2700.0,NM,,,,,,,,,,,,,,,,,,,,5.568636235841013,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3
4169,CHEMBL234926,XXROGKLTLUQVRX-UHFFFAOYSA-N,ALLYL ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCO
4170,CHEMBL234926,XXROGKLTLUQVRX-UHFFFAOYSA-N,ALLYL ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCO
4171,CHEMBL1535,XXSMGPRMXLTPCZ-UHFFFAOYSA-N,HYDROXYCHLOROQUINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO
4172,CHEMBL1535,XXSMGPRMXLTPCZ-UHFFFAOYSA-N,HYDROXYCHLOROQUINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO
4173,CHEMBL485549,XXUXXCZCUGIGPP-WLRTZDKTSA-N,NIFURSOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)C2=C(C(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-])O
4174,CHEMBL485549,XXUXXCZCUGIGPP-WLRTZDKTSA-N,NIFURSOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)C2=C(C(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-])O
4175,CHEMBL844,XYLJNLCSTIOKRM-UHFFFAOYSA-N,BRIMONIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br
4176,CHEMBL844,XYLJNLCSTIOKRM-UHFFFAOYSA-N,BRIMONIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br
4178,CHEMBL318801,XZKDSZJJFHAYFJ-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,5623.41,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.250000251143582,C1CN(C[C@H]1O)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
4179,CHEMBL104669,XZKDSZJJFHAYFJ-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,4466.84,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.349999603463148,C1CN(C[C@@H]1O)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N
4180,CHEMBL1431,XZWYZXLIPXDOLR-UHFFFAOYSA-N,METFORMIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=N)N=C(N)N
4181,CHEMBL1431,XZWYZXLIPXDOLR-UHFFFAOYSA-N,METFORMIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=N)N=C(N)N
4182,CHEMBL1774496,YAMCEGJVTDPCJX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,530.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.275724130399211,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4OCC5=C3C=C(C=C5)C(=O)O
4183,CHEMBL1767168,YANGEESWIGIKOP-UMSFTDKQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.599980364934842,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl
4184,CHEMBL1767164,YANGEESWIGIKOP-UUWRZZSWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21062081.0,Ki,=,15.85,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Histamine H3 receptor as a drug discovery target.,J. Med. Chem.,PUBLICATION,,7.79997073344623,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl
4187,CHEMBL1767164,YANGEESWIGIKOP-UUWRZZSWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,10.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.0,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl
4189,CHEMBL1767164,YANGEESWIGIKOP-UUWRZZSWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,10.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,8.0,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl
4190,CHEMBL121,YASAKCUCGLMORW-UHFFFAOYSA-N,ROSIGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3
4191,CHEMBL121,YASAKCUCGLMORW-UHFFFAOYSA-N,ROSIGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3
4192,CHEMBL1399,YBBLVLTVTVSKRW-UHFFFAOYSA-N,ANASTROZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N
4193,CHEMBL1399,YBBLVLTVTVSKRW-UHFFFAOYSA-N,ANASTROZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N
4194,CHEMBL1259174,YBCFDDCJLZVHPZ-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,2.5,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,8.602059991327963,CC(=O)NCC1=CC2=C(C=C1)SC3=CC=CC=C3C[C@@H]2N4CCN(CC4)C
4195,CHEMBL1259173,YBCFDDCJLZVHPZ-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,3.6,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,8.443697499232712,CC(=O)NCC1=CC2=C(C=C1)SC3=CC=CC=C3C[C@H]2N4CCN(CC4)C
4196,CHEMBL1259144,YBCFDDCJLZVHPZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,,,,Non-toxic,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,,CC(=O)NCC1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCN(CC4)C
4197,CHEMBL1669422,YBDNLKCSUIZMPU-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,8.8,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.05551732784983,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CN4
4198,CHEMBL85728,YBRVSVVVWCFQMG-UHFFFAOYSA-N,"4,4'-METHYLENEDIANILINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N
4199,CHEMBL85728,YBRVSVVVWCFQMG-UHFFFAOYSA-N,"4,4'-METHYLENEDIANILINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N
4200,CHEMBL272775,YBTBFDQBPQHZEV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)N=C(O5)C(C)(F)F
4202,CHEMBL599570,YCFWTCQCXNKWLE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20045641.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human cloned histamine H1 receptor,"9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC2=CC3=C(CC4=CC=CC=C4C3CN)C=C2C=C1
4203,CHEMBL280998,YCIMNLLNPGFGHC-UHFFFAOYSA-N,CATECHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)O)O
4204,CHEMBL280998,YCIMNLLNPGFGHC-UHFFFAOYSA-N,CATECHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)O)O
4205,CHEMBL495778,YCOFRPYSZKIPBQ-UHFFFAOYSA-N,PENICILLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)C1(C(=CC(=O)O1)OC)O
4206,CHEMBL495778,YCOFRPYSZKIPBQ-UHFFFAOYSA-N,PENICILLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)C1(C(=CC(=O)O1)OC)O
4209,CHEMBL15928,YDBCEBYHYKAFRX-UHFFFAOYSA-N,GR-127935,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)N5CCN(CC5)C
4210,CHEMBL315424,YDCWINJIBUMKOY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C(=CC=C3)Cl
4211,CHEMBL269646,YDDXVAXDYKBWDX-UHFFFAOYSA-N,TIOTIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN=C(NCCSCC1=CSC(=N1)N=C(N)N)NC#N
4212,CHEMBL2158787,YDHQRFQQOKRWAD-MHZLTWQESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450609,C[C@](CC1=CC=C(C=C1)F)(C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
4213,CHEMBL1403281,YDOTUXAWKBPQJW-NSLWYYNWSA-N,ERGOCRYPTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O
4214,CHEMBL1403281,YDOTUXAWKBPQJW-NSLWYYNWSA-N,ERGOCRYPTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O
4215,CHEMBL2158836,YDRCHQQFHSPVMO-RUZDIDTESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@H](CC4=CC=CC=C4)C(=O)O
4216,CHEMBL2158835,YDRCHQQFHSPVMO-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=CC=C4)C(=O)O
4218,CHEMBL346993,YDUBNWZTTFIXEZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,398107170553497.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.6,C1=CC=C(C=C1)C(CCC2=NC=C(N2)CCN)C3=CC=C(C=C3)Br
4220,CHEMBL294349,YDZORJBZHVTZSS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,21379.62,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6700000181810175,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C(C)(C)O
4221,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27876250.0,IC50,=,1.4,NM,,,cell_based,binding,,,,,,,,,,,,,,,,8.853871964321762,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4222,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,4.0,NM,,,,,,,,,,,,,,,,,,,,8.397940008672037,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4223,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,3.98,NM,,,,,,,,,,,,,,,,,,,,8.400116927926312,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4224,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8335064.0,Ki,=,4.7,NM,,,,,,,,,,,,,,,,,,,,8.327902142064282,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4225,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,3.7,NM,,,,,,,,,,,,,,,,,,,,8.431798275933005,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4226,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,2.5,NM,,,,,,,,,,,,,,,,,,,,8.602059991327963,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4227,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.01,NM,,,,,,,,,,,,,,,,,,,,8.995678626217357,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4228,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.18,NM,,,,,,,,,,,,,,,,,,,,8.928117992693874,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4231,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,12.59,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.899974269892137,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4232,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,5.0118723362727104e+17,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-8.7,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4234,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16408006.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,Inverse agonist activity at human wild-type histamine H1 receptor assessed as NF-kappaB activation after 48 hrs by luciferase reporter gene assay,Linking agonist binding to histamine H1 receptor activation.,Nat. Chem. Biol.,PUBLICATION,,8.0,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4235,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16562853.0,EC50,=,2.6,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO-K1 cells,Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.,J. Nat. Prod.,PUBLICATION,,8.585026652029182,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4236,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18588282.0,IC50,=,1.8,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,"Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.",J. Med. Chem.,PUBLICATION,,8.744727494896694,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4237,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18983139.0,IC50,=,6.2,NM,,,,,,,,,,,,,,,Displacement of radiolabeled pyrilamine from human histamine H1 receptor,"cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.",J. Med. Chem.,PUBLICATION,,8.207608310501746,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4238,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18983139.0,Ki,=,2.2,NM,,,,,,,,,,,,,,,Displacement of radiolabeled pyrilamine from human histamine H1 receptor,"cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.",J. Med. Chem.,PUBLICATION,,8.657577319177793,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4239,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,4.47,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.349692476868064,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4241,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,2.09,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,8.679853713888946,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4242,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,46.77,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,7.3300326300914955,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4243,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23403082.0,IC50,=,3.3,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells after 3 hrs,Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.481486060122112,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4245,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23403082.0,Ki,=,1.6,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells after 3 hrs,Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.795880017344075,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4246,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23466604.0,IC50,=,1.5,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor by radioligand displacement assay,Synthesis and structure-activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds.,Eur. J. Med. Chem.,PUBLICATION,,8.823908740944319,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4247,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23466604.0,Ki,=,0.95,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor by radioligand displacement assay,Synthesis and structure-activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds.,Eur. J. Med. Chem.,PUBLICATION,,9.022276394711152,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4248,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23582449.0,IC50,=,0.82,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor by radioligand displacement assay,Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.,Bioorg. Med. Chem.,PUBLICATION,,9.086186147616283,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4249,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24805037.0,IC50,=,3.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant H1 receptor assessed as inhibition of histamine-induced intracellular Ca2+ release,Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia.,J. Med. Chem.,PUBLICATION,,8.522878745280337,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4250,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24805037.0,Ki,=,1.7,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant H1 receptor expressed in HEK293 cells,Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia.,J. Med. Chem.,PUBLICATION,,8.769551078621726,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4251,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25557493.0,Ki,=,1.7,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in HEK-293 cells,Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.,Eur. J. Med. Chem.,PUBLICATION,,8.769551078621726,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4252,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26988801.0,IC50,=,0.013999999999999999,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in HEK293 cells,"Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.",Bioorg. Med. Chem.,PUBLICATION,,10.853871964321762,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4253,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,3.72,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.429457060118102,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4254,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.43200000000000005,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.364516253185087,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2
4256,CHEMBL603,YEEZWCHGZNKEEK-UHFFFAOYSA-N,ZAFIRLUKAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC
4257,CHEMBL603,YEEZWCHGZNKEEK-UHFFFAOYSA-N,ZAFIRLUKAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC
4258,CHEMBL603,YEEZWCHGZNKEEK-UHFFFAOYSA-N,ZAFIRLUKAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC
4259,CHEMBL1767146,YEFYNZHDZSJWCN-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,1.58,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.801342913045577,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC(=CC=C4)Cl
4260,CHEMBL2207281,YEGSREZTMOWGTG-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC(=C4)S(=O)(=O)NCCO)O
4261,CHEMBL531,YEHCICAEULNIGD-MZMPZRCHSA-N,PERGOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC
4262,CHEMBL531,YEHCICAEULNIGD-MZMPZRCHSA-N,PERGOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC
4263,CHEMBL148489,YFCWBKBNFCDPDF-UHFFFAOYSA-N,N-(3-PYRIDYLMETHYL)PYRROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CC2=CN=CC=C2
4264,CHEMBL1373,YFGHCGITMMYXAQ-UHFFFAOYSA-N,MODAFINIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N
4265,CHEMBL1373,YFGHCGITMMYXAQ-UHFFFAOYSA-N,MODAFINIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N
4266,CHEMBL104618,YFHPQEMWPYAXGG-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,9400.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.026872146400302,C1CN(C[C@H]1NS(=O)(=O)C2=CC=CC=C2F)CCCOC3=CC=C(C=C3)C(=O)C4CC4
4267,CHEMBL3092650,YFRBKEVUUCQYOW-UHFFFAOYSA-N,GSK239512,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24269482.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,C1CC(C1)N2CCC3=C(CC2)C=C(C=C3)OC4=NC=C(C=C4)N5CCCC5=O
4268,CHEMBL2158839,YFTFPJHCROIDGR-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=CC=C4F)C(=O)O
4270,CHEMBL542908,YFWUUKSPYPKQPB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,9447.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.024706084643793,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCCOC6=CC=CC=C6C(=O)O)C7=CC=CC=C7.Cl
4272,CHEMBL272378,YGOJZWAMJUGUJD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)CCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)Br
4273,CHEMBL556450,YGQQBKYVKLZEMA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,6.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.161150909262744,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
4274,CHEMBL556450,YGQQBKYVKLZEMA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20347297.0,Ki,=,6.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.161150909262744,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
4275,CHEMBL556450,YGQQBKYVKLZEMA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,6.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.161150909262744,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
4276,CHEMBL424,YGSDEFSMJLZEOE-UHFFFAOYSA-N,SALICYLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)O)O
4277,CHEMBL424,YGSDEFSMJLZEOE-UHFFFAOYSA-N,SALICYLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)O)O
4278,CHEMBL2207671,YGYJEYXHZXOPGM-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,CS(=O)(=O)C1=CC2=C(C=C1)C(=CNC2=O)C(=O)NC[C@H](CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl)O
4279,CHEMBL272695,YHBNNSZPKVUPMG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803203,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C7CC7
4280,CHEMBL610739,YHDCGYWZEFIUHE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,75.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,7.1249387366083,CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=C2
4283,CHEMBL1277400,YHPLTCSZJDWTFK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.100015437450609,C1CN(CC(=C1)C(=O)O)C2CCC3(C2)C4=CC=CC=C4CC5=CC=CC=C5C3=O
4284,CHEMBL583014,YHSRTUXPXLVIAG-CALCHBBNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,1210.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.91721462968355,CC1=CC(=NC(=N1)NC2CCC(CC2)NC(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N(C)C
4285,CHEMBL86304,YHXISWVBGDMDLQ-UHFFFAOYSA-N,MOCLOBEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl
4286,CHEMBL86304,YHXISWVBGDMDLQ-UHFFFAOYSA-N,MOCLOBEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl
4287,CHEMBL491889,YHXSELHUXJAOLR-UHFFFAOYSA-N,KF-A6,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17846138.0,IC50,=,3600.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine receptor subtype 1 expressed in CHO cells,"Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.",Antimicrob. Agents Chemother.,PUBLICATION,,5.443697499232713,CCN(CC)CCCCCCN1C2=CC=CC=C2C(=O)C3=CC=CC=C31
4289,CHEMBL1783955,YIVBCXIAPLXDDK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,4670.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.330683119433888,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)OC
4290,CHEMBL1783955,YIVBCXIAPLXDDK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)OC
4291,CHEMBL61,YJGVMLPVUAXIQN-XVVDYKMHSA-N,PODOFILOX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O
4292,CHEMBL61,YJGVMLPVUAXIQN-XVVDYKMHSA-N,PODOFILOX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O
4293,CHEMBL559665,YJGZARVVQHKNAU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,23.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.638272163982407,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CC(=O)O
4294,CHEMBL271034,YJTUMJAALUNJJT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)OC(=N6)C(C(F)(F)F)(F)F
4295,CHEMBL562792,YJYGESNCQHFTHG-BENRWUELSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,323.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.490797477668897,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)/C=C\C(=O)O
4296,CHEMBL177756,YKGGGCXBWXHKIZ-UHFFFAOYSA-N,FLUORESCEIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)O)C(=O)O
4297,CHEMBL177756,YKGGGCXBWXHKIZ-UHFFFAOYSA-N,FLUORESCEIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)O)C(=O)O
4298,CHEMBL423192,YKJYKKNCCRKFSL-RDBSUJKOSA-N,ANISOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O
4299,CHEMBL423192,YKJYKKNCCRKFSL-RDBSUJKOSA-N,ANISOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O
4301,CHEMBL1935438,YKMYFJKVCCQVAY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,C1CC(CNC1)C2=NC3=CC=CC=C3N2CCOC4=CC=CC=C4
4302,CHEMBL294199,YKPUWZUDDOIDPM-SOFGYWHQSA-N,CAPSAICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC
4303,CHEMBL294199,YKPUWZUDDOIDPM-SOFGYWHQSA-N,CAPSAICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC
4304,CHEMBL407135,YKQOSKADJPQZHB-YNWHQGOSSA-N,COLISTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@H](C)O
4305,CHEMBL407135,YKQOSKADJPQZHB-YNWHQGOSSA-N,COLISTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@H](C)O
4306,CHEMBL185905,YKSKLZDPBLSMIO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,19.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.721246399047171,C1CC2=C(C=CC(=C2)Cl)C(=C3CCN(CC3)CCOC4=CC=C(C=C4)C#CCCN(C(=O)N)O)C5=C1C=CC=N5
4307,CHEMBL95,YLJREFDVOIBQDA-UHFFFAOYSA-N,TACRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2=NC3=CC=CC=C3C(=C2C1)N
4308,CHEMBL95,YLJREFDVOIBQDA-UHFFFAOYSA-N,TACRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2=NC3=CC=CC=C3C(=C2C1)N
4309,CHEMBL2151155,YLMVVEDAZPUKCY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21062081.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Histamine H3 receptor as a drug discovery target.,J. Med. Chem.,PUBLICATION,,5.59999938302362,CS(=O)(=O)C1=CC=C(C=C1)C(=O)N2CCN(CC2)C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5
4314,CHEMBL2146808,YLWRKTVVIPNRDE-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,1.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.0,COCCN1CCC[C@@H]1CN2C(=O)C3=C(C=CC=N3)C(=N2)CC4=CC=C(C=C4)Cl
4315,CHEMBL116,YMARZQAQMVYCKC-OEMFJLHTSA-N,AMPRENAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
4316,CHEMBL116,YMARZQAQMVYCKC-OEMFJLHTSA-N,AMPRENAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
4317,CHEMBL19299,YMBXTVYHTMGZDW-UHFFFAOYSA-N,LOXOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O
4318,CHEMBL19299,YMBXTVYHTMGZDW-UHFFFAOYSA-N,LOXOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O
4319,CHEMBL1767148,YMFHXRKTKHBRIX-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.794,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.100179497572904,CC1=CC(=CC=C1)CC2=NN(C(=O)C3=CC=CC=C32)C[C@H]4CCCN4C
4320,CHEMBL329055,YMHZUQFCCIVBOA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.67,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.175874166083451,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC(=C(C=C7)Cl)Cl
4321,CHEMBL1910385,YMLNOWNONRZEDQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,213.8,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.669992299127241,CC(CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2)NC3=CC4=C(C=C3)NC(=C4)C(=O)N5CCN(CC5)C
4324,CHEMBL672,YMTINGFKWWXKFG-UHFFFAOYSA-N,FENOFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
4325,CHEMBL672,YMTINGFKWWXKFG-UHFFFAOYSA-N,FENOFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
4326,CHEMBL275035,YMVWDVNGNLXSKR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,370.0,NM,,,,,,,,,,,,,,,,,,,,6.431798275933005,CNCCC1=CN=C(N1)CCC(C2=CC=CC=C2)C3=CC=CC=C3
4327,CHEMBL419316,YMYZKGIHGMHZDL-WDAWEKNVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771448.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to Histamine H1 receptor,Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.,J. Med. Chem.,PUBLICATION,,6.0,C/C(=C\CN1CCN(CC1)C[C@H]2[C@@H]3COC4=CC(=C(C=C4C3=NO2)OC)OC)/C5=CC=CC=C5
4328,CHEMBL2207283,YMYZSITWBGWUAF-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,63.1,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755866,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=C(C=C4)S(=O)(=O)C)O)Cl
4329,CHEMBL1504,YNDXUCZADRHECN-JNQJZLCISA-N,TRIAMCINOLONE ACETONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O
4330,CHEMBL1504,YNDXUCZADRHECN-JNQJZLCISA-N,TRIAMCINOLONE ACETONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O
4332,CHEMBL14053,YNJBWRMUSHSURL-UHFFFAOYSA-N,TRICHLOROACETIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(C(Cl)(Cl)Cl)O
4333,CHEMBL14053,YNJBWRMUSHSURL-UHFFFAOYSA-N,TRICHLOROACETIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(C(Cl)(Cl)Cl)O
4334,CHEMBL432144,YNNQILILZIBLOF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,3388.44,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.470000200122707,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)CCC
4335,CHEMBL1626,YNNUSGIPVFPVBX-NHCUHLMSSA-N,CLEMASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,0.42100000000000004,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.37571790416433,C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C
4336,CHEMBL1626,YNNUSGIPVFPVBX-NHCUHLMSSA-N,CLEMASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.049,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,10.309803919971486,C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C
4337,CHEMBL1633,YNQQEYBLVYAWNX-WLHGVMLRSA-N,KETOTIFEN FUMARATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,1.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1.C(=C/C(=O)O)\C(=O)O
4338,CHEMBL257716,YNRYXTYLZKMJRP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)N6C=C(C=CC6=N5)Cl
4339,CHEMBL983,YOEWQQVKRJEPAE-UHFFFAOYSA-L,SUCCINYLCHOLINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-]
4340,CHEMBL983,YOEWQQVKRJEPAE-UHFFFAOYSA-L,SUCCINYLCHOLINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-]
4341,CHEMBL1513,YOSHYTLCDANDAN-UHFFFAOYSA-N,IRBESARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
4342,CHEMBL1513,YOSHYTLCDANDAN-UHFFFAOYSA-N,IRBESARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
4343,CHEMBL60889,YPELFRMCRYSPKZ-UHFFFAOYSA-N,MOSAPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N
4344,CHEMBL60889,YPELFRMCRYSPKZ-UHFFFAOYSA-N,MOSAPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N
4345,CHEMBL123292,YPHMISFOHDHNIV-FSZOTQKASA-N,CYCLOHEXIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@@H](C(=O)[C@@H](C1)[C@@H](CC2CC(=O)NC(=O)C2)O)C
4346,CHEMBL123292,YPHMISFOHDHNIV-FSZOTQKASA-N,CYCLOHEXIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@@H](C(=O)[C@@H](C1)[C@@H](CC2CC(=O)NC(=O)C2)O)C
4349,CHEMBL1372,YPZRWBKMTBYPTK-BJDJZHNGSA-N,OXIGLUTATIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N
4350,CHEMBL1372,YPZRWBKMTBYPTK-BJDJZHNGSA-N,OXIGLUTATIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N
4351,CHEMBL742,YQEZLKZALYSWHR-UHFFFAOYSA-N,KETAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNC1(CCCCC1=O)C2=CC=CC=C2Cl
4352,CHEMBL742,YQEZLKZALYSWHR-UHFFFAOYSA-N,KETAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNC1(CCCCC1=O)C2=CC=CC=C2Cl
4353,CHEMBL172233,YRDKYTTYDOWYLC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,7.24,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,8.140261433802854,CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)CCF
4354,CHEMBL1219,YREYEVIYCVEVJK-UHFFFAOYSA-N,RABEPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC
4355,CHEMBL1219,YREYEVIYCVEVJK-UHFFFAOYSA-N,RABEPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC
4356,CHEMBL1783971,YRIQXMPDJZLBBB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,1290.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.889410289700751,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)C#N
4357,CHEMBL1783971,YRIQXMPDJZLBBB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)C#N
4358,CHEMBL404404,YROMCCIDISNCOF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC=C(C=C1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(F)(F)F
4359,CHEMBL399203,YRQLRCRBEYSAIN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17524641.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,"3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1=CC=C(C=C1)OC2=CC=CC=C2NC3=NS(=O)(=O)C4=CC(=CC(=C4N3)O)[N+](=O)[O-]
4360,CHEMBL1923529,YRYLHJCFIVNEIH-UHFFFAOYSA-N,BAS 04061445,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,2630.27,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.579999668433626,C1CCN(CC1)CCN2C=NN3C2=NC4=CC=CC=C43
4361,CHEMBL83731,YRZFLXOYFQEHFH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,199.53,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446187,C1C(ON2C1C3=CC=CC=C3CC4=CC=CC=C42)CN
4362,CHEMBL1632413,YSEFYTJOKARSSH-VKAVYKQESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,Ki,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Binding affinity to human recombinant histamine H1 receptor expressed in human SK-N-MC cells by radioligand displacement assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)/C(=N\O)/C2=CC3=C(N2)C=CC(=C3)Cl
4363,CHEMBL1189234,YSEXVIPNIGQQMN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC=CC=C7)O
4364,CHEMBL1189234,YSEXVIPNIGQQMN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC=CC=C7)O
4365,CHEMBL1935440,YSFFIZSLOXOSOV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,24.6,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.609064892896621,C1CC(CN(C1)CC2=NC=CO2)C3=NC4=CC=CC=C4N3CCOC5=CC=CC=C5
4366,CHEMBL1277770,YSGLQQUCJIOYSX-TUXUZCGSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.299988937677887,C1C[C@@]2(CC1N3CCC(CC3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25
4367,CHEMBL1566956,YSIITVVESCNIPR-UHFFFAOYSA-N,TROXIPIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=CC(=C1OC)OC)C(=O)NC2CCCNC2
4368,CHEMBL1566956,YSIITVVESCNIPR-UHFFFAOYSA-N,TROXIPIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=CC(=C1OC)OC)C(=O)NC2CCCNC2
4369,CHEMBL3357045,YSJZQHPNURRVLN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,441.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,6.355561410532162,C1CCC(CC1)CC(=O)N2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2
4370,CHEMBL2207666,YSQQOGOBORIIMG-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,3.98,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=CC=CC=C43)O
4372,CHEMBL2207666,YSQQOGOBORIIMG-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,3.98,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=CC=CC=C43)O
4375,CHEMBL14812,YTCGNPGLMAECND-UHFFFAOYSA-N,GT-2016,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15033391.0,Ki,=,2560.0,NM,,,,,,,,,,,,,,,,,,,,5.59176003468815,C1CCC(CC1)CCCCC(=O)N2CCC(CC2)C3=CN=CN3
4376,CHEMBL60598,YTEDUXKJYQFEKR-AREMUKBSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,3311.31,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.480000159330324,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](C(C)C)NC(=O)OC(C)(C)C
4377,CHEMBL312958,YTEDUXKJYQFEKR-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,21379.62,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6700000181810175,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@H](C(C)C)NC(=O)OC(C)(C)C
4378,CHEMBL1078896,YTIWDXUZCLTCIF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,923.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.034798298974088,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=C(O3)C=CC(=C4)NC(=O)C5CCC5)OC
4380,CHEMBL38737,YUKQRDCYNOVPGJ-UHFFFAOYSA-N,THIOACETAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=S)N
4381,CHEMBL38737,YUKQRDCYNOVPGJ-UHFFFAOYSA-N,THIOACETAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=S)N
4382,CHEMBL537219,YUWFKFBORNVPBT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.59999938302362,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)F.Cl
4383,CHEMBL3217984,YVENIGOVHPMTDH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,3.16,NM,,,,,,,,,,,,,,,Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay,,MedChemComm,PUBLICATION,,8.500312917381596,CN1CCC2C(C1)C3=C4N2C5=CC=CC=C5CSC4=CC=C3
4384,CHEMBL1767150,YVEQOJSJKIAGFC-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,1584.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,5.800000874803203,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC(=C(C=C4)OC)OC
4385,CHEMBL1092662,YVEWHDHDFNFTCD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.7,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.769551078621726,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NN=CC=C3
4386,CHEMBL1092662,YVEWHDHDFNFTCD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20800486.0,Ki,=,1.7,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.769551078621726,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NN=CC=C3
4387,CHEMBL1243366,YVGCLDBDDBQLIK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20690643.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,5.0,CC(C)(C)C1=CC=C(C=C1)SCC(C2=CN=CC=C2)C3=CN=CN3
4390,CHEMBL1201220,YVPYQUNUQOZFHG-UHFFFAOYSA-N,DIATRIZOIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I
4391,CHEMBL1201220,YVPYQUNUQOZFHG-UHFFFAOYSA-N,DIATRIZOIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I
4392,CHEMBL1423,YVUQSNJEYSNKRX-UHFFFAOYSA-N,PIMOZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,25.0,NM,,,,,,,,,,,,,,,,,,,,7.6020599913279625,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
4393,CHEMBL1423,YVUQSNJEYSNKRX-UHFFFAOYSA-N,PIMOZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,692.0,NM,,,,,,,,,,,,,,,,,,,,6.1598939055432425,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F
4395,CHEMBL476109,YWOYXYWGFUHWBM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,1014.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,5.993962045002683,C1CC2CN(CCC1N2CCCC(=O)C3=CC=C(C=C3)F)C4=CC=C(C=C4)Cl
4397,CHEMBL1243367,YXEZVHWJNRFKSI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20690643.0,Ki,=,540.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,6.267606240177032,C1=CC(=CC=C1C(F)(F)F)SCC(C2=CC=NC=C2)C3=CN=CN3
4398,CHEMBL570296,YYCDRZDDLBLWPS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19632840.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,CCCNCC1=CC=C(C=C1)CCN2C=CC(=CC2=O)OCC3=CC=C(C=C3)F
4399,CHEMBL62948,YYEJTQDGUKFSBP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1412.54,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.849999245077863,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3
4401,CHEMBL1093623,YYRVJJWBIQUZNR-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,2.5,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.602059991327963,C[C@H](C1=C(CC2=C1C=CC(=C2)OC)CCN(C)C)C3=NC=CS3
4403,CHEMBL2146802,YZAHEHXQIMZHAJ-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.912,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.040005161671584,CCCCN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl
4404,CHEMBL7002,YZFWTZACSRHJQD-UHFFFAOYSA-N,CIGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(CCCCC1)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
4405,CHEMBL7002,YZFWTZACSRHJQD-UHFFFAOYSA-N,CIGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(CCCCC1)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
4406,CHEMBL92337,YZIDTWIJPIHTCE-BPAKYRGESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,3.7,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.431798275933005,C1CN(CCN1CCO)CC2C[C@H]3[C@H](O2)C4=CC=CC=C4CC5=CC=CC=C35
4407,CHEMBL255620,YZVLQPHHXCJUBM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.499999678657065,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)N(C)C
4408,CHEMBL1767153,ZAIFESHMEUUZQE-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,1.58,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.801342913045577,CCCCCC1=NN(C(=O)C2=CC=CC=C21)C[C@H]3CCCN3C
4409,CHEMBL1727,ZAIPMKNFIOOWCQ-UEKVPHQBSA-N,CEPHALEXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O
4410,CHEMBL1727,ZAIPMKNFIOOWCQ-UEKVPHQBSA-N,CEPHALEXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O
4412,CHEMBL471,ZBMZVLHSJCTVON-UHFFFAOYSA-N,SOTALOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O
4413,CHEMBL471,ZBMZVLHSJCTVON-UHFFFAOYSA-N,SOTALOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O
4414,CHEMBL1077,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,BROMFENAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O
4415,CHEMBL1077,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,BROMFENAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O
4416,CHEMBL74688,ZBUWQTCXTJMDCD-JIMJEQGWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,180.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.7447274948966935,C1C[C@@H](O[C@H]1CN2CCN(CC2)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl)C#CCCN(C(=O)N)O
4417,CHEMBL305662,ZBUWQTCXTJMDCD-UODIDJSMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,50.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,C1C[C@H](O[C@@H]1CN2CCN(CC2)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl)C#CCCN(C(=O)N)O
4418,CHEMBL1087367,ZCRCTVHOBQJBNB-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20347297.0,Ki,=,8.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.075720713938118,CN(C)[C@@H]1CCN(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)OC
4420,CHEMBL534,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,KETOTIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,2300.0,NM,,,,binding,,,,,,,,,,,,,,,,5.638272163982407,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1
4421,CHEMBL534,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,KETOTIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,0.158,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,9.801342913045577,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1
4422,CHEMBL534,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,KETOTIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,1.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,9.0,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1
4423,CHEMBL534,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,KETOTIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,1.19,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.924453038607469,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1
4424,CHEMBL534,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,KETOTIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.138,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.860120913598763,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1
4425,CHEMBL811,ZDIGNSYAACHWNL-UHFFFAOYSA-N,BROMPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,6.06,NM,,,,,,,,,,,,,,,,,,,,8.217527375833713,CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2
4426,CHEMBL105483,ZDLIRTGAWPEEKB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,354.81,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.450004148469349,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)OC
4427,CHEMBL561,ZEKZLJVOYLTDKK-UHFFFAOYSA-N,LOMEFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O
4428,CHEMBL561,ZEKZLJVOYLTDKK-UHFFFAOYSA-N,LOMEFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O
4429,CHEMBL1915534,ZELKFGCESYLZNT-NSHDSACASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21955944.0,Ki,>,40000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,CC(C)(C)CCNC1=CC(=NC=N1)N[C@H]2CCNC2
4430,CHEMBL256652,ZENBFJWQHFZSBC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,251.19,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OCC(=O)N6C
4431,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11750180.0,Ki,=,2300.0,NM,,,,,,,,,,,,,,,,,,,,5.638272163982407,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32
4432,CHEMBL422,ZEWQUBUPAILYHI-UHFFFAOYSA-N,TRIFLUOPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,62.5,NM,,,,,,,,,,,,,,,,,,,,7.204119982655925,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
4433,CHEMBL422,ZEWQUBUPAILYHI-UHFFFAOYSA-N,TRIFLUOPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,62.0,NM,,,,,,,,,,,,,,,,,,,,7.2076083105017466,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
4434,CHEMBL422,ZEWQUBUPAILYHI-UHFFFAOYSA-N,TRIFLUOPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,63.0,NM,,,,,,,,,,,,,,,,,,,,7.200659450546418,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
4435,CHEMBL422,ZEWQUBUPAILYHI-UHFFFAOYSA-N,TRIFLUOPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
4436,CHEMBL422,ZEWQUBUPAILYHI-UHFFFAOYSA-N,TRIFLUOPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
4438,CHEMBL802,ZFMITUMMTDLWHR-UHFFFAOYSA-N,MINOXIDIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O
4439,CHEMBL802,ZFMITUMMTDLWHR-UHFFFAOYSA-N,MINOXIDIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O
4440,CHEMBL316705,ZFPPUHTZTYNOKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,994.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.002613615602686,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCCOC6=CC=CC=C6C(=O)OC)C7=CC=CC=C7
4441,CHEMBL1935439,ZFUMGFQOKSXSLS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,4.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.309803919971486,CN(C)C(=O)CN1CCCC(C1)C2=NC3=CC=CC=C3N2CCOC4=CC=CC=C4
4442,CHEMBL1935439,ZFUMGFQOKSXSLS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,11.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.924453038607469,CN(C)C(=O)CN1CCCC(C1)C2=NC3=CC=CC=C3N2CCOC4=CC=CC=C4
4443,CHEMBL482496,ZFUOLNAKPBFDIJ-VQBNBCTGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18468904.0,Ki,=,189.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,"High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.",Bioorg. Med. Chem.,PUBLICATION,,6.723538195826756,[3H]C([3H])([3H])OC1=CC=CC=C1CNCCC2=CC(=C(C=C2OC([3H])([3H])[3H])I)OC
4444,CHEMBL2171043,ZFVQRQOPWCBDOI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,7.94,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC(=CC=C4)Cl
4446,CHEMBL190,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,THEOPHYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2
4447,CHEMBL190,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,THEOPHYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2
4450,CHEMBL564,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,PROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,,,,,,8.698970004336019,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31
4451,CHEMBL564,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,PROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,,,,,,8.698970004336019,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31
4452,CHEMBL564,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,PROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,2454.71,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,5.6099998081597775,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31
4453,CHEMBL564,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,PROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,3.44,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.46344155742847,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31
4454,CHEMBL564,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,PROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.39899999999999997,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.399027104313252,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31
4455,CHEMBL1824777,ZHHLHBNBIKLLJG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21788137.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of H1 receptor by NIMH PDSP,N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (s) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2CC3CC1CC(C2)(N3CC4=CC=CC=C4)O.Cl
4457,CHEMBL260823,ZHYJMAJSBAQRIU-IAGOWNOFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18387300.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,C1CO[C@H](CN1)[C@@H](C2=CC=CC=C2)OC3=C(C=C(C=C3)F)Cl
4461,CHEMBL1824785,ZILQWXOKQUVSTI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21788137.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of H1 receptor by NIMH PDSP,N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (s) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2CC3CC1CC(C2)N3CC4=CC(=CC=C4)F.Cl
4463,CHEMBL666,ZJAOAACCNHFJAH-UHFFFAOYSA-N,FOSCARNET,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(O)P(=O)(O)O
4464,CHEMBL666,ZJAOAACCNHFJAH-UHFFFAOYSA-N,FOSCARNET,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(O)P(=O)(O)O
4465,CHEMBL442456,ZJBDUXLBLPXVOM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CCC1=NC2=C(O1)C=CC3=C2CCN(CC3)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C
4466,CHEMBL1073,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,GLIPIZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
4467,CHEMBL1073,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,GLIPIZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
4468,CHEMBL3233412,ZJYUQATUAGWNGI-FPOVZHCZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24559051.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,J. Med. Chem.,PUBLICATION,,,CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC5=NOC6=C5C=CC(=C6)F
4469,CHEMBL571073,ZJZNOPQUDXUEDU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,3200.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.494850021680094,CC1=CC=C(C=C1)CCCCN2CCCCC2
4470,CHEMBL1783960,ZKAVOICTUKPVNY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,500.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=CC=C4
4471,CHEMBL1783960,ZKAVOICTUKPVNY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,3160.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5003129173815966,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=CC=C4
4474,CHEMBL1632414,ZKDRIYJOVIMHFC-AQTBWJFISA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,Ki,>,1000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Binding affinity to human recombinant histamine H1 receptor expressed in human SK-N-MC cells by radioligand displacement assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN1CCC(CC1)/C(=N/O)/C2=NC3=C(N2)C=C(C=C3)Cl
4475,CHEMBL2441619,ZKHOZLXKYFBVMY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,399.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,6.399027104313252,CC1=CC2=C(C=C1)N=C(C=C2N3CCNCC3)C(F)(F)F
4476,CHEMBL28902,ZKHUZIGQNHJVGZ-WEVVVXLNSA-N,CP-96486,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=NC2=C(N1C3=CC=C(C=C3)OCC4=CC(=CC=C4)/C=C/C5=NC6=C(C=CC(=C6)Cl)C=C5)C=CN=C2
4477,CHEMBL329450,ZKIRNRZUIHQPCN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,446.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.350665141287858,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCOC6=CC=CO6)C7=CC=CC=C7
4478,CHEMBL1334217,ZKLPARSLTMPFCP-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,3.16,NM,,,,,,,,,,,,,,,,,,,,8.500312917381596,C1CN(CCN1CCOCC(=O)O)[C@@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl
4479,CHEMBL1334217,ZKLPARSLTMPFCP-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,,,,,,7.100015437450609,C1CN(CCN1CCOCC(=O)O)[C@@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl
4480,CHEMBL1201191,ZKLPARSLTMPFCP-OAQYLSRUSA-N,LEVOCETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,,,,,,7.0,C1CN(CCN1CCOCC(=O)O)[C@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl
4481,CHEMBL1000,ZKLPARSLTMPFCP-UHFFFAOYSA-N,CETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,3.16,NM,,,,,,,,,,,,,,,,,,,,8.500312917381596,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
4482,CHEMBL1000,ZKLPARSLTMPFCP-UHFFFAOYSA-N,CETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,14.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.853871964321762,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
4483,CHEMBL1000,ZKLPARSLTMPFCP-UHFFFAOYSA-N,CETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,14.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.853871964321762,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
4484,CHEMBL1000,ZKLPARSLTMPFCP-UHFFFAOYSA-N,CETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,5.89,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human Histamine H1 receptor in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.229884705212898,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
4485,CHEMBL1000,ZKLPARSLTMPFCP-UHFFFAOYSA-N,CETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,Ki,=,14.0,NM,,,,,,,,,,,,,,,Inhibition constant against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,7.853871964321762,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
4486,CHEMBL1000,ZKLPARSLTMPFCP-UHFFFAOYSA-N,CETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16408006.0,Ki,=,50.12,NM,,,cell_based,,,,,COS-7,,,,,,,Displacement of [3H]mepyramine from human wild-type histamine H1 receptor expressed in COS-7 cells by liquid scintillation counting,Linking agonist binding to histamine H1 receptor activation.,Nat. Chem. Biol.,PUBLICATION,,7.299988937677887,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
4487,CHEMBL2205811,ZKOQRCXMSDAJIR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,=,8858.0,NM,,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.05266432405126,COC1=CC=CC(=C1)CCN2C3C4C5CC6C4C2(C7C6C5C73)O
4488,CHEMBL256442,ZLAONGKKHFSBFL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,398.11,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.399996913372259,CCC1=NC2=C(S1)C3=C(CCN(CC3)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)C=C2
4490,CHEMBL2171036,ZLPRNWIDJZJYMH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,COC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
4492,CHEMBL599913,ZLTIDZRETNUAHX-KAMYIIQDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,33.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.481486060122113,CN1CCC2=C(C1)C3=CC=CC=C3N2/C=C\C4=CC=CC=C4
4493,CHEMBL599913,ZLTIDZRETNUAHX-KAMYIIQDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,181.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as reduction of histamine-induced intracellular calcium spike at phase 2 treated 20 to 30 seconds after histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.7423214251308154,CN1CCC2=C(C1)C3=CC=CC=C3N2/C=C\C4=CC=CC=C4
4494,CHEMBL343324,ZLTWNSXILLAQPT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,794.33,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,6.0999990348465305,CNCCCOC1=CC=CC2=CC=CC=C21
4495,CHEMBL411691,ZLXCEBAWAKEHFS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,4.47,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.349692476868064,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)C(=O)O)C7=CC=CC=C7
4496,CHEMBL127508,ZMISODWVFHHWNR-UHFFFAOYSA-N,AZACYCLONOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,659.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.18111458540599,C1CNCCC1C(C2=CC=CC=C2)(C3=CC=CC=C3)O
4499,CHEMBL1627,ZMOPTLXEYOVARP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18783208.0,Ki,=,4.2,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function.,J. Med. Chem.,PUBLICATION,,8.3767507096021,CNC(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4
4500,CHEMBL242273,ZMQAAUBTXCXRIC-UHFFFAOYSA-N,SAFROLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCC1=CC2=C(C=C1)OCO2
4501,CHEMBL242273,ZMQAAUBTXCXRIC-UHFFFAOYSA-N,SAFROLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCC1=CC2=C(C=C1)OCO2
4502,CHEMBL98076,ZMTLNBBVFMZHTB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,7.33,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.134896025358872,COC1=CC=C(C=C1)CCN2CCC(=NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F)CC2
4503,CHEMBL268291,ZMXDDKWLCZADIW-UHFFFAOYSA-N,DIMETHYLFORMAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C=O
4504,CHEMBL268291,ZMXDDKWLCZADIW-UHFFFAOYSA-N,DIMETHYLFORMAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C=O
4505,CHEMBL1669417,ZMXXHEQIAQJFTR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,10.5,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.978810700930062,C1CN(CC1F)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4
4508,CHEMBL472,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,GLYBURIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
4509,CHEMBL472,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,GLYBURIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
4510,CHEMBL2158786,ZNOFXQRZLXBDTB-MHZLTWQESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C[C@](CC1=CC=CC=C1)(C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl
4511,CHEMBL1783966,ZNPXEYURFNQPAK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,390.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4089353929735005,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)OC
4512,CHEMBL1783966,ZNPXEYURFNQPAK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)OC
4513,CHEMBL56564,ZNRGQMMCGHDTEI-ITGUQSILSA-N,TROPISETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43
4514,CHEMBL56564,ZNRGQMMCGHDTEI-ITGUQSILSA-N,TROPISETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43
4515,CHEMBL84810,ZNWOCPPAOLYORT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,47.86,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.320027305722581,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC=C3C(F)(F)F
4516,CHEMBL63632,ZOABVQXODSFSPN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,13489.63,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.869999962200743,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)S(=O)(=O)C3=CC=C(C=C3)C#N
4517,CHEMBL1783958,ZOAGXBRERPVMMX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,560.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.251811972993799,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)C(F)(F)F
4518,CHEMBL1783958,ZOAGXBRERPVMMX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,1590.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.798602875679548,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)C(F)(F)F
4519,CHEMBL1779060,ZOAKYUHDXICZSY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21555222.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,"Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (s) receptor ligands modulates off-target activity and subtype selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC(=C(C=C1)OC)C(=O)NCCN2C3C4C5CC6C4C2(C7C6C5C73)O
4520,CHEMBL1779060,ZOAKYUHDXICZSY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC(=C(C=C1)OC)C(=O)NCCN2C3C4C5CC6C4C2(C7C6C5C73)O
4522,CHEMBL240394,ZOCDSDXGMIDSSE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC(=CC(=C4)F)F.C(=O)O
4524,CHEMBL2208419,ZOYPHDPQFYRSLG-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,3.16,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.500312917381596,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](COC3=CC=CC(=C3)C#N)O
4525,CHEMBL593103,ZPAHWVAWJGJPSL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773175.0,Ki,>,1000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in Sf9 cells co-expressing RGS4,"2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CN1CCN(CC1)C2=NC(=NC(=C2)NCC3=CC=C(C=C3)F)N
4526,CHEMBL563520,ZPASDZSMHRZWEN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,46.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.337242168318426,CN1C(=CC(=O)N(C1=O)C)NCCCN2CCC(CC2)CN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(=O)O
4527,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,9.09,NM,,,,,,,,,,,,,,,,,,,,8.041436116778032,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
4528,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,3.0,NM,,,,,,,,,,,,,,,,,,,,8.522878745280337,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
4529,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,9.0,NM,,,,,,,,,,,,,,,,,,,,8.045757490560675,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
4530,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,6.0,NM,,,,,,,,,,,,,,,,,,,,8.221848749616356,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
4531,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,4.25,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.371611069949688,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
4532,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23919353.0,IC50,=,12.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by radioligand binding assay,Polypharmacology - foe or friend?,J. Med. Chem.,PUBLICATION,,7.920818753952375,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
4533,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,17.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.769551078621726,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
4534,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.96,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.707743928643524,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl
4535,CHEMBL117287,ZPMNHBXQOOVQJL-UHFFFAOYSA-N,PRUCALOPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11438309.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl
4536,CHEMBL2179217,ZPUAIXYROPYWKA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23006002.0,Ki,=,681.8,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,6.166343003107127,CC1=CN(C2=C1C=C(C=C2)Cl)S(=O)(=O)C3=CC(=C(C=C3)OC)NC4CCN(CC4)C
4537,CHEMBL1092495,ZQADELCMZHYIPT-ZDUSSCGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,13.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.886056647693163,C[C@@H](C1=NC=C(C=C1)F)C2=C(SC3=CC=CC=C32)CCN(C)C
4538,,ZQAHOENZMFACFJ-UHFFFAOYSA-N,AC1O5RVW,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,1200.0,NM,,,,,,,,,,,,,,,,,,,,5.920818753952375,
4539,,ZQAHOENZMFACFJ-UHFFFAOYSA-N,AC1O5RVW,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,2.51,NM,,,,,,,,,,,,,,,,,,,,8.600326278518962,
4540,,ZQAHOENZMFACFJ-UHFFFAOYSA-N,AC1O5RVW,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,211.0,NM,,,,,,,,,,,,,,,,,,,,6.675717544702307,
4541,,ZQAHOENZMFACFJ-UHFFFAOYSA-N,AC1O5RVW,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,361.0,NM,,,,,,,,,,,,,,,,,,,,6.442492798094342,
4542,CHEMBL1651219,ZQBPXBADOJMCRU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23009245.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of radioligand binding to human histamine H1 receptor,Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence.,J. Med. Chem.,PUBLICATION,,5.0,C1CCC(C1)N2C(=O)C3=C(S2)C=C(C=C3)OCC4=CC(=CC=C4)C5=CC(=C(C=C5)Cl)C(=O)O
4544,CHEMBL896,ZQDWXGKKHFNSQK-UHFFFAOYSA-N,HYDROXYZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,,,,,,9.0,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
4545,CHEMBL896,ZQDWXGKKHFNSQK-UHFFFAOYSA-N,HYDROXYZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,,,,,,8.698970004336019,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
4546,CHEMBL305313,ZQJARSFDPKNFNT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,354.81,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.450004148469349,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C=C(C)C
4548,CHEMBL556449,ZQXPNWSXFWKXRZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,1.3,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693163,C1CN(CCC1N2C=CN=C2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F
4549,CHEMBL1255901,ZRJBHWIHUMBLCN-HZRLMBICSA-N,HUPERZINE A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C/C=C/1\[C@@H]2CC3=C([C@@]1(CC(=C2)C)N)C=CC(=O)N3
4550,CHEMBL1255901,ZRJBHWIHUMBLCN-HZRLMBICSA-N,HUPERZINE A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C/C=C/1\[C@@H]2CC3=C([C@@]1(CC(=C2)C)N)C=CC(=O)N3
4551,CHEMBL291821,ZRMVWXJDKQRJLR-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,46773.51,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.330000038335378,CCC[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N
4552,CHEMBL599,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,MELOXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
4553,CHEMBL599,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,MELOXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O
4554,CHEMBL64799,ZRYOOEBGABRJDU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,933.25,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.030002001401658,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)CC3=CC=CC=C3
4555,CHEMBL644,ZSCDBOWYZJWBIY-UHFFFAOYSA-N,TRIMIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,1.4,NM,,,,,,,,,,,,,,,,,,,,8.853871964321762,CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C
4557,CHEMBL1651906,ZSJLQEPLLKMAKR-YDEIVXIUSA-N,STREPTOZOTOCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)O)O)N=O
4558,CHEMBL1651906,ZSJLQEPLLKMAKR-YDEIVXIUSA-N,STREPTOZOTOCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)O)O)N=O
4560,CHEMBL1940402,ZTBBOIYRZHAFIN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,128.5,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.891096872332687,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCCC3=CC=C(C=C3)F
4563,CHEMBL269995,ZTSFFHIKWHSHGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3981.07,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,CC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CC(=C(C=C5)F)F
4564,CHEMBL314795,ZTXJDBYCWAXXCA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,11.75,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.9299621333922445,CC1=C2C3CC(ON3C4=CC=CC=C4CC2=CC=C1)CN(C)C
4566,CHEMBL1935571,ZULPGIJFVSVHRG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153663.0,Ki,=,7373.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human H1 receptor expressed in HEK cell membranes,Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.132355766096902,CN1CCN(CC1)C2=NC(=NC3=C2C=CC(=C3)C4=COC=C4)N
4567,CHEMBL444083,ZUSSMNOENOGGGY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,26.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.585026652029182,C1CN(CCN1CCCCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
4568,CHEMBL444083,ZUSSMNOENOGGGY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,3.63,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for recombinant human Histamine H1 receptor expressed in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.440093374963887,C1CN(CCN1CCCCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F
4569,CHEMBL1783973,ZVMAXLHJDKBSDN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,>,10000.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C4CCN(CC4)C)CCC5=CC=CC=N5
4570,CHEMBL1783973,ZVMAXLHJDKBSDN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C4CCN(CC4)C)CCC5=CC=CC=N5
4572,CHEMBL1130,ZWAOHEXOSAUJHY-ZIYNGMLESA-N,DOXIFLURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O
4573,CHEMBL1130,ZWAOHEXOSAUJHY-ZIYNGMLESA-N,DOXIFLURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O
4575,CHEMBL157217,ZWBZUWWQDRQBAX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,398.11,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.399996913372259,C1CCN(C1)CCCCCCCCCCC2=CN=CN2
4576,CHEMBL157217,ZWBZUWWQDRQBAX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,251188643150958.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.4,C1CCN(C1)CCCCCCCCCCC2=CN=CN2
4577,CHEMBL2432045,ZWCQZHOWEDKJBN-CAUKCHDASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC6=CC=CC=C6
4578,CHEMBL257534,ZWHFNBRLUSRMFB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OCC(=O)N5C
4579,CHEMBL485543,ZWUFGBNOUKQGBR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18841880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human histamine H1 receptor,Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.,J. Med. Chem.,PUBLICATION,,5.0,CC1=NC2=CC=CC(=C2C(=O)N1C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5)C(F)(F)F
4581,CHEMBL559251,ZWZGWXZGAUJLHN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,4.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,8.397940008672037,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3
4582,CHEMBL559251,ZWZGWXZGAUJLHN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,4.0,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3
4583,CHEMBL559251,ZWZGWXZGAUJLHN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,4.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3
4584,CHEMBL1222624,ZXFALDNPMLUADA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977233,CC1CN(CC(N1CCC(=O)O)C)C2=CC3=CC=CC=C3CN4C2=NC=C4
4585,CHEMBL81435,ZXIPGUHBRFTYRJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1C(ON2C1C3=CC=CC=C3CC4=CC=CC=C42)CN5C(=O)C6=CC=CC=C6C5=O
4586,CHEMBL64894,ZXJXZNDDNMQXFV-UHFFFAOYSA-M,GENTIAN VIOLET,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-]
4587,CHEMBL64894,ZXJXZNDDNMQXFV-UHFFFAOYSA-M,GENTIAN VIOLET,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-]
4588,CHEMBL36994,ZXNRTKGTQJPIJK-UHFFFAOYSA-N,ANIRACETAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=C(C=C1)C(=O)N2CCCC2=O
4589,CHEMBL36994,ZXNRTKGTQJPIJK-UHFFFAOYSA-N,ANIRACETAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=C(C=C1)C(=O)N2CCCC2=O
4590,CHEMBL6466,ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,COUMARIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC(=O)O2
4591,CHEMBL6466,ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,COUMARIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC(=O)O2
4593,CHEMBL62840,ZYPSPPAGXNKFQM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,2238.72,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.650000220873455,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C
4594,CHEMBL328209,ZYRROKHYEJZYKQ-RMNMTYGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,20.6,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.686132779630847,CN(C)CC1C[C@H]2[C@H](O1)C3=CC=CC=C3OCC4=CC=CC=C24
4595,CHEMBL73307,ZZEQOXMRTJPRMI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,189.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,6.723538195826756,CNCC1C2=CC=CC=C2CC3=CC=CC=C13
4596,CHEMBL8514,ZZJYIKPMDIWRSN-HWBMXIPRSA-N,BUTACLAMOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,384.61,NM,,,,,,,,,,,,,,,,,,,,6.414979428136126,CC(C)(C)[C@@]1(CCN2C[C@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@@H]2C1)O
4597,CHEMBL8514,ZZJYIKPMDIWRSN-HWBMXIPRSA-N,BUTACLAMOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,390.0,NM,,,,,,,,,,,,,,,,,,,,6.4089353929735005,CC(C)(C)[C@@]1(CCN2C[C@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@@H]2C1)O
4598,CHEMBL62193,ZZORFUFYDOWNEF-UHFFFAOYSA-N,SULFADIMETHOXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=NC(=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N)OC
4599,CHEMBL62193,ZZORFUFYDOWNEF-UHFFFAOYSA-N,SULFADIMETHOXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=NC(=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N)OC
4600,CHEMBL35,ZZUFCTLCJUWOSV-UHFFFAOYSA-N,FUROSEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl
4601,CHEMBL35,ZZUFCTLCJUWOSV-UHFFFAOYSA-N,FUROSEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl
4602,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,84000.0,NM,,,,binding,,,,,,,,,,,,,,,,4.075720713938118,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
4603,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,14.08,NM,,,,,,,,,,,,,,,,,,,,7.851397345193907,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
4604,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,62.0,NM,,,,,,,,,,,,,,,,,,,,7.2076083105017466,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
4605,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,11.7,NM,,,,,,,,,,,,,,,,,,,,7.931814138253839,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
4606,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,13.5,NM,,,,,,,,,,,,,,,,,,,,7.8696662315049934,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
4607,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,14.79,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.830031826003108,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
4608,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,171.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.767003889607846,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
4609,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,20.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.698970004336019,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2
4610,CHEMBL449040,ZZZDSDWPAFVIDN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,562.34,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2500010234416505,CCCCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCC
4611,CHEMBL1200431,,GADOPENTETATE DIMEGLUMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4612,CHEMBL1200431,,GADOPENTETATE DIMEGLUMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4613,CHEMBL1200528,,CHROMIC CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4614,CHEMBL1200528,,CHROMIC CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4615,CHEMBL1200693,,MANGANESE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4616,CHEMBL1200693,,MANGANESE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4617,CHEMBL1201469,,GRAMICIDIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4618,CHEMBL1201469,,GRAMICIDIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4619,CHEMBL1201631,,INSULIN HUMAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4620,CHEMBL1201631,,INSULIN HUMAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4621,CHEMBL1351,,CARBOPLATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4622,CHEMBL1351,,CARBOPLATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4623,CHEMBL136478,,SODIUM NITROPRUSSIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4624,CHEMBL136478,,SODIUM NITROPRUSSIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4625,CHEMBL1366,,AURANOFIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4626,CHEMBL1366,,AURANOFIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4627,CHEMBL1386,,TRANSPLATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4628,CHEMBL1386,,TRANSPLATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4629,CHEMBL1458880,,CADMIUM DICHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4630,CHEMBL1458880,,CADMIUM DICHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4631,CHEMBL1476898,,CADMIUM ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4632,CHEMBL1476898,,CADMIUM ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4633,CHEMBL1909054,,CARBOXYMETHYLCELLULOSE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4634,CHEMBL1909054,,CARBOXYMETHYLCELLULOSE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4635,CHEMBL1909055,,COBALTOUS CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4636,CHEMBL1909055,,COBALTOUS CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4637,CHEMBL1909056,,COBALT(II) ACETYLACETONATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4638,CHEMBL1909056,,COBALT(II) ACETYLACETONATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4639,CHEMBL1909057,,COPPER(II) OXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4640,CHEMBL1909057,,COPPER(II) OXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4641,CHEMBL1909062,,LEAD (II) ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4642,CHEMBL1909062,,LEAD (II) ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4643,CHEMBL1909063,,LEAD(IV) ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4644,CHEMBL1909063,,LEAD(IV) ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4645,CHEMBL1909064,,LIPOPOLYSACCHARIDE E. COLI O55:B5,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4646,CHEMBL1909064,,LIPOPOLYSACCHARIDE E. COLI O55:B5,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4647,CHEMBL1909067,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4648,CHEMBL1909067,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4649,CHEMBL1909068,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4650,CHEMBL1909068,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4651,CHEMBL1909069,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4652,CHEMBL1909069,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4653,CHEMBL1909071,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4654,CHEMBL1909071,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4655,CHEMBL1909074,,POLYVINYLPYRROLIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4656,CHEMBL1909074,,POLYVINYLPYRROLIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4657,CHEMBL1909075,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4658,CHEMBL1909075,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4659,CHEMBL1909079,,STANNOUS FLUORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4660,CHEMBL1909079,,STANNOUS FLUORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4661,CHEMBL1909083,,ZIRCONIUM(IV) CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4662,CHEMBL1909083,,ZIRCONIUM(IV) CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4663,CHEMBL2068237,,CISPLATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4664,CHEMBL2068237,,CISPLATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4665,CHEMBL306043,,GOLD SODIUM THIOMALATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4666,CHEMBL306043,,GOLD SODIUM THIOMALATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4667,CHEMBL3559671,,POLYVINYL ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4668,CHEMBL3559671,,POLYVINYL ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4669,CHEMBL3735756,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1297.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 Histamine receptors stably expressed in HEK cell membrane after 90 mins by scintillation counting method,Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists,MedChemComm,PUBLICATION,,5.88706002391592,COC1=C(C=C(C=C1)CCN(CCCC2=CC=CC=C2)CCC3=CC4=C(C=C3)OCO4)OC
4670,CHEMBL3739949,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-mepyramine from human histamine H1 receptor expressed in HEK293T cells after 1 to 1.5 hrs by liquid scintillation counting analysis,Structure-based virtual screening for fragment-like ligands of the G protein-coupled histamine H4receptor,MedChemComm,PUBLICATION,,5.0,CC1=CC2=C(C=C1C)N=C(N2)SCCN(C)C
4674,CHEMBL3740846,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-mepyramine from human histamine H1 receptor expressed in HEK293T cells after 1 to 1.5 hrs by liquid scintillation counting analysis,Structure-based virtual screening for fragment-like ligands of the G protein-coupled histamine H4receptor,MedChemComm,PUBLICATION,,5.0,CC1=NN=C2N1C3=CC=CC=C3N=C2N4CCN(CC4)C
4681,CHEMBL3752085,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1122.02,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.949999401714238,CN1CCN(CC1)C2=NC(=NC(=C2)C3=CC=CC=C3)NCC4=CC=CC=C4
4682,CHEMBL3752195,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,5248.07,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.280000380871156,CN1CCN(CC1)C2=NC(=NC(=C2)C3=CC=CC=C3)NCC4=CC=C(C=C4)OC
4683,CHEMBL3752225,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,5754.4,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2399999527072705,CN1CCN(CC1)C2=NC(=NC3=C2CCC4=CC=CC=C43)NCC5=CC=C(C=C5)OC
4684,CHEMBL3752270,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,2089.3,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.679999195735272,CN1CCN(CC1)C2=NC(=NC3=C2CCC4=CC=CC=C43)NCC5=CC=CC=C5
4685,CHEMBL3752383,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,3311.31,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.480000159330324,CN1CCN(CC1)C2=NC(=NC(=C2)C3=CC=CC=C3)NCCC4=CC=CC=C4
4686,CHEMBL3752576,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CCN(CCC1=CNC2=CC=CC=C21)CC=C
4687,CHEMBL3752576,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,=,125.89,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455316,C=CCN(CCC1=CNC2=CC=CC=C21)CC=C
4688,CHEMBL3752885,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,891.25,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.050000457140078,CN1CCN(CC1)C2=NC3=C(CCC4=CC=CC=C43)C(=N2)NCC5=CC=CC=C5
4689,CHEMBL3752900,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CCN(CCC1=CNC2=C1C=C(C=C2)Cl)CC=C
4690,CHEMBL3752900,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C=CCN(CCC1=CNC2=C1C=C(C=C2)Cl)CC=C
4691,CHEMBL3752972,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1071.52,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.9699997184078955,CN1CCN(CC1)C2=NC(=NC3=C2C4=CC=CC=C4CC3)NCC5=CC=C(C=C5)OC
4692,CHEMBL3752978,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1949.84,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.710001024518514,CN1CCN(CC1)C2=NC(=CC(=N2)NCCC3=CC=CC=C3)C4=CC=CC=C4
4693,CHEMBL3753318,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C
4694,CHEMBL3753318,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,=,676.08,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.170001911302621,CC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C
4695,CHEMBL3753334,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1949.84,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.710001024518514,CN1CCN(CC1)C2=NC(=NC3=C2CCC4=CC=CC=C43)NCC5=CC=C(C=C5)F
4696,CHEMBL3753621,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,8128.31,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.089999741487069,CN1CCN(CC1)C2=NC3=C(CCC4=CC=CC=C43)C(=N2)NCCC5=CC=CC=C5
4697,CHEMBL3753705,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1174.9,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.929999096197655,CN1CCN(CC1)C2=NC(=NC3=C2C4=CC=CC=C4CC3)N5CCN(CC5)C
4698,CHEMBL3753784,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,6309.57,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200000237109354,CN1CCN(CC1)C2=NC3=C(CCC4=CC=CC=C43)C(=N2)NCC5=CC(=C(C=C5)OC)C6=CC=C(C=C6)Cl
4699,CHEMBL3753849,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59999938302362,CN1CCN(CC1)C2=NC(=CC(=N2)NCC3=CC=CC=C3)C4=CC=CC=C4
4700,CHEMBL3753962,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,9332.54,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.030000139977383,CN1CCN(CC1)C2=NC(=NC3=C2CCC4=CC=CC=C43)NCCC5=CC=CC=C5
4701,CHEMBL3753967,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1905.46,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.720000163638921,CN1CCN(CC1)C2=NC(=NC3=C2C4=CC=CC=C4CC3)NCC5=CC=CC=C5
4702,CHEMBL3753985,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1862.09,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7299993321845495,CN1CCN(CC1)C2=NC(=NC3=C2C4=CC=CC=C4CC3)NCCC5=CC=CC=C5
4703,CHEMBL3754008,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,4168.69,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.380000399499541,CN1CCN(CC1)C2=NC(=CC(=N2)NCC3=CC=C(C=C3)OC)C4=CC=CC=C4
4705,CHEMBL3754166,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CCN(CCC1=CNC2=C1C=C(C=C2)Br)CC=C
4706,CHEMBL3754166,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C=CCN(CCC1=CNC2=C1C=C(C=C2)Br)CC=C
4707,CHEMBL3754176,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,3388.44,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.470000200122707,CC1=CC=C(C=C1)CNC2=NC3=C(CCC4=CC=CC=C43)C(=N2)N5CCN(CC5)C
4708,CHEMBL3754496,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CCN(CCC1=CNC2=C1C=C(C=C2)F)CC=C
4709,CHEMBL3754496,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450609,C=CCN(CCC1=CNC2=C1C=C(C=C2)F)CC=C
4732,CHEMBL3804837,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@H]1CN=C(NC#N)NC2CC2)C3=CN=CN3
4734,CHEMBL3804862,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@H]1CN=C(NCCOC2=CC=CC=C2)NC#N)C3=CN=CN3
4736,CHEMBL3804906,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,CN=C(NC[C@H]1CC[C@@H](C1)C2=CN=CN2)NC#N
4738,CHEMBL3805003,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,8350.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.078313524516398,CC(C)CN=C(NC[C@@H]1CC[C@@H](C1)C2=CN=CN2)NC#N
4740,CHEMBL3805178,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@@H]1CN=C(NCCNC2=CC=CC=C2)NC#N)C3=CN=CN3
4742,CHEMBL3805220,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,7910.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.101823516502323,C1C[C@H](C[C@@H]1CN=C(NCCSC2=CC=CC=C2)NC#N)C3=CN=CN3
4744,CHEMBL3805264,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@H]1CN=C(NCCNC2=CC=CC=C2)NC#N)C3=CN=CN3
4747,CHEMBL3805361,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,6080.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.216096420727265,C1C[C@@H](C[C@H]1CN=C(NCCSC2=CC=CC=C2)NC#N)C3=CN=CN3
4748,CHEMBL3805361,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,6520.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.185752404268079,C1C[C@@H](C[C@H]1CN=C(NCCSC2=CC=CC=C2)NC#N)C3=CN=CN3
4750,CHEMBL3805431,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,6780.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.168770306132936,C1C[C@H](C[C@H]1CN=C(NCCSC2=CC=CC=C2)NC#N)C3=CN=CN3
4752,CHEMBL3805437,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,CN=C(NC[C@@H]1CC[C@H](C1)C2=CN=CN2)NC#N
4753,CHEMBL3805518,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27173799.0,IC50,=,972.0,NM,,,,,,,,,,,,,,,Antagonistic activity at histamine1 receptor (unknown origin) after 10 mins by FLIPR assay,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.012333735073725,CNC(=O)C1=C(C=CC(=C1)OCCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)F
4754,CHEMBL3805559,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27173799.0,IC50,=,2560.0,NM,,,,,,,,,,,,,,,Antagonistic activity at histamine1 receptor (unknown origin) after 10 mins by FLIPR assay,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.59176003468815,CNC(=O)C1=CC(=CC=C1)OCCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F
4756,CHEMBL3805663,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,9350.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.029188389127482,C1C[C@@H](C[C@@H]1CN=C(NCCCC2=CC=CC=C2)NC#N)C3=CN=CN3
4758,CHEMBL3805813,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@H]1CN)C2=CN=CN2
4760,CHEMBL3805995,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@@H]1CN)C2=CN=CN2
4762,CHEMBL3806015,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@@H]1CN=C(NCCOC2=CC=CC=C2)NC#N)C3=CN=CN3
4765,CHEMBL3806079,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,3050.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.515700160653214,C1C[C@@H](C[C@@H]1CN=C(NCCSC2=CC=CC=C2)NC#N)C3=CN=CN3
4766,CHEMBL3806079,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,3800.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.42021640338319,C1C[C@@H](C[C@@H]1CN=C(NCCSC2=CC=CC=C2)NC#N)C3=CN=CN3
4768,CHEMBL3806098,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@H]1CN=C(NCCCC2=CC=CC=C2)NC#N)C3=CN=CN3
4770,CHEMBL3806146,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@@H]1CN=C(NC#N)NC2CC2)C3=CN=CN3
4772,CHEMBL3806162,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,CN=C(NC[C@H]1CC[C@H](C1)C2=CN=CN2)NC#N
4774,CHEMBL3806206,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,CN=C(NC[C@@H]1CC[C@@H](C1)C2=CN=CN2)NC#N
4776,CHEMBL3806255,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,8750.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.057991946977687,CC(C)CN=C(NC[C@H]1CC[C@@H](C1)C2=CN=CN2)NC#N
4777,CHEMBL3817898,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,199.53,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.699991797446187,COC1=CC=C(C=C1)C(=O)CCCN2CCC3=CC=CC=C3C2
4778,CHEMBL3817898,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,216.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.665546248849069,COC1=CC=C(C=C1)C(=O)CCCN2CCC3=CC=CC=C3C2
4779,CHEMBL3817911,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,3630.78,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,5.44000006551306,C1CCC2CN(CCC2C1)CCCCN3C(=O)C4=CC=CC=C4C3=O
4780,CHEMBL3817911,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,3632.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,5.4398541601509525,C1CCC2CN(CCC2C1)CCCCN3C(=O)C4=CC=CC=C4C3=O
4781,CHEMBL3818047,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,597.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.224025668870631,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)Cl
4782,CHEMBL3818047,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,602.56,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.219999701663429,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)Cl
4784,CHEMBL3818124,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,263.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.580044251510242,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=NC5=C(S4)C=CC(=C5)Cl
4785,CHEMBL3818124,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,275.42,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.560004526046192,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=NC5=C(S4)C=CC(=C5)Cl
4786,CHEMBL3818128,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,738.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.131943638176958,C1CN(CC2=CC=CC=C21)CCCCC3=CC=C(C=C3)F.Cl
4787,CHEMBL3818128,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,741.31,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.130000141365475,C1CN(CC2=CC=CC=C21)CCCCC3=CC=C(C=C3)F.Cl
4788,CHEMBL3818200,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,158.49,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.799998134593398,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)C#N
4789,CHEMBL3818200,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,177.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.752026733638194,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)C#N
4790,CHEMBL3818478,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,273.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.5638373529592435,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=CNC5=CC=CC=C54
4791,CHEMBL3818478,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,275.42,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.560004526046192,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=CNC5=CC=CC=C54
4793,CHEMBL3818805,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,245.47,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.610001577392667,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCCC4=CNC5=CC=CC=C54
4794,CHEMBL3818805,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,255.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.5934598195660445,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCCC4=CNC5=CC=CC=C54
4795,CHEMBL3818881,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,1023.29,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,5.990001269951939,C1CC2CC(CC1N2CCCCC(=O)C3=NC4=CC=CC=C4S3)(C5=CC=C(C=C5)Cl)O.Cl
4796,CHEMBL3818881,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,1028.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,5.988006885340743,C1CC2CC(CC1N2CCCCC(=O)C3=NC4=CC=CC=C4S3)(C5=CC=C(C=C5)Cl)O.Cl
4797,CHEMBL3818935,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,535.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.2716462179787715,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=NC5=CC=CC=C5O4
4798,CHEMBL3818935,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,537.03,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.270001452716577,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=NC5=CC=CC=C5O4
4799,CHEMBL3818989,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,7.199970640755866,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=CC=C3
4800,CHEMBL3818989,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,68.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,7.167491087293763,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=CC=C3
4801,CHEMBL3818994,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,86.3,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,7.06398920428479,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)F
4802,CHEMBL3819153,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.299997602857746,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCCC4=NC5=CC=CC=C5O4
4803,CHEMBL3819153,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,510.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.292429823902063,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCCC4=NC5=CC=CC=C5O4
4804,CHEMBL3819366,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,380.19,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.41999931041096,C1CN(CC2=CC=CC=C21)CCCOC3=CC=C(C=C3)F.Cl
4805,CHEMBL3819366,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,382.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.4179366370882915,C1CN(CC2=CC=CC=C21)CCCOC3=CC=C(C=C3)F.Cl
4806,CHEMBL3819427,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,1427.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,5.845576026885353,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)C(=O)N
4807,CHEMBL3819427,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,5.800000874803203,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)C(=O)N
4808,CHEMBL3819434,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,186.21,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.729996999894941,C1CC2CC(CC1N2CCCCC3=NC4=CC=CC=C4S3)(C5=CC=C(C=C5)Cl)O.Cl
4809,CHEMBL3819434,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,187.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.728158393463501,C1CC2CC(CC1N2CCCCC3=NC4=CC=CC=C4S3)(C5=CC=C(C=C5)Cl)O.Cl
4810,CHEMBL3819494,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,831.76,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.0800019690359814,C1CN(CC2=CC=CC=C21)CCCCC3=CNC4=CC=CC=C43
4811,CHEMBL3819494,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,836.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.077793722560983,C1CN(CC2=CC=CC=C21)CCCCC3=CNC4=CC=CC=C43
4812,CHEMBL3819567,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,1.175,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,8.929962133392245,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=NC5=CC=CC=C5S4
4813,CHEMBL3819567,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,504.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.297569463554475,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=NC5=CC=CC=C5S4
4815,CHEMBL414804,,OXALIPLATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4816,CHEMBL414804,,OXALIPLATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4817,CHEMBL508338,,THIOMERSAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
4818,CHEMBL508338,,THIOMERSAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,
